{"docstore/data": {"1d8cc600-46b6-4e9e-9077-7273ab74c0f9": {"__data__": {"id_": "1d8cc600-46b6-4e9e-9077-7273ab74c0f9", "embedding": null, "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c9e8e13-fb2a-4bfc-822b-26af95097774", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2e1229bd187c6fbc2d96dc8a903f48d5fe6ec45b1396fbe68ea74bfeac01306", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474", "node_type": "1", "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": "All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)"}, "hash": "a73179fd4df5d6aad2930221c975a3a4525cb39c687ee8f164938e3d150b99af", "class_name": "RelatedNodeInfo"}}, "text": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "start_char_idx": 0, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474": {"__data__": {"id_": "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474", "embedding": null, "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": "All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c9e8e13-fb2a-4bfc-822b-26af95097774", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2e1229bd187c6fbc2d96dc8a903f48d5fe6ec45b1396fbe68ea74bfeac01306", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8cc600-46b6-4e9e-9077-7273ab74c0f9", "node_type": "1", "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbb6403513da33f2394439c904734cd113f86eaf458ca6a2b4ca4f4653e6b5a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baae4b4f-0de7-4a6a-a960-26321b79a458", "node_type": "1", "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. "}, "hash": "13a5d4b93e47f15e0e6338e93a3d8d912ed4985142e61bbf284cbf64ad466e1f", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "start_char_idx": 85, "end_char_idx": 741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baae4b4f-0de7-4a6a-a960-26321b79a458": {"__data__": {"id_": "baae4b4f-0de7-4a6a-a960-26321b79a458", "embedding": null, "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffc0b564-2124-4402-a81d-adf214726bb8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c375d4d0d167f48c8773ab43709425ee4cf240096f13c694dcfe0e3b18f4549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474", "node_type": "1", "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": "All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4569c9cd1e00ed7d69c55414e6e2d040336e2646e954603126b9b71f733fb57a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f2b9d66-a604-412c-aeb4-a12ffc1158d6", "node_type": "1", "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11"}, "hash": "eba3e45184423c09435069c1eb772e825e4ca1a58de86b508f21e7fb36f987f6", "class_name": "RelatedNodeInfo"}}, "text": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "start_char_idx": 0, "end_char_idx": 92, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f2b9d66-a604-412c-aeb4-a12ffc1158d6": {"__data__": {"id_": "2f2b9d66-a604-412c-aeb4-a12ffc1158d6", "embedding": null, "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffc0b564-2124-4402-a81d-adf214726bb8", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c375d4d0d167f48c8773ab43709425ee4cf240096f13c694dcfe0e3b18f4549", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baae4b4f-0de7-4a6a-a960-26321b79a458", "node_type": "1", "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9650aaff3fcc4555086f3224ca7479224191b300d4838fbb7796edc7a02e7271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1be5bca-3a7a-4620-8cb8-43b9b5d0323a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "67a469dda8c24b408dd08f4719d249d29083201d3053da6a029ff8a706b2a1f0", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "start_char_idx": 92, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1be5bca-3a7a-4620-8cb8-43b9b5d0323a": {"__data__": {"id_": "d1be5bca-3a7a-4620-8cb8-43b9b5d0323a", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c248cc7-d698-499f-af53-4d027dfd69d2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ada4dff44b401b8205a3f42f98409c18dabff40c551d67325cf42f0dc6d64f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f2b9d66-a604-412c-aeb4-a12ffc1158d6", "node_type": "1", "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c35797bc9d563410175ab747f2e1680747ef3730105e857d81d60fe7f0f1a13b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2f39111-412c-4945-8be0-9c0fd51e04ec", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "All Rights reserved.\n"}, "hash": "014a08bcf284e61b1f7801c27395dc5f9c777a918dcaf467bf865c4ac461027d", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2f39111-412c-4945-8be0-9c0fd51e04ec": {"__data__": {"id_": "b2f39111-412c-4945-8be0-9c0fd51e04ec", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "All Rights reserved.\n", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c248cc7-d698-499f-af53-4d027dfd69d2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ada4dff44b401b8205a3f42f98409c18dabff40c551d67325cf42f0dc6d64f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1be5bca-3a7a-4620-8cb8-43b9b5d0323a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a84dcc253949d45799e933ed6b1bea89bc8db757130b8c5655c9ee43cc8718", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3816a440-6d24-4ef7-af85-8cd39aa32266", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division"}, "hash": "0b2f2aecd8f4325943fa122e491a212ff12c17e6df7220a6c6b4ce5171bfdde6", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3816a440-6d24-4ef7-af85-8cd39aa32266": {"__data__": {"id_": "3816a440-6d24-4ef7-af85-8cd39aa32266", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8c248cc7-d698-499f-af53-4d027dfd69d2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ada4dff44b401b8205a3f42f98409c18dabff40c551d67325cf42f0dc6d64f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2f39111-412c-4945-8be0-9c0fd51e04ec", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "All Rights reserved.\n", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83011f8ba926e32a0718ba7af2e0f45cb11f1b0833fe4e4b82f6cb7c219de689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b39f8481-da0b-4b5a-9fcf-a7ce743f321a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "5fd78db41608dedd2bec92b30e9a4ca133ee918f7a07c5d8ea81b36fc035741d", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "start_char_idx": 158, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b39f8481-da0b-4b5a-9fcf-a7ce743f321a": {"__data__": {"id_": "b39f8481-da0b-4b5a-9fcf-a7ce743f321a", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3816a440-6d24-4ef7-af85-8cd39aa32266", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f7ed2a01b6a6901100c6bf94b5a0bb3cc87f90f9a87901a4f31510935ca228d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af166dfd-e8a9-4296-9851-7d8e79ef15d1", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "All Rights reserved.\n"}, "hash": "2f2ec0c46e0e0585f1ff84ca5349722f8c3ccc9758d1c1b99a549ae8d0f75f07", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af166dfd-e8a9-4296-9851-7d8e79ef15d1": {"__data__": {"id_": "af166dfd-e8a9-4296-9851-7d8e79ef15d1", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "All Rights reserved.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b39f8481-da0b-4b5a-9fcf-a7ce743f321a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd7223a70c685befcfcac9697ac5fa58316c11acf896c4a92fe70df1c2dd5deb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bfb3e56-5936-4050-9e09-6abece9f8bca", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n", "original_text": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call. "}, "hash": "dd9c5a13336fe4f665fd4ef14e0d9e2cefb11f389afd6063052fa5864c8a10cf", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bfb3e56-5936-4050-9e09-6abece9f8bca": {"__data__": {"id_": "4bfb3e56-5936-4050-9e09-6abece9f8bca", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n", "original_text": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af166dfd-e8a9-4296-9851-7d8e79ef15d1", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "All Rights reserved.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "032b86d7f9485035cfced4922a7360e23c1178405bd18fac0e90cd57ca656143", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33abce5-8de1-402a-bb56-148d3302f4af", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator. ", "original_text": "Please be advised that today's conference is being\nrecorded.\n"}, "hash": "df950bcdfa87547abed8b269ed246a66e4a7c49794a2db6adc07aaf487fdb019", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call. ", "start_char_idx": 158, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d33abce5-8de1-402a-bb56-148d3302f4af": {"__data__": {"id_": "d33abce5-8de1-402a-bb56-148d3302f4af", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator. ", "original_text": "Please be advised that today's conference is being\nrecorded.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bfb3e56-5936-4050-9e09-6abece9f8bca", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n", "original_text": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3adf1a2237b8c4ed2a6e1c5f9a10db2b4381f8e81e3438a017e06453ece6c644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "b8fb7f092f6d794a24a766861cdaed1f4ecafe997d6587552c10065567052eb3", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that today's conference is being\nrecorded.\n", "start_char_idx": 288, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af": {"__data__": {"id_": "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33abce5-8de1-402a-bb56-148d3302f4af", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator. ", "original_text": "Please be advised that today's conference is being\nrecorded.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdd1d8517e0e7d4230db41bf1524326fc1a5e9c9fd17abb6dfb40f106db5aa21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "243475d2-de7e-4a57-a970-11d259b5ea08", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.\n"}, "hash": "6f4413591f4ea2f321aac26c89c74d43e59beb2b8855ae7689caefd612d2bf53", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 349, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "243475d2-de7e-4a57-a970-11d259b5ea08": {"__data__": {"id_": "243475d2-de7e-4a57-a970-11d259b5ea08", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "original_text": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8cc62e64249d24506c99138b8ef9fdade15b2fab141e7371a6e188de54c43ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f55382f0-cb94-45cc-8d32-f00da51ef2f1", "node_type": "1", "metadata": {"window": "Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "original_text": "Rachel Rodriguez\nThank you, operator. "}, "hash": "394ca7cecdcce6150ce2518e77e9e8a157a4374580f736efbed5ad86ca476e6d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.\n", "start_char_idx": 445, "end_char_idx": 462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f55382f0-cb94-45cc-8d32-f00da51ef2f1": {"__data__": {"id_": "f55382f0-cb94-45cc-8d32-f00da51ef2f1", "embedding": null, "metadata": {"window": "Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "original_text": "Rachel Rodriguez\nThank you, operator. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "243475d2-de7e-4a57-a970-11d259b5ea08", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "Please go ahead.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a9f1f43aa49e7b7a3b69fca967688e57a07a3e97cc6ebca8bd139723ca99668", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0af511e0-2f59-4f85-bff1-0db6ba7bd316", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. "}, "hash": "6e5e1193857b2b17d1e8c59202b8cc9d6eb96cacf96f8898a1fff9e2ea626c76", "class_name": "RelatedNodeInfo"}}, "text": "Rachel Rodriguez\nThank you, operator. ", "start_char_idx": 462, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0af511e0-2f59-4f85-bff1-0db6ba7bd316": {"__data__": {"id_": "0af511e0-2f59-4f85-bff1-0db6ba7bd316", "embedding": null, "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55382f0-cb94-45cc-8d32-f00da51ef2f1", "node_type": "1", "metadata": {"window": "Please be advised that today's conference is being\nrecorded.\n At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "original_text": "Rachel Rodriguez\nThank you, operator. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b371021e1591a80d70b41cd54a00ef3ea9c5077a2ef2090aab02ec68d2f40dfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d1cb41-f84b-4cd3-9f17-d7f8673391cc", "node_type": "1", "metadata": {"window": "Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "original_text": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. "}, "hash": "49259661d799b4fd636ec812e5f2e76b1ecb858fe17fb090ae3fb7a57346c84d", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "start_char_idx": 500, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d1cb41-f84b-4cd3-9f17-d7f8673391cc": {"__data__": {"id_": "23d1cb41-f84b-4cd3-9f17-d7f8673391cc", "embedding": null, "metadata": {"window": "Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "original_text": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0af511e0-2f59-4f85-bff1-0db6ba7bd316", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the call over to Rachel Rodriguez, VP of Investor Relations.  Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "original_text": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27a0c301ab6c905a7473de109c7ae51186efea1511677962905f895860e5a274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2282afa6-208a-4b29-8d72-7053a47f0dde", "node_type": "1", "metadata": {"window": "Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n"}, "hash": "113793d74ad7d1117e49087c7a141c3fa71af95518377f4b5238cc6512799b1a", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "start_char_idx": 594, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2282afa6-208a-4b29-8d72-7053a47f0dde": {"__data__": {"id_": "2282afa6-208a-4b29-8d72-7053a47f0dde", "embedding": null, "metadata": {"window": "Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d1cb41-f84b-4cd3-9f17-d7f8673391cc", "node_type": "1", "metadata": {"window": "Please go ahead.\n Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "original_text": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad47c95e564d6f665db91ce07c54f8a0534ca6f1768d78ca914def62e3a032db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea3994d0-5084-4527-9729-896decc25a5b", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "original_text": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. "}, "hash": "7eb59e798045289e4e990316ab59ba89d1aaaa4113b2bdc02368cb6aa6f00c20", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "start_char_idx": 706, "end_char_idx": 802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea3994d0-5084-4527-9729-896decc25a5b": {"__data__": {"id_": "ea3994d0-5084-4527-9729-896decc25a5b", "embedding": null, "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "original_text": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2282afa6-208a-4b29-8d72-7053a47f0dde", "node_type": "1", "metadata": {"window": "Rachel Rodriguez\nThank you, operator.  Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "original_text": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71c2dfc870fef219fde42f0a66252d5213a2f7613f09b91588b2cbde91205d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0126c6d-0d2d-433a-8398-ce246f4aa0a2", "node_type": "1", "metadata": {"window": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n"}, "hash": "d1d7f2067b1145fcf1b5868dfec9686cf6e47b15ea5e50ca8a8da5790e3bcf37", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "start_char_idx": 802, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0126c6d-0d2d-433a-8398-ce246f4aa0a2": {"__data__": {"id_": "e0126c6d-0d2d-433a-8398-ce246f4aa0a2", "embedding": null, "metadata": {"window": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea3994d0-5084-4527-9729-896decc25a5b", "node_type": "1", "metadata": {"window": "Good afternoon and welcome, everyone, to McKesson's Second Quarter Fiscal 2023 Earnings Call.  Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "original_text": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d548db63c08fa7bbdfb5e1a16f8a90ffdf249b85560fa06de17f604b0409cffb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06564a24-4c14-45cb-b4c6-fc96b104b2e2", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "original_text": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. "}, "hash": "f99a252a37390720aa1686a3c2d75159ad47fe3d6acbe58736facdcdb2cc8637", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "start_char_idx": 928, "end_char_idx": 1286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06564a24-4c14-45cb-b4c6-fc96b104b2e2": {"__data__": {"id_": "06564a24-4c14-45cb-b4c6-fc96b104b2e2", "embedding": null, "metadata": {"window": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "original_text": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0126c6d-0d2d-433a-8398-ce246f4aa0a2", "node_type": "1", "metadata": {"window": "Today, I'm\njoined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n", "original_text": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b40bc227ac2f98d285341fb8653bd12515e3df3dd1a07c49f4f79fab7ae45bd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6969423-8138-421a-929f-f9c4ce9eb3b6", "node_type": "1", "metadata": {"window": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "original_text": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n"}, "hash": "2ccda8cd3dc4700d993f0c7bb02805593b6c5b8e062dde44d05ca3848d25209e", "class_name": "RelatedNodeInfo"}}, "text": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "start_char_idx": 1286, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6969423-8138-421a-929f-f9c4ce9eb3b6": {"__data__": {"id_": "f6969423-8138-421a-929f-f9c4ce9eb3b6", "embedding": null, "metadata": {"window": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "original_text": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06564a24-4c14-45cb-b4c6-fc96b104b2e2", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by\nBritt, and then we will move to a question-and-answer session.\n Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "original_text": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6702a72b433b5903378840fbb175ae42bec450d2f0c9c20887733fb8f3d023a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228030f0-d592-4b69-85b1-ab3a0666cc9d", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "original_text": "With that, let me turn it over to Brian.\n"}, "hash": "7f796942e39f94586386046deb4bf442ceaf41a97e1c418e4eaa8c42922517c1", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "start_char_idx": 1502, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228030f0-d592-4b69-85b1-ab3a0666cc9d": {"__data__": {"id_": "228030f0-d592-4b69-85b1-ab3a0666cc9d", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "original_text": "With that, let me turn it over to Brian.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6969423-8138-421a-929f-f9c4ce9eb3b6", "node_type": "1", "metadata": {"window": "Today's discussion will include forward-looking statements, such as forecasts about McKesson's operations and future\nresults.  Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "original_text": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c39c9c3b9d485870cc9e2b9be552fc0589adf9f011e92f0967f8039d112d554", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59431d34-0849-45d4-909d-bb47d6a56d3d", "node_type": "1", "metadata": {"window": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "original_text": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. "}, "hash": "048400500a46c2b94763399fb2bbec4426663a73d274b2c9f8531a20678d3981", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.\n", "start_char_idx": 1615, "end_char_idx": 1656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59431d34-0849-45d4-909d-bb47d6a56d3d": {"__data__": {"id_": "59431d34-0849-45d4-909d-bb47d6a56d3d", "embedding": null, "metadata": {"window": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "original_text": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228030f0-d592-4b69-85b1-ab3a0666cc9d", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at\ninvestor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors\nthat could cause our actual results to materially differ from those in our forward-looking statements.\n Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "original_text": "With that, let me turn it over to Brian.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cebd5abba65a7d187b44409d5f334fa04d21f319f00a34839fa7d8c1a1483f86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31467483-fa82-46d8-b9bb-8b2979ac0755", "node_type": "1", "metadata": {"window": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "original_text": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. "}, "hash": "c8dd211fd028a0f2d71713793a722d0de248d25ba9d86a7c75b00d156e4a94d4", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "start_char_idx": 1656, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31467483-fa82-46d8-b9bb-8b2979ac0755": {"__data__": {"id_": "31467483-fa82-46d8-b9bb-8b2979ac0755", "embedding": null, "metadata": {"window": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "original_text": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59431d34-0849-45d4-909d-bb47d6a56d3d", "node_type": "1", "metadata": {"window": "Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those\nmeasures to GAAP results, can be found in today's earnings release and presentation slides.  The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "original_text": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d39d61c56d1fb18777c2e1f40960a95e95d6ad9a0278dd541db9e34b3f137ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "944fba87-926b-401f-8559-223a13a4422d", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "original_text": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n"}, "hash": "1afeb3fe5a2d006f40558cbf98e85faf53628ce1dffec59b2e3182645ad35e2d", "class_name": "RelatedNodeInfo"}}, "text": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "start_char_idx": 1753, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "944fba87-926b-401f-8559-223a13a4422d": {"__data__": {"id_": "944fba87-926b-401f-8559-223a13a4422d", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "original_text": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31467483-fa82-46d8-b9bb-8b2979ac0755", "node_type": "1", "metadata": {"window": "The presentation slides also includes a\nsummary of our results for the quarter and updated guidance assumptions.\n With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "original_text": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af19be521f503e2994dba4d2f17a42c490c2d6d77b669d9ebeb7b9f9727e7efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "original_text": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. "}, "hash": "99be518974bcd315dc7cebeb0f8be64d2188020aa883b56e6ea34004c53cc1fe", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "start_char_idx": 1894, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6": {"__data__": {"id_": "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "original_text": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "944fba87-926b-401f-8559-223a13a4422d", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.\n Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "original_text": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6243c8f0d1af38be550ebb4f2e8995462027e6516118a75409ecb5d14e3ba691", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7705f094-6ffb-4e7f-a771-eacd78f8fdd4", "node_type": "1", "metadata": {"window": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "original_text": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. "}, "hash": "d54d61b57153f2695c57095c722f68f4e422bd3884657ac5f42dce1e6c3c30da", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "start_char_idx": 2053, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7705f094-6ffb-4e7f-a771-eacd78f8fdd4": {"__data__": {"id_": "7705f094-6ffb-4e7f-a771-eacd78f8fdd4", "embedding": null, "metadata": {"window": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "original_text": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThanks, Rachel, and thanks to everyone for joining us on the call.  Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "original_text": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b40ee356ac55d68bfd71177dad09d0df552b315db1c7d13c0b7a591a415acab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83aea93a-3d79-40f7-9c6f-892b87494da1", "node_type": "1", "metadata": {"window": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "original_text": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n"}, "hash": "44b97e1225ce07d805f2d4ee8730c219c3cd4aabb70ba45c09fb3721606db369", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "start_char_idx": 2270, "end_char_idx": 2423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83aea93a-3d79-40f7-9c6f-892b87494da1": {"__data__": {"id_": "83aea93a-3d79-40f7-9c6f-892b87494da1", "embedding": null, "metadata": {"window": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "original_text": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7705f094-6ffb-4e7f-a771-eacd78f8fdd4", "node_type": "1", "metadata": {"window": "Today, McKesson reported another good quarter with total company\nrevenues of $70.2 billion and adjusted earnings per diluted share of $6.06.  When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "original_text": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2177d579bd2bc1e180e35bd5baa25ca46692078de6564842a10a3f48806fd1a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7b269ea-e83e-47f6-96f2-45805924f723", "node_type": "1", "metadata": {"window": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "original_text": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. "}, "hash": "cdb70b830358c8bed6946ce2df1201f98f760e01a59ff292d7c6e2f4afa01e14", "class_name": "RelatedNodeInfo"}}, "text": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "start_char_idx": 2423, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7b269ea-e83e-47f6-96f2-45805924f723": {"__data__": {"id_": "c7b269ea-e83e-47f6-96f2-45805924f723", "embedding": null, "metadata": {"window": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "original_text": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83aea93a-3d79-40f7-9c6f-892b87494da1", "node_type": "1", "metadata": {"window": "When excluding the contributions from COVID-19-related\nitems and McKesson Ventures, our adjusted earnings per diluted share increased 11% from the prior year.\n As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "original_text": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3f08423bc6e3f48d4976cd1e4988d7408d3e008542a6a0bc0bcc49edcf44c51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d17c5d69-be55-4482-8d1c-2bc2bf547b62", "node_type": "1", "metadata": {"window": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "original_text": "We have\nestablished a differentiated position to win in both oncology and biopharma services. "}, "hash": "a11b30348f654bea6cd5bb98db5e94e0e72ef95a11327ed80e87776621860b9a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "start_char_idx": 2571, "end_char_idx": 2812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d17c5d69-be55-4482-8d1c-2bc2bf547b62": {"__data__": {"id_": "d17c5d69-be55-4482-8d1c-2bc2bf547b62", "embedding": null, "metadata": {"window": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "original_text": "We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7b269ea-e83e-47f6-96f2-45805924f723", "node_type": "1", "metadata": {"window": "As a result of our second quarter performance and business outlook, we are raising our guidance range for fiscal 2023 adjusted\nearnings per diluted share from $23.95 to $24.65 to an updated range of $24.45 to $24.95.  We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "original_text": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36a6ab7ae21e7e235247d8c6190463280a62c05889c2abe8463d38b8ae46bad8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4670465-d3a5-48c7-b69b-0e767b092dfe", "node_type": "1", "metadata": {"window": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture. ", "original_text": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n"}, "hash": "9602ad680f1ee2562e06e4a925293d1631d9b4e9c45411bd4ccc3b738f189c3d", "class_name": "RelatedNodeInfo"}}, "text": "We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "start_char_idx": 2812, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4670465-d3a5-48c7-b69b-0e767b092dfe": {"__data__": {"id_": "a4670465-d3a5-48c7-b69b-0e767b092dfe", "embedding": null, "metadata": {"window": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture. ", "original_text": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d17c5d69-be55-4482-8d1c-2bc2bf547b62", "node_type": "1", "metadata": {"window": "We're pleased with the financial\nperformance through the first half of our fiscal 2023 driven by continued execution and momentum across the enterprise.  Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "original_text": "We have\nestablished a differentiated position to win in both oncology and biopharma services. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fc55a1f320989c9648ce90b5a2c7f8c8152440df4973fd53237b0fca972da25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75639319-e82b-4c09-b2de-41739f3f9c15", "node_type": "1", "metadata": {"window": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "original_text": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. "}, "hash": "8574f37fe3646c802f3097eb12c5700686a14524984f3c3e4a08458e87e55192", "class_name": "RelatedNodeInfo"}}, "text": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "start_char_idx": 2906, "end_char_idx": 3079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75639319-e82b-4c09-b2de-41739f3f9c15": {"__data__": {"id_": "75639319-e82b-4c09-b2de-41739f3f9c15", "embedding": null, "metadata": {"window": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "original_text": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4670465-d3a5-48c7-b69b-0e767b092dfe", "node_type": "1", "metadata": {"window": "Our core\ndistribution businesses have performed well and shown great resilience in navigating the dynamic macro environment we're all\noperating in.\n We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture. ", "original_text": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97380045c33c84497d70156bbe66adc822b516d159d4b879656989c2c48a8e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5", "node_type": "1", "metadata": {"window": "We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "original_text": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n"}, "hash": "b5ad0e8da4620571a02fa3e04020524076f7219e887006c79e61cc13c8d2f162", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "start_char_idx": 3079, "end_char_idx": 3222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5": {"__data__": {"id_": "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5", "embedding": null, "metadata": {"window": "We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "original_text": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75639319-e82b-4c09-b2de-41739f3f9c15", "node_type": "1", "metadata": {"window": "We continue to strengthen our competitive advantage in oncology and biopharma services through both internal investment and\nacquisition as evidenced by the recent Rx Savings Solutions acquisition and the Sarah Cannon joint venture with HCA.  We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "original_text": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d693457c5872c67c1f9d28089f7d19a5bdb0af24632bd319ebc3320758c1d85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6663ccc4-d80b-4d40-b655-2fd5981a7737", "node_type": "1", "metadata": {"window": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "original_text": "Let me start where I always start, and that's with our focus on people and culture. "}, "hash": "f1ae858783726d3bd10fd3c2f66d8218505fdf9b33ba97478af7011fdbed2b82", "class_name": "RelatedNodeInfo"}}, "text": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "start_char_idx": 3222, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6663ccc4-d80b-4d40-b655-2fd5981a7737": {"__data__": {"id_": "6663ccc4-d80b-4d40-b655-2fd5981a7737", "embedding": null, "metadata": {"window": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "original_text": "Let me start where I always start, and that's with our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5", "node_type": "1", "metadata": {"window": "We have\nestablished a differentiated position to win in both oncology and biopharma services.  And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "original_text": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c07ae5cbf5959a6c9fd26c8b7a412a79ab759c08648dc3968deaf7f5765a4d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe65cf83-e80b-4169-8842-dd56af2fef54", "node_type": "1", "metadata": {"window": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "original_text": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. "}, "hash": "a4f48bb0d89463e57d5bed8ef6a109ee34718b91c25ef38612e3b7799d590040", "class_name": "RelatedNodeInfo"}}, "text": "Let me start where I always start, and that's with our focus on people and culture. ", "start_char_idx": 3349, "end_char_idx": 3433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe65cf83-e80b-4169-8842-dd56af2fef54": {"__data__": {"id_": "fe65cf83-e80b-4169-8842-dd56af2fef54", "embedding": null, "metadata": {"window": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "original_text": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6663ccc4-d80b-4d40-b655-2fd5981a7737", "node_type": "1", "metadata": {"window": "And our defined growth strategy, combined with\nour company vision, is a powerful reflection of how McKesson has transformed into a diversified health care services company.\n Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "original_text": "Let me start where I always start, and that's with our focus on people and culture. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0daf7b51e16acaed5d36946ffe9c3657e4d7f2e47ae117441b0fd69984b364a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bde5e349-568a-46d4-912b-366c9b270a68", "node_type": "1", "metadata": {"window": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay. ", "original_text": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. "}, "hash": "97b890006ae2c6fa655349df829fdc998811f30124fa39a8b1bb4fff1ebdd7d7", "class_name": "RelatedNodeInfo"}}, "text": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "start_char_idx": 3433, "end_char_idx": 3569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bde5e349-568a-46d4-912b-366c9b270a68": {"__data__": {"id_": "bde5e349-568a-46d4-912b-366c9b270a68", "embedding": null, "metadata": {"window": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay. ", "original_text": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe65cf83-e80b-4169-8842-dd56af2fef54", "node_type": "1", "metadata": {"window": "Today, I'm going to focus my remarks on our strategy and highlight the significant progress we've been making across our 4 company\npriorities.  Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "original_text": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7084528b64c330bc5c5c596ccc9c0d4fc51b458a44869ce24f7fcee0b0cd435", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aafbf8ca-4c3f-4cf3-99ea-5223d916d541", "node_type": "1", "metadata": {"window": "Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday. ", "original_text": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n"}, "hash": "1aa8f4018e196dd31ac40f927e0fa7dc3f8bfe50863d540cbb119daa9a67d01a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "start_char_idx": 3569, "end_char_idx": 3676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aafbf8ca-4c3f-4cf3-99ea-5223d916d541": {"__data__": {"id_": "aafbf8ca-4c3f-4cf3-99ea-5223d916d541", "embedding": null, "metadata": {"window": "Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday. ", "original_text": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bde5e349-568a-46d4-912b-366c9b270a68", "node_type": "1", "metadata": {"window": "Then I'm going to turn it over to Britt, who's going to go into more detail on the business performance in our second quarter.\n Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay. ", "original_text": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f47241535de333d976a91f2842a7a8dd61217e3c0c93b9d440c95271a81e22c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41d1437a-4a1a-4f41-8571-afd87f990888", "node_type": "1", "metadata": {"window": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "original_text": "Around this time last year, we were really excited to announce a new wellness program at McKesson. "}, "hash": "b7c8cc18adba4a698dbe05c28f187f16f9eff7082bd96185c0fcb8e7c959663b", "class_name": "RelatedNodeInfo"}}, "text": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "start_char_idx": 3676, "end_char_idx": 3824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41d1437a-4a1a-4f41-8571-afd87f990888": {"__data__": {"id_": "41d1437a-4a1a-4f41-8571-afd87f990888", "embedding": null, "metadata": {"window": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "original_text": "Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aafbf8ca-4c3f-4cf3-99ea-5223d916d541", "node_type": "1", "metadata": {"window": "Let me start where I always start, and that's with our focus on people and culture.  We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday. ", "original_text": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b375a22b51b92ae8aeefd90c0faf524e29653dce072c3b8c3e4f07c73f59ff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af466a80-0294-49b8-8ded-c35fc5718b4d", "node_type": "1", "metadata": {"window": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace. ", "original_text": "We called it Your Day, Your\nWay. "}, "hash": "0eb55d2687c6c47bca79e8430ba735f3e3de59d029aff2aaec645024db4cc420", "class_name": "RelatedNodeInfo"}}, "text": "Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "start_char_idx": 3824, "end_char_idx": 3923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af466a80-0294-49b8-8ded-c35fc5718b4d": {"__data__": {"id_": "af466a80-0294-49b8-8ded-c35fc5718b4d", "embedding": null, "metadata": {"window": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace. ", "original_text": "We called it Your Day, Your\nWay. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41d1437a-4a1a-4f41-8571-afd87f990888", "node_type": "1", "metadata": {"window": "We firmly believe that having the best talent\nis essential to our ability to consistently execute and deliver strong operating results.  We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "original_text": "Around this time last year, we were really excited to announce a new wellness program at McKesson. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5f41724733f68027494fa9a55d532145b63f227fbd4e5ee80fa94f05c3d7d2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b709c23-0409-4261-9ff6-ef6e29c0a8f7", "node_type": "1", "metadata": {"window": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work. ", "original_text": "And we celebrated the second anniversary this past Friday. "}, "hash": "50ade47a47f54f2a6cf0c468845e930c22fd384e4e7d6394992aa730d54fdfbc", "class_name": "RelatedNodeInfo"}}, "text": "We called it Your Day, Your\nWay. ", "start_char_idx": 3923, "end_char_idx": 3956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b709c23-0409-4261-9ff6-ef6e29c0a8f7": {"__data__": {"id_": "0b709c23-0409-4261-9ff6-ef6e29c0a8f7", "embedding": null, "metadata": {"window": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work. ", "original_text": "And we celebrated the second anniversary this past Friday. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af466a80-0294-49b8-8ded-c35fc5718b4d", "node_type": "1", "metadata": {"window": "We continue to invest in our people, which\nallows us to attract and retain talent in a tight labor market.  It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace. ", "original_text": "We called it Your Day, Your\nWay. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c055ec63887f653e177638b83f1bf3e8780aca3c118fce74490230b8c449846a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2029d801-9050-4d82-90f4-350291475b07", "node_type": "1", "metadata": {"window": "Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n"}, "hash": "00327827c54cc3b06b282c424403cc87e13de2ae81ab5acd34d455d30ccb4557", "class_name": "RelatedNodeInfo"}}, "text": "And we celebrated the second anniversary this past Friday. ", "start_char_idx": 3956, "end_char_idx": 4015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2029d801-9050-4d82-90f4-350291475b07": {"__data__": {"id_": "2029d801-9050-4d82-90f4-350291475b07", "embedding": null, "metadata": {"window": "Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b709c23-0409-4261-9ff6-ef6e29c0a8f7", "node_type": "1", "metadata": {"window": "It's important to us that our employees are provided with the support and\nflexibility they need to thrive both in work and in their personal lives.\n Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work. ", "original_text": "And we celebrated the second anniversary this past Friday. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "158776c0ba9b4f8a7d85cfd74c854cb37c8682c4f44e2a7ec1988f6314a43b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12d9e72f-9773-4906-b958-e3903fc8b757", "node_type": "1", "metadata": {"window": "We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We're also committed to diversity, equity and inclusion in the workplace. "}, "hash": "82318175a5a93f4553dd742b6d4c14593f769529e3efa5710dbb6f8133db2514", "class_name": "RelatedNodeInfo"}}, "text": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "start_char_idx": 4015, "end_char_idx": 4149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12d9e72f-9773-4906-b958-e3903fc8b757": {"__data__": {"id_": "12d9e72f-9773-4906-b958-e3903fc8b757", "embedding": null, "metadata": {"window": "We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We're also committed to diversity, equity and inclusion in the workplace. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2029d801-9050-4d82-90f4-350291475b07", "node_type": "1", "metadata": {"window": "Around this time last year, we were really excited to announce a new wellness program at McKesson.  We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d90083b4413e9460c87fad0b70c02c1d6dbd9aba4f9d6f50bec0bfdbe0c1cea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7578ec0-716c-4c98-ac2a-0ff7dc62629c", "node_type": "1", "metadata": {"window": "And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We have a culture where everyone can bring their true\nauthentic selves to work. "}, "hash": "23e86af0ff30b08641e91e68b1a574c7612e59dd4fde3de3a77efc6633570ed3", "class_name": "RelatedNodeInfo"}}, "text": "We're also committed to diversity, equity and inclusion in the workplace. ", "start_char_idx": 4149, "end_char_idx": 4223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7578ec0-716c-4c98-ac2a-0ff7dc62629c": {"__data__": {"id_": "f7578ec0-716c-4c98-ac2a-0ff7dc62629c", "embedding": null, "metadata": {"window": "And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We have a culture where everyone can bring their true\nauthentic selves to work. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12d9e72f-9773-4906-b958-e3903fc8b757", "node_type": "1", "metadata": {"window": "We called it Your Day, Your\nWay.  And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We're also committed to diversity, equity and inclusion in the workplace. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8299efe6e3957396f8ebc73b4bd436571effbd53cc4a9077f7aeea9a6cb5081", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa10f87-1834-4fd7-9954-bc23724e1d1f", "node_type": "1", "metadata": {"window": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating"}, "hash": "17920e355abb28e6fe6bf7758017b95ef3597fe1dd186a5aa2f0108305feaeac", "class_name": "RelatedNodeInfo"}}, "text": "We have a culture where everyone can bring their true\nauthentic selves to work. ", "start_char_idx": 4223, "end_char_idx": 4303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa10f87-1834-4fd7-9954-bc23724e1d1f": {"__data__": {"id_": "8aa10f87-1834-4fd7-9954-bc23724e1d1f", "embedding": null, "metadata": {"window": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a90beb30-aaa4-4486-af2f-62db4522e765", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88293f480a795794dad6cf1f2742fd802ae8a1388819373d5fa3cb55e352ea15", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7578ec0-716c-4c98-ac2a-0ff7dc62629c", "node_type": "1", "metadata": {"window": "And we celebrated the second anniversary this past Friday.  It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "We have a culture where everyone can bring their true\nauthentic selves to work. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dedbf12e24d49b35f1b0c5fc62fba2e3b5243ecb32379519b56447493ace8a89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "220a8f8f-a531-49dc-a014-0ae9b00f04bd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "d3abec8c8e775c4e1e62a29bd3f79b03c500cc1ba1f7e637ced0fc7f04c86d9a", "class_name": "RelatedNodeInfo"}}, "text": "In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "start_char_idx": 4303, "end_char_idx": 4412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "220a8f8f-a531-49dc-a014-0ae9b00f04bd": {"__data__": {"id_": "220a8f8f-a531-49dc-a014-0ae9b00f04bd", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa10f87-1834-4fd7-9954-bc23724e1d1f", "node_type": "1", "metadata": {"window": "It was a great pleasure to give our employees a company-sponsored\nday-off to promote their mental, physical and emotional well-being.\n We're also committed to diversity, equity and inclusion in the workplace.  We have a culture where everyone can bring their true\nauthentic selves to work.  In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "original_text": "In October, I signed the CEO Letter on Disability Inclusion, joining a group of inspiring leaders on creating", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecddb8cf022e7d1e2dda1ac74c46d1c7ac87eedd2eeb3b8061a2d70822c399b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80aa23ff-586b-4568-b6e8-2aa67d16fff4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board. ", "original_text": "All Rights reserved.\n"}, "hash": "7f7f3848456e3fda034c948cfc222ea97278c78a9d39ee8894d2558f8000c7f8", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80aa23ff-586b-4568-b6e8-2aa67d16fff4": {"__data__": {"id_": "80aa23ff-586b-4568-b6e8-2aa67d16fff4", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board. ", "original_text": "All Rights reserved.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "220a8f8f-a531-49dc-a014-0ae9b00f04bd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9efc1c756e9bf8daff701e6fe2434a9518492e08c25f16be837f3ab2bbd90a72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e37ac073-4ef3-4751-b265-077ef5ab3c26", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n", "original_text": "spglobal.com/marketintelligence 5a more inclusive world. "}, "hash": "c915d87053f3dd4387944dba9f4fe173022e76e6f19c6412a2e7d257c891dd71", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e37ac073-4ef3-4751-b265-077ef5ab3c26": {"__data__": {"id_": "e37ac073-4ef3-4751-b265-077ef5ab3c26", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n", "original_text": "spglobal.com/marketintelligence 5a more inclusive world. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80aa23ff-586b-4568-b6e8-2aa67d16fff4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board. ", "original_text": "All Rights reserved.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fee227b444efbc3194d45e3a80cc72a1baf50162a018b7439ede0f0b61913d4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53a9a98f-c21c-44de-b9ed-c4e027812c41", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "original_text": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n"}, "hash": "6a465097f4fd63713eddc042afc14443d9068a8eb3d6a97f9fac4c4d3c3a151c", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 5a more inclusive world. ", "start_char_idx": 158, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53a9a98f-c21c-44de-b9ed-c4e027812c41": {"__data__": {"id_": "53a9a98f-c21c-44de-b9ed-c4e027812c41", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "original_text": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e37ac073-4ef3-4751-b265-077ef5ab3c26", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n", "original_text": "spglobal.com/marketintelligence 5a more inclusive world. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1310888ba5ca1be7ca4167958a26063db820ef58a130e1c4b90779260369062a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b67cd999-986a-412a-b4b9-7ef1e5442a05", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n", "original_text": "Our commitment to diversity is also reflected in our Board. "}, "hash": "c1502641111100ad5b3b3713916784960db5fa79d07bd4e9cb64c7cd1703ab5a", "class_name": "RelatedNodeInfo"}}, "text": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "start_char_idx": 215, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b67cd999-986a-412a-b4b9-7ef1e5442a05": {"__data__": {"id_": "b67cd999-986a-412a-b4b9-7ef1e5442a05", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n", "original_text": "Our commitment to diversity is also reflected in our Board. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53a9a98f-c21c-44de-b9ed-c4e027812c41", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "original_text": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74049acc771bd6057f218322755fbdf6bb658d342eea89b7372f08ff36eb8102", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18a4b935-54b9-434b-8fcf-f1162cbf7768", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core. ", "original_text": "Nearly half of our Board of Directors are women and/or people of color.\n"}, "hash": "68a510ff8349b7dcc7dd52d29b3a14be98aa6f774d2daf84ec02e59d339c861f", "class_name": "RelatedNodeInfo"}}, "text": "Our commitment to diversity is also reflected in our Board. ", "start_char_idx": 352, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18a4b935-54b9-434b-8fcf-f1162cbf7768": {"__data__": {"id_": "18a4b935-54b9-434b-8fcf-f1162cbf7768", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core. ", "original_text": "Nearly half of our Board of Directors are women and/or people of color.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b67cd999-986a-412a-b4b9-7ef1e5442a05", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n", "original_text": "Our commitment to diversity is also reflected in our Board. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ee594c3429db0ffab8c46ca35a794d9139b3f5054e9dce43e6e9f5c01fc971c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1abd09c6-6492-4acd-9dbb-95fc204239bc", "node_type": "1", "metadata": {"window": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "original_text": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n"}, "hash": "1bd0890b4e32efafcac550a6e239dab3241b59e3519a2d79aa779bde4575a5aa", "class_name": "RelatedNodeInfo"}}, "text": "Nearly half of our Board of Directors are women and/or people of color.\n", "start_char_idx": 412, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1abd09c6-6492-4acd-9dbb-95fc204239bc": {"__data__": {"id_": "1abd09c6-6492-4acd-9dbb-95fc204239bc", "embedding": null, "metadata": {"window": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "original_text": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18a4b935-54b9-434b-8fcf-f1162cbf7768", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core. ", "original_text": "Nearly half of our Board of Directors are women and/or people of color.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "166ab255c27783c14f395a73d42c2d379f431f368df2d72b110b80fb2a736f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6", "node_type": "1", "metadata": {"window": "Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "original_text": "We're grateful for Kathleen's leadership and her inspiration.\n"}, "hash": "0f7346788a176667463cae75c4124d78b1e40802fa4013b46d89f1b4507dfe02", "class_name": "RelatedNodeInfo"}}, "text": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "start_char_idx": 484, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6": {"__data__": {"id_": "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6", "embedding": null, "metadata": {"window": "Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "original_text": "We're grateful for Kathleen's leadership and her inspiration.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1abd09c6-6492-4acd-9dbb-95fc204239bc", "node_type": "1", "metadata": {"window": "This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "original_text": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1370f86de519ae43fe558f827dc245dbd7db521c3b50b5862cb414f75a1b626b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82", "node_type": "1", "metadata": {"window": "Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment. ", "original_text": "Our second company priority is to drive sustainable growth in our core. "}, "hash": "3aa798b2e8bbcca06b91491910e4129484a2f6c2f23e6cbf8ecb1052d05f51ff", "class_name": "RelatedNodeInfo"}}, "text": "We're grateful for Kathleen's leadership and her inspiration.\n", "start_char_idx": 736, "end_char_idx": 798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82": {"__data__": {"id_": "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82", "embedding": null, "metadata": {"window": "Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment. ", "original_text": "Our second company priority is to drive sustainable growth in our core. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6", "node_type": "1", "metadata": {"window": "Our commitment to diversity is also reflected in our Board.  Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "original_text": "We're grateful for Kathleen's leadership and her inspiration.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62a13d3c1cd14f33474837fb61078cfddcae0bd3f514daf02ea0fcaf4de683ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09467d52-1f6d-4cd5-8bb9-74307d68e813", "node_type": "1", "metadata": {"window": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "original_text": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. "}, "hash": "d976ae003b2fdc695165e6a151302899f8ef2a0b2a2a6a93a37c4d81a58cba6f", "class_name": "RelatedNodeInfo"}}, "text": "Our second company priority is to drive sustainable growth in our core. ", "start_char_idx": 798, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09467d52-1f6d-4cd5-8bb9-74307d68e813": {"__data__": {"id_": "09467d52-1f6d-4cd5-8bb9-74307d68e813", "embedding": null, "metadata": {"window": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "original_text": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82", "node_type": "1", "metadata": {"window": "Nearly half of our Board of Directors are women and/or people of color.\n Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment. ", "original_text": "Our second company priority is to drive sustainable growth in our core. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fa32c6657aa35eac4b655943c6ee58ed09778516246d5b90d09a855e5abe99f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54b72461-7e37-4867-998d-8d0011eb3844", "node_type": "1", "metadata": {"window": "We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers. ", "original_text": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. "}, "hash": "c579c5456f095aea8b6315b7d908ecb169afe6722205bcbb23abd201fb302355", "class_name": "RelatedNodeInfo"}}, "text": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "start_char_idx": 870, "end_char_idx": 1004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54b72461-7e37-4867-998d-8d0011eb3844": {"__data__": {"id_": "54b72461-7e37-4867-998d-8d0011eb3844", "embedding": null, "metadata": {"window": "We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers. ", "original_text": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09467d52-1f6d-4cd5-8bb9-74307d68e813", "node_type": "1", "metadata": {"window": "Recently, Kathleen Wilson-Thompson, one of McKesson's independent directors, was presented with the Distinguished Alumna\nAward by the DirectWomen Organization, recognizing her contribution to diversity in the boardroom and excellence in Board service.\n We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "original_text": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23c546b4a3a4714180e396f6bb1d058c6bd61022894a380749dd6d5b48b4f8c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1895063-caa5-44af-9f36-e8b543af38c1", "node_type": "1", "metadata": {"window": "Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "original_text": "Pharmaceutical segment. "}, "hash": "cd83c4a5b6c7ba3cfd4f6979af6359d752885fab278ecf7232fe2fbc55b0bb60", "class_name": "RelatedNodeInfo"}}, "text": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "start_char_idx": 1004, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1895063-caa5-44af-9f36-e8b543af38c1": {"__data__": {"id_": "f1895063-caa5-44af-9f36-e8b543af38c1", "embedding": null, "metadata": {"window": "Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "original_text": "Pharmaceutical segment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54b72461-7e37-4867-998d-8d0011eb3844", "node_type": "1", "metadata": {"window": "We're grateful for Kathleen's leadership and her inspiration.\n Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers. ", "original_text": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed36c71caf5f8ab6d69784cbf296a44cc61dfbf2b352f6f074d3a470f7791947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "036379f0-a38a-417b-bc38-fdc99f556c52", "node_type": "1", "metadata": {"window": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "original_text": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n"}, "hash": "fa4f1666a5639132959e47973eb33ce9ad042ee00a3fc86849b527cadd163801", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment. ", "start_char_idx": 1115, "end_char_idx": 1139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "036379f0-a38a-417b-bc38-fdc99f556c52": {"__data__": {"id_": "036379f0-a38a-417b-bc38-fdc99f556c52", "embedding": null, "metadata": {"window": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "original_text": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1895063-caa5-44af-9f36-e8b543af38c1", "node_type": "1", "metadata": {"window": "Our second company priority is to drive sustainable growth in our core.  Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "original_text": "Pharmaceutical segment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9edef9d27558b0388c107aad09a8d7f5de1b695d536be4e9f3fe93f36813e59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "029f9e01-4807-47aa-9f2f-2b601527da43", "node_type": "1", "metadata": {"window": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "original_text": "We continue to expand our reach and deliver unique value propositions to all customers. "}, "hash": "8293ecbd3fac640fc62729d1b38f37dc2b22041da6f1ba877df334d94a7e652d", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "start_char_idx": 1139, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "029f9e01-4807-47aa-9f2f-2b601527da43": {"__data__": {"id_": "029f9e01-4807-47aa-9f2f-2b601527da43", "embedding": null, "metadata": {"window": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "original_text": "We continue to expand our reach and deliver unique value propositions to all customers. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "036379f0-a38a-417b-bc38-fdc99f556c52", "node_type": "1", "metadata": {"window": "Our business is built on a strong foundation of pharmaceutical\nand medical distribution assets and capabilities across North America.  In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "original_text": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "995dd42bec25581535f40832e2be196eecbdff5788a75b6a9d9b83951d81d916", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9ffa04a-c71b-482c-bfea-86f31aa49fbb", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "original_text": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. "}, "hash": "b1a9addc157cb86b4f5ab960baca4a9a5baeba8ce5a3c53fbbc2130a7c34b61a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expand our reach and deliver unique value propositions to all customers. ", "start_char_idx": 1258, "end_char_idx": 1346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9ffa04a-c71b-482c-bfea-86f31aa49fbb": {"__data__": {"id_": "a9ffa04a-c71b-482c-bfea-86f31aa49fbb", "embedding": null, "metadata": {"window": "Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "original_text": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "029f9e01-4807-47aa-9f2f-2b601527da43", "node_type": "1", "metadata": {"window": "In the U.S., the steady performance of pharmaceutical\ndistribution underpins the operating results of the U.S.  Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "original_text": "We continue to expand our reach and deliver unique value propositions to all customers. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3338e5c2cc991a3a9b9adcaf9a48fb4d1985e06d356b3ea7d33bb979670c3678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1e34f55-209d-4999-b397-3cb0fc82866c", "node_type": "1", "metadata": {"window": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "original_text": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n"}, "hash": "e6b11a27db60aca005056c74924aa4b429d9079288cc5861f91c9c4c37dabac1", "class_name": "RelatedNodeInfo"}}, "text": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "start_char_idx": 1346, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1e34f55-209d-4999-b397-3cb0fc82866c": {"__data__": {"id_": "c1e34f55-209d-4999-b397-3cb0fc82866c", "embedding": null, "metadata": {"window": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "original_text": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9ffa04a-c71b-482c-bfea-86f31aa49fbb", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.  In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "original_text": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb14f472dcb4029cf02beeedabb6d8910b929f34c299e36975b53e5b173ea335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "476a9c91-e73d-448e-825e-83a65cbf1c2c", "node_type": "1", "metadata": {"window": "We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027. ", "original_text": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. "}, "hash": "34fa689e9c6e91f07a27995d129ce20e2bd045ee0cc7d877d9ffe0c4a1768bdf", "class_name": "RelatedNodeInfo"}}, "text": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "start_char_idx": 1459, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "476a9c91-e73d-448e-825e-83a65cbf1c2c": {"__data__": {"id_": "476a9c91-e73d-448e-825e-83a65cbf1c2c", "embedding": null, "metadata": {"window": "We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027. ", "original_text": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1e34f55-209d-4999-b397-3cb0fc82866c", "node_type": "1", "metadata": {"window": "In the second quarter, segment revenues increased by\n12% year-over-year with growth across multiple customer channels.\n We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "original_text": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33358b10733a92cccf09bfc8df370092fd0b3ed0f0c10c436c8f68a40be21fdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb16c6d7-d49b-4985-98c4-7d085c864e56", "node_type": "1", "metadata": {"window": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "original_text": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. "}, "hash": "8dd59ba93e69fea0b2f1d217a9db5b084d7bac3cbcf5f00696dc9d6020b9519c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "start_char_idx": 1594, "end_char_idx": 1763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb16c6d7-d49b-4985-98c4-7d085c864e56": {"__data__": {"id_": "fb16c6d7-d49b-4985-98c4-7d085c864e56", "embedding": null, "metadata": {"window": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "original_text": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "476a9c91-e73d-448e-825e-83a65cbf1c2c", "node_type": "1", "metadata": {"window": "We continue to expand our reach and deliver unique value propositions to all customers.  In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027. ", "original_text": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f79e1ae7688af6eeb5db6288ec5572abbf3764212327f1758beb4d1bb3cf821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22fbcaa4-a606-4906-b740-a91a29d073f8", "node_type": "1", "metadata": {"window": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "original_text": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. "}, "hash": "7a5e02d9c655c4e30f976c2c39b3dc35a7a324571ea5ad0325dd7c092cf8a014", "class_name": "RelatedNodeInfo"}}, "text": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "start_char_idx": 1763, "end_char_idx": 1861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22fbcaa4-a606-4906-b740-a91a29d073f8": {"__data__": {"id_": "22fbcaa4-a606-4906-b740-a91a29d073f8", "embedding": null, "metadata": {"window": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "original_text": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb16c6d7-d49b-4985-98c4-7d085c864e56", "node_type": "1", "metadata": {"window": "In July, we hosted our annual ideaShare\nconference that brought together more than 2,100 independent pharmacies.  It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "original_text": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4bc521796de5948e0c454527670806af9f0652c986fe206812d7334cb012c7ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "840c2560-d4a0-4675-ae6b-60171f4d3e9e", "node_type": "1", "metadata": {"window": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "original_text": "This agreement goes through June 2027. "}, "hash": "36e78b87afc22734bb0e363cfea1f0750935dfb09afc1f5ba01a8aa0c42413ed", "class_name": "RelatedNodeInfo"}}, "text": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "start_char_idx": 1861, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "840c2560-d4a0-4675-ae6b-60171f4d3e9e": {"__data__": {"id_": "840c2560-d4a0-4675-ae6b-60171f4d3e9e", "embedding": null, "metadata": {"window": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "original_text": "This agreement goes through June 2027. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22fbcaa4-a606-4906-b740-a91a29d073f8", "node_type": "1", "metadata": {"window": "It was a great forum that encouraged knowledge sharing,\ncollaboration and really deeper connections across our Health Mart pharmacies.\n McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "original_text": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48853375366a5a8805fc188117a9587e87997a114cf876e3e8e49d8901c2ddcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e09316-ee27-4959-a596-77fb111a5f52", "node_type": "1", "metadata": {"window": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "original_text": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n"}, "hash": "c18591b6a44ca184f5f7c1c4a1f46fed400cfeeebc09b4b70dcc4518de315235", "class_name": "RelatedNodeInfo"}}, "text": "This agreement goes through June 2027. ", "start_char_idx": 2067, "end_char_idx": 2106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e09316-ee27-4959-a596-77fb111a5f52": {"__data__": {"id_": "a4e09316-ee27-4959-a596-77fb111a5f52", "embedding": null, "metadata": {"window": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "original_text": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "840c2560-d4a0-4675-ae6b-60171f4d3e9e", "node_type": "1", "metadata": {"window": "McKesson has a long history of supporting and investing in independent pharmacies who have and continue to play such an important\nrole in the health of our communities.  We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "original_text": "This agreement goes through June 2027. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "471e305cf772afbeba7afb45d1fe7390e5a6b547168c49d1cbd32b0f3dd4207c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38889468-8b67-497d-ac53-d74572bf3126", "node_type": "1", "metadata": {"window": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "original_text": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. "}, "hash": "2a1a4371583a08decf3b145bb8a801b5d8aa074378ad01d1dae82b52637af35c", "class_name": "RelatedNodeInfo"}}, "text": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "start_char_idx": 2106, "end_char_idx": 2233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38889468-8b67-497d-ac53-d74572bf3126": {"__data__": {"id_": "38889468-8b67-497d-ac53-d74572bf3126", "embedding": null, "metadata": {"window": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "original_text": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e09316-ee27-4959-a596-77fb111a5f52", "node_type": "1", "metadata": {"window": "We're also proud of the work our retail pharmacy chain partners play in improving access to\ncare.  In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "original_text": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8583777dcb01b882ca4c06d47d7afc77a78d7e927781fb278c444acc7bf0f158", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65792761-58a3-43ec-a4f2-0d6ae123d603", "node_type": "1", "metadata": {"window": "This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "original_text": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. "}, "hash": "22f1bc395cdf33341b6c767f5a9d030ae093a6c54cc7e826438c5a9d1460578e", "class_name": "RelatedNodeInfo"}}, "text": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "start_char_idx": 2233, "end_char_idx": 2360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65792761-58a3-43ec-a4f2-0d6ae123d603": {"__data__": {"id_": "65792761-58a3-43ec-a4f2-0d6ae123d603", "embedding": null, "metadata": {"window": "This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "original_text": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38889468-8b67-497d-ac53-d74572bf3126", "node_type": "1", "metadata": {"window": "In September, we announced an agreement in principle to extend our relationship with CVS Health to distribute pharmaceuticals\nto mail-order specialty pharmacies, retail pharmacies and distribution centers.  This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "original_text": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a14a2437202e6cd5ddcac53ef58e11ce7ece125454394693ea7d7352f35a3a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13d50da7-5293-4773-8213-973698c2bebb", "node_type": "1", "metadata": {"window": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "original_text": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n"}, "hash": "ed777ec1cad01a0bb85c101d045149a1b7155acf2386e74b3c5812692dd6d9b1", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "start_char_idx": 2360, "end_char_idx": 2478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13d50da7-5293-4773-8213-973698c2bebb": {"__data__": {"id_": "13d50da7-5293-4773-8213-973698c2bebb", "embedding": null, "metadata": {"window": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "original_text": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65792761-58a3-43ec-a4f2-0d6ae123d603", "node_type": "1", "metadata": {"window": "This agreement goes through June 2027.  We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "original_text": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0147bb1a36e36f928e913ca458c975abbbf867bdf5dad4ef2c0dbb5d6134d4a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c799a55-ec88-41b9-9416-4552c31f15cf", "node_type": "1", "metadata": {"window": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "original_text": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. "}, "hash": "906ce0604a011fff94dadb367ff011a5b8e2fabb97e25fc0c239150f70812fec", "class_name": "RelatedNodeInfo"}}, "text": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "start_char_idx": 2478, "end_char_idx": 2577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c799a55-ec88-41b9-9416-4552c31f15cf": {"__data__": {"id_": "0c799a55-ec88-41b9-9416-4552c31f15cf", "embedding": null, "metadata": {"window": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "original_text": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13d50da7-5293-4773-8213-973698c2bebb", "node_type": "1", "metadata": {"window": "We have been\npartners with CVS for more than 20 years, and we're extremely pleased to further this long-standing relationship.\n In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "original_text": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29167cf132be8c6bcd3465a2085bc73b8967825db20ee7259d71675a9cf4ee15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60c7a3b0-94f2-4da3-af78-1e691793b804", "node_type": "1", "metadata": {"window": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "original_text": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. "}, "hash": "86aa90b0cc7378946b3c857ad447a9a02b80079caf7e1a8e91433001f96e0837", "class_name": "RelatedNodeInfo"}}, "text": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "start_char_idx": 2577, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60c7a3b0-94f2-4da3-af78-1e691793b804": {"__data__": {"id_": "60c7a3b0-94f2-4da3-af78-1e691793b804", "embedding": null, "metadata": {"window": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "original_text": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c799a55-ec88-41b9-9416-4552c31f15cf", "node_type": "1", "metadata": {"window": "In addition to pharmaceutical distribution, we also have sustainable core distribution assets in the Medical-Surgical segment.  In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "original_text": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4055334924a7693df83e936772e1248bb3b4ae94d983c8739b2c70ebbd6ff8b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025a11da-0296-4a71-9760-ec35ff9c2be3", "node_type": "1", "metadata": {"window": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter. ", "original_text": "We continue to build out one of the largest, most tenured sales forces in the\nindustry. "}, "hash": "98f1d149ae62ab506373b50f2f3289ea0172c52ba40c8b3895f04974f67d9e33", "class_name": "RelatedNodeInfo"}}, "text": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "start_char_idx": 2749, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025a11da-0296-4a71-9760-ec35ff9c2be3": {"__data__": {"id_": "025a11da-0296-4a71-9760-ec35ff9c2be3", "embedding": null, "metadata": {"window": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter. ", "original_text": "We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60c7a3b0-94f2-4da3-af78-1e691793b804", "node_type": "1", "metadata": {"window": "In\nthe second quarter, segment adjusted operating profit grew 7% when excluding the impact of COVID-19-related items.  The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "original_text": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26723a0cbe56fbbb648a33b8b5667fb002088e19878bc971e8c7f0ecc3d8945e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8af9fda-e368-4363-855e-3fbadc42333c", "node_type": "1", "metadata": {"window": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "original_text": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n"}, "hash": "035e0c30c73d2d7c57402252e19938e24525acbc36fe868ea4bd9811a9cce662", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "start_char_idx": 2895, "end_char_idx": 2983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8af9fda-e368-4363-855e-3fbadc42333c": {"__data__": {"id_": "c8af9fda-e368-4363-855e-3fbadc42333c", "embedding": null, "metadata": {"window": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "original_text": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025a11da-0296-4a71-9760-ec35ff9c2be3", "node_type": "1", "metadata": {"window": "The solid\nperformance is primarily driven by our scale and reach across the alternate site market.\n Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter. ", "original_text": "We continue to build out one of the largest, most tenured sales forces in the\nindustry. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d23cbb79748fc4be3b7463d759a632674aa4bafc82cf157e1c614ee21624cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e7bdfd3-60fd-417f-8826-25cf0a186152", "node_type": "1", "metadata": {"window": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "original_text": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. "}, "hash": "19cca8f91afdf0831ac63895c75b11013352efa67ac35fdafb9f29dee59ae012", "class_name": "RelatedNodeInfo"}}, "text": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "start_char_idx": 2983, "end_char_idx": 3102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e7bdfd3-60fd-417f-8826-25cf0a186152": {"__data__": {"id_": "7e7bdfd3-60fd-417f-8826-25cf0a186152", "embedding": null, "metadata": {"window": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "original_text": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8af9fda-e368-4363-855e-3fbadc42333c", "node_type": "1", "metadata": {"window": "Through years of intentional investment and expansion, the Medical-Surgical segment has established market-leading positions in the\nprimary care and extended care markets.  Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "original_text": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce6d2cef0c579ee51db3091bf15d27705dd0107eb5f33e16770287e252974d06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca", "node_type": "1", "metadata": {"window": "We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "original_text": "The Canadian business performed well in the second quarter. "}, "hash": "add3a34138d9cc93ac98e5eedf47e45f0c2fe8ccc2de6b4a7fa550dcfdb4b313", "class_name": "RelatedNodeInfo"}}, "text": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "start_char_idx": 3102, "end_char_idx": 3245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca": {"__data__": {"id_": "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca", "embedding": null, "metadata": {"window": "We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "original_text": "The Canadian business performed well in the second quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e7bdfd3-60fd-417f-8826-25cf0a186152", "node_type": "1", "metadata": {"window": "Following the needs of the patients, we're also expanding our services to other channels such\nas government, consumer and direct-to-home markets.  We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "original_text": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73d620e7dcead3ea47f3e64a631c8d87e0f61d1d42aa73f23b0d37d969d8ab7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09ebb750-fca1-4572-b7e1-148b1f5c20b5", "node_type": "1", "metadata": {"window": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe. ", "original_text": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n"}, "hash": "fef3c0bab89b46c734f23f39f47a36a1416950d00b993678a622624f8d4c2dea", "class_name": "RelatedNodeInfo"}}, "text": "The Canadian business performed well in the second quarter. ", "start_char_idx": 3245, "end_char_idx": 3305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09ebb750-fca1-4572-b7e1-148b1f5c20b5": {"__data__": {"id_": "09ebb750-fca1-4572-b7e1-148b1f5c20b5", "embedding": null, "metadata": {"window": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe. ", "original_text": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca", "node_type": "1", "metadata": {"window": "We continue to build out one of the largest, most tenured sales forces in the\nindustry.  These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "original_text": "The Canadian business performed well in the second quarter. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c08be25f6cc6f900d2b4e718521a14b7edbd7790db6c7f5df894798a01a140f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b949729-f200-4928-9856-e639869057fe", "node_type": "1", "metadata": {"window": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "original_text": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. "}, "hash": "db2d37eb0788fd1415085e119e41cbb433ff5fc608aa9162047effedd9cd037e", "class_name": "RelatedNodeInfo"}}, "text": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "start_char_idx": 3305, "end_char_idx": 3460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b949729-f200-4928-9856-e639869057fe": {"__data__": {"id_": "2b949729-f200-4928-9856-e639869057fe", "embedding": null, "metadata": {"window": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "original_text": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09ebb750-fca1-4572-b7e1-148b1f5c20b5", "node_type": "1", "metadata": {"window": "These seasoned sales professionals help foster trust and strategic relationships and bring us closer to our customers.\n Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe. ", "original_text": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3369e2426f420032da52d7860382effe5e7436cff97d6ece71b85ee825ff64a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69db5cb8-b821-46bd-a4d1-99158dc60cab", "node_type": "1", "metadata": {"window": "The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson. ", "original_text": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. "}, "hash": "38eb0d8f4838320abb3148c9654ecf2517fac098ab37703911cd428d9d1449d7", "class_name": "RelatedNodeInfo"}}, "text": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "start_char_idx": 3460, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69db5cb8-b821-46bd-a4d1-99158dc60cab": {"__data__": {"id_": "69db5cb8-b821-46bd-a4d1-99158dc60cab", "embedding": null, "metadata": {"window": "The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson. ", "original_text": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b949729-f200-4928-9856-e639869057fe", "node_type": "1", "metadata": {"window": "Also, I want to remind you that while we continue to execute on the European exit, our strategy for our Canadian operations remains\nunchanged.  The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "original_text": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db5e049f562c1df59644ea9e77eec84f37c97daf0fbc302e0b5d22a2acbfe138", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7", "node_type": "1", "metadata": {"window": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures. ", "original_text": "We have now successfully exited 11 of the 12 countries in Europe. "}, "hash": "5bd8dd6faf849c58c9a21c4fed41cebc164bb20b34e37b0477e4b0cff42e807a", "class_name": "RelatedNodeInfo"}}, "text": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "start_char_idx": 3603, "end_char_idx": 3761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7": {"__data__": {"id_": "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7", "embedding": null, "metadata": {"window": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures. ", "original_text": "We have now successfully exited 11 of the 12 countries in Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69db5cb8-b821-46bd-a4d1-99158dc60cab", "node_type": "1", "metadata": {"window": "The Canadian business performed well in the second quarter.  Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson. ", "original_text": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c55eb27824148f14be38ad9a89ee9d89e26e962c684a02b8d28ccf0ee382aaae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c21c0172-a052-4c23-bb9a-5113043cec14", "node_type": "1", "metadata": {"window": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "original_text": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n"}, "hash": "ac142f5b92dbd972967671132a2637b17ec93fd45868901b7971496561243295", "class_name": "RelatedNodeInfo"}}, "text": "We have now successfully exited 11 of the 12 countries in Europe. ", "start_char_idx": 3761, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c21c0172-a052-4c23-bb9a-5113043cec14": {"__data__": {"id_": "c21c0172-a052-4c23-bb9a-5113043cec14", "embedding": null, "metadata": {"window": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "original_text": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7", "node_type": "1", "metadata": {"window": "Aligning with the company's strategy, McKesson Canada is\nexpanding its offering to higher-growth, higher-margin areas, including digital health solutions.\n Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures. ", "original_text": "We have now successfully exited 11 of the 12 countries in Europe. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "868b69d168f6a5ec6afdc6e22940dd2993d7451ce664c975c60f876c9d67d53e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792829ab-6660-4661-9864-64b116948b39", "node_type": "1", "metadata": {"window": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "original_text": "Streamlining the portfolio is an ongoing process at McKesson. "}, "hash": "ce3a6135b0ca475a6fea0f19371e2b44dcb199c0fbe30c2c35fc40a870f6f6df", "class_name": "RelatedNodeInfo"}}, "text": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "start_char_idx": 3827, "end_char_idx": 3964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792829ab-6660-4661-9864-64b116948b39": {"__data__": {"id_": "792829ab-6660-4661-9864-64b116948b39", "embedding": null, "metadata": {"window": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "original_text": "Streamlining the portfolio is an ongoing process at McKesson. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c21c0172-a052-4c23-bb9a-5113043cec14", "node_type": "1", "metadata": {"window": "Our third company priority is to streamline the portfolio, which includes our continued progress in exiting our business operations\nin Europe.  Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "original_text": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f64e0448f277e4c33b0a3ff81a024abab90d9854edab973daeff225a50789d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f47c15-efe4-4946-94d6-d3c90f435e33", "node_type": "1", "metadata": {"window": "We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally. ", "original_text": "It doesn't end with the European divestitures. "}, "hash": "814d83cca3913bcb6b6808680928b4de76227674487dc676e1ee280b10ca90e2", "class_name": "RelatedNodeInfo"}}, "text": "Streamlining the portfolio is an ongoing process at McKesson. ", "start_char_idx": 3964, "end_char_idx": 4026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f47c15-efe4-4946-94d6-d3c90f435e33": {"__data__": {"id_": "76f47c15-efe4-4946-94d6-d3c90f435e33", "embedding": null, "metadata": {"window": "We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally. ", "original_text": "It doesn't end with the European divestitures. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792829ab-6660-4661-9864-64b116948b39", "node_type": "1", "metadata": {"window": "Today, we announced the completion of the sale to the PHOENIX Group, which includes the operations in France, Italy,\nIreland, Portugal, Belgium and Slovenia.  We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "original_text": "Streamlining the portfolio is an ongoing process at McKesson. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58303af46020d8a23b994b8f57a5f75b57bd4707d15cd6e6ffc54949bde9754a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45f177de-4c60-4694-a133-1c5953319be8", "node_type": "1", "metadata": {"window": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "original_text": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. "}, "hash": "8c980b5b08752e96968b458a3f611caec05db0f1301f3be64435ca7c298cacee", "class_name": "RelatedNodeInfo"}}, "text": "It doesn't end with the European divestitures. ", "start_char_idx": 4026, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45f177de-4c60-4694-a133-1c5953319be8": {"__data__": {"id_": "45f177de-4c60-4694-a133-1c5953319be8", "embedding": null, "metadata": {"window": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "original_text": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f47c15-efe4-4946-94d6-d3c90f435e33", "node_type": "1", "metadata": {"window": "We have now successfully exited 11 of the 12 countries in Europe.  Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally. ", "original_text": "It doesn't end with the European divestitures. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4679993ce2e6d6aba687f392b5028f0084bcad8cfb50a0838a1bcd6c57446719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f2b676c-4972-4d77-83d5-adcafb6f6b74", "node_type": "1", "metadata": {"window": "Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "original_text": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n"}, "hash": "bb5dc9b68008c66931be392257874f24b738875bef5788f3d061db9ab4d67977", "class_name": "RelatedNodeInfo"}}, "text": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "start_char_idx": 4073, "end_char_idx": 4173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f2b676c-4972-4d77-83d5-adcafb6f6b74": {"__data__": {"id_": "8f2b676c-4972-4d77-83d5-adcafb6f6b74", "embedding": null, "metadata": {"window": "Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "original_text": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45f177de-4c60-4694-a133-1c5953319be8", "node_type": "1", "metadata": {"window": "Norway remains the only\ncountry that's not been divested, but we remain committed to exploring strategic alternatives for this business.\n Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "original_text": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84527469d29810fcf5d8e3af7e8dcea2ea4db4c2710a228705f65e6d2e99c900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d15d888d-990b-4078-a682-fb865e62fdf1", "node_type": "1", "metadata": {"window": "It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "original_text": "We're also focused on streamlining our businesses internally. "}, "hash": "95497dfa161a4da1808294243fef73681a1c6abd30668cd303b7500986319e4a", "class_name": "RelatedNodeInfo"}}, "text": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "start_char_idx": 4173, "end_char_idx": 4344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d15d888d-990b-4078-a682-fb865e62fdf1": {"__data__": {"id_": "d15d888d-990b-4078-a682-fb865e62fdf1", "embedding": null, "metadata": {"window": "It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "original_text": "We're also focused on streamlining our businesses internally. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f2b676c-4972-4d77-83d5-adcafb6f6b74", "node_type": "1", "metadata": {"window": "Streamlining the portfolio is an ongoing process at McKesson.  It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "original_text": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ceeabb2cb1f1b25b5f6f5ea49803ed604b55c90f227c3c0b2dad47770b46329", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0ebdd65-4f57-462d-adc9-6f76275777e6", "node_type": "1", "metadata": {"window": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "original_text": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. "}, "hash": "327f4005f69477450586a4688d119ab957f08a585a79e5d88b2c3f92b08a7405", "class_name": "RelatedNodeInfo"}}, "text": "We're also focused on streamlining our businesses internally. ", "start_char_idx": 4344, "end_char_idx": 4406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0ebdd65-4f57-462d-adc9-6f76275777e6": {"__data__": {"id_": "c0ebdd65-4f57-462d-adc9-6f76275777e6", "embedding": null, "metadata": {"window": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "original_text": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d15d888d-990b-4078-a682-fb865e62fdf1", "node_type": "1", "metadata": {"window": "It doesn't end with the European divestitures.  It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "original_text": "We're also focused on streamlining our businesses internally. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a3d47ac75f6faa031b933f5db46ffda2691ac7a2ace91c7511a42d93aa4c8f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381", "node_type": "1", "metadata": {"window": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "original_text": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n"}, "hash": "3e4ef89586bfc4dd16eb3e40e1d523a8468970dbba9916ca113808bd2f00b4df", "class_name": "RelatedNodeInfo"}}, "text": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "start_char_idx": 4406, "end_char_idx": 4519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381": {"__data__": {"id_": "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381", "embedding": null, "metadata": {"window": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "original_text": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0ebdd65-4f57-462d-adc9-6f76275777e6", "node_type": "1", "metadata": {"window": "It's really an ongoing\npractice for us to continually assess our portfolio for strategic alignment.  We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "original_text": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "155181c1cce271aae3f4e6f5888bdbb9a725d5a71f13f2d67096bc0722eb3d0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18e88f85-76de-4b4f-af4c-df7ea4625d45", "node_type": "1", "metadata": {"window": "We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "original_text": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. "}, "hash": "50afacc39db1014125e211e850d57569980407738444ac6de77e4199422a72b2", "class_name": "RelatedNodeInfo"}}, "text": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "start_char_idx": 4519, "end_char_idx": 4721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18e88f85-76de-4b4f-af4c-df7ea4625d45": {"__data__": {"id_": "18e88f85-76de-4b4f-af4c-df7ea4625d45", "embedding": null, "metadata": {"window": "We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "original_text": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381", "node_type": "1", "metadata": {"window": "We have a rigorous evaluation process to ensure that the\nallocation of resources is optimized to generate shareholder return and support long-term growth for the company.\n We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "original_text": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1781195c95357d5fb37b1ecdad5e239c603d630e1e4214eb871d24a48c8db953", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0b203d4-f4b4-4869-9b18-92a98c63bd4b", "node_type": "1", "metadata": {"window": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "original_text": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n"}, "hash": "c217bdc9f924077f824a5d681170e3928356898c79677beda9539bc758494121", "class_name": "RelatedNodeInfo"}}, "text": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "start_char_idx": 4721, "end_char_idx": 4904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0b203d4-f4b4-4869-9b18-92a98c63bd4b": {"__data__": {"id_": "b0b203d4-f4b4-4869-9b18-92a98c63bd4b", "embedding": null, "metadata": {"window": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "original_text": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18e88f85-76de-4b4f-af4c-df7ea4625d45", "node_type": "1", "metadata": {"window": "We're also focused on streamlining our businesses internally.  We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "original_text": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71f16ed103f0d8f86e8280f4f532fbb685a5f0fbcf38c1cf3f2eea93a9c6aeaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3795dcb-651c-44c9-8cd9-66c56cec1aaa", "node_type": "1", "metadata": {"window": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "original_text": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. "}, "hash": "586d6765932c357d1d423a739f5c94529e2d2bac6b13d82ec83cfc6d3d270b2b", "class_name": "RelatedNodeInfo"}}, "text": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "start_char_idx": 4904, "end_char_idx": 5130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3795dcb-651c-44c9-8cd9-66c56cec1aaa": {"__data__": {"id_": "a3795dcb-651c-44c9-8cd9-66c56cec1aaa", "embedding": null, "metadata": {"window": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "original_text": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0b203d4-f4b4-4869-9b18-92a98c63bd4b", "node_type": "1", "metadata": {"window": "We have and will continue to modernize technology, improve levels of\nautomation and simplify business processes.  Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "original_text": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d53767584b67e40e0c99126bf91e63ceaa8df50b9a0855e5b6404aef644629", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d068037-3a23-4c9b-a932-5e8c23a88773", "node_type": "1", "metadata": {"window": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. "}, "hash": "fb1a656617bf3f12487c5cdc12fc8743fddf6c45f0079569b959cea0e1ff8ae5", "class_name": "RelatedNodeInfo"}}, "text": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "start_char_idx": 5130, "end_char_idx": 5248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d068037-3a23-4c9b-a932-5e8c23a88773": {"__data__": {"id_": "7d068037-3a23-4c9b-a932-5e8c23a88773", "embedding": null, "metadata": {"window": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3795dcb-651c-44c9-8cd9-66c56cec1aaa", "node_type": "1", "metadata": {"window": "Taking these actions allows our team to execute with more speed and focus and to make\nour operational processes less labor-intensive and more efficient to better serve our customers and their patients.\n Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "original_text": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8296a8205cf2f3c141d515dd41a98fd84fc0d49be493deda48ba6ef8c2babd58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cd86607-fc75-4a1b-a7fc-cb7d0572665f", "node_type": "1", "metadata": {"window": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. "}, "hash": "68dbbf9a7f3b5059075cb5d92a4c08bb3d3d9379ced8f0b15374fc4fceab8621", "class_name": "RelatedNodeInfo"}}, "text": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "start_char_idx": 5248, "end_char_idx": 5405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cd86607-fc75-4a1b-a7fc-cb7d0572665f": {"__data__": {"id_": "7cd86607-fc75-4a1b-a7fc-cb7d0572665f", "embedding": null, "metadata": {"window": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d068037-3a23-4c9b-a932-5e8c23a88773", "node_type": "1", "metadata": {"window": "Building on the foundation of pharmaceutical and medical distribution, let me now expand on our 2 growth -- strategic growth areas:\nthe biopharma services and the oncology ecosystem.  In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a0de158db77d40c7cccced138b58c8d9d8cfd8f47d7e2b34ac218bc3c48c2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69ace939-7e53-4857-b4f8-0d06f37a3e4c", "node_type": "1", "metadata": {"window": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We also have\ncapabilities for in-office provider education through groups of experienced field nurses. "}, "hash": "cd4fe135944f183e9112757dbf7032be32d31a29fc061d663feec75b69e117ba", "class_name": "RelatedNodeInfo"}}, "text": "We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "start_char_idx": 5405, "end_char_idx": 5509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69ace939-7e53-4857-b4f8-0d06f37a3e4c": {"__data__": {"id_": "69ace939-7e53-4857-b4f8-0d06f37a3e4c", "embedding": null, "metadata": {"window": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cd86607-fc75-4a1b-a7fc-cb7d0572665f", "node_type": "1", "metadata": {"window": "In the biopharma ecosystem, we have a portfolio of differentiated assets that\nfocus on connecting key stakeholders throughout the patient's journey and reducing prescription hurdles around access, affordability\nand adherence.\n On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c5dcb8b18455107441e3675f19315dd6acc13c3bf643c5b142e0fd45042e166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72183ed8-14bf-499f-9b92-df70d79413a0", "node_type": "1", "metadata": {"window": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "Our adherence services help patients navigate"}, "hash": "9da1ec4371e8e9993a4bba08e43f4209a91e876a093464bd71a5ba8142e2dd90", "class_name": "RelatedNodeInfo"}}, "text": "We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "start_char_idx": 5509, "end_char_idx": 5612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72183ed8-14bf-499f-9b92-df70d79413a0": {"__data__": {"id_": "72183ed8-14bf-499f-9b92-df70d79413a0", "embedding": null, "metadata": {"window": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "Our adherence services help patients navigate", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66707fdcae716c065ec934a0f012296d6161180f611ab14893210c6d8bc0a142", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69ace939-7e53-4857-b4f8-0d06f37a3e4c", "node_type": "1", "metadata": {"window": "On our last earnings call, we shared with you examples of the affordability solutions within our biopharma ecosystem.  While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "We also have\ncapabilities for in-office provider education through groups of experienced field nurses. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "206f2fba51e224f73afb7bc47204f697b15e93a73a9be54f392feefbdba18b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e488cf2-4980-4ee1-9403-92b0f5b7abc6", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "4e867c680fc74ffc583343c0eb83488dc75a5a69bea6fa35bd5149675b1d6e4d", "class_name": "RelatedNodeInfo"}}, "text": "Our adherence services help patients navigate", "start_char_idx": 5612, "end_char_idx": 5657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e488cf2-4980-4ee1-9403-92b0f5b7abc6": {"__data__": {"id_": "1e488cf2-4980-4ee1-9403-92b0f5b7abc6", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72183ed8-14bf-499f-9b92-df70d79413a0", "node_type": "1", "metadata": {"window": "While these\nsolutions can help make prescriptions more affordable for patients, McKesson also has a significant offering of adherence-specific\ncapabilities.  We have a powerful network of over 4,000 field-based nurses who help patients manage therapies at home.  We also have\ncapabilities for in-office provider education through groups of experienced field nurses.  Our adherence services help patients navigate", "original_text": "Our adherence services help patients navigate", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3e21d777390b284a221744f7a04d6129487e1c12806389a41b52b97920df1d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620bf846-42bb-4c35-a77e-17d69486dd87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "original_text": "All Rights reserved.\n"}, "hash": "29089e94b083eec8cb2c444d55a49fc9a2cba958ce0557fddaea674030a34c2c", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620bf846-42bb-4c35-a77e-17d69486dd87": {"__data__": {"id_": "620bf846-42bb-4c35-a77e-17d69486dd87", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "original_text": "All Rights reserved.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e488cf2-4980-4ee1-9403-92b0f5b7abc6", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3b4e6c1241e869718f9b55627ab07d6cc0cbd3b156c5ab8079549ddb220908e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6177d96a-5932-4c13-98a6-a4d52c7ae5c2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "original_text": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%. "}, "hash": "8973b852365fd6a5fe5d0ed234905d7946a4e48e2b5057ed123a7e7536cd2173", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6177d96a-5932-4c13-98a6-a4d52c7ae5c2": {"__data__": {"id_": "6177d96a-5932-4c13-98a6-a4d52c7ae5c2", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "original_text": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620bf846-42bb-4c35-a77e-17d69486dd87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "original_text": "All Rights reserved.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6152187193ffc24f86cd38d747e6d2dc92f7d8f5f3e8972f5b92baad6b050325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7a07aaa-7443-45db-8781-e06fb7ccde96", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "original_text": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n"}, "hash": "808858295940b616c5764bd61a239aeebe198015f2713982cfd338ecc04870e6", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%. ", "start_char_idx": 158, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7a07aaa-7443-45db-8781-e06fb7ccde96": {"__data__": {"id_": "d7a07aaa-7443-45db-8781-e06fb7ccde96", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "original_text": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6177d96a-5932-4c13-98a6-a4d52c7ae5c2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "original_text": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fcb26c1e5fd9944ca58d00c726cc5de60e43b9dfe5dd5bfb1048bb77405a926", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61fd6d27-9fe1-4eb4-b435-7cdface11cbc", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "original_text": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. "}, "hash": "aa9629d6b9802ac8da739832daa0784269f7b528948aa0f3e15a8cfcbd0a7cca", "class_name": "RelatedNodeInfo"}}, "text": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "start_char_idx": 255, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61fd6d27-9fe1-4eb4-b435-7cdface11cbc": {"__data__": {"id_": "61fd6d27-9fe1-4eb4-b435-7cdface11cbc", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "original_text": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7a07aaa-7443-45db-8781-e06fb7ccde96", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "original_text": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1000aad9dbf9320c7f51a7a9f339b68ddc6a8fd219b482bc8dd9a576857d5d69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "147ba826-9a62-422b-ae5a-92af14352241", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "original_text": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. "}, "hash": "2fce9fd2d29f0619f1116e74b8fa14f8e7ef0edf852d4466a7180edcea86e3ad", "class_name": "RelatedNodeInfo"}}, "text": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "start_char_idx": 398, "end_char_idx": 539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "147ba826-9a62-422b-ae5a-92af14352241": {"__data__": {"id_": "147ba826-9a62-422b-ae5a-92af14352241", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "original_text": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61fd6d27-9fe1-4eb4-b435-7cdface11cbc", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "original_text": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4775895ab0d4349de01f96cda0019b9100b8d7904f1b9e0e123628acff1a220e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bdbe49e-5125-4116-b981-2e88cc6eb5e6", "node_type": "1", "metadata": {"window": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "original_text": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. "}, "hash": "7f34cb23a118ca703096c021f4ef51daca6402c09b70b29e915dd63920c31d99", "class_name": "RelatedNodeInfo"}}, "text": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "start_char_idx": 539, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bdbe49e-5125-4116-b981-2e88cc6eb5e6": {"__data__": {"id_": "8bdbe49e-5125-4116-b981-2e88cc6eb5e6", "embedding": null, "metadata": {"window": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "original_text": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "147ba826-9a62-422b-ae5a-92af14352241", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "original_text": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d096aa3394e260b2840ab6e0e56d9ae01b616e52860999e2f63ed8156776dbb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2153f38-13d6-4a99-a4f1-4574e68fe5f6", "node_type": "1", "metadata": {"window": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "original_text": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n"}, "hash": "1f2ec07ae7d2a7fa78255390eb413e29ecc0aba68a35ad803ef869fadee33e6c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "start_char_idx": 680, "end_char_idx": 765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2153f38-13d6-4a99-a4f1-4574e68fe5f6": {"__data__": {"id_": "f2153f38-13d6-4a99-a4f1-4574e68fe5f6", "embedding": null, "metadata": {"window": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "original_text": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bdbe49e-5125-4116-b981-2e88cc6eb5e6", "node_type": "1", "metadata": {"window": "Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "original_text": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "101d52a3edd5f1388aa4ecdb99e64e14984f5832d21654e1deba3cec5ab03b82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56195842-7ff5-4fb9-99fc-905a888c9ea7", "node_type": "1", "metadata": {"window": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "original_text": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. "}, "hash": "da3539c586c9b1bf94e6cbea9558d4528d3f3cf193f93cf22dc4d984829dff7b", "class_name": "RelatedNodeInfo"}}, "text": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "start_char_idx": 765, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56195842-7ff5-4fb9-99fc-905a888c9ea7": {"__data__": {"id_": "56195842-7ff5-4fb9-99fc-905a888c9ea7", "embedding": null, "metadata": {"window": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "original_text": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2153f38-13d6-4a99-a4f1-4574e68fe5f6", "node_type": "1", "metadata": {"window": "To accelerate our growth in biopharma services, we've been assessing strategic opportunities through both internal and external\ninvestments.  Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "original_text": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0b11487e9b13e0c44b98487023d51ad9742cedb3744309dbfff86824ca5229a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce", "node_type": "1", "metadata": {"window": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "original_text": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n"}, "hash": "29e45fa612606ae876125549bf03723cd8e0b90ea9fb45113b895f9f08a7e164", "class_name": "RelatedNodeInfo"}}, "text": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "start_char_idx": 945, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce": {"__data__": {"id_": "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce", "embedding": null, "metadata": {"window": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "original_text": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56195842-7ff5-4fb9-99fc-905a888c9ea7", "node_type": "1", "metadata": {"window": "Today, we completed the acquisition of Rx Savings Solutions, which is a benefit insights company that reaches more\nthan 17 million patients.  McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "original_text": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05d3000bbef6eb8c179f6009729e4582af814e287f6dc5232e8ad7c7da60175e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24cd5dd4-8f44-47be-b764-c4417f2e32e5", "node_type": "1", "metadata": {"window": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "original_text": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. "}, "hash": "764614afccf3c105332a14a7d3a4aaebf934d7d7322322ae49fb0921c9156ac6", "class_name": "RelatedNodeInfo"}}, "text": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "start_char_idx": 1069, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24cd5dd4-8f44-47be-b764-c4417f2e32e5": {"__data__": {"id_": "24cd5dd4-8f44-47be-b764-c4417f2e32e5", "embedding": null, "metadata": {"window": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "original_text": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce", "node_type": "1", "metadata": {"window": "McKesson, in fact, has been a customer of Rx Savings Solutions for more than a year.  And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "original_text": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da737fb82f1605e7eb43121cafe3a983a42d9ad356f61a208116b3d540d6cc92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6be7aff6-b152-4376-9539-68ef228d7c85", "node_type": "1", "metadata": {"window": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem. ", "original_text": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. "}, "hash": "ef4530bcf49af175c52e52f55114e74ef90f82a3dc7c66385d8ae583d12f7968", "class_name": "RelatedNodeInfo"}}, "text": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "start_char_idx": 1257, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6be7aff6-b152-4376-9539-68ef228d7c85": {"__data__": {"id_": "6be7aff6-b152-4376-9539-68ef228d7c85", "embedding": null, "metadata": {"window": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem. ", "original_text": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24cd5dd4-8f44-47be-b764-c4417f2e32e5", "node_type": "1", "metadata": {"window": "And as a result, we've\nseen significant improvements in medication affordability and adherence for our members or employees as well as significant savings\nat the enterprise level.\n Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "original_text": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a15808df41a0ac67d46ea792bdf2a194c06a662f528dea62101a287ec4d503f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f494ae6-ebc7-48a7-8159-b21e79212864", "node_type": "1", "metadata": {"window": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "original_text": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n"}, "hash": "acb83c1bba8e0576936b51c25e58471b8424d81ea5cde3aed8da4efc83b69dcf", "class_name": "RelatedNodeInfo"}}, "text": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "start_char_idx": 1421, "end_char_idx": 1525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f494ae6-ebc7-48a7-8159-b21e79212864": {"__data__": {"id_": "2f494ae6-ebc7-48a7-8159-b21e79212864", "embedding": null, "metadata": {"window": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "original_text": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6be7aff6-b152-4376-9539-68ef228d7c85", "node_type": "1", "metadata": {"window": "Rx Savings Solutions brings a unique portfolio of product and channel access that are complementary to our existing assets.  We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem. ", "original_text": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a1d28588331fef9ef5f1fee682b13b529a31282a66d807598ffc5955aa81254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b", "node_type": "1", "metadata": {"window": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "original_text": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n"}, "hash": "7e205411820647971506d5063e4bdf4d5f7b527b7f549b2f97d96db18431a05f", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "start_char_idx": 1525, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b": {"__data__": {"id_": "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b", "embedding": null, "metadata": {"window": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "original_text": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f494ae6-ebc7-48a7-8159-b21e79212864", "node_type": "1", "metadata": {"window": "We're\nexcited to leverage our combined resources to create new capabilities around access, affordability and adherence as well as new\noutcome management programs for biopharma and payers.\n Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "original_text": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf1440ef443451ace74c284becc8305d8c33fac1f5d9b6c049264f0cbb1ae389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab69f861-f910-479e-8014-88b12cea650c", "node_type": "1", "metadata": {"window": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "original_text": "We're also making good progress within our oncology ecosystem. "}, "hash": "1f6bf9d4f0cba6c9417316f1a7140f2f68e2d7d7be5e15a94943913e7279f97a", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "start_char_idx": 1670, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab69f861-f910-479e-8014-88b12cea650c": {"__data__": {"id_": "ab69f861-f910-479e-8014-88b12cea650c", "embedding": null, "metadata": {"window": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "original_text": "We're also making good progress within our oncology ecosystem. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b", "node_type": "1", "metadata": {"window": "Prescription Technology Solutions segment has been delivering strong performance in the past year, and we continue to support the\ngrowth with investment in talent.  We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "original_text": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a338aefd56201e4b4b8ac2c565902437a2a193c912eeaf6530284e0c8af2925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54", "node_type": "1", "metadata": {"window": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "original_text": "On October 31, we completed the transaction that brings together\nMcKesson's U.S. "}, "hash": "f6bb9231e7324be629487417d80991e7a77033c11b20a989a15e7b9d080af5b6", "class_name": "RelatedNodeInfo"}}, "text": "We're also making good progress within our oncology ecosystem. ", "start_char_idx": 1927, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54": {"__data__": {"id_": "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54", "embedding": null, "metadata": {"window": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "original_text": "On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab69f861-f910-479e-8014-88b12cea650c", "node_type": "1", "metadata": {"window": "We usually ramp up staffing to prepare for the anticipated support needed for annual customer\nprograms.  In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "original_text": "We're also making good progress within our oncology ecosystem. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ceb9cc4920cbda7f5c71fdb78bc3882f936633759353d73e9c17096c3356410", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c72f446b-1931-4227-a955-cc307982f51d", "node_type": "1", "metadata": {"window": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "original_text": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. "}, "hash": "0c911a1c622905e4ba948d4b6230c1760a96b2f2b3626e0269e59607390c1d6a", "class_name": "RelatedNodeInfo"}}, "text": "On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "start_char_idx": 1990, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c72f446b-1931-4227-a955-cc307982f51d": {"__data__": {"id_": "c72f446b-1931-4227-a955-cc307982f51d", "embedding": null, "metadata": {"window": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "original_text": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54", "node_type": "1", "metadata": {"window": "In the second quarter, the timing and cadence of hiring has led to a slight year-over-year decline in adjusted operating profit\nin this segment.\n Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "original_text": "On October 31, we completed the transaction that brings together\nMcKesson's U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7644f8825346e52ab0329ae099ca85e6a7cfbb9f3ba7619bfe8f700f169da726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7922870a-c667-4194-9481-b30cb9873b2a", "node_type": "1", "metadata": {"window": "We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "original_text": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n"}, "hash": "485679974acb68a9d00f547e4d46c7d3f1239efa421f1427bb58c6ecf845c29a", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "start_char_idx": 2071, "end_char_idx": 2151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7922870a-c667-4194-9481-b30cb9873b2a": {"__data__": {"id_": "7922870a-c667-4194-9481-b30cb9873b2a", "embedding": null, "metadata": {"window": "We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "original_text": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c72f446b-1931-4227-a955-cc307982f51d", "node_type": "1", "metadata": {"window": "Looking ahead to the remainder of fiscal 2023 and beyond, biopharma services remains a large and growing opportunity, and we're\nconfident in our differentiated market position that will help us achieve the long-term growth target laid out for this segment.\n We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "original_text": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8ef1465afbde3ad0662fabcfc4b83ab82c6152150b79a7ed62897babb200567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dd6cff-0080-4d4b-a14b-f9e21e42870b", "node_type": "1", "metadata": {"window": "On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "original_text": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. "}, "hash": "d7a9651411ac0347cb4ef8b51ac21f6c9b993551facfc2b9f83a3f969eef1cae", "class_name": "RelatedNodeInfo"}}, "text": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "start_char_idx": 2151, "end_char_idx": 2381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dd6cff-0080-4d4b-a14b-f9e21e42870b": {"__data__": {"id_": "19dd6cff-0080-4d4b-a14b-f9e21e42870b", "embedding": null, "metadata": {"window": "On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "original_text": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7922870a-c667-4194-9481-b30cb9873b2a", "node_type": "1", "metadata": {"window": "We're also making good progress within our oncology ecosystem.  On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "original_text": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d944a9916e34860a87efe6ec1368be3a174c51c6350468010d34e772de4aecc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b414088a-12cb-4c9d-827a-d81617ca928f", "node_type": "1", "metadata": {"window": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "original_text": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n"}, "hash": "3c6017a262369f981f8fda9e5f1b761f25b9680a992033ebc396c926c94bbd7b", "class_name": "RelatedNodeInfo"}}, "text": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "start_char_idx": 2381, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b414088a-12cb-4c9d-827a-d81617ca928f": {"__data__": {"id_": "b414088a-12cb-4c9d-827a-d81617ca928f", "embedding": null, "metadata": {"window": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "original_text": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dd6cff-0080-4d4b-a14b-f9e21e42870b", "node_type": "1", "metadata": {"window": "On October 31, we completed the transaction that brings together\nMcKesson's U.S.  Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "original_text": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a29b9fef071558a19f525c77a69e5f2a3cda62510c097e21ec92e226cd6edb38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598", "node_type": "1", "metadata": {"window": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "original_text": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. "}, "hash": "fefac7300bc2d61bb625d3ad0b4875424e7792b682e497fd3857b07419086a21", "class_name": "RelatedNodeInfo"}}, "text": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "start_char_idx": 2508, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598": {"__data__": {"id_": "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598", "embedding": null, "metadata": {"window": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "original_text": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b414088a-12cb-4c9d-827a-d81617ca928f", "node_type": "1", "metadata": {"window": "Oncology Research and HCA's Sarah Cannon Research Institute in a joint venture.  The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "original_text": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ec2d0cd60c342094a24fd42a4de53d0a24cc5a9cbea34d56f0d7e3085fd0de5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9214301-7cb8-4248-bae0-1efd81f6c0c7", "node_type": "1", "metadata": {"window": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment. ", "original_text": "It was recently announced that Ontada formed a new strategic alliance with BeiGene. "}, "hash": "ef5688467c27311a58b29c106430a9de0a8da70f5fabeb12dc85fe50300c5055", "class_name": "RelatedNodeInfo"}}, "text": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "start_char_idx": 2640, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9214301-7cb8-4248-bae0-1efd81f6c0c7": {"__data__": {"id_": "f9214301-7cb8-4248-bae0-1efd81f6c0c7", "embedding": null, "metadata": {"window": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment. ", "original_text": "It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598", "node_type": "1", "metadata": {"window": "The team is energized to work\ntogether on integrating the 2 businesses, and we're excited by this opportunity to advance the next generation of cancer care by\nincreasing patient access to clinical trials in the community setting.\n As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "original_text": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c69191c70c04875acf2bb854fb684c5b3c6731caba85815454d076bb9a6d4fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2afda02-ebc1-4c31-8487-e6c42088ecc9", "node_type": "1", "metadata": {"window": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "original_text": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n"}, "hash": "4c81a8e9a05623a0a7def09500d505dd08d284e9bc27a2a5b6a884a3f70e34e7", "class_name": "RelatedNodeInfo"}}, "text": "It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "start_char_idx": 2790, "end_char_idx": 2874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2afda02-ebc1-4c31-8487-e6c42088ecc9": {"__data__": {"id_": "a2afda02-ebc1-4c31-8487-e6c42088ecc9", "embedding": null, "metadata": {"window": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "original_text": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9214301-7cb8-4248-bae0-1efd81f6c0c7", "node_type": "1", "metadata": {"window": "As part of the transaction, we also acquired Genospace, a leading innovator in precision medicine and clinical trial matching.  It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment. ", "original_text": "It was recently announced that Ontada formed a new strategic alliance with BeiGene. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "799c22e57acb086954c788ab9c9ebb3d991667be72b3ad0cc8e44859ea32682b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe", "node_type": "1", "metadata": {"window": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S. ", "original_text": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. "}, "hash": "d7e4b768fd322d1ed3c0ce5048bda040d119d74bcc693e2c942eadd3c12afe63", "class_name": "RelatedNodeInfo"}}, "text": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "start_char_idx": 2874, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe": {"__data__": {"id_": "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe", "embedding": null, "metadata": {"window": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S. ", "original_text": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2afda02-ebc1-4c31-8487-e6c42088ecc9", "node_type": "1", "metadata": {"window": "It will\npower oncology data and analytics capabilities for the joint venture and bring enhanced solutions to our provider partners.\n Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "original_text": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dab26e8d57af8d6c9264e67584091ab9aab7576ad74bac9313e06fb0a26c8fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984", "node_type": "1", "metadata": {"window": "It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "original_text": "Pharmaceutical\nsegment. "}, "hash": "fbbbc24ae6f0dfb7e9d3d3164a2df1c3e9d33ad7105186d686f45da3023ccb16", "class_name": "RelatedNodeInfo"}}, "text": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "start_char_idx": 3044, "end_char_idx": 3153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984": {"__data__": {"id_": "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984", "embedding": null, "metadata": {"window": "It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "original_text": "Pharmaceutical\nsegment. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe", "node_type": "1", "metadata": {"window": "Also within the oncology ecosystem, Ontada, our data and insights business, continues to partner with biopharma companies to\nadvance cancer research.  It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S. ", "original_text": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f92e85ee8e42c332b045c804cc4977d233648bd0aaf68ca99bdf783ca9da56ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd4c7aa9-630d-492b-9923-117872a49d63", "node_type": "1", "metadata": {"window": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "original_text": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n"}, "hash": "80683a6a1b836a9e083e1167c894f7bf7e6659cb80c8bc518e3640d709c72ca9", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical\nsegment. ", "start_char_idx": 3153, "end_char_idx": 3177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd4c7aa9-630d-492b-9923-117872a49d63": {"__data__": {"id_": "fd4c7aa9-630d-492b-9923-117872a49d63", "embedding": null, "metadata": {"window": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "original_text": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984", "node_type": "1", "metadata": {"window": "It was recently announced that Ontada formed a new strategic alliance with BeiGene.  Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "original_text": "Pharmaceutical\nsegment. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88229ff4270a0cabf07c7d806bc58305f9985986cdde7e09aec2d27187a52972", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b97f191-2348-41b9-b719-ff2b4cddea2e", "node_type": "1", "metadata": {"window": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "original_text": "The U.S. "}, "hash": "9d55ec381c1eaa25ac26fe30b5a403b9b40e34d12f4c9c9ebfa766e78354e51c", "class_name": "RelatedNodeInfo"}}, "text": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "start_char_idx": 3177, "end_char_idx": 3338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b97f191-2348-41b9-b719-ff2b4cddea2e": {"__data__": {"id_": "0b97f191-2348-41b9-b719-ff2b4cddea2e", "embedding": null, "metadata": {"window": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "original_text": "The U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd4c7aa9-630d-492b-9923-117872a49d63", "node_type": "1", "metadata": {"window": "Together, they will\nfocus on accelerating the development of real-world evidence to improve community education as well as increase patient access to\noncology medicines.\n The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "original_text": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f6b8cdd1a1fdbc8281d2557c608426e5e33838883c5d220589098c1a5f54bfc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5712b8d2-42ce-4137-8455-893a245f8eae", "node_type": "1", "metadata": {"window": "Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "original_text": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. "}, "hash": "7f79107bc908ee9917b3815778e60103b5d3fe9e3b1c5849629569aa097fafb2", "class_name": "RelatedNodeInfo"}}, "text": "The U.S. ", "start_char_idx": 3338, "end_char_idx": 3347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5712b8d2-42ce-4137-8455-893a245f8eae": {"__data__": {"id_": "5712b8d2-42ce-4137-8455-893a245f8eae", "embedding": null, "metadata": {"window": "Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "original_text": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b97f191-2348-41b9-b719-ff2b4cddea2e", "node_type": "1", "metadata": {"window": "The oncology ecosystem is expanding and becoming an increasingly important driver for the growth of the U.S.  Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "original_text": "The U.S. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be298ca29b044a14781460ef5b07660e079c98d428cabbb3bfdd2f54495187f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8", "node_type": "1", "metadata": {"window": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "original_text": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n"}, "hash": "d2dfb933b8db862eea28d1820a0b5976aece62ebb8272fec8c42bfa005ad1ba9", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "start_char_idx": 3347, "end_char_idx": 3532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8": {"__data__": {"id_": "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8", "embedding": null, "metadata": {"window": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "original_text": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5712b8d2-42ce-4137-8455-893a245f8eae", "node_type": "1", "metadata": {"window": "Pharmaceutical\nsegment.  Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "original_text": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4f9cdce8833b6fc1f439ada154e6255aa68c24b304746cbe019270d7504d6f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a0b175c-d5fd-4122-bdbe-3d213cde7271", "node_type": "1", "metadata": {"window": "The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "original_text": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. "}, "hash": "46079562a39711cceaa08a87c5041047d8c69e5471471fc8e429d70ab4b4ae8a", "class_name": "RelatedNodeInfo"}}, "text": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "start_char_idx": 3532, "end_char_idx": 3860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a0b175c-d5fd-4122-bdbe-3d213cde7271": {"__data__": {"id_": "1a0b175c-d5fd-4122-bdbe-3d213cde7271", "embedding": null, "metadata": {"window": "The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "original_text": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8", "node_type": "1", "metadata": {"window": "Our leading market position in community oncology distribution allows us to capture the growing market opportunity driven\nby a strong pipeline in drug launches.\n The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "original_text": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fcd3be6b1c39c626a8d16252436e8314e036246fa1c00664684886ab12c0826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7322196c-3c55-4abd-8ffe-2eff8b3172dc", "node_type": "1", "metadata": {"window": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "original_text": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. "}, "hash": "204b488fb96ed3f89b3be248164dd5b21d16429cf7ad41af8b931e683330442b", "class_name": "RelatedNodeInfo"}}, "text": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "start_char_idx": 3860, "end_char_idx": 4049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7322196c-3c55-4abd-8ffe-2eff8b3172dc": {"__data__": {"id_": "7322196c-3c55-4abd-8ffe-2eff8b3172dc", "embedding": null, "metadata": {"window": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "original_text": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a0b175c-d5fd-4122-bdbe-3d213cde7271", "node_type": "1", "metadata": {"window": "The U.S.  Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "original_text": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06c2219b3f41c751a77d7ed9458bdbcc5039a33efdb0a8efad0644b9a4cbef9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c2ecbe2-fbf2-44b7-8971-a422b005609e", "node_type": "1", "metadata": {"window": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "original_text": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n"}, "hash": "aa537360fe3885e07ed54e1ba1f0094653a433f684992592041cf8f48b8d5203", "class_name": "RelatedNodeInfo"}}, "text": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "start_char_idx": 4049, "end_char_idx": 4161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c2ecbe2-fbf2-44b7-8971-a422b005609e": {"__data__": {"id_": "7c2ecbe2-fbf2-44b7-8971-a422b005609e", "embedding": null, "metadata": {"window": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "original_text": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7322196c-3c55-4abd-8ffe-2eff8b3172dc", "node_type": "1", "metadata": {"window": "Oncology Network serves approximately 15% of all new cancer patients in the U.S., and we're pleased that the network\ncontinues to attract new physicians to expand its reach and impact.  The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "original_text": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d169844e50a713112798167e0b89017c79e406d9f723411a1817dec98b1bef67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896e722f-8e70-4cc7-a5c4-80140ab5aba8", "node_type": "1", "metadata": {"window": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "original_text": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. "}, "hash": "5123308d1393dd0fd126edc3c3a7d19ea770f2a7cc923d543582295fcb4dfe2b", "class_name": "RelatedNodeInfo"}}, "text": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "start_char_idx": 4161, "end_char_idx": 4340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896e722f-8e70-4cc7-a5c4-80140ab5aba8": {"__data__": {"id_": "896e722f-8e70-4cc7-a5c4-80140ab5aba8", "embedding": null, "metadata": {"window": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "original_text": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c2ecbe2-fbf2-44b7-8971-a422b005609e", "node_type": "1", "metadata": {"window": "The combined effort and progress on our company priorities,\nour focus on people and culture, on driving sustainable core growth, on streamlining the portfolio and expanding the oncology\nand biopharma services ecosystems are the driving force in advancing our growth strategy and generating long-term value for our\nshareholders.\n As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "original_text": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b5d23769038fc26932718641aacaa9718e8c193190efec495b02b9a9b9b2dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "420de852-acf5-4af5-976b-6043eba7f522", "node_type": "1", "metadata": {"window": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "original_text": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. "}, "hash": "4a92f867cbdd46d622711f5e46f980a31cbafa94451d876177e9baec350e8aa5", "class_name": "RelatedNodeInfo"}}, "text": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "start_char_idx": 4340, "end_char_idx": 4470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "420de852-acf5-4af5-976b-6043eba7f522": {"__data__": {"id_": "420de852-acf5-4af5-976b-6043eba7f522", "embedding": null, "metadata": {"window": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "original_text": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896e722f-8e70-4cc7-a5c4-80140ab5aba8", "node_type": "1", "metadata": {"window": "As I review our strategic priorities, I want to make sure I highlight an important part of our enterprise strategy, which is our continued\ncommitment to sustainability and ESG initiatives.  As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "original_text": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0cad01e3d698c93572c1a4e60e92c174911594ec864eaf895180e365e387918", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a29d893c-7b5c-4daa-802a-9fa6fdc26c84", "node_type": "1", "metadata": {"window": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "original_text": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n"}, "hash": "7e8cda1aaf64ffe5eae48bc326fdf2a697ef99a2b8628f9ba4ad70e8f3c3999d", "class_name": "RelatedNodeInfo"}}, "text": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "start_char_idx": 4470, "end_char_idx": 4588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a29d893c-7b5c-4daa-802a-9fa6fdc26c84": {"__data__": {"id_": "a29d893c-7b5c-4daa-802a-9fa6fdc26c84", "embedding": null, "metadata": {"window": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "original_text": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "420de852-acf5-4af5-976b-6043eba7f522", "node_type": "1", "metadata": {"window": "As an impact-driven organization, we're dedicated to bringing positive changes to\nour stakeholders and society.  While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "original_text": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0485b9270b9197b4131406794287a1947d79a61a99757114560bf4be50f651a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6394d05b-3f54-48be-ba5b-e07af8a06b62", "node_type": "1", "metadata": {"window": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. "}, "hash": "fbdc0b887e6510e211b3649f7f02e4c639d0f341d47e49a45ff346b1e7ae339c", "class_name": "RelatedNodeInfo"}}, "text": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "start_char_idx": 4588, "end_char_idx": 4814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6394d05b-3f54-48be-ba5b-e07af8a06b62": {"__data__": {"id_": "6394d05b-3f54-48be-ba5b-e07af8a06b62", "embedding": null, "metadata": {"window": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a29d893c-7b5c-4daa-802a-9fa6fdc26c84", "node_type": "1", "metadata": {"window": "While many impactful projects are happening across the enterprise, our focus has included improving\naccess to health care, advancing health equity and protecting our environment.\n 2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "original_text": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2a23bb873661dffb55095f63c8b9437f2f348f4e95fb1f37c9995c53c1817b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a44ee0-9f1c-4021-8d12-7900e0560426", "node_type": "1", "metadata": {"window": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. "}, "hash": "5bb85a539c535bd790d5063a4a5439d189bbae54a25b06f76ddba259752e7902", "class_name": "RelatedNodeInfo"}}, "text": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "start_char_idx": 4814, "end_char_idx": 4948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a44ee0-9f1c-4021-8d12-7900e0560426": {"__data__": {"id_": "64a44ee0-9f1c-4021-8d12-7900e0560426", "embedding": null, "metadata": {"window": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6394d05b-3f54-48be-ba5b-e07af8a06b62", "node_type": "1", "metadata": {"window": "2 years ago, we created our first-ever global impact organization, bringing all ESG initiatives under a single business function.  We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d9d24e98d6b9c243fcfdc0160d0e850bd5d439c15fc04d1a216b72a951fb22a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8907bb9a-ef4a-43fe-b231-fa4f89c77677", "node_type": "1", "metadata": {"window": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. "}, "hash": "84da641e5573b74a876627f6b35f488bbdf895800526ba50b6ed4d4d2fed7c9f", "class_name": "RelatedNodeInfo"}}, "text": "In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "start_char_idx": 4948, "end_char_idx": 5083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8907bb9a-ef4a-43fe-b231-fa4f89c77677": {"__data__": {"id_": "8907bb9a-ef4a-43fe-b231-fa4f89c77677", "embedding": null, "metadata": {"window": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a44ee0-9f1c-4021-8d12-7900e0560426", "node_type": "1", "metadata": {"window": "We're\nalso enhancing the governance structure to ensure visibility and accountability to these important initiatives.  With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41aa85599ac331f5542a98a37578eeda70e58e9321e8ebdeed7131bacd969c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47286145-a31d-41d1-b587-f659e4ddeeb2", "node_type": "1", "metadata": {"window": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "And I would say this is similar to what we have observed in past economic cycles."}, "hash": "2008313e6e2b1ef311c9ffc6683085dacfc00306c2796f442a627b50d5ccd9cf", "class_name": "RelatedNodeInfo"}}, "text": "While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "start_char_idx": 5083, "end_char_idx": 5229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47286145-a31d-41d1-b587-f659e4ddeeb2": {"__data__": {"id_": "47286145-a31d-41d1-b587-f659e4ddeeb2", "embedding": null, "metadata": {"window": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "And I would say this is similar to what we have observed in past economic cycles.", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c035e33-56c4-448e-bcae-ca731807c653", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3f4c47ea535abd2a3ee005690a467f224448107ea7016ae909d36b06459e62b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8907bb9a-ef4a-43fe-b231-fa4f89c77677", "node_type": "1", "metadata": {"window": "With consultation from\nan executive steering committee and direct oversight from our Board of Directors, our ESG initiatives are deeply intertwined with how\nwe operate our business, foster our culture and define our strategy.\n Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ]. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "119ef74b1154b20323c7a89856ce898850c2c9f44779d5e084dac9e420ee1dd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "302daaf6-25f9-42c9-a48f-d0d651c7dbf2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "e127fc74954b975ef5a73caddc6ac7e1d244f4c2e4ca94280040789afb0e501b", "class_name": "RelatedNodeInfo"}}, "text": "And I would say this is similar to what we have observed in past economic cycles.", "start_char_idx": 5229, "end_char_idx": 5310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "302daaf6-25f9-42c9-a48f-d0d651c7dbf2": {"__data__": {"id_": "302daaf6-25f9-42c9-a48f-d0d651c7dbf2", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47286145-a31d-41d1-b587-f659e4ddeeb2", "node_type": "1", "metadata": {"window": "Before I hand it over to Britt, I wanted to make just a few comments on the macroeconomic trends in the general business\nenvironment.  In the past quarter, we observed stable prescription volumes and patient utilization trends, which were in line with our\nexpectations.  While the general economic environment remains quite fluid, the demand for health care proves to be fairly resilient and\nlargely [ un-impacted ].  And I would say this is similar to what we have observed in past economic cycles.", "original_text": "And I would say this is similar to what we have observed in past economic cycles.", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e645ea1dcff8aa510a3a64c3003c050cbb530d86a01d60e66b0fdc3a1966cb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33b3abc-4153-4af7-989c-ec7f61a93fd7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "original_text": "All Rights reserved.\n"}, "hash": "cccce4cdaf81fa3c08374bad112736b596be7f8535e425772de21c2c2005c81a", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d33b3abc-4153-4af7-989c-ec7f61a93fd7": {"__data__": {"id_": "d33b3abc-4153-4af7-989c-ec7f61a93fd7", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "original_text": "All Rights reserved.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "302daaf6-25f9-42c9-a48f-d0d651c7dbf2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "984dae5c9a4415ad20965c50a644a293f9c5fad062839cb77543926e80c55ede", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b7ccfa7-e857-454b-8432-02a11fe38e8a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment. ", "original_text": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways. "}, "hash": "270185d482a17f546cbbf656d5b1efcd0afd69f6c458ac0d34018803ce0a472e", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b7ccfa7-e857-454b-8432-02a11fe38e8a": {"__data__": {"id_": "3b7ccfa7-e857-454b-8432-02a11fe38e8a", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment. ", "original_text": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33b3abc-4153-4af7-989c-ec7f61a93fd7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "original_text": "All Rights reserved.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d82d3e4a8d3f90567bb443f4e285919ceb5757b497a9b1889028fdd62711e3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e138dc6e-b664-44b4-8e40-1f1d0cf4779f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "original_text": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n"}, "hash": "86137dca099032aef790be347da3fdbba5ce46eee9195fb17d5476c452827303", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways. ", "start_char_idx": 158, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e138dc6e-b664-44b4-8e40-1f1d0cf4779f": {"__data__": {"id_": "e138dc6e-b664-44b4-8e40-1f1d0cf4779f", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "original_text": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b7ccfa7-e857-454b-8432-02a11fe38e8a", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment. ", "original_text": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34f46dadba5fd57a981140a6d7aae37c8f5eeeadb81c00b4c8ae7d3c5afcc5a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a253a9d-ae5a-4f3a-8a38-2a798a868e87", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together. ", "original_text": "Through the first half of the fiscal year, the financial impact has not been material to McKesson. "}, "hash": "5ac0feabf4c2ace3ac5684b0813dba18a87a12d0ecda975e4fc6e777481c7c2e", "class_name": "RelatedNodeInfo"}}, "text": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "start_char_idx": 326, "end_char_idx": 448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a253a9d-ae5a-4f3a-8a38-2a798a868e87": {"__data__": {"id_": "8a253a9d-ae5a-4f3a-8a38-2a798a868e87", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together. ", "original_text": "Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e138dc6e-b664-44b4-8e40-1f1d0cf4779f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "original_text": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f77cb7f13846ddf19d3964b6796cef5e8ae0da90dceef67159dbe012da75d24d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023. ", "original_text": "We continue to monitor the dynamic\nenvironment. "}, "hash": "706d4dd87c243f3f06b6e6a2f745b5464a51722c492af3c8bd7b5bbacdfe2142", "class_name": "RelatedNodeInfo"}}, "text": "Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "start_char_idx": 448, "end_char_idx": 547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb": {"__data__": {"id_": "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023. ", "original_text": "We continue to monitor the dynamic\nenvironment. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a253a9d-ae5a-4f3a-8a38-2a798a868e87", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together. ", "original_text": "Through the first half of the fiscal year, the financial impact has not been material to McKesson. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a635a6e7f0333347a38e5e383a5ac76772c672a00652788069f798b9b1bdc0f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85086d6e-e59d-4004-a62c-d0808b35df17", "node_type": "1", "metadata": {"window": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "original_text": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n"}, "hash": "4573f5f065b9fffd9c90aa698975d2da21b57b7e0d6281b89800cd2dff15c931", "class_name": "RelatedNodeInfo"}}, "text": "We continue to monitor the dynamic\nenvironment. ", "start_char_idx": 547, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85086d6e-e59d-4004-a62c-d0808b35df17": {"__data__": {"id_": "85086d6e-e59d-4004-a62c-d0808b35df17", "embedding": null, "metadata": {"window": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "original_text": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023. ", "original_text": "We continue to monitor the dynamic\nenvironment. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f90517355f8e20e1f20f456def163a8653a36ba6c207c51fc36516ce74aec5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a20b8d28-7f49-4413-8681-bac27458d0a4", "node_type": "1", "metadata": {"window": "Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "original_text": "Let me pull it all together. "}, "hash": "bff454f3e5619b476901c7d26428d6394b4c563eeba7d75e490c21f965ea2959", "class_name": "RelatedNodeInfo"}}, "text": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "start_char_idx": 595, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a20b8d28-7f49-4413-8681-bac27458d0a4": {"__data__": {"id_": "a20b8d28-7f49-4413-8681-bac27458d0a4", "embedding": null, "metadata": {"window": "Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "original_text": "Let me pull it all together. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85086d6e-e59d-4004-a62c-d0808b35df17", "node_type": "1", "metadata": {"window": "However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "original_text": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d95097ea42ecc033012997691b21cbcafd2c5ba61b4ab8c239cdf1f1e57af6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd", "node_type": "1", "metadata": {"window": "We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "original_text": "McKesson reported a solid second quarter of fiscal 2023. "}, "hash": "d6e83ea29e8fa1b1ff883745eedfad5474799c917694cdab8811ad5057bf2527", "class_name": "RelatedNodeInfo"}}, "text": "Let me pull it all together. ", "start_char_idx": 731, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd": {"__data__": {"id_": "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd", "embedding": null, "metadata": {"window": "We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "original_text": "McKesson reported a solid second quarter of fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a20b8d28-7f49-4413-8681-bac27458d0a4", "node_type": "1", "metadata": {"window": "Through the first half of the fiscal year, the financial impact has not been material to McKesson.  We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "original_text": "Let me pull it all together. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ff51ecd130deb315f72c04d8fb0e17472758fa3c3b92847d87d0c79a8567ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dee5a5cf-191a-4abf-a2db-84709f94e0b1", "node_type": "1", "metadata": {"window": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "original_text": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. "}, "hash": "cc0d7a2c76e256e5fbd573d265c793f7cea80a17aee3fabee2ef861adee8f977", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported a solid second quarter of fiscal 2023. ", "start_char_idx": 760, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dee5a5cf-191a-4abf-a2db-84709f94e0b1": {"__data__": {"id_": "dee5a5cf-191a-4abf-a2db-84709f94e0b1", "embedding": null, "metadata": {"window": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "original_text": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd", "node_type": "1", "metadata": {"window": "We continue to monitor the dynamic\nenvironment.  At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "original_text": "McKesson reported a solid second quarter of fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ad1cb2e62b89178899caaf56051947918be8fa22e572e53acdc6f5381fddff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85559d6-8cf0-4009-a0e1-2e438499e8d0", "node_type": "1", "metadata": {"window": "Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees. ", "original_text": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. "}, "hash": "c28c4047a2a21c3cb934dcaa6875ae913f5e3beb45ebbebafb47d37f7b3c1924", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "start_char_idx": 817, "end_char_idx": 953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85559d6-8cf0-4009-a0e1-2e438499e8d0": {"__data__": {"id_": "a85559d6-8cf0-4009-a0e1-2e438499e8d0", "embedding": null, "metadata": {"window": "Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees. ", "original_text": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dee5a5cf-191a-4abf-a2db-84709f94e0b1", "node_type": "1", "metadata": {"window": "At this time, we do not anticipate any incremental impact in addition to what has already been contemplated in our fiscal\n2023 outlook.\n Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "original_text": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b5b80f6e5bd62d160edc4bf6ff63ca6124b5dc3a3dbd8c6ef6c8ccaeb071961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3589ff8-2c1e-41f6-8290-4ea14a056332", "node_type": "1", "metadata": {"window": "McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "original_text": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n"}, "hash": "5e980039020acf3bce43504157728f8aed46ba237d44c1ced64142bbf3c28749", "class_name": "RelatedNodeInfo"}}, "text": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "start_char_idx": 953, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3589ff8-2c1e-41f6-8290-4ea14a056332": {"__data__": {"id_": "b3589ff8-2c1e-41f6-8290-4ea14a056332", "embedding": null, "metadata": {"window": "McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "original_text": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85559d6-8cf0-4009-a0e1-2e438499e8d0", "node_type": "1", "metadata": {"window": "Let me pull it all together.  McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees. ", "original_text": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b4debe81a0ba5493c4f27573abb3766febf818bbfb82c0fa88021d5060565b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37f2f017-6058-46a9-86fa-193e68cd1342", "node_type": "1", "metadata": {"window": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n", "original_text": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. "}, "hash": "3fdee4b6f03bdd6abaf47af83e1a7b48a6350f409ee8372270bad24321cf8495", "class_name": "RelatedNodeInfo"}}, "text": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "start_char_idx": 1092, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37f2f017-6058-46a9-86fa-193e68cd1342": {"__data__": {"id_": "37f2f017-6058-46a9-86fa-193e68cd1342", "embedding": null, "metadata": {"window": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n", "original_text": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3589ff8-2c1e-41f6-8290-4ea14a056332", "node_type": "1", "metadata": {"window": "McKesson reported a solid second quarter of fiscal 2023.  Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "original_text": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "742bed69bf43f2edbcd8d5b33b9e25fc7ea98ee1fc2bc9a278485dabd8fa6a37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdd060a2-d10b-4b86-a1f1-3ead72212972", "node_type": "1", "metadata": {"window": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "original_text": "I want\nto thank all the McKesson employees. "}, "hash": "008201ef0dcf8408d7d828fedace8fe10ac8f4f3d482349ee27f873d156babb0", "class_name": "RelatedNodeInfo"}}, "text": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "start_char_idx": 1207, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdd060a2-d10b-4b86-a1f1-3ead72212972": {"__data__": {"id_": "cdd060a2-d10b-4b86-a1f1-3ead72212972", "embedding": null, "metadata": {"window": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "original_text": "I want\nto thank all the McKesson employees. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37f2f017-6058-46a9-86fa-193e68cd1342", "node_type": "1", "metadata": {"window": "Excluding the impact from COVID-19-related\nitems and European divestitures, we're pleased with the momentum in the underlying business.  We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n", "original_text": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90652a8bfee2666a6a615ff95e362073f05e68908b99b9d5e15c77cdda1c364b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4e737b5-b438-422f-9203-84838d67346d", "node_type": "1", "metadata": {"window": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "original_text": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n"}, "hash": "70d43c8b40cfe2f359bd98af96af3eb9744e54904b93f16068a4e08dd1dcd6ec", "class_name": "RelatedNodeInfo"}}, "text": "I want\nto thank all the McKesson employees. ", "start_char_idx": 1333, "end_char_idx": 1377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4e737b5-b438-422f-9203-84838d67346d": {"__data__": {"id_": "b4e737b5-b438-422f-9203-84838d67346d", "embedding": null, "metadata": {"window": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "original_text": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdd060a2-d10b-4b86-a1f1-3ead72212972", "node_type": "1", "metadata": {"window": "We've demonstrated our ability to\nexecute for growth and strategic advancement while navigating a quite dynamic macroeconomic environment.  We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "original_text": "I want\nto thank all the McKesson employees. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f7aee2562e661e2cfe6e45a08cb1944434af110940f0c184e3636d1f9969de4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f", "node_type": "1", "metadata": {"window": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "original_text": "With that, I'll turn it over to Britt for additional comments.\n"}, "hash": "a7bee9af06893ae97a64c5b1305dff64fe7389f9726536edf27b430988828d3e", "class_name": "RelatedNodeInfo"}}, "text": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "start_char_idx": 1377, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f": {"__data__": {"id_": "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f", "embedding": null, "metadata": {"window": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "original_text": "With that, I'll turn it over to Britt for additional comments.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4e737b5-b438-422f-9203-84838d67346d", "node_type": "1", "metadata": {"window": "We are confident about\nour market positions and growth trajectory heading into the second half of the fiscal year.\n Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "original_text": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07e426f47cb3e107384c30f4c5444e067ff9833c4cd0b9d1793f194fb29b8a0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb607440-95f7-42c7-867e-f0a276efe673", "node_type": "1", "metadata": {"window": "I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. "}, "hash": "b77f7229285e1eafe093a9ac4a88543f34f1a655730da7eb3215d799f6a1ddac", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll turn it over to Britt for additional comments.\n", "start_char_idx": 1555, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb607440-95f7-42c7-867e-f0a276efe673": {"__data__": {"id_": "bb607440-95f7-42c7-867e-f0a276efe673", "embedding": null, "metadata": {"window": "I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f", "node_type": "1", "metadata": {"window": "Of course, this isn't possible without a talented team committed to working together in service of our partners and patients.  I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "original_text": "With that, I'll turn it over to Britt for additional comments.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "334087525ea4abaad50124a4a91f54be0b24e446b1283158f949cacac1d1f651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8140c79f-2f0b-4724-ac6d-23f6d877175f", "node_type": "1", "metadata": {"window": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "original_text": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. "}, "hash": "d7bbac476ca0b80cddf7da809d8811c366f31bb282a80290f8f16e9907653635", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "start_char_idx": 1618, "end_char_idx": 1709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8140c79f-2f0b-4724-ac6d-23f6d877175f": {"__data__": {"id_": "8140c79f-2f0b-4724-ac6d-23f6d877175f", "embedding": null, "metadata": {"window": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "original_text": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb607440-95f7-42c7-867e-f0a276efe673", "node_type": "1", "metadata": {"window": "I want\nto thank all the McKesson employees.  Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bf6272799efdb86881bab12bf4c638f578a6c4dfecf73687a0e1d9e608e00a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c", "node_type": "1", "metadata": {"window": "With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "original_text": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n"}, "hash": "51f903511053c6f4c510ab5cb00736e5ca6c751bce5742f8819c6532ef14a87e", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "start_char_idx": 1709, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c": {"__data__": {"id_": "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c", "embedding": null, "metadata": {"window": "With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "original_text": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8140c79f-2f0b-4724-ac6d-23f6d877175f", "node_type": "1", "metadata": {"window": "Their dedication, their hard work, their innovation, their spirit of collaboration are truly\ntransformative and enabling positive impact to our partners, customers and patients.\n With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "original_text": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9ac44ec6c3c04983082e66c781410e0578b00e9437268bf517f581c0d5added", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "beb108af-ed15-43cb-b1f4-8319b8d2dc03", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe. ", "original_text": "Let me start with a few company updates before reviewing our second quarter results. "}, "hash": "3e0358859e655e34009377ba308e14a1237f08f0eed529ab4b069ca718e4e62d", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "start_char_idx": 1866, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "beb108af-ed15-43cb-b1f4-8319b8d2dc03": {"__data__": {"id_": "beb108af-ed15-43cb-b1f4-8319b8d2dc03", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe. ", "original_text": "Let me start with a few company updates before reviewing our second quarter results. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c", "node_type": "1", "metadata": {"window": "With that, I'll turn it over to Britt for additional comments.\n Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "original_text": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e83ca0def57e1600a91a91ab2ac4360aec2a0aea44161fa415cb07cd61984b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d88c9a61-5943-41ed-99b4-856cfdcdf03d", "node_type": "1", "metadata": {"window": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "original_text": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. "}, "hash": "27a983f3ec70b986555d1ce8ada5c31133555e2c494f2ec0faa71a2b53147eb5", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with a few company updates before reviewing our second quarter results. ", "start_char_idx": 2180, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d88c9a61-5943-41ed-99b4-856cfdcdf03d": {"__data__": {"id_": "d88c9a61-5943-41ed-99b4-856cfdcdf03d", "embedding": null, "metadata": {"window": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "original_text": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "beb108af-ed15-43cb-b1f4-8319b8d2dc03", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nWell, thank you, Brian, and good afternoon, everyone.  We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe. ", "original_text": "Let me start with a few company updates before reviewing our second quarter results. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "364f8a7bac05ed35fc53452542610f27ca9eee32d7f48548bbf98f5db6f6054f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dc381cc-c48f-4f38-8296-4b1790be1941", "node_type": "1", "metadata": {"window": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "original_text": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n"}, "hash": "6751d6e9c50984a02d0114a0703f8e8ded01bb8d5f90989216b8c1a1d5ae4b88", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "start_char_idx": 2265, "end_char_idx": 2355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dc381cc-c48f-4f38-8296-4b1790be1941": {"__data__": {"id_": "2dc381cc-c48f-4f38-8296-4b1790be1941", "embedding": null, "metadata": {"window": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "original_text": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d88c9a61-5943-41ed-99b4-856cfdcdf03d", "node_type": "1", "metadata": {"window": "We're pleased to report solid financial results for our fiscal second quarter,\nwhich reflect operating execution and progress against our growth strategies.  As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "original_text": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e84994137bb66017d21c3e597d568ca179367cd8bf2b2b71a4c166248718e212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07", "node_type": "1", "metadata": {"window": "Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "original_text": "Let me begin with Europe. "}, "hash": "5778c32de1a6ced2834494ade33c30c89ca814eac9f1a21053b794bae21f3571", "class_name": "RelatedNodeInfo"}}, "text": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "start_char_idx": 2355, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07": {"__data__": {"id_": "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07", "embedding": null, "metadata": {"window": "Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "original_text": "Let me begin with Europe. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dc381cc-c48f-4f38-8296-4b1790be1941", "node_type": "1", "metadata": {"window": "As a result of our fiscal second quarter operational and\nfinancial performance, combined with our strong financial position and outlook for continued execution in the second half, we are\nnarrowing and increasing our full year fiscal 2023 adjusted earnings per diluted share outlook to a range of $24.45 to $24.95.\n Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "original_text": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9634fc705f528baff7d5fa0fdbcd26546cda8dd16943990ad2362c6b4065ec28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce9020f4-c766-4f51-8902-39310c98356b", "node_type": "1", "metadata": {"window": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "original_text": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. "}, "hash": "96a89939e88d77abbcd0361844b630176fe5729657fac3c13dd5139d8b71e0c1", "class_name": "RelatedNodeInfo"}}, "text": "Let me begin with Europe. ", "start_char_idx": 2457, "end_char_idx": 2483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce9020f4-c766-4f51-8902-39310c98356b": {"__data__": {"id_": "ce9020f4-c766-4f51-8902-39310c98356b", "embedding": null, "metadata": {"window": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "original_text": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07", "node_type": "1", "metadata": {"window": "Let me start with a few company updates before reviewing our second quarter results.  During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "original_text": "Let me begin with Europe. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c12aadd8200e1b40226d092fda012757c23e39e30867c2963183c4fb3bb40419", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ef1f69e-666f-4d07-833c-7c92518d8ff3", "node_type": "1", "metadata": {"window": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "original_text": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n"}, "hash": "76bb7c92b12d674281e09b5e3e5b6549b163fcdde00bd8a5a998471a7b5e9f18", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "start_char_idx": 2483, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ef1f69e-666f-4d07-833c-7c92518d8ff3": {"__data__": {"id_": "4ef1f69e-666f-4d07-833c-7c92518d8ff3", "embedding": null, "metadata": {"window": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "original_text": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce9020f4-c766-4f51-8902-39310c98356b", "node_type": "1", "metadata": {"window": "During the quarter, we made meaningful\nprogress refining and strengthening our portfolio.  We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "original_text": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25b8716709f6fa2a6f2c5890babddcf172850eb2e6244b498093decc0f976273", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2b984e4-3098-4a1f-ae0f-38dc69314cee", "node_type": "1", "metadata": {"window": "Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology. ", "original_text": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n"}, "hash": "e59b3af21a28278691afaa93b613e8e54bf02e9bcfa75ccf1ef24cdf534f97ca", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "start_char_idx": 2612, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2b984e4-3098-4a1f-ae0f-38dc69314cee": {"__data__": {"id_": "d2b984e4-3098-4a1f-ae0f-38dc69314cee", "embedding": null, "metadata": {"window": "Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology. ", "original_text": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ef1f69e-666f-4d07-833c-7c92518d8ff3", "node_type": "1", "metadata": {"window": "We completed several key transactions executing against our disciplined capital\nallocation framework.\n Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "original_text": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a06591e64b89efdf4bbcad87a8fadb6ae43d2c77fba48fe2380c73641fcfc3c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb8c6f3-5a1e-4f86-a06d-13f548f05088", "node_type": "1", "metadata": {"window": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "original_text": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n"}, "hash": "bd7c926a8879d175a9c9373e541bec869aeeaf274b5631d3bfe32dc057bfd96e", "class_name": "RelatedNodeInfo"}}, "text": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "start_char_idx": 2717, "end_char_idx": 2959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb8c6f3-5a1e-4f86-a06d-13f548f05088": {"__data__": {"id_": "bfb8c6f3-5a1e-4f86-a06d-13f548f05088", "embedding": null, "metadata": {"window": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "original_text": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2b984e4-3098-4a1f-ae0f-38dc69314cee", "node_type": "1", "metadata": {"window": "Let me begin with Europe.  As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology. ", "original_text": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "126ab48ff3ed0a71d82bdf1e71964a02dac7f18d18f3b4901d5082d1c45ed315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ec54921-df5b-482a-93db-940f653fc629", "node_type": "1", "metadata": {"window": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "original_text": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. "}, "hash": "bfed870edec40e679086fb0e2cf221915897ba61681c2b5c16b4d850c31f45db", "class_name": "RelatedNodeInfo"}}, "text": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "start_char_idx": 2959, "end_char_idx": 3130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ec54921-df5b-482a-93db-940f653fc629": {"__data__": {"id_": "3ec54921-df5b-482a-93db-940f653fc629", "embedding": null, "metadata": {"window": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "original_text": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb8c6f3-5a1e-4f86-a06d-13f548f05088", "node_type": "1", "metadata": {"window": "As Brian mentioned, on October 31, we completed the sale of certain European operations and other assets\nwith the PHOENIX Group.  We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "original_text": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54b4c8b76d1a0b986b5ce7ef18deb0153b91ca67b7ad8996ab7ae499111c0d67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97382acf-c93d-4a95-adc1-ea7a149af439", "node_type": "1", "metadata": {"window": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture. ", "original_text": "Let me\nstart with oncology. "}, "hash": "8698ffa92a5c7aa4ab2fbba0de7b6aebf5b56037c6d028854078a42bb868e9fc", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "start_char_idx": 3130, "end_char_idx": 3253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97382acf-c93d-4a95-adc1-ea7a149af439": {"__data__": {"id_": "97382acf-c93d-4a95-adc1-ea7a149af439", "embedding": null, "metadata": {"window": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture. ", "original_text": "Let me\nstart with oncology. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ec54921-df5b-482a-93db-940f653fc629", "node_type": "1", "metadata": {"window": "We're pleased that we were able to close this transaction sooner than our original fiscal 2023 guidance.\n To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "original_text": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce6707a656fffcb1432040b8cb86eecdc3c39c6a48e65e3b5c2e601535cf3e02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e40ef72d-ec60-4b66-8a1f-db1385f36ef2", "node_type": "1", "metadata": {"window": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "original_text": "In June, we announced an agreement to form a joint venture combining McKesson's U.S. "}, "hash": "cfde68148397eb205f7ae5b5ed984646791a44522de645eddef4de8492f0473a", "class_name": "RelatedNodeInfo"}}, "text": "Let me\nstart with oncology. ", "start_char_idx": 3253, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e40ef72d-ec60-4b66-8a1f-db1385f36ef2": {"__data__": {"id_": "e40ef72d-ec60-4b66-8a1f-db1385f36ef2", "embedding": null, "metadata": {"window": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "original_text": "In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97382acf-c93d-4a95-adc1-ea7a149af439", "node_type": "1", "metadata": {"window": "To date, we've successfully exited 11 of the 12 European countries that we operated in, and Norway remains the only country that we\nhave not entered into an agreement to sell, and we continue to explore strategic alternatives to exit Norway.\n Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture. ", "original_text": "Let me\nstart with oncology. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24374eadeb64db611ec916b0dff04011392dcc8c16f575eb4670a14e5dc12ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8", "node_type": "1", "metadata": {"window": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter. ", "original_text": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n"}, "hash": "7459c50eb75ef7af7237e2cbf29af4de50606937f9c833bdef23f77389ce8046", "class_name": "RelatedNodeInfo"}}, "text": "In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "start_char_idx": 3281, "end_char_idx": 3366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8": {"__data__": {"id_": "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8", "embedding": null, "metadata": {"window": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter. ", "original_text": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e40ef72d-ec60-4b66-8a1f-db1385f36ef2", "node_type": "1", "metadata": {"window": "Our European exit activities have created a focused portfolio, streamlined capital allocation, and it positions the company for growth\nin oncology and biopharma services.\n Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "original_text": "In June, we announced an agreement to form a joint venture combining McKesson's U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c563d86f0dbffc42d3166f16044ddc4579034fd74e1256c7e3fd01198fdf0a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097f4dc6-e351-4e30-a1ad-18fa7f01ba49", "node_type": "1", "metadata": {"window": "Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "original_text": "On October 31, we closed the transaction and successfully formed the joint venture. "}, "hash": "ba6ffc64984f8a75d93281b140937e427c959142de7f9ac5e66f4c0470c2d000", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "start_char_idx": 3366, "end_char_idx": 3525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097f4dc6-e351-4e30-a1ad-18fa7f01ba49": {"__data__": {"id_": "097f4dc6-e351-4e30-a1ad-18fa7f01ba49", "embedding": null, "metadata": {"window": "Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "original_text": "On October 31, we closed the transaction and successfully formed the joint venture. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8", "node_type": "1", "metadata": {"window": "Next, I'm pleased to report on substantial progress with respect to our oncology and biopharma services growth strategies.  Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter. ", "original_text": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60d0c01d4f104adb25e11f3d9361b87e8e8eb04525d26ac0d166bc73e6a225ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f", "node_type": "1", "metadata": {"window": "In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "original_text": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. "}, "hash": "512ebfd7883935c00bb6b3a8c949f0e61398d7367c2487b7af78d22b6b7ffb1f", "class_name": "RelatedNodeInfo"}}, "text": "On October 31, we closed the transaction and successfully formed the joint venture. ", "start_char_idx": 3525, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f": {"__data__": {"id_": "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f", "embedding": null, "metadata": {"window": "In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "original_text": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097f4dc6-e351-4e30-a1ad-18fa7f01ba49", "node_type": "1", "metadata": {"window": "Let me\nstart with oncology.  In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "original_text": "On October 31, we closed the transaction and successfully formed the joint venture. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c64f3871b18ec41c88c40b3587fbea1d419055bad59af8eaa05f33b42d0005ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d50827-d984-47bb-95ba-091758a4389a", "node_type": "1", "metadata": {"window": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Pharmaceutical segment, beginning with our fiscal third quarter. "}, "hash": "321465a3bc17ba38071a2a5ac8b4bb686fed01daae56a86ce17a230918c53306", "class_name": "RelatedNodeInfo"}}, "text": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "start_char_idx": 3609, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d50827-d984-47bb-95ba-091758a4389a": {"__data__": {"id_": "93d50827-d984-47bb-95ba-091758a4389a", "embedding": null, "metadata": {"window": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Pharmaceutical segment, beginning with our fiscal third quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f", "node_type": "1", "metadata": {"window": "In June, we announced an agreement to form a joint venture combining McKesson's U.S.  Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "original_text": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0dada9c60ae5f7cf37b06470676f0fb0dc89c7ba54dd61c745323ee8e36a666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb", "node_type": "1", "metadata": {"window": "On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services. ", "original_text": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. "}, "hash": "f0ab7a2ad5376a9987d273dcba8c423f4933fbdece6fbe0bd51336bb98beeb94", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment, beginning with our fiscal third quarter. ", "start_char_idx": 3710, "end_char_idx": 3775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb": {"__data__": {"id_": "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb", "embedding": null, "metadata": {"window": "On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services. ", "original_text": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d50827-d984-47bb-95ba-091758a4389a", "node_type": "1", "metadata": {"window": "Oncology Research and\nHCA Healthcare's Sarah Cannon Research Institute, including the acquisition of Genospace, Sarah Cannon's personalized medicine\nplatform.\n On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Pharmaceutical segment, beginning with our fiscal third quarter. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a17dc7cbf109028759771de89b7864d4580998a158eea9f0e5acde999c16170a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca935a0-c211-4727-8d63-c551626961f3", "node_type": "1", "metadata": {"window": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "original_text": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. "}, "hash": "a687ca750f2762f8cb820336d4721e03253c90e8042d0563e894f20eff09c101", "class_name": "RelatedNodeInfo"}}, "text": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "start_char_idx": 3775, "end_char_idx": 3916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca935a0-c211-4727-8d63-c551626961f3": {"__data__": {"id_": "6ca935a0-c211-4727-8d63-c551626961f3", "embedding": null, "metadata": {"window": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "original_text": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb", "node_type": "1", "metadata": {"window": "On October 31, we closed the transaction and successfully formed the joint venture.  McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services. ", "original_text": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31d245aa92045c654eb640cca6250a05e166aac403cfd65b6768bc6bd411d02a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d922699f-09de-4459-9425-0401a7206e1d", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "original_text": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n"}, "hash": "79a389d00051a956cbb1c10e633dbbec0cffbd2f0502da936f071240687b8a21", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "start_char_idx": 3916, "end_char_idx": 4016, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d922699f-09de-4459-9425-0401a7206e1d": {"__data__": {"id_": "d922699f-09de-4459-9425-0401a7206e1d", "embedding": null, "metadata": {"window": "Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "original_text": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca935a0-c211-4727-8d63-c551626961f3", "node_type": "1", "metadata": {"window": "McKesson has a 51% ownership interest and will\nconsolidate the results of operations within our U.S.  Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "original_text": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbe3674dc86c2ed9cea5794f121efe128b755898215a943a8a674eb91528ad10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d227c2ab-f426-40ef-9ef5-b6ff5730414b", "node_type": "1", "metadata": {"window": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "original_text": "Let me next move to biopharma services. "}, "hash": "987ce89cac4b08c4186d68c47ae8462988cbfa97a7d2850bcb4dbde829d470d0", "class_name": "RelatedNodeInfo"}}, "text": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "start_char_idx": 4016, "end_char_idx": 4172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d227c2ab-f426-40ef-9ef5-b6ff5730414b": {"__data__": {"id_": "d227c2ab-f426-40ef-9ef5-b6ff5730414b", "embedding": null, "metadata": {"window": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "original_text": "Let me next move to biopharma services. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d922699f-09de-4459-9425-0401a7206e1d", "node_type": "1", "metadata": {"window": "Pharmaceutical segment, beginning with our fiscal third quarter.  This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "original_text": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87a22888e94412b741d57bb683c70c6ea80bdc63ee340c6b4b11113331001663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581", "node_type": "1", "metadata": {"window": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "original_text": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. "}, "hash": "423febdc49f0ecb1949723f24dbfe4e2fbfa88d00a2381d07718cf553319123b", "class_name": "RelatedNodeInfo"}}, "text": "Let me next move to biopharma services. ", "start_char_idx": 4172, "end_char_idx": 4212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581": {"__data__": {"id_": "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581", "embedding": null, "metadata": {"window": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "original_text": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d227c2ab-f426-40ef-9ef5-b6ff5730414b", "node_type": "1", "metadata": {"window": "This transaction\nfurther advances our oncology ecosystem, which contains a broad range of scaled and differentiated assets and capabilities.  For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "original_text": "Let me next move to biopharma services. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aa94c9acfde8f708ea1db43a6777d6205f6b3a4c1def76e0c53702e02428d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05b6cfdc-0745-49ff-bd0c-636a0cc822d1", "node_type": "1", "metadata": {"window": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n"}, "hash": "e59a36052fab669cfdc8a1d0b817e3a447c887bcc9760e61ae608254fff4882c", "class_name": "RelatedNodeInfo"}}, "text": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "start_char_idx": 4212, "end_char_idx": 4428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05b6cfdc-0745-49ff-bd0c-636a0cc822d1": {"__data__": {"id_": "05b6cfdc-0745-49ff-bd0c-636a0cc822d1", "embedding": null, "metadata": {"window": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581", "node_type": "1", "metadata": {"window": "For fiscal\n2023, we anticipate that this transaction will have an immaterial impact on our results.  We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "original_text": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19bf0d892ae71ac08368f181ee714a8172bd36115c2c5f87ca12529a9c21fca9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a35a835a-645b-48fc-90e4-81698127584c", "node_type": "1", "metadata": {"window": "Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "original_text": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. "}, "hash": "b780844423a8760a8350d3ac8a400f14ac0e6515618fda0a8e47ec1806740375", "class_name": "RelatedNodeInfo"}}, "text": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "start_char_idx": 4428, "end_char_idx": 4580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a35a835a-645b-48fc-90e4-81698127584c": {"__data__": {"id_": "a35a835a-645b-48fc-90e4-81698127584c", "embedding": null, "metadata": {"window": "Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "original_text": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05b6cfdc-0745-49ff-bd0c-636a0cc822d1", "node_type": "1", "metadata": {"window": "We expect the joint venture and the Genospace\nacquisition to be $0.10 to $0.20 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "original_text": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b146916a189177a18cf5fa467f46dcc3b80b23ac545924733443fd7ce62aae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d61c32a-25ef-4900-9e37-21bce5dfa4ab", "node_type": "1", "metadata": {"window": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate this transaction will represent a modest headwind to fiscal 2023. "}, "hash": "71ac9fa0ef5606caa87ea4b528b7086bd3ca32d643aad1ddbb8d205ac02c7835", "class_name": "RelatedNodeInfo"}}, "text": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "start_char_idx": 4580, "end_char_idx": 4740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d61c32a-25ef-4900-9e37-21bce5dfa4ab": {"__data__": {"id_": "2d61c32a-25ef-4900-9e37-21bce5dfa4ab", "embedding": null, "metadata": {"window": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a35a835a-645b-48fc-90e4-81698127584c", "node_type": "1", "metadata": {"window": "Let me next move to biopharma services.  In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "original_text": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76c3c6f3d82fd3171b34e0ada9474a00ea078cb78e874f256fe0c72491d396da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb6c183-53f7-403e-a77c-7cf0a7076ca8", "node_type": "1", "metadata": {"window": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n"}, "hash": "346f1194b0ff5bdf826db09bc139e4f93d812237c28a9bf006f9933e0fb34cfe", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "start_char_idx": 4740, "end_char_idx": 4820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb6c183-53f7-403e-a77c-7cf0a7076ca8": {"__data__": {"id_": "9fb6c183-53f7-403e-a77c-7cf0a7076ca8", "embedding": null, "metadata": {"window": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d61c32a-25ef-4900-9e37-21bce5dfa4ab", "node_type": "1", "metadata": {"window": "In September, we announced an agreement to acquire Rx Savings Solutions, a prescription\nprice transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers.  Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate this transaction will represent a modest headwind to fiscal 2023. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "954b9324eba6256f9c92de417ed92475dddd54dbdbf64811c8ad80e17997d99f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ccdf695-69f6-41c2-876a-dcf234e919e8", "node_type": "1", "metadata": {"window": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. "}, "hash": "2d450ee635bc9d422701a26d9ed3ca75151a38fc5da8a0b421b0c2a76b7d9f8b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "start_char_idx": 4820, "end_char_idx": 4960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ccdf695-69f6-41c2-876a-dcf234e919e8": {"__data__": {"id_": "1ccdf695-69f6-41c2-876a-dcf234e919e8", "embedding": null, "metadata": {"window": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb6c183-53f7-403e-a77c-7cf0a7076ca8", "node_type": "1", "metadata": {"window": "Today,\nwe announced the completion of the acquisition of Rx Savings Solutions, which will be included in our Prescription Technology\nSolutions segment.\n The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0433a2e94680d0b6f42e43284bb2f25c4bb1f128076c37bb7039a5a97eeecc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e653d964-e876-46c7-83ea-561a834217cd", "node_type": "1", "metadata": {"window": "We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "These\ntransactions represent capital deployment that make both great strategic and great financial sense."}, "hash": "fca1317e9787f0ae51c4c8a72f64bbc488d6158e7dc651585d6ac0959aa3ccbb", "class_name": "RelatedNodeInfo"}}, "text": "As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "start_char_idx": 4960, "end_char_idx": 5218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e653d964-e876-46c7-83ea-561a834217cd": {"__data__": {"id_": "e653d964-e876-46c7-83ea-561a834217cd", "embedding": null, "metadata": {"window": "We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "128a2057-a810-45cf-855e-0452a45818f1", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc8cef0a019c4eb130ab87943f55fb4ba482e497ba41434ad19e4952a0cf9853", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ccdf695-69f6-41c2-876a-dcf234e919e8", "node_type": "1", "metadata": {"window": "The addition of Rx Savings Solutions complements our existing biopharma services assets and supports our vision to improve access,\naffordability and adherence.  We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b766b5ad6106db62a041e630a2486956e166acf4ef8a8492638fe6fb22ae4f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7fac0df-da88-4aa7-9d55-fe9399f2dd2b", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "9beab0d1dbc293e3c048c6add4187607a9e4065e8122476566811d64c9181bf2", "class_name": "RelatedNodeInfo"}}, "text": "These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "start_char_idx": 5218, "end_char_idx": 5323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7fac0df-da88-4aa7-9d55-fe9399f2dd2b": {"__data__": {"id_": "b7fac0df-da88-4aa7-9d55-fe9399f2dd2b", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e653d964-e876-46c7-83ea-561a834217cd", "node_type": "1", "metadata": {"window": "We anticipate this transaction will represent a modest headwind to fiscal 2023.  We anticipate that Rx\nSavings Solutions will be $0.50 to $0.60 accretive by the end of fiscal 2026 on an adjusted earnings per share basis.\n As you've heard me say before and as is the case with all our recent acquisitions, we prioritize the deployment of capital towards\ngrowth directly on our stated strategies of oncology and biopharma services in a manner that delivers sound financial returns.  These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "original_text": "These\ntransactions represent capital deployment that make both great strategic and great financial sense.", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bd50739f932429e837dd1968b3bb7bc7736a63701de39b670aab2dcead11b5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d259c082-668d-4fbe-bade-43b0948a2113", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "original_text": "All Rights reserved.\n"}, "hash": "add3f5f3dc9c4542fafc1f456fb5dcc7e8d8e93995c57931e94acfb77f030bfa", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d259c082-668d-4fbe-bade-43b0948a2113": {"__data__": {"id_": "d259c082-668d-4fbe-bade-43b0948a2113", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "original_text": "All Rights reserved.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7fac0df-da88-4aa7-9d55-fe9399f2dd2b", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0659a771b844c0555f2c670fb2047e669861720847b0d429b16aa18382d82e61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b5cdd09-2983-48b6-b69e-6ec2a11a676f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "original_text": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results. "}, "hash": "20b02ea05fbb86b1e78b07939b2b4ee0d40ca04c3fa14f098c6cef9fcb5e17fe", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b5cdd09-2983-48b6-b69e-6ec2a11a676f": {"__data__": {"id_": "2b5cdd09-2983-48b6-b69e-6ec2a11a676f", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "original_text": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d259c082-668d-4fbe-bade-43b0948a2113", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "original_text": "All Rights reserved.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43bd7f48c5893b00c5607585f66718eb9e95f33bbe571eb2e4dafb91ed075254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a15e31c-d69d-4abf-929d-aa3ab4999ad0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "original_text": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. "}, "hash": "44e3c7ce55c0a5ff083ba93eb40b00dd8c4baa6e7bdec300030d243b57400697", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results. ", "start_char_idx": 158, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a15e31c-d69d-4abf-929d-aa3ab4999ad0": {"__data__": {"id_": "6a15e31c-d69d-4abf-929d-aa3ab4999ad0", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "original_text": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b5cdd09-2983-48b6-b69e-6ec2a11a676f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "original_text": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be0f823756e45a5d44e65af681e434d6c77ff3227b13d62b6c9b1d9f4bf0fedc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97cb06d0-723c-49d4-95db-3a0680a26b3d", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "original_text": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. "}, "hash": "3cc5e6b80864aeae01420391239370d001976f9e7bfbb351bea4275f4184ad49", "class_name": "RelatedNodeInfo"}}, "text": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "start_char_idx": 253, "end_char_idx": 360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97cb06d0-723c-49d4-95db-3a0680a26b3d": {"__data__": {"id_": "97cb06d0-723c-49d4-95db-3a0680a26b3d", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "original_text": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a15e31c-d69d-4abf-929d-aa3ab4999ad0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "original_text": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc24315e5618f0aa6a37645c32e937d7491cf239920ac658f3f22d5db6a47f14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "169d161b-c378-45da-86a9-de2c0370fd3f", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n"}, "hash": "1534b3e5e8b0c491310860d252200c995f98dcb93f432dbb3c40719e4463435e", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "start_char_idx": 360, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "169d161b-c378-45da-86a9-de2c0370fd3f": {"__data__": {"id_": "169d161b-c378-45da-86a9-de2c0370fd3f", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97cb06d0-723c-49d4-95db-3a0680a26b3d", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "original_text": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a883f961821d3447e8e670a0cb4dc314adf9a97d08e5ee18247e5712f1b336f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aa913f4-d2b4-4491-8817-ca4a7afa1099", "node_type": "1", "metadata": {"window": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 7%. "}, "hash": "0104c1bb1abf59ebff9998000c8b921df0e9a4b013a76b87adfb61adc7a71f2a", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "start_char_idx": 443, "end_char_idx": 592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aa913f4-d2b4-4491-8817-ca4a7afa1099": {"__data__": {"id_": "8aa913f4-d2b4-4491-8817-ca4a7afa1099", "embedding": null, "metadata": {"window": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "169d161b-c378-45da-86a9-de2c0370fd3f", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43ac96964c594a7d22c6299b07bd0f64d2858ecc5291877bc18d46a5672a8d77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be639a61-ffe1-4d71-8ac1-be854f4b18b0", "node_type": "1", "metadata": {"window": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "original_text": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. "}, "hash": "0f26700f786ae65517c32605f9b8b684460348eeb88f694f4305dd2f068ed012", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "start_char_idx": 592, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be639a61-ffe1-4d71-8ac1-be854f4b18b0": {"__data__": {"id_": "be639a61-ffe1-4d71-8ac1-be854f4b18b0", "embedding": null, "metadata": {"window": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "original_text": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aa913f4-d2b4-4491-8817-ca4a7afa1099", "node_type": "1", "metadata": {"window": "My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise.  Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "original_text": "Gross profit was $3.1 billion for the quarter, a decrease of 7%. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7aa0a67fe69e2cff0676e6146e0662c58991d68d8e1b79c8b0f0fe24bfad41ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2", "node_type": "1", "metadata": {"window": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical segment.\n"}, "hash": "76ea3fee2906ee238d741fac96d6cd227cb50a84e86081c749df473937cd021d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "start_char_idx": 657, "end_char_idx": 821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2": {"__data__": {"id_": "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2", "embedding": null, "metadata": {"window": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical segment.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be639a61-ffe1-4d71-8ac1-be854f4b18b0", "node_type": "1", "metadata": {"window": "Consolidated revenues of $70.2 billion increased 5%, reflecting growth in the U.S.  Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "original_text": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c138a684637ce903b3b50985846430d74b08c8594808262f9c5ac3b6336e1f66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "045c1632-0426-4af6-9c06-5ccc71b30fe5", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "original_text": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n"}, "hash": "893ccb277efb18345c6651330993be9003de956fdd0d7eed404029bfc286c8d6", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment.\n", "start_char_idx": 821, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "045c1632-0426-4af6-9c06-5ccc71b30fe5": {"__data__": {"id_": "045c1632-0426-4af6-9c06-5ccc71b30fe5", "embedding": null, "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "original_text": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2", "node_type": "1", "metadata": {"window": "Pharmaceutical\nsegment, partially offset by lower revenues in the International segment, which were a result of our European divestiture activities.\n Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n", "original_text": "Pharmaceutical segment.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8df3bd67b136e8c28540b87f68f7394f8c8df5adbde26f8e282abde52c2bc5c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd389d65-1fe8-4f25-a317-65c7ece519ab", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line. ", "original_text": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. "}, "hash": "eda6d0d282df97ada0f20b69320f0ed251105ab0df850eda022da4b20e0c5cb9", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "start_char_idx": 845, "end_char_idx": 1008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd389d65-1fe8-4f25-a317-65c7ece519ab": {"__data__": {"id_": "bd389d65-1fe8-4f25-a317-65c7ece519ab", "embedding": null, "metadata": {"window": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line. ", "original_text": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "045c1632-0426-4af6-9c06-5ccc71b30fe5", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, a decrease of 7%.  Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "original_text": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fa1734b213c7dd069c17a4594de86d0b1e54f3dc602c08154b7cc98b0463589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "521e1d4d-52ca-4816-9f18-c66161a61ab9", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "original_text": "Pharmaceutical segment.\n"}, "hash": "9d6866e5aeff2dc6d32b1319d0fdf1dd6e266407b1757f25470276d4504af160", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "start_char_idx": 1008, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "521e1d4d-52ca-4816-9f18-c66161a61ab9": {"__data__": {"id_": "521e1d4d-52ca-4816-9f18-c66161a61ab9", "embedding": null, "metadata": {"window": "Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "original_text": "Pharmaceutical segment.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd389d65-1fe8-4f25-a317-65c7ece519ab", "node_type": "1", "metadata": {"window": "Excluding the impact of our European business operations and\ncompleted divestitures, gross profit increased 5%, primarily a result of increased volumes in our U.S.  Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line. ", "original_text": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "831bb8bda385696c220230550ce3b0c9a72f09127f38ec9ee4f6080628b27fcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22fc483f-700c-48a9-b61a-33036d3087c3", "node_type": "1", "metadata": {"window": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "original_text": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n"}, "hash": "80b98a968ab0dccf7bb9e6247c18d458acdc894f7291b94fb3fbf89899d799e2", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment.\n", "start_char_idx": 821, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22fc483f-700c-48a9-b61a-33036d3087c3": {"__data__": {"id_": "22fc483f-700c-48a9-b61a-33036d3087c3", "embedding": null, "metadata": {"window": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "original_text": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "521e1d4d-52ca-4816-9f18-c66161a61ab9", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "original_text": "Pharmaceutical segment.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8cbdc6f9a66aee3de22ffe044ee91e29d3aceeabb353a37a01311b18ca988021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cee5af91-9152-46b5-b4dd-e7e67f1fa79c", "node_type": "1", "metadata": {"window": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n", "original_text": "Moving below the line. "}, "hash": "eb019be5bad76d68d6982a1c33affa5db5984a6bd66f0b1ed14f230cc536bd2f", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "start_char_idx": 1268, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cee5af91-9152-46b5-b4dd-e7e67f1fa79c": {"__data__": {"id_": "cee5af91-9152-46b5-b4dd-e7e67f1fa79c", "embedding": null, "metadata": {"window": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n", "original_text": "Moving below the line. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22fc483f-700c-48a9-b61a-33036d3087c3", "node_type": "1", "metadata": {"window": "Operating expenses in the quarter decreased 11%, largely driven by completed European divestitures in the International segment and\nlower opioid litigation costs.\n Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "original_text": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf5b8475f58111546abd485fdadf4e276e4873bc39ae1284723938ef2d1271ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60c48808-9d68-4bd1-ad22-1646a79497fd", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results. ", "original_text": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. "}, "hash": "4ee8c0982e59cb495e4c237a613523b4ef8efc93a29ed2e05d962e8a567a6d90", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line. ", "start_char_idx": 1462, "end_char_idx": 1485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60c48808-9d68-4bd1-ad22-1646a79497fd": {"__data__": {"id_": "60c48808-9d68-4bd1-ad22-1646a79497fd", "embedding": null, "metadata": {"window": "Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results. ", "original_text": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cee5af91-9152-46b5-b4dd-e7e67f1fa79c", "node_type": "1", "metadata": {"window": "Operating profit was $1.2 billion, a decrease of 6% due to lapping of prior year equity investment gains within McKesson Ventures\nportfolio and completed divestitures in the International segment, partially offset by growth in the U.S.  Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n", "original_text": "Moving below the line. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37113926e3b64c53ebbdba599acbdb96d4c3c713341b6682c58b958fe03a8abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "704575c9-02ea-4a4c-848a-efdc7457e91f", "node_type": "1", "metadata": {"window": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "original_text": "These impacts were partially offset by a net reduction of debt year-over-\nyear. "}, "hash": "3e8921db7ec22d640b9a312ac6c0f651ccee44959a2147e0a3a527dbebf7a66c", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "start_char_idx": 1485, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "704575c9-02ea-4a4c-848a-efdc7457e91f": {"__data__": {"id_": "704575c9-02ea-4a4c-848a-efdc7457e91f", "embedding": null, "metadata": {"window": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "original_text": "These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60c48808-9d68-4bd1-ad22-1646a79497fd", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results. ", "original_text": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77a03022a4459c4553e57bfae817b28f69589d6e44d125e18e0db56551af56b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f", "node_type": "1", "metadata": {"window": "Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "original_text": "And the effective tax rate was 19.9% for the quarter.\n"}, "hash": "6c09dd3e19e75054b16444f5a900ef99d2356daad0dbfb4ae004673f382b4b54", "class_name": "RelatedNodeInfo"}}, "text": "These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "start_char_idx": 1654, "end_char_idx": 1734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f": {"__data__": {"id_": "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f", "embedding": null, "metadata": {"window": "Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "original_text": "And the effective tax rate was 19.9% for the quarter.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "704575c9-02ea-4a4c-848a-efdc7457e91f", "node_type": "1", "metadata": {"window": "When excluding the impact related to the distribution of COVID-19-related products and net gains and losses associated with\nMcKesson Ventures' equity investments, operating profit increased 6%.\n Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "original_text": "These impacts were partially offset by a net reduction of debt year-over-\nyear. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c454dcf1a99c848780d99fe75fbcfe718c9a762b90451c644893e45d21d6565f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e754b99-3252-4e64-8dc8-bc4fe527d62c", "node_type": "1", "metadata": {"window": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "original_text": "Wrapping up our consolidated results. "}, "hash": "a41f1c0f5cb7f74f97169ea14417330beff6aff1d540fe3b7aa1eba442bbd374", "class_name": "RelatedNodeInfo"}}, "text": "And the effective tax rate was 19.9% for the quarter.\n", "start_char_idx": 1734, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e754b99-3252-4e64-8dc8-bc4fe527d62c": {"__data__": {"id_": "9e754b99-3252-4e64-8dc8-bc4fe527d62c", "embedding": null, "metadata": {"window": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "original_text": "Wrapping up our consolidated results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f", "node_type": "1", "metadata": {"window": "Moving below the line.  Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "original_text": "And the effective tax rate was 19.9% for the quarter.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "279d66a59f3ee0f36797c7e20fead2ecd26ab6352146f7c686ee22674a5a125d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "039e5f69-f7d1-4cbd-821c-d266762022ac", "node_type": "1", "metadata": {"window": "These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n", "original_text": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. "}, "hash": "db1ed534024a6d349d4bd84cc6777525ba2d56e9a9392164ead5de3f78d41cea", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results. ", "start_char_idx": 1788, "end_char_idx": 1826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "039e5f69-f7d1-4cbd-821c-d266762022ac": {"__data__": {"id_": "039e5f69-f7d1-4cbd-821c-d266762022ac", "embedding": null, "metadata": {"window": "These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n", "original_text": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e754b99-3252-4e64-8dc8-bc4fe527d62c", "node_type": "1", "metadata": {"window": "Interest expense was $55 million in the quarter, an increase of 22% primarily due to the unfavorable impacts\nin our derivative portfolio as we exit the European region.  These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "original_text": "Wrapping up our consolidated results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4655da97b2313035590f0e07a7a0be2f0cd1fd228872021ae129d84ef73a1b39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9bc1837-1151-48a4-a63e-a74dedd5f534", "node_type": "1", "metadata": {"window": "And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "original_text": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n"}, "hash": "27702f988c4489ffef5dbaee420a55253f9fe2d2cc3e12bee440c2fd1f3fab66", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "start_char_idx": 1826, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9bc1837-1151-48a4-a63e-a74dedd5f534": {"__data__": {"id_": "b9bc1837-1151-48a4-a63e-a74dedd5f534", "embedding": null, "metadata": {"window": "And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "original_text": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "039e5f69-f7d1-4cbd-821c-d266762022ac", "node_type": "1", "metadata": {"window": "These impacts were partially offset by a net reduction of debt year-over-\nyear.  And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n", "original_text": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "feee67a0a8f647cba8d8fe35216835f29c34ddc25a864b92571fca37c1c3b4a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "original_text": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. "}, "hash": "fd384c64828d144624a6908301e87c8e8e3d1420019433a7bdcee72002ad2fa3", "class_name": "RelatedNodeInfo"}}, "text": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "start_char_idx": 2005, "end_char_idx": 2121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20": {"__data__": {"id_": "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "original_text": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9bc1837-1151-48a4-a63e-a74dedd5f534", "node_type": "1", "metadata": {"window": "And the effective tax rate was 19.9% for the quarter.\n Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "original_text": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb57cc2e89559fda22c5776551547e92f29d6409795e1b03d77fbda53997cf3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c97d77c4-b572-406b-9087-2037661a5ffb", "node_type": "1", "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S. ", "original_text": "Pharmaceutical.\n"}, "hash": "2ceefc48bb4401c146b473e669b2e7ee45c6719278676cc44dc83a8466c54276", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "start_char_idx": 2121, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c97d77c4-b572-406b-9087-2037661a5ffb": {"__data__": {"id_": "c97d77c4-b572-406b-9087-2037661a5ffb", "embedding": null, "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S. ", "original_text": "Pharmaceutical.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results.  Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "original_text": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e20e6965a5590828a4efc6cd9f7b05fe8ff2c117adede62c40cc4660ee6fd06c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1", "node_type": "1", "metadata": {"window": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "original_text": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. "}, "hash": "0517c996fee6e4e283f0f90fa2d66d292ceb01b935f562e844a45b5ad3b964d1", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical.\n", "start_char_idx": 2236, "end_char_idx": 2252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1": {"__data__": {"id_": "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1", "embedding": null, "metadata": {"window": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "original_text": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c97d77c4-b572-406b-9087-2037661a5ffb", "node_type": "1", "metadata": {"window": "Second quarter diluted weighted average shares outstanding was 144.1 million, a decrease of\n8%, resulting from share repurchases in fiscal 2022 and the first half of fiscal 2023.  Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S. ", "original_text": "Pharmaceutical.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a48c107b1e4d77939e215c87f9f21a75589481177f1fbbba00ab05d88e36eff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d3f2665-77f2-4c05-b799-b34018ac7e04", "node_type": "1", "metadata": {"window": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "original_text": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n"}, "hash": "02f0e33a9eace914cf293cd52ac3628ca6c7041f6638a34a38cbab7f95f7eb77", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "start_char_idx": 2252, "end_char_idx": 2516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d3f2665-77f2-4c05-b799-b34018ac7e04": {"__data__": {"id_": "5d3f2665-77f2-4c05-b799-b34018ac7e04", "embedding": null, "metadata": {"window": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "original_text": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1", "node_type": "1", "metadata": {"window": "Overall, second quarter adjusted earnings per\ndiluted share was $6.06, a decrease of 1% compared to the prior year.\n Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "original_text": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4c22a5a7c2a4f18614bab6975357bf5c0a48b74cc7480b85cdfaed03172884a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60463a2e-255d-4e53-ba4e-f9f20b185843", "node_type": "1", "metadata": {"window": "Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n", "original_text": "The contribution from our contract with U.S. "}, "hash": "9ac8719d424a610a53ffc13ac43a97a92d5ecf69d34d7abf19fc204b7fdf1b5b", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "start_char_idx": 2516, "end_char_idx": 2719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60463a2e-255d-4e53-ba4e-f9f20b185843": {"__data__": {"id_": "60463a2e-255d-4e53-ba4e-f9f20b185843", "embedding": null, "metadata": {"window": "Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n", "original_text": "The contribution from our contract with U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d3f2665-77f2-4c05-b799-b34018ac7e04", "node_type": "1", "metadata": {"window": "Moving now to our second quarter segment results, which can be found on Slides 7 through 12 and starting with U.S.  Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "original_text": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0436824d3658a898f999f743363d1bbaff0183035348aab3ef2038bd7216e19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d17ed5-5db7-436d-84d7-20aa641fe6da", "node_type": "1", "metadata": {"window": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "original_text": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. "}, "hash": "521291dea1ae087480fc0c45cf87a13338e8662c3dd88eedadc9061c61083b30", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from our contract with U.S. ", "start_char_idx": 2719, "end_char_idx": 2764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d17ed5-5db7-436d-84d7-20aa641fe6da": {"__data__": {"id_": "68d17ed5-5db7-436d-84d7-20aa641fe6da", "embedding": null, "metadata": {"window": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "original_text": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60463a2e-255d-4e53-ba4e-f9f20b185843", "node_type": "1", "metadata": {"window": "Pharmaceutical.\n Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n", "original_text": "The contribution from our contract with U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d09db263d68ccaf70c6bd98b979e2ed6b5889d96b8d368b0f2e2844508c83423", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3f56c6f-e329-43d4-9931-5c446fd937b3", "node_type": "1", "metadata": {"window": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "original_text": "Excluding the impact of COVID-19\nvaccine distribution, the U.S. "}, "hash": "bd60b67f003f7cdb210b27f5b24da9febcefbd25b5858c3166de661dd5ee9b5f", "class_name": "RelatedNodeInfo"}}, "text": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "start_char_idx": 2764, "end_char_idx": 2942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3f56c6f-e329-43d4-9931-5c446fd937b3": {"__data__": {"id_": "e3f56c6f-e329-43d4-9931-5c446fd937b3", "embedding": null, "metadata": {"window": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "original_text": "Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d17ed5-5db7-436d-84d7-20aa641fe6da", "node_type": "1", "metadata": {"window": "Revenues were $60.1 billion, an increase of 12% year-over-year, resulting from increased volume of specialty products, including\nhigher volumes from retail national account customers and market growth, which was partially offset by branded-to-generic\nconversions.  Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "original_text": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78cb5a787ad8fb52ec4842eba1a71b2c32e8acc15d07ab2aa1080e8ee6567776", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a0b34bb-5e79-40d8-940c-9c491fbf53f6", "node_type": "1", "metadata": {"window": "The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "original_text": "Pharmaceutical segment delivered operating profit growth of 5%.\n"}, "hash": "581e4b6d70ad96622e91de0c070e2bb3d4cfc7a4f002528630e96b1988e81c92", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "start_char_idx": 2942, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a0b34bb-5e79-40d8-940c-9c491fbf53f6": {"__data__": {"id_": "0a0b34bb-5e79-40d8-940c-9c491fbf53f6", "embedding": null, "metadata": {"window": "The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "original_text": "Pharmaceutical segment delivered operating profit growth of 5%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3f56c6f-e329-43d4-9931-5c446fd937b3", "node_type": "1", "metadata": {"window": "Operating profit increased 3% to $756 million, led by growth in the distribution of specialty products to providers and\nhealth systems, partially offset by lower demand of COVID-19 vaccine distribution.\n The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "original_text": "Excluding the impact of COVID-19\nvaccine distribution, the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16e4c4be97c94a7e8f6e0812abc367c84b1d42df4a7b5f4d61f6631974a74a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aa00263-c244-4eba-a291-7f2bdc51018d", "node_type": "1", "metadata": {"window": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions. ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. "}, "hash": "5f14dedae93afaf83749c6d7a2a43cb2feff7005bde190e55ee362387c65a25c", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment delivered operating profit growth of 5%.\n", "start_char_idx": 3006, "end_char_idx": 3070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aa00263-c244-4eba-a291-7f2bdc51018d": {"__data__": {"id_": "3aa00263-c244-4eba-a291-7f2bdc51018d", "embedding": null, "metadata": {"window": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions. ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a0b34bb-5e79-40d8-940c-9c491fbf53f6", "node_type": "1", "metadata": {"window": "The contribution from our contract with U.S.  government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "original_text": "Pharmaceutical segment delivered operating profit growth of 5%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "868a0617c640dd1b15a69927396d9d6538ed7cd14ce84e015e149d570ec4af7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21b495ab-a558-4a74-81d5-1c6403b501d9", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "original_text": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n"}, "hash": "b20d42ac16d0633234fb6a1da465aea61a2b489f6ea4a31ec61496d48d8d2905", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "start_char_idx": 3070, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21b495ab-a558-4a74-81d5-1c6403b501d9": {"__data__": {"id_": "21b495ab-a558-4a74-81d5-1c6403b501d9", "embedding": null, "metadata": {"window": "Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "original_text": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aa00263-c244-4eba-a291-7f2bdc51018d", "node_type": "1", "metadata": {"window": "government for COVID-19 vaccine distribution provided a benefit of approximately\n$0.24 per share in the quarter compared to $0.28 per share in the second quarter of fiscal 2022.  Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions. ", "original_text": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c00a125d016ef6803d9398c7b7b9320e9d78a470a76980f58780b6f6cb56275b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b6bc75d-2884-47f7-ae01-edee16b0752c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "original_text": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n"}, "hash": "2337b2d1b6fc91f8e1d36605c23c4c5e3ec446ba87e8dda151b16c992cc01d22", "class_name": "RelatedNodeInfo"}}, "text": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "start_char_idx": 3292, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b6bc75d-2884-47f7-ae01-edee16b0752c": {"__data__": {"id_": "1b6bc75d-2884-47f7-ae01-edee16b0752c", "embedding": null, "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "original_text": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21b495ab-a558-4a74-81d5-1c6403b501d9", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-19\nvaccine distribution, the U.S.  Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "original_text": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba5656463daed979830e5481e98eee215112767b5bca42f252710ec43aad9050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84222969-ae65-456e-9d1f-9e28463d9c23", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "original_text": "Moving now to Medical-Surgical Solutions. "}, "hash": "032f90fb8f69a1c68aeea839d5103f555d1e87a8fb74fcae97177aa7a7858c3d", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "start_char_idx": 3465, "end_char_idx": 3697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84222969-ae65-456e-9d1f-9e28463d9c23": {"__data__": {"id_": "84222969-ae65-456e-9d1f-9e28463d9c23", "embedding": null, "metadata": {"window": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "original_text": "Moving now to Medical-Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b6bc75d-2884-47f7-ae01-edee16b0752c", "node_type": "1", "metadata": {"window": "Pharmaceutical segment delivered operating profit growth of 5%.\n In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "original_text": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e784818edc2519cbfcf8a5d3f92a2a451e208aaa44be81ce6b57172e6850278", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6", "node_type": "1", "metadata": {"window": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S. ", "original_text": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. "}, "hash": "7b8c41d23d6e304ef9508e51ca817215a3861cbb30227bdad1f21f980e1474aa", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical-Surgical Solutions. ", "start_char_idx": 3697, "end_char_idx": 3739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6": {"__data__": {"id_": "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6", "embedding": null, "metadata": {"window": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S. ", "original_text": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84222969-ae65-456e-9d1f-9e28463d9c23", "node_type": "1", "metadata": {"window": "In the Prescription Technology Solutions segment, revenues were $1 billion, an increase of 9% year-over-year, driven by growth in\nprescription volumes in our third-party logistics business and technology service revenues.  Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "original_text": "Moving now to Medical-Surgical Solutions. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d94f9fddddcb8111d026795d7252bd869087529170c46cea111ee0ae2df09ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eae0a37-f57b-419f-8bfc-f4006826bda1", "node_type": "1", "metadata": {"window": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "original_text": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. "}, "hash": "80a302aa60eab12fdd274c8a211722fa24a1006a1dbe1b9f2cc23376b3d699dc", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "start_char_idx": 3739, "end_char_idx": 3885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eae0a37-f57b-419f-8bfc-f4006826bda1": {"__data__": {"id_": "3eae0a37-f57b-419f-8bfc-f4006826bda1", "embedding": null, "metadata": {"window": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "original_text": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6", "node_type": "1", "metadata": {"window": "Compared to Q1, revenues were lower\ndue in part to the timing of customer-driven promotional activity recognized in the first quarter in our third-party logistics business.\n Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S. ", "original_text": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38afd843e37b34ad11012306bba72adc7f78f0e712305a2264d0a4b288ebe8e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1e0bd63-309c-4aeb-b475-4238e0239d99", "node_type": "1", "metadata": {"window": "Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "original_text": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n"}, "hash": "4c680b248f8f94dad3169f560052e624c93191f36a50b9b4eb69d56e21974f78", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "start_char_idx": 3885, "end_char_idx": 4041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1e0bd63-309c-4aeb-b475-4238e0239d99": {"__data__": {"id_": "a1e0bd63-309c-4aeb-b475-4238e0239d99", "embedding": null, "metadata": {"window": "Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "original_text": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eae0a37-f57b-419f-8bfc-f4006826bda1", "node_type": "1", "metadata": {"window": "Operating profit decreased 2% to $141 million driven by higher operating expenses resulting from the timing of increased head count\nto support customer annual verification activities, which include hub and patient support programs.\n Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "original_text": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "664af77039c13d6503f7235bd4a0c201ec13a0f68701d5fbc8662e7e2dfbe77d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f42ae78c-c230-4eaa-adc9-35c93b2fcd54", "node_type": "1", "metadata": {"window": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results. ", "original_text": "The contribution from COVID-19 tests and our contract with the U.S. "}, "hash": "be0f0fbd8c5f40a5bdc5b46b790192d40eb7e9974baf9c68fb96085c2c68e1de", "class_name": "RelatedNodeInfo"}}, "text": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "start_char_idx": 4041, "end_char_idx": 4163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f42ae78c-c230-4eaa-adc9-35c93b2fcd54": {"__data__": {"id_": "f42ae78c-c230-4eaa-adc9-35c93b2fcd54", "embedding": null, "metadata": {"window": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results. ", "original_text": "The contribution from COVID-19 tests and our contract with the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1e0bd63-309c-4aeb-b475-4238e0239d99", "node_type": "1", "metadata": {"window": "Moving now to Medical-Surgical Solutions.  Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "original_text": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d16832961320852cd813a104782854517fcddbb17a0caeab75b7ed5d4b729055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa945f95-5911-452f-9bbe-d56ad3136c1e", "node_type": "1", "metadata": {"window": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "original_text": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. "}, "hash": "2d42e214f34efb23a656c7d5d54b5884c66dc07ee9d7b8e76745e5ca75c7e957", "class_name": "RelatedNodeInfo"}}, "text": "The contribution from COVID-19 tests and our contract with the U.S. ", "start_char_idx": 4163, "end_char_idx": 4231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa945f95-5911-452f-9bbe-d56ad3136c1e": {"__data__": {"id_": "fa945f95-5911-452f-9bbe-d56ad3136c1e", "embedding": null, "metadata": {"window": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "original_text": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f42ae78c-c230-4eaa-adc9-35c93b2fcd54", "node_type": "1", "metadata": {"window": "Revenues were $2.8 billion, a decrease of 9%, as growth in the primary care business\nwas offset by lower sales for COVID-19 tests year-over-year.  Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results. ", "original_text": "The contribution from COVID-19 tests and our contract with the U.S. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8b9193ec31b7a854663f7a37ec7db9c3cafb32c7f5a5a53fd5e369d1be92111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33768011-ce03-432d-b611-543100d3824f", "node_type": "1", "metadata": {"window": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "original_text": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n"}, "hash": "18c5d9a1c0b23e288dcc1773804e84f5a4f818ba714626a0c8829090e68188e6", "class_name": "RelatedNodeInfo"}}, "text": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "start_char_idx": 4231, "end_char_idx": 4445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33768011-ce03-432d-b611-543100d3824f": {"__data__": {"id_": "33768011-ce03-432d-b611-543100d3824f", "embedding": null, "metadata": {"window": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "original_text": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa945f95-5911-452f-9bbe-d56ad3136c1e", "node_type": "1", "metadata": {"window": "Operating profit decreased 4% to $307 million driven by lower sales of\nCOVID-19 tests, partially mitigated by performance within primary care distribution.  Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "original_text": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba1f7803e284ebb904a46e705edad18c55ef5219ffc16ba26dc7ad73f262b527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "265b9baa-72a9-4e03-87dd-771f03240cd1", "node_type": "1", "metadata": {"window": "The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "original_text": "Next, let me address our International results. "}, "hash": "15f2da3c6ba053fe7414c5b0e655ccf958635fdd6ee75f442ff42f2ffe77b934", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "start_char_idx": 4445, "end_char_idx": 4570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "265b9baa-72a9-4e03-87dd-771f03240cd1": {"__data__": {"id_": "265b9baa-72a9-4e03-87dd-771f03240cd1", "embedding": null, "metadata": {"window": "The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33768011-ce03-432d-b611-543100d3824f", "node_type": "1", "metadata": {"window": "Within our Primary Care business, we continue\nto see the effect of a stronger flu season when compared to the prior year.\n The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "original_text": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65007fa9996db5c55eeb6331d654d745d87660219cadf10d8761eddd86d5542e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "654f8d7a-cc5b-47df-bef7-d32d88465f82", "node_type": "1", "metadata": {"window": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n", "original_text": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n"}, "hash": "949680288e0c193bf31b4e703adabdf79beaae0911cd7f1c92ae21bc5b27e4c7", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our International results. ", "start_char_idx": 4570, "end_char_idx": 4618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "654f8d7a-cc5b-47df-bef7-d32d88465f82": {"__data__": {"id_": "654f8d7a-cc5b-47df-bef7-d32d88465f82", "embedding": null, "metadata": {"window": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n", "original_text": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "265b9baa-72a9-4e03-87dd-771f03240cd1", "node_type": "1", "metadata": {"window": "The contribution from COVID-19 tests and our contract with the U.S.  government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fc0d8cf6d4a8ed39e01ca9dfd3aa803703dd585213fea932511567482fe7ba5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fef9720-cd25-44d3-a59c-1ce95565f637", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate. ", "original_text": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n"}, "hash": "ca987b92ff0fb7b8e808a8f76bdbf7770354d7d78f515a91b2848709bfabd017", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "start_char_idx": 4618, "end_char_idx": 4703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fef9720-cd25-44d3-a59c-1ce95565f637": {"__data__": {"id_": "4fef9720-cd25-44d3-a59c-1ce95565f637", "embedding": null, "metadata": {"window": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate. ", "original_text": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "654f8d7a-cc5b-47df-bef7-d32d88465f82", "node_type": "1", "metadata": {"window": "government for the kitting, storage and distribution of ancillary\nsupplies provided a total benefit of approximately $0.33 per share in the quarter compared to $0.44 per share in the second quarter of\nfiscal 2022.  Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n", "original_text": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b7e2b30f607836e485c92358b01565c885f93e6994d0403ad7aaa1f9b3e1dcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year. ", "original_text": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. "}, "hash": "51d9f3a32b1502f77948337d26a9f4bc7a0a0a7818c72d966022c893fe8d45f0", "class_name": "RelatedNodeInfo"}}, "text": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "start_char_idx": 4703, "end_char_idx": 4831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6": {"__data__": {"id_": "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6", "embedding": null, "metadata": {"window": "Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year. ", "original_text": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fef9720-cd25-44d3-a59c-1ce95565f637", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-related items, the Medical-Surgical Solutions segment delivered operating profit growth\nof 7%.\n Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate. ", "original_text": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d42eab3ff834354a56d79b2bb216baf64aeb3921c3054f7d90e8bf861c0f7083", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd3ab8b2-7b15-45c9-a00e-a59b87738a23", "node_type": "1", "metadata": {"window": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "original_text": "and Austrian businesses.\n"}, "hash": "37c0b8983b15147b3be8426806e6e60e85457cb6d6a30297c362c33c389ff708", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "start_char_idx": 4831, "end_char_idx": 4929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd3ab8b2-7b15-45c9-a00e-a59b87738a23": {"__data__": {"id_": "cd3ab8b2-7b15-45c9-a00e-a59b87738a23", "embedding": null, "metadata": {"window": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "original_text": "and Austrian businesses.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year. ", "original_text": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b815dd1506ad287ebf34518bd5f9870cad4a5e51ce0794d4c268c124e99743e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10aea57e-cb69-49a7-be21-799bb0fa89c9", "node_type": "1", "metadata": {"window": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "original_text": "Moving on to Corporate. "}, "hash": "b8c2fbc5b6926d32e0edfeecc072edcbe0430a35347649dd3de23d578dbee42a", "class_name": "RelatedNodeInfo"}}, "text": "and Austrian businesses.\n", "start_char_idx": 4929, "end_char_idx": 4954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10aea57e-cb69-49a7-be21-799bb0fa89c9": {"__data__": {"id_": "10aea57e-cb69-49a7-be21-799bb0fa89c9", "embedding": null, "metadata": {"window": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "original_text": "Moving on to Corporate. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd3ab8b2-7b15-45c9-a00e-a59b87738a23", "node_type": "1", "metadata": {"window": "Revenues were $6.2 billion and operating profit was $137 million, a decrease of 16%.\n On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "original_text": "and Austrian businesses.\n", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b15b09c0e97f5445aaba6519f6115732951a00b848e05edf4e05a3661ed66647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b141ed97-0c31-4e00-a2c7-322ed86b39d8", "node_type": "1", "metadata": {"window": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "Corporate expenses were $144 million, an increase of 73% year-over-year. "}, "hash": "197857b1d979656c140346cf77ee71afc93e81455011bed36de461e512d0c5e9", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to Corporate. ", "start_char_idx": 4954, "end_char_idx": 4978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b141ed97-0c31-4e00-a2c7-322ed86b39d8": {"__data__": {"id_": "b141ed97-0c31-4e00-a2c7-322ed86b39d8", "embedding": null, "metadata": {"window": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "Corporate expenses were $144 million, an increase of 73% year-over-year. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10aea57e-cb69-49a7-be21-799bb0fa89c9", "node_type": "1", "metadata": {"window": "On an FX-adjusted basis, revenues were $6.9 billion, a decrease of 25% and operating profit was $151 million, a decrease of 7%.\n Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "original_text": "Moving on to Corporate. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21683b68487e9c53b78821d53a099aba6f0ca0cc5909a828e940fa23ed8c2c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee", "node_type": "1", "metadata": {"window": "and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. "}, "hash": "f62872c1801911f73fb6e16ab13e34535fdc36db013a135eda90d341f812625a", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses were $144 million, an increase of 73% year-over-year. ", "start_char_idx": 4978, "end_char_idx": 5051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee": {"__data__": {"id_": "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee", "embedding": null, "metadata": {"window": "and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b141ed97-0c31-4e00-a2c7-322ed86b39d8", "node_type": "1", "metadata": {"window": "Second quarter results reflect the year-over-year effect from the divestitures of McKesson's U.K.  and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "Corporate expenses were $144 million, an increase of 73% year-over-year. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d61b3bafbd3db466556e34cf2c6e6fe65b4624eecf251162cacce269919e38ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2", "node_type": "1", "metadata": {"window": "Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. "}, "hash": "f6ffc9979c469c666f01a64f688bff1aea24cc0a65b5fee1b5c6b3b918bdb48d", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "start_char_idx": 5051, "end_char_idx": 5261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2": {"__data__": {"id_": "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2", "embedding": null, "metadata": {"window": "Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee", "node_type": "1", "metadata": {"window": "and Austrian businesses.\n Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a000e62147efbf887e44886b8c4dfe6815839290704b388b5c2ac0c7fc17e8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7045026e-1df8-48c7-ad6b-e666c65c5a24", "node_type": "1", "metadata": {"window": "Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment."}, "hash": "b6e1087d429aca39e35bbbe89c7ad4abc248300ba9888b80988093f398429e9f", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "start_char_idx": 5261, "end_char_idx": 5399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7045026e-1df8-48c7-ad6b-e666c65c5a24": {"__data__": {"id_": "7045026e-1df8-48c7-ad6b-e666c65c5a24", "embedding": null, "metadata": {"window": "Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c51790be6c45240e9ea01781603a9f60a33f07cf563699d67875991c4a654a12", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2", "node_type": "1", "metadata": {"window": "Moving on to Corporate.  Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "368323b429a721b04c9ebe8086226ee27a55bc9586413518c742f2b035037d50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "ad8b99b1c6aef3a952241cda0d98ed4d06b3e0f4a2244943103a9b1e81d2c528", "class_name": "RelatedNodeInfo"}}, "text": "As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "start_char_idx": 5399, "end_char_idx": 5529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6": {"__data__": {"id_": "3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7045026e-1df8-48c7-ad6b-e666c65c5a24", "node_type": "1", "metadata": {"window": "Corporate expenses were $144 million, an increase of 73% year-over-year.  During the quarter, we had net\nlosses of $3 million related to equity investments within the McKesson Ventures portfolio compared to net gains of approximately $97\nmillion in the second quarter of fiscal 2022.  As a reminder, the impacts on consolidated results can be influenced by the performance\nof each individual investment quarter-to-quarter.  As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "original_text": "As a result, McKesson's investments may result in gains or losses, the timing and\nmagnitude of which can vary for each investment.", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8ecaf664ff33f1d1a1f5994532f5858b583f3a8ba06485c0c87ee0003df84af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4b110ed-11ba-48d2-b6dd-5363e456f7c3", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13. ", "original_text": "All Rights reserved.\n"}, "hash": "91cb04bebb63beb6d635fd7e01cb87c65e4b07c8f449badc592ed767930a93cd", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4b110ed-11ba-48d2-b6dd-5363e456f7c3": {"__data__": {"id_": "f4b110ed-11ba-48d2-b6dd-5363e456f7c3", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13. ", "original_text": "All Rights reserved.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eaa8812fee4600475afcf13592c1a2ed819e078eb0b87baf822041b9250dc8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f02b6453-5e96-4b49-8498-376fd357d24f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "original_text": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter. "}, "hash": "856bacff76b3257fe560d25a1850b11db41a66a8bce064c9bd66cc8778bd7bba", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f02b6453-5e96-4b49-8498-376fd357d24f": {"__data__": {"id_": "f02b6453-5e96-4b49-8498-376fd357d24f", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "original_text": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4b110ed-11ba-48d2-b6dd-5363e456f7c3", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13. ", "original_text": "All Rights reserved.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfea212e418bd7c299ae9a443dad4d5feb9d6b95230e23ef2a553a3425287e45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "original_text": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n"}, "hash": "9958377118ac131003fa499ffa5db94cb6c5cd2a8c8610540a13c512777dfd84", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter. ", "start_char_idx": 158, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd": {"__data__": {"id_": "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "original_text": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f02b6453-5e96-4b49-8498-376fd357d24f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "original_text": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c2f65a3d1f8260d303fd7ae82c1d24378c014e6851d6c9492cd78119b795788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2999dfe-cc7c-44ce-820d-98e22e05c3e9", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "original_text": "Turning now to our cash position, which can be found on Slide 13. "}, "hash": "553b7f7996473fc7c089cf948b91ae5d20e6a84bc7db832ada0411f2762fe283", "class_name": "RelatedNodeInfo"}}, "text": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "start_char_idx": 335, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2999dfe-cc7c-44ce-820d-98e22e05c3e9": {"__data__": {"id_": "d2999dfe-cc7c-44ce-820d-98e22e05c3e9", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "original_text": "Turning now to our cash position, which can be found on Slide 13. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "original_text": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e766ba19b036350efa6d384b8b11a0a7cfa4fb13f030cd3f96e48db4592ac0f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c393e74-c882-4259-80f6-9da79819fac7", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "original_text": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. "}, "hash": "54b20a67cdc979223b234e2bd86107722c937b935d2c32d8597c065ff481dd68", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to our cash position, which can be found on Slide 13. ", "start_char_idx": 524, "end_char_idx": 590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c393e74-c882-4259-80f6-9da79819fac7": {"__data__": {"id_": "6c393e74-c882-4259-80f6-9da79819fac7", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "original_text": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2999dfe-cc7c-44ce-820d-98e22e05c3e9", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "original_text": "Turning now to our cash position, which can be found on Slide 13. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4145a2fecc0ef77a648ac7bb21bfedd703f89422899be3efa41cbb2196b385ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722", "node_type": "1", "metadata": {"window": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "original_text": "We ended the quarter with $2.9 billion in\ncash and cash equivalents. "}, "hash": "727a36dc164820e9102e2350a5f8897f79590de427d4d585c5840d42427baa20", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "start_char_idx": 590, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722": {"__data__": {"id_": "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722", "embedding": null, "metadata": {"window": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "original_text": "We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c393e74-c882-4259-80f6-9da79819fac7", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "original_text": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e98e51cc5e5a3bf09ea3c929514da9ac0e1fb6513010ec56a07e63dc7667b71a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b", "node_type": "1", "metadata": {"window": "Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n", "original_text": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n"}, "hash": "c8ff022611f5e4419a4806d865fdf460d745d40fc9504c5de04af93e5d36a1db", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "start_char_idx": 738, "end_char_idx": 807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b": {"__data__": {"id_": "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b", "embedding": null, "metadata": {"window": "Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n", "original_text": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722", "node_type": "1", "metadata": {"window": "We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "original_text": "We ended the quarter with $2.9 billion in\ncash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b387049f5ceeab0b0039a2c022d7d902d71b670e185c6bce8cd2ab71d9f0304", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82ab64ed-b796-462f-b240-128c52857b50", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook. ", "original_text": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. "}, "hash": "13ffdb209ff63fb7a2f116688c14c98c2640b5a6b62dc8302ef8cff20069e7f8", "class_name": "RelatedNodeInfo"}}, "text": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "start_char_idx": 807, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82ab64ed-b796-462f-b240-128c52857b50": {"__data__": {"id_": "82ab64ed-b796-462f-b240-128c52857b50", "embedding": null, "metadata": {"window": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook. ", "original_text": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b", "node_type": "1", "metadata": {"window": "Turning now to our cash position, which can be found on Slide 13.  As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n", "original_text": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc0f469902d24510a79050c7ce639d4e46bea85209bb4cb166e313cee6fa97c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6913a13-cb84-49cb-88c7-49a663e905af", "node_type": "1", "metadata": {"window": "We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "original_text": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. "}, "hash": "2249d4ccaf1c4cda8af0ae7e046bc08cd346d9acf6e3546ad0f4eed887776caa", "class_name": "RelatedNodeInfo"}}, "text": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "start_char_idx": 1109, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6913a13-cb84-49cb-88c7-49a663e905af": {"__data__": {"id_": "c6913a13-cb84-49cb-88c7-49a663e905af", "embedding": null, "metadata": {"window": "We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "original_text": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82ab64ed-b796-462f-b240-128c52857b50", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital metrics and\nresulting cash flows can each be impacted by timing and vary from quarter-to-quarter.  We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook. ", "original_text": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4585be41037167f9b4ceb8a1d0e68848a89b19fb80e5802d243d544e0d0bcc24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6f42480-4183-415f-bfb0-959d47fd1b3d", "node_type": "1", "metadata": {"window": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook. ", "original_text": "And we have $5.8 billion remaining on our share repurchase authorization.\n"}, "hash": "ead6b3c2439628da15198c7ea551f2a305a021c103f004065b34b83c3dbbd466", "class_name": "RelatedNodeInfo"}}, "text": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "start_char_idx": 1235, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6f42480-4183-415f-bfb0-959d47fd1b3d": {"__data__": {"id_": "f6f42480-4183-415f-bfb0-959d47fd1b3d", "embedding": null, "metadata": {"window": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook. ", "original_text": "And we have $5.8 billion remaining on our share repurchase authorization.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6913a13-cb84-49cb-88c7-49a663e905af", "node_type": "1", "metadata": {"window": "We ended the quarter with $2.9 billion in\ncash and cash equivalents.  During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "original_text": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bde1e50e1ba92933a69280a455680d98e7d27ed7c01fd2d95c75c2e4de8db40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7817642e-5d3e-47bb-80b5-88f78b00cb2f", "node_type": "1", "metadata": {"window": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "original_text": "Let me turn now to our fiscal 2023 outlook. "}, "hash": "c546596b5eb1d525d775fbb35c13adb7172efac63811f082e26d860f250297be", "class_name": "RelatedNodeInfo"}}, "text": "And we have $5.8 billion remaining on our share repurchase authorization.\n", "start_char_idx": 1392, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7817642e-5d3e-47bb-80b5-88f78b00cb2f": {"__data__": {"id_": "7817642e-5d3e-47bb-80b5-88f78b00cb2f", "embedding": null, "metadata": {"window": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "original_text": "Let me turn now to our fiscal 2023 outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6f42480-4183-415f-bfb0-959d47fd1b3d", "node_type": "1", "metadata": {"window": "During the first 6 months of the fiscal year, we made $222 million of capital expenditures, which include\ninvestment in distribution center capacity and automation and investments in technology, data and analytics to support growth\npriorities, including our oncology and biopharma services ecosystems.\n For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook. ", "original_text": "And we have $5.8 billion remaining on our share repurchase authorization.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab0a38650bfd0e2716a93fe084163f3e13979f82c9032a38823104c420d805f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68f71b01-b16d-40cb-a0f7-59ecadcd601a", "node_type": "1", "metadata": {"window": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "original_text": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. "}, "hash": "a509f109bef38982173dd5fd0381ca2533992b0cac74f50dfdd61bcbceff371f", "class_name": "RelatedNodeInfo"}}, "text": "Let me turn now to our fiscal 2023 outlook. ", "start_char_idx": 1466, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68f71b01-b16d-40cb-a0f7-59ecadcd601a": {"__data__": {"id_": "68f71b01-b16d-40cb-a0f7-59ecadcd601a", "embedding": null, "metadata": {"window": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "original_text": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7817642e-5d3e-47bb-80b5-88f78b00cb2f", "node_type": "1", "metadata": {"window": "For the first 6 months of fiscal 2023 and 2022, we had negative free cash flow of $56 million and $109 million, respectively.  Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "original_text": "Let me turn now to our fiscal 2023 outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24520938d4446656ed8c02aff138ebbe1a69b1834f92612ae531ea2306a81595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05833ffa-5966-4176-89e8-e5b286672a04", "node_type": "1", "metadata": {"window": "And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "original_text": "And I'll begin with our consolidated outlook. "}, "hash": "9db5fd99a85e0f956258fd18c5a73bf107a1b5d93f1edbb1d74786cca1839959", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "start_char_idx": 1510, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05833ffa-5966-4176-89e8-e5b286672a04": {"__data__": {"id_": "05833ffa-5966-4176-89e8-e5b286672a04", "embedding": null, "metadata": {"window": "And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "original_text": "And I'll begin with our consolidated outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68f71b01-b16d-40cb-a0f7-59ecadcd601a", "node_type": "1", "metadata": {"window": "Year-\nto-date, we returned $1.6 billion of cash to our shareholders, which included $1.5 billion of share repurchases and $139 million in\ndividend payments.  And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "original_text": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6075ed1877204144a92cf8ef7a8758123c1544a02ad7aa13ad4ccf438797092b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b5dc453-93fa-4404-b8db-48b7cc3c1f79", "node_type": "1", "metadata": {"window": "Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S. ", "original_text": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. "}, "hash": "362e3c0ae597503fa64c011be65483650dffec6079e04550f35189104afee012", "class_name": "RelatedNodeInfo"}}, "text": "And I'll begin with our consolidated outlook. ", "start_char_idx": 1618, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b5dc453-93fa-4404-b8db-48b7cc3c1f79": {"__data__": {"id_": "5b5dc453-93fa-4404-b8db-48b7cc3c1f79", "embedding": null, "metadata": {"window": "Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S. ", "original_text": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05833ffa-5966-4176-89e8-e5b286672a04", "node_type": "1", "metadata": {"window": "And we have $5.8 billion remaining on our share repurchase authorization.\n Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "original_text": "And I'll begin with our consolidated outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "beaae50aded9fa131320743f215eeff34ef326baf7fd0fe0069021aefcdb8494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fbd3203-5126-448d-abfa-e1344c5fb78e", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "original_text": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n"}, "hash": "1cb8db87336a99c7e15514c1e91a06677a3b654cb1128c7953f91af06d1347fe", "class_name": "RelatedNodeInfo"}}, "text": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "start_char_idx": 1664, "end_char_idx": 1795, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fbd3203-5126-448d-abfa-e1344c5fb78e": {"__data__": {"id_": "9fbd3203-5126-448d-abfa-e1344c5fb78e", "embedding": null, "metadata": {"window": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "original_text": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b5dc453-93fa-4404-b8db-48b7cc3c1f79", "node_type": "1", "metadata": {"window": "Let me turn now to our fiscal 2023 outlook.  A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S. ", "original_text": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96de83029a522a39f0576cb88f1b22cff0eeb77a1b14f71759dd81362658149f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031ce94e-1d68-4c5f-8263-e078400fb3f1", "node_type": "1", "metadata": {"window": "And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "original_text": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n"}, "hash": "4eb4a39efe244ba96c4b37a5bdcd78b0392f6cdb777850c866877b6ad25d7164", "class_name": "RelatedNodeInfo"}}, "text": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "start_char_idx": 1795, "end_char_idx": 1868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031ce94e-1d68-4c5f-8263-e078400fb3f1": {"__data__": {"id_": "031ce94e-1d68-4c5f-8263-e078400fb3f1", "embedding": null, "metadata": {"window": "And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "original_text": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fbd3203-5126-448d-abfa-e1344c5fb78e", "node_type": "1", "metadata": {"window": "A full list of our assumptions can be found on Slides 15 through 18 in our supplemental\nslide presentation.  And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "original_text": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7ea7fe08f218be38376fa2f42c25b1bf035319776e1c11f17e6377b078a3c86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac983dfc-7983-4f70-9026-49fc3f1e9915", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "original_text": "government's vaccine distribution in our U.S. "}, "hash": "e47cc3e769b3f877c005080ead12dacc49fb49fcd0582a316a2247595ae72829", "class_name": "RelatedNodeInfo"}}, "text": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "start_char_idx": 1868, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac983dfc-7983-4f70-9026-49fc3f1e9915": {"__data__": {"id_": "ac983dfc-7983-4f70-9026-49fc3f1e9915", "embedding": null, "metadata": {"window": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "original_text": "government's vaccine distribution in our U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031ce94e-1d68-4c5f-8263-e078400fb3f1", "node_type": "1", "metadata": {"window": "And I'll begin with our consolidated outlook.  Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "original_text": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "299d515978f91d1dcc76010b09f9e701ab563df8f091e90a1dc11356c0b2272a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fab75678-f8d1-4683-a78a-8b0ef8d87870", "node_type": "1", "metadata": {"window": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S. ", "original_text": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n"}, "hash": "dcf87939cd592d962cd7e47e8de639c64b42c7c0d7588e357a4e8f4cf04a594e", "class_name": "RelatedNodeInfo"}}, "text": "government's vaccine distribution in our U.S. ", "start_char_idx": 2001, "end_char_idx": 2047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fab75678-f8d1-4683-a78a-8b0ef8d87870": {"__data__": {"id_": "fab75678-f8d1-4683-a78a-8b0ef8d87870", "embedding": null, "metadata": {"window": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S. ", "original_text": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac983dfc-7983-4f70-9026-49fc3f1e9915", "node_type": "1", "metadata": {"window": "Our fiscal 2023 guidance assumes 3% to 7% revenue growth and 4%\ndecline to 2% growth for operating profit compared to fiscal 2022.  Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "original_text": "government's vaccine distribution in our U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75a629f19d9d392002eb4b90cfe035b3a085c27e05c85f6671d5079eec3bf78d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db3f039-b699-4059-a82b-d229b1a44a92", "node_type": "1", "metadata": {"window": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "original_text": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. "}, "hash": "090d849991b8132d5ab020ccc2f60c8d50e057f8f6ee51cdfe665ad967c212af", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "start_char_idx": 2047, "end_char_idx": 2309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db3f039-b699-4059-a82b-d229b1a44a92": {"__data__": {"id_": "7db3f039-b699-4059-a82b-d229b1a44a92", "embedding": null, "metadata": {"window": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "original_text": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fab75678-f8d1-4683-a78a-8b0ef8d87870", "node_type": "1", "metadata": {"window": "Let me provide updated guidance for contribution from COVID-19\nprograms.\n Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S. ", "original_text": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cf1fb6dea59e6ddffbb5c8e742258e0befb0a60b241b4900abf15f9cc15169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8044e8f7-89c9-4b62-843f-727feea9c77c", "node_type": "1", "metadata": {"window": "government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line. ", "original_text": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n"}, "hash": "f39be9ab162ec2895a77bfe2ac129484a31ff485d67c41a8c315d4df40c8e80f", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "start_char_idx": 2309, "end_char_idx": 2525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8044e8f7-89c9-4b62-843f-727feea9c77c": {"__data__": {"id_": "8044e8f7-89c9-4b62-843f-727feea9c77c", "embedding": null, "metadata": {"window": "government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line. ", "original_text": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db3f039-b699-4059-a82b-d229b1a44a92", "node_type": "1", "metadata": {"window": "Our revised guidance includes $1.45 to $1.65 of contribution attributable to the following items: $0.60 to $0.70 related to the U.S.\n government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "original_text": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9c364ed7926691d95b1058f3f0f2a780c5a3abad93e0986164b06fd8f27ce18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5248f8d-601a-4f23-9024-458f7eaeed59", "node_type": "1", "metadata": {"window": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million. ", "original_text": "When excluding the impacts related to the U.S. "}, "hash": "a5706a9c64434537e7b61235e0c1285fc3139b77e10891d92999e442bacf232a", "class_name": "RelatedNodeInfo"}}, "text": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "start_char_idx": 2525, "end_char_idx": 2785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5248f8d-601a-4f23-9024-458f7eaeed59": {"__data__": {"id_": "d5248f8d-601a-4f23-9024-458f7eaeed59", "embedding": null, "metadata": {"window": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million. ", "original_text": "When excluding the impacts related to the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8044e8f7-89c9-4b62-843f-727feea9c77c", "node_type": "1", "metadata": {"window": "government's vaccine distribution in our U.S.  Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line. ", "original_text": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c467fbc9c886cc382be95aa12503bfe81e287944e7b2b7d37d40c09697dbb21a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bb32650-a9b0-44e5-a141-262401fddb9e", "node_type": "1", "metadata": {"window": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "original_text": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n"}, "hash": "a8930b92f9ddc2b278f18f48234177cc3780d4a578f52c517e744601b4fcbefc", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impacts related to the U.S. ", "start_char_idx": 2785, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bb32650-a9b0-44e5-a141-262401fddb9e": {"__data__": {"id_": "8bb32650-a9b0-44e5-a141-262401fddb9e", "embedding": null, "metadata": {"window": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "original_text": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5248f8d-601a-4f23-9024-458f7eaeed59", "node_type": "1", "metadata": {"window": "Pharmaceutical segment; $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies in our Medical-Surgical Solutions segment; and approximately $0.15 of net losses associated\nwith McKesson Ventures' equity investments.\n We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million. ", "original_text": "When excluding the impacts related to the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79257e997b14cdf288f7636a37e75e850b842aa26b93aba2f41134e16284afd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a", "node_type": "1", "metadata": {"window": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "Moving below the line. "}, "hash": "439c889866a71eb8bf442e9d5a822f7fc777fd10b16cb1a5647a42b23ee20385", "class_name": "RelatedNodeInfo"}}, "text": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "start_char_idx": 2832, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a": {"__data__": {"id_": "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a", "embedding": null, "metadata": {"window": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "Moving below the line. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bb32650-a9b0-44e5-a141-262401fddb9e", "node_type": "1", "metadata": {"window": "We anticipate corporate expenses in the range of $580 million to $620 million, which includes net losses associated with McKesson\nVentures' equity investments, which we reported in the first half of the fiscal year.  As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "original_text": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31f2a7edce061ae27cd561a710eea5013063dfffed99e413583c35ed65e093d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21405c6e-4a17-46e3-bb55-a359d38a2fe4", "node_type": "1", "metadata": {"window": "When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "original_text": "We anticipate interest expense to be in the range of $225 million to $235 million. "}, "hash": "67d1b72f385fc34e3b05c48c9189107588f7426c52e7d072af5b9226794bc624", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line. ", "start_char_idx": 3100, "end_char_idx": 3123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21405c6e-4a17-46e3-bb55-a359d38a2fe4": {"__data__": {"id_": "21405c6e-4a17-46e3-bb55-a359d38a2fe4", "embedding": null, "metadata": {"window": "When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "original_text": "We anticipate interest expense to be in the range of $225 million to $235 million. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a", "node_type": "1", "metadata": {"window": "As you've heard me say before, it's difficult to\npredict when gains and losses on the McKesson Ventures portfolio companies may occur, and therefore, our practice has been and will\ncontinue to not include McKesson Ventures portfolio estimates in our guidance.\n When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "original_text": "Moving below the line. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9e00d83020c63ded14790c474dbfd95a05e95dac1d2de166a3fa168a4c99b00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fdc412b-7c6c-491e-bc37-b5fd7508d829", "node_type": "1", "metadata": {"window": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "original_text": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. "}, "hash": "f948c37edd56dd03fa0020f6408e5ea4b966e30966114bdb731e2f61fbc1b773", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate interest expense to be in the range of $225 million to $235 million. ", "start_char_idx": 3123, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fdc412b-7c6c-491e-bc37-b5fd7508d829": {"__data__": {"id_": "8fdc412b-7c6c-491e-bc37-b5fd7508d829", "embedding": null, "metadata": {"window": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "original_text": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21405c6e-4a17-46e3-bb55-a359d38a2fe4", "node_type": "1", "metadata": {"window": "When excluding the impacts related to the U.S.  government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "original_text": "We anticipate interest expense to be in the range of $225 million to $235 million. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "742dd260e2d9cd86f3d420f9436c4ef5989b4792f1601c48f59d05f24e2bec52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f8eadd0-05c1-4479-a5af-772c6e7d4a61", "node_type": "1", "metadata": {"window": "Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "original_text": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. "}, "hash": "575770a494be5d6776f1cbc3bc7b4317397ee566b013d2452f7c9ebb273f6f03", "class_name": "RelatedNodeInfo"}}, "text": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "start_char_idx": 3206, "end_char_idx": 3343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f8eadd0-05c1-4479-a5af-772c6e7d4a61": {"__data__": {"id_": "3f8eadd0-05c1-4479-a5af-772c6e7d4a61", "embedding": null, "metadata": {"window": "Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "original_text": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fdc412b-7c6c-491e-bc37-b5fd7508d829", "node_type": "1", "metadata": {"window": "government's centralized COVID-19 vaccine distribution and the kitting, storage and\ndistribution of ancillary supplies, COVID-19 tests and net gains or losses associated with McKesson Ventures' equity investments, we\nanticipate operating profit to increase 4% to 10%.\n Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "original_text": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6c3390bb06fcfd11060b8728b1b1001e25b2eac2179959aded95de26d096765", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3ddbdf9-97b9-4af0-8092-d91f4788df3b", "node_type": "1", "metadata": {"window": "We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "original_text": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n"}, "hash": "2fca8a4c10d5fa952cea87e00119755f7b71ffeda7bb3813c6b24c4d56d6118d", "class_name": "RelatedNodeInfo"}}, "text": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "start_char_idx": 3343, "end_char_idx": 3435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3ddbdf9-97b9-4af0-8092-d91f4788df3b": {"__data__": {"id_": "c3ddbdf9-97b9-4af0-8092-d91f4788df3b", "embedding": null, "metadata": {"window": "We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "original_text": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f8eadd0-05c1-4479-a5af-772c6e7d4a61", "node_type": "1", "metadata": {"window": "Moving below the line.  We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "original_text": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1fe069c9f235490258fe33b42687bf3889005a010a478d6c173242d0e3714a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "464446dc-1b84-44c1-8754-c390afcc57fb", "node_type": "1", "metadata": {"window": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook. ", "original_text": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. "}, "hash": "dc359a9e5cf684d31455a8e42f2c1ce995c3ec9a2b65ed687c99e2105270cd80", "class_name": "RelatedNodeInfo"}}, "text": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "start_char_idx": 3435, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "464446dc-1b84-44c1-8754-c390afcc57fb": {"__data__": {"id_": "464446dc-1b84-44c1-8754-c390afcc57fb", "embedding": null, "metadata": {"window": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook. ", "original_text": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3ddbdf9-97b9-4af0-8092-d91f4788df3b", "node_type": "1", "metadata": {"window": "We anticipate interest expense to be in the range of $225 million to $235 million.  The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "original_text": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26bc7bd3ddaa8507e95e5f56dca1892290203778b04c836e90c9a25d9dad32bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cec1413c-19a5-476b-a75a-f41db188444a", "node_type": "1", "metadata": {"window": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S. ", "original_text": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. "}, "hash": "547d5a8a134d64f5cd5e6797ee1b51e074cc92d7a96c31737518dc6bd3a2b888", "class_name": "RelatedNodeInfo"}}, "text": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "start_char_idx": 3717, "end_char_idx": 3894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cec1413c-19a5-476b-a75a-f41db188444a": {"__data__": {"id_": "cec1413c-19a5-476b-a75a-f41db188444a", "embedding": null, "metadata": {"window": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S. ", "original_text": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "464446dc-1b84-44c1-8754-c390afcc57fb", "node_type": "1", "metadata": {"window": "The increase compared to\nthe prior guidance reflects our intent to partially finance the Rx Savings Solutions acquisition with new debt.  Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook. ", "original_text": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c495541cafbd47c714f52b3c1271a3c542ce6eae4ab8f9de98c16dcb29193165", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "038cd020-2de0-4d00-9992-8bd8db351bee", "node_type": "1", "metadata": {"window": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n", "original_text": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n"}, "hash": "31d06682b83d9908e405bbc7c2ce3611b15f5801a30df717ecd0e08be7cd5932", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "start_char_idx": 3894, "end_char_idx": 4172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "038cd020-2de0-4d00-9992-8bd8db351bee": {"__data__": {"id_": "038cd020-2de0-4d00-9992-8bd8db351bee", "embedding": null, "metadata": {"window": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n", "original_text": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cec1413c-19a5-476b-a75a-f41db188444a", "node_type": "1", "metadata": {"window": "Our anticipated full year\neffective tax rate of approximately 18% to 20% remains unchanged.  And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S. ", "original_text": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "162319335e9394f370474eaf548e1670a01e1e97107adcb6572339460dd58716", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d593be33-7df8-4564-a9ef-5ed5638ef1ad", "node_type": "1", "metadata": {"window": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "original_text": "Moving now to the segment outlook. "}, "hash": "80e8aba38266d8cefb72d077edf7e00234217bf7f8802dde23816141653306ff", "class_name": "RelatedNodeInfo"}}, "text": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "start_char_idx": 4172, "end_char_idx": 4317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d593be33-7df8-4564-a9ef-5ed5638ef1ad": {"__data__": {"id_": "d593be33-7df8-4564-a9ef-5ed5638ef1ad", "embedding": null, "metadata": {"window": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "original_text": "Moving now to the segment outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "038cd020-2de0-4d00-9992-8bd8db351bee", "node_type": "1", "metadata": {"window": "And based on our second quarter results and continued solid\noperating performance, including the contribution from COVID-19-related items, we are increasing and narrowing our guidance range\nfor fiscal 2023 to a range of $24.45 to $24.95 from the previous range of $23.95 to $24.65.\n The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n", "original_text": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01e146b8545763f556ec47ff4c4ac17e4c2c4c430cdd1026594db43215e6b513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739cc948-9230-44fc-b12d-e489fddbd111", "node_type": "1", "metadata": {"window": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "original_text": "We continue to be pleased with the growth we are seeing in the U.S. "}, "hash": "4f9eefaabb192c5ae1510c3bfefab13224b90e28b1328c9302a478d05c4b3843", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to the segment outlook. ", "start_char_idx": 4317, "end_char_idx": 4352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739cc948-9230-44fc-b12d-e489fddbd111": {"__data__": {"id_": "739cc948-9230-44fc-b12d-e489fddbd111", "embedding": null, "metadata": {"window": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "original_text": "We continue to be pleased with the growth we are seeing in the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d593be33-7df8-4564-a9ef-5ed5638ef1ad", "node_type": "1", "metadata": {"window": "The increased guidance also includes the reduced outlook in our International segment from the earlier-than-expected European\nclosing of the transaction with the PHOENIX Group.  Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "original_text": "Moving now to the segment outlook. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5969bbdd673453b3e6708c1c9ced9997ec511f738b2c98e05b903adc201b61d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d66ea2d5-3efd-43d8-88bf-dc1993e0198b", "node_type": "1", "metadata": {"window": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "original_text": "Pharmaceutical segment.\n"}, "hash": "c6c91bcd872d41271490b07615e8bc58d3353c0e1eb27f08a79cecb2d5beb55d", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be pleased with the growth we are seeing in the U.S. ", "start_char_idx": 4352, "end_char_idx": 4420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d66ea2d5-3efd-43d8-88bf-dc1993e0198b": {"__data__": {"id_": "d66ea2d5-3efd-43d8-88bf-dc1993e0198b", "embedding": null, "metadata": {"window": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "original_text": "Pharmaceutical segment.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739cc948-9230-44fc-b12d-e489fddbd111", "node_type": "1", "metadata": {"window": "Excluding the impacts of COVID-19-related items and net gains and losses from\nMcKesson Ventures' equity investments from both fiscal 2023 guidance and fiscal 2022 results, our fiscal 2023 adjusted earnings\nguidance indicates approximately 11% to 14% growth over the prior year.  This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "original_text": "We continue to be pleased with the growth we are seeing in the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61366f4e390394cb310cf656f62622849c7021d482ec91bb528e3e6b50935c0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd2f1ef0-b153-484a-bde4-8c0991acbddc", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "original_text": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. "}, "hash": "908d355fe620d27116581d6f6c09d9e51887bda3e9109d2f7bd99299d2bc6c9a", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical segment.\n", "start_char_idx": 4420, "end_char_idx": 4444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd2f1ef0-b153-484a-bde4-8c0991acbddc": {"__data__": {"id_": "cd2f1ef0-b153-484a-bde4-8c0991acbddc", "embedding": null, "metadata": {"window": "Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "original_text": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d66ea2d5-3efd-43d8-88bf-dc1993e0198b", "node_type": "1", "metadata": {"window": "This outlook aligns with the previously communicated\nlong-term growth targets, and it demonstrates the commitment to deliver sustainable growth.\n Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "original_text": "Pharmaceutical segment.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9370acced7905f0751cef0e93afbc0dbf4bf09365c7ee0d2f3d47d80932a28b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c60e1ed-b114-4c10-bcc0-e36cd876ac66", "node_type": "1", "metadata": {"window": "We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "original_text": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n"}, "hash": "be8e49709a771dcd60f7eca422d79a868de696c964526ad48f8fb0155255a4d4", "class_name": "RelatedNodeInfo"}}, "text": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "start_char_idx": 4444, "end_char_idx": 4560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c60e1ed-b114-4c10-bcc0-e36cd876ac66": {"__data__": {"id_": "2c60e1ed-b114-4c10-bcc0-e36cd876ac66", "embedding": null, "metadata": {"window": "We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "original_text": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd2f1ef0-b153-484a-bde4-8c0991acbddc", "node_type": "1", "metadata": {"window": "Moving now to the segment outlook.  We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "original_text": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de41cbcf9a23ed4a7b5ee9a26ddcd83631699ce1e1969e18160a350c81d0f6a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72ff80ce-ae07-40c0-8896-b8c063b20f5f", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "original_text": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. "}, "hash": "488fccb78bb09c6f25b68356d5c29cad1558a482ecdd4efd9c5f7f8f429bfa18", "class_name": "RelatedNodeInfo"}}, "text": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "start_char_idx": 4560, "end_char_idx": 4749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72ff80ce-ae07-40c0-8896-b8c063b20f5f": {"__data__": {"id_": "72ff80ce-ae07-40c0-8896-b8c063b20f5f", "embedding": null, "metadata": {"window": "Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "original_text": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c60e1ed-b114-4c10-bcc0-e36cd876ac66", "node_type": "1", "metadata": {"window": "We continue to be pleased with the growth we are seeing in the U.S.  Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "original_text": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "289d3828959a20e5702071343687438db2fb2d0b085808d6005dc6a197d561f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5474aedc-0457-47a5-990c-bd60bb487112", "node_type": "1", "metadata": {"window": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "original_text": "Oncology\nResearch and HCA's Sarah Cannon Research Institute. "}, "hash": "4d8b5b8bca802cb159a9fc8e9e0c29f5eeb3f63522ae44ee92f91fd79ab45245", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "start_char_idx": 4749, "end_char_idx": 4864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5474aedc-0457-47a5-990c-bd60bb487112": {"__data__": {"id_": "5474aedc-0457-47a5-990c-bd60bb487112", "embedding": null, "metadata": {"window": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "original_text": "Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72ff80ce-ae07-40c0-8896-b8c063b20f5f", "node_type": "1", "metadata": {"window": "Pharmaceutical segment.\n The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "original_text": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5b06f6aebc1c89d96c1932dea798180509f99523618a25eb5e7926f6132afb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f0be01d-2d2d-407b-a656-2be407aecffc", "node_type": "1", "metadata": {"window": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "original_text": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n"}, "hash": "13648b13cc840780b5b4965f579fea60e6122a731a5b057d1d62184e7e9c0864", "class_name": "RelatedNodeInfo"}}, "text": "Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "start_char_idx": 4864, "end_char_idx": 4925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f0be01d-2d2d-407b-a656-2be407aecffc": {"__data__": {"id_": "7f0be01d-2d2d-407b-a656-2be407aecffc", "embedding": null, "metadata": {"window": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "original_text": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5474aedc-0457-47a5-990c-bd60bb487112", "node_type": "1", "metadata": {"window": "The breadth of our services and solutions continue to resonate across retail, health systems and provider settings.  The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "original_text": "Oncology\nResearch and HCA's Sarah Cannon Research Institute. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ec9762bc9136b811c70734b45048d70cc9a880d1ee80cf1a3d273244a08c5b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69973add-edff-4cae-ad3e-f9502b321be4", "node_type": "1", "metadata": {"window": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "original_text": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. "}, "hash": "911e944894b08938054f5038e973312f3f05f939ad072ffc09c917fdecf51231", "class_name": "RelatedNodeInfo"}}, "text": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "start_char_idx": 4925, "end_char_idx": 5072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69973add-edff-4cae-ad3e-f9502b321be4": {"__data__": {"id_": "69973add-edff-4cae-ad3e-f9502b321be4", "embedding": null, "metadata": {"window": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "original_text": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f0be01d-2d2d-407b-a656-2be407aecffc", "node_type": "1", "metadata": {"window": "The value of our core\ndistribution platform was exemplified by the recent agreement in principle to extend our pharmaceutical distribution partnership with\nCVS Health through June of 2027.\n We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "original_text": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c6688dfaf2a421e286a799f27dd8619217b173d9a5702e20cfcb651614c2499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44efc2e8-0685-4c5c-ac8e-04a09f43d776", "node_type": "1", "metadata": {"window": "Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "original_text": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. "}, "hash": "5dae37bab9814d6600bfecf12184af34ef27db93d6e9f7176c08182076292bd1", "class_name": "RelatedNodeInfo"}}, "text": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "start_char_idx": 5072, "end_char_idx": 5170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44efc2e8-0685-4c5c-ac8e-04a09f43d776": {"__data__": {"id_": "44efc2e8-0685-4c5c-ac8e-04a09f43d776", "embedding": null, "metadata": {"window": "Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "original_text": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69973add-edff-4cae-ad3e-f9502b321be4", "node_type": "1", "metadata": {"window": "We also anticipate further growth across our oncology ecosystem, including a joint venture between McKesson's U.S.  Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "original_text": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9c86122a6a690662de58419b801359112c897e7d490708dec290b8cb54785f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79", "node_type": "1", "metadata": {"window": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. "}, "hash": "51ebea1cc58dbaa54805438206ec038d331952fa00614c92054159748b17ae73", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "start_char_idx": 5170, "end_char_idx": 5267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79": {"__data__": {"id_": "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79", "embedding": null, "metadata": {"window": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44efc2e8-0685-4c5c-ac8e-04a09f43d776", "node_type": "1", "metadata": {"window": "Oncology\nResearch and HCA's Sarah Cannon Research Institute.  And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "original_text": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d3fa6c78e2179e2facbee9b55d7dc0b61961b34c114ac441640953229e30eca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc73d6fe-890a-418b-9fcf-58b2b2df7966", "node_type": "1", "metadata": {"window": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, a result of the previously disclosed contract extension\nthrough July of 2023. "}, "hash": "afcff919cb75b3fa92b8290f9e9497a280276b12e10992dea553c01584bb96d6", "class_name": "RelatedNodeInfo"}}, "text": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "start_char_idx": 5267, "end_char_idx": 5393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc73d6fe-890a-418b-9fcf-58b2b2df7966": {"__data__": {"id_": "cc73d6fe-890a-418b-9fcf-58b2b2df7966", "embedding": null, "metadata": {"window": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79", "node_type": "1", "metadata": {"window": "And we intend to accelerate operating expense investments in the second half\nof fiscal 2023 to further extend our leadership position in oncology.\n Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c85465062e7bab4fe1271e0ec7c42f2d50922546856f1fccbffb07d039c3f88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1", "node_type": "1", "metadata": {"window": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "When excluding the impact of COVID-19 vaccine distribution for the U.S. "}, "hash": "0ce66683ad90fb777793d83e547fa00b220cae7145529c93658c683d85640997", "class_name": "RelatedNodeInfo"}}, "text": "government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "start_char_idx": 5393, "end_char_idx": 5483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1": {"__data__": {"id_": "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1", "embedding": null, "metadata": {"window": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc73d6fe-890a-418b-9fcf-58b2b2df7966", "node_type": "1", "metadata": {"window": "Our positive outlook on the growth trajectory of this segment is reflected in our updated ranges.  We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, a result of the previously disclosed contract extension\nthrough July of 2023. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80afb9df18dc491975f3b9b384f542c32fce01e0662e491ab83dc2d9a511880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f2e7298-ef4e-4787-a49b-960a83aad4c2", "node_type": "1", "metadata": {"window": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target."}, "hash": "f1019904d6f695dcb41bc38d66ddc05e4af7a440c6b8ecb5882f09ec10a682c9", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "start_char_idx": 5483, "end_char_idx": 5555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f2e7298-ef4e-4787-a49b-960a83aad4c2": {"__data__": {"id_": "0f2e7298-ef4e-4787-a49b-960a83aad4c2", "embedding": null, "metadata": {"window": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d80dfb3b4b1b14b056d261d74ec8b6fb23c14d44968e0ef25e4de12ea0a8de87", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1", "node_type": "1", "metadata": {"window": "We anticipate reported revenue to\nincrease 12% to 15% and operating profit to increase 3% to 6%.  As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "When excluding the impact of COVID-19 vaccine distribution for the U.S. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0201cbfc46569ae3f1b9494ff42d6f8b3711bbe346a91a1c346b98248445f4ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd27e1b2-a175-4b92-9507-f50aa05a11b7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "255a577e8f14268c8d286ab3e3e5b43f917fd3176a73f3051b48b7957ecae703", "class_name": "RelatedNodeInfo"}}, "text": "government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "start_char_idx": 5555, "end_char_idx": 5658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd27e1b2-a175-4b92-9507-f50aa05a11b7": {"__data__": {"id_": "cd27e1b2-a175-4b92-9507-f50aa05a11b7", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f2e7298-ef4e-4787-a49b-960a83aad4c2", "node_type": "1", "metadata": {"window": "As I outlined earlier, our outlook includes approximately $0.60\nto $0.70 related to COVID-19 vaccine distribution to the U.S.  government, a result of the previously disclosed contract extension\nthrough July of 2023.  When excluding the impact of COVID-19 vaccine distribution for the U.S.  government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "original_text": "government, we anticipate 5% to 7%\noperating profit growth, which is above the long-term growth target.", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3156f24d68b4ebe4403752ed241dce717fd9b9ec9661d8c341afa4002047db73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities. ", "original_text": "All Rights reserved.\n"}, "hash": "c3f0c631c697b52c1767600c03249e2541d2176e963929999ad05d2b20d6f7c0", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d": {"__data__": {"id_": "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities. ", "original_text": "All Rights reserved.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd27e1b2-a175-4b92-9507-f50aa05a11b7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b482e5f0c740e814daac802e6650f70546c9ad47e88da78c666b63ca158e8a58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "191ad042-b7f6-4474-aab2-348abf26c95b", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "original_text": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%. "}, "hash": "b2b715100996ca3f7568b6ad3b96d1952f1c23e475ae26366d43882474fb852b", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "191ad042-b7f6-4474-aab2-348abf26c95b": {"__data__": {"id_": "191ad042-b7f6-4474-aab2-348abf26c95b", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "original_text": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities. ", "original_text": "All Rights reserved.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "432bdf6f0c0a6ccdf2f56e2f85765941ab13d63d8e6e2b5c6fe1ec97ff473ac9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3eda61b2-90e0-41ac-8b78-6a900ce667f1", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "original_text": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. "}, "hash": "72aacb26450e6c376fd633728f32d67f76d7d3ce23b81d8c6e1ac88b1c2bdfac", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%. ", "start_char_idx": 158, "end_char_idx": 328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3eda61b2-90e0-41ac-8b78-6a900ce667f1": {"__data__": {"id_": "3eda61b2-90e0-41ac-8b78-6a900ce667f1", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "original_text": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "191ad042-b7f6-4474-aab2-348abf26c95b", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "original_text": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "612e43b2d63b993ffd9fd1a5f5a6ecda7f17a05af43dc8961f4ac9ef34f2ba9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b9a455-49cb-40ba-91b6-64e17a878652", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "original_text": "The acquisition of Rx Savings Solutions accelerates our capabilities. "}, "hash": "f5852029e0f1e4e5586cc7e6aced91913c49e4ac9ddd4d0c822d6162f369bce1", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "start_char_idx": 328, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b9a455-49cb-40ba-91b6-64e17a878652": {"__data__": {"id_": "a9b9a455-49cb-40ba-91b6-64e17a878652", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "original_text": "The acquisition of Rx Savings Solutions accelerates our capabilities. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3eda61b2-90e0-41ac-8b78-6a900ce667f1", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "original_text": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28ae187ddccc7a606c665e5d370b212695dfd0600181b495cda757fc52c46921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S. ", "original_text": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n"}, "hash": "e2fd6836086857fe69d99d88f89c6f49d74c5627d4bfbdc3a07be1efc676df31", "class_name": "RelatedNodeInfo"}}, "text": "The acquisition of Rx Savings Solutions accelerates our capabilities. ", "start_char_idx": 463, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8": {"__data__": {"id_": "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S. ", "original_text": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b9a455-49cb-40ba-91b6-64e17a878652", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "original_text": "The acquisition of Rx Savings Solutions accelerates our capabilities. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a41306adf0ca06b9057a054ec86f57df259edd6ddc319bdd760c32a087db277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5b1e038-1225-4eae-aa38-8dc359ee383b", "node_type": "1", "metadata": {"window": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023. ", "original_text": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. "}, "hash": "f02e5146e3a4e5b9951d85ec5f7489170e7b227fce52fda3bff5cc5538246cfe", "class_name": "RelatedNodeInfo"}}, "text": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "start_char_idx": 533, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5b1e038-1225-4eae-aa38-8dc359ee383b": {"__data__": {"id_": "b5b1e038-1225-4eae-aa38-8dc359ee383b", "embedding": null, "metadata": {"window": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023. ", "original_text": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S. ", "original_text": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6e77f487213e228cd6e930f22bc423678f9b8c164d4d68a9852044205ee4623", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef", "node_type": "1", "metadata": {"window": "The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "original_text": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. "}, "hash": "c8eebffdac3bded2601445e743d5fe26e25020f8709f8330c9d33c0734c3b7b2", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "start_char_idx": 711, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef": {"__data__": {"id_": "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef", "embedding": null, "metadata": {"window": "The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "original_text": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5b1e038-1225-4eae-aa38-8dc359ee383b", "node_type": "1", "metadata": {"window": "We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients.  The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023. ", "original_text": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "700d3896989a8f894c470d446d38132b5c577f93bb8220dfe0e251138e2ce3c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9868df5a-4c67-4f54-add9-7e331b00bd4d", "node_type": "1", "metadata": {"window": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "original_text": "government, which incorporates the contract extension with the U.S. "}, "hash": "582c89088ab47832e1e286edf008df31ea9d2945914c3ff58d76a87fc0c43d91", "class_name": "RelatedNodeInfo"}}, "text": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "start_char_idx": 850, "end_char_idx": 1025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9868df5a-4c67-4f54-add9-7e331b00bd4d": {"__data__": {"id_": "9868df5a-4c67-4f54-add9-7e331b00bd4d", "embedding": null, "metadata": {"window": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "original_text": "government, which incorporates the contract extension with the U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef", "node_type": "1", "metadata": {"window": "The acquisition of Rx Savings Solutions accelerates our capabilities.  This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "original_text": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab89c71249394fac655d79cfeb68e7d6406386b8ff2e68b624040f4075d40c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f4535f1-9074-493d-a085-815af228221c", "node_type": "1", "metadata": {"window": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "original_text": "government to\nJanuary of 2023. "}, "hash": "d9691873e6758011f74d407645708f9a14b6302d2b08cee369cbcdcd41ddd421", "class_name": "RelatedNodeInfo"}}, "text": "government, which incorporates the contract extension with the U.S. ", "start_char_idx": 1025, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f4535f1-9074-493d-a085-815af228221c": {"__data__": {"id_": "7f4535f1-9074-493d-a085-815af228221c", "embedding": null, "metadata": {"window": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "original_text": "government to\nJanuary of 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9868df5a-4c67-4f54-add9-7e331b00bd4d", "node_type": "1", "metadata": {"window": "This segment continues to perform in line with the\ntrajectory assumed in our long-term outlook, and its growth over the last few years reflects the ongoing investment and focus.\n In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "original_text": "government, which incorporates the contract extension with the U.S. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df53f1a914a6b9319c1a51aaf68a5d6ba23acfe3481275fe108a5c215d32d85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efdc524c-f379-43d3-8fd7-901a2968bbb8", "node_type": "1", "metadata": {"window": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "original_text": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n"}, "hash": "08070f9463fc5d72a9f0b8aad72988c096cff203ddcc9f53436d0581bedcb691", "class_name": "RelatedNodeInfo"}}, "text": "government to\nJanuary of 2023. ", "start_char_idx": 1093, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efdc524c-f379-43d3-8fd7-901a2968bbb8": {"__data__": {"id_": "efdc524c-f379-43d3-8fd7-901a2968bbb8", "embedding": null, "metadata": {"window": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "original_text": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f4535f1-9074-493d-a085-815af228221c", "node_type": "1", "metadata": {"window": "In the Medical-Surgical Solutions segment, we anticipate reported revenues to decrease 4% to 8% and operating profit to decrease 3%\nto 6%.  As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "original_text": "government to\nJanuary of 2023. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "38742b041411087e13543ef134c645fe815be4c7f8efcaa6d34b0f8ac71ee881", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21152ddd-2907-4258-a910-5f7f0c457ff5", "node_type": "1", "metadata": {"window": "government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n"}, "hash": "41f7a0d05adb5f19fcc34381701fc8e2547a807767693c8d325a161f7b7b5aec", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "start_char_idx": 1124, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21152ddd-2907-4258-a910-5f7f0c457ff5": {"__data__": {"id_": "21152ddd-2907-4258-a910-5f7f0c457ff5", "embedding": null, "metadata": {"window": "government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efdc524c-f379-43d3-8fd7-901a2968bbb8", "node_type": "1", "metadata": {"window": "As previously mentioned, our outlook includes approximately $1 to $1.10 related to COVID-19 tests and the kitting, storage\nand distribution of ancillary supplies for the U.S.  government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "original_text": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d282e3299c8852d4bb53c3f18c2123bc7d5422d0aa86a51298b0ef1d36bb5448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b701b318-a11f-4bb6-8ec6-79ae3cacf540", "node_type": "1", "metadata": {"window": "government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group. ", "original_text": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n"}, "hash": "afc0db4b68519e0e144599690d089b83e369e51dfddbcb7a7a921ca6c0fe2e78", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "start_char_idx": 1244, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b701b318-a11f-4bb6-8ec6-79ae3cacf540": {"__data__": {"id_": "b701b318-a11f-4bb6-8ec6-79ae3cacf540", "embedding": null, "metadata": {"window": "government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group. ", "original_text": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21152ddd-2907-4258-a910-5f7f0c457ff5", "node_type": "1", "metadata": {"window": "government, which incorporates the contract extension with the U.S.  government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4798c159bcd3fdb1f0739a46a124b6a3ada6dcb26dd05cfe40aa66529a4eeb0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. "}, "hash": "e655344079bf0cbad5cf2eed0c94eb8ee602f07d6f432394c3dcf595b032add7", "class_name": "RelatedNodeInfo"}}, "text": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "start_char_idx": 1378, "end_char_idx": 1581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b": {"__data__": {"id_": "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b", "embedding": null, "metadata": {"window": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b701b318-a11f-4bb6-8ec6-79ae3cacf540", "node_type": "1", "metadata": {"window": "government to\nJanuary of 2023.  Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group. ", "original_text": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cb0fe1bd9190704d55a2b215303e7ec40b646202e237613e052c22833ef1e27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03cd378-2db7-470e-b8fe-cc52724b936d", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "original_text": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n"}, "hash": "f9252b19cc4af78e82e70c6b4ffa139859a129db4a97d9b91878f3e0a03a36ff", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "start_char_idx": 1581, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03cd378-2db7-470e-b8fe-cc52724b936d": {"__data__": {"id_": "b03cd378-2db7-470e-b8fe-cc52724b936d", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "original_text": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b", "node_type": "1", "metadata": {"window": "Excluding the impact of COVID-19-related items, we anticipate Medical-Surgical operating profit to increase 11% to\n15%.\n Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "original_text": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b82e80caae3f7f4f4af477735f8b53ed514825a8c8b2cd2a8a751b8ffda8efc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10725406-27a0-434b-aced-458059020722", "node_type": "1", "metadata": {"window": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "original_text": "We are pleased to have closed the transaction with the PHOENIX Group. "}, "hash": "9bd2e13ec4254693a41f544d0ca3bae76a86b80211274e4932499149e1f925dd", "class_name": "RelatedNodeInfo"}}, "text": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "start_char_idx": 1768, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10725406-27a0-434b-aced-458059020722": {"__data__": {"id_": "10725406-27a0-434b-aced-458059020722", "embedding": null, "metadata": {"window": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "original_text": "We are pleased to have closed the transaction with the PHOENIX Group. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03cd378-2db7-470e-b8fe-cc52724b936d", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 42% to 46% and operating profit to decline by 27% to 33%.\n This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "original_text": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc8b1164e6de5f7a2b18e63604d2dcccea4548a44d96ec00dfd3c421d67df2b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53120c3d-b6c1-46d4-a75a-e27a8c818fa3", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "original_text": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n"}, "hash": "70bad24fa4eb124d68570d2f480f7f0dfc9caad954a8f1e3221ebde953d37e6e", "class_name": "RelatedNodeInfo"}}, "text": "We are pleased to have closed the transaction with the PHOENIX Group. ", "start_char_idx": 1974, "end_char_idx": 2044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53120c3d-b6c1-46d4-a75a-e27a8c818fa3": {"__data__": {"id_": "53120c3d-b6c1-46d4-a75a-e27a8c818fa3", "embedding": null, "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "original_text": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10725406-27a0-434b-aced-458059020722", "node_type": "1", "metadata": {"window": "This year-over-year decrease includes the loss of operating profit contribution from businesses and transactions we have closed to\ndate, including the recently closed transaction with the PHOENIX Group.\n For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "original_text": "We are pleased to have closed the transaction with the PHOENIX Group. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39e6c332e544d5f4de98f04adb0ded6486944b54ee1cb0cfe89cc2bbbe335c68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c", "node_type": "1", "metadata": {"window": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "original_text": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. "}, "hash": "e45a16a13c2441414c1affb2b9ed616d90ad2105505032270693ccbfa22cbb0d", "class_name": "RelatedNodeInfo"}}, "text": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "start_char_idx": 2044, "end_char_idx": 2226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c": {"__data__": {"id_": "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c", "embedding": null, "metadata": {"window": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "original_text": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53120c3d-b6c1-46d4-a75a-e27a8c818fa3", "node_type": "1", "metadata": {"window": "For fiscal 2023, we anticipate our European operations will contribute operating profit of approximately $0.85 to $1 per diluted share\nprimarily in the first 9 months of the fiscal year.  This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "original_text": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14b88d131d8e030c81fa8da365868455700f3bb126b9b6469e2b644c517f4e91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "979472f9-21c0-434f-b8e7-ca53f5eb2173", "node_type": "1", "metadata": {"window": "We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow. ", "original_text": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. "}, "hash": "f35be454cab57390032d593a13c9dd6324911f5cfab35da5351afbf51b69e310", "class_name": "RelatedNodeInfo"}}, "text": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "start_char_idx": 2226, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "979472f9-21c0-434f-b8e7-ca53f5eb2173": {"__data__": {"id_": "979472f9-21c0-434f-b8e7-ca53f5eb2173", "embedding": null, "metadata": {"window": "We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow. ", "original_text": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c", "node_type": "1", "metadata": {"window": "This includes year-to-date contributions from operations prior to completed sales, our\noperations in Norway and contribution related to held-for-sale accounting from the transaction with the PHOENIX Group.\n We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "original_text": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fada2a84cb7f7e2a267518f1f365428f55326bf5768ec398452093ced5ff3c17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "787bebfc-26c5-44a8-b6c6-12033a3a9003", "node_type": "1", "metadata": {"window": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "original_text": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n"}, "hash": "bac4c6d9e57528d3bc15804480e9eff5bdcb429bff1ef0d17234eae28f39ded5", "class_name": "RelatedNodeInfo"}}, "text": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "start_char_idx": 2324, "end_char_idx": 2470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "787bebfc-26c5-44a8-b6c6-12033a3a9003": {"__data__": {"id_": "787bebfc-26c5-44a8-b6c6-12033a3a9003", "embedding": null, "metadata": {"window": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "original_text": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "979472f9-21c0-434f-b8e7-ca53f5eb2173", "node_type": "1", "metadata": {"window": "We are pleased to have closed the transaction with the PHOENIX Group.  This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow. ", "original_text": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e28da446279d1d83a29f52462e52d83be6b8893e5313b254c5e0683a2ea49b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb64bed6-c105-4fe0-ba2f-ff7d7898978b", "node_type": "1", "metadata": {"window": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "original_text": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. "}, "hash": "82402b63ca591c58318d6d4e1d0aa82a3aca778888169bf85040bf35a4ba7dfe", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "start_char_idx": 2470, "end_char_idx": 2648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb64bed6-c105-4fe0-ba2f-ff7d7898978b": {"__data__": {"id_": "bb64bed6-c105-4fe0-ba2f-ff7d7898978b", "embedding": null, "metadata": {"window": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "original_text": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "787bebfc-26c5-44a8-b6c6-12033a3a9003", "node_type": "1", "metadata": {"window": "This transaction closed earlier than we had anticipated,\nnegatively impacting prior operating profit guidance, and is the main driver behind the change in guidance for this segment.\n Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "original_text": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77c7cdb954a092c3d35a83a1a16d7aec2b5574d9b88981d49bdbf617f513339b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "279e595c-0382-4c62-b08d-5e98db8b7e27", "node_type": "1", "metadata": {"window": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders. ", "original_text": "our North American businesses continue to generate strong free cash flow. "}, "hash": "35e57e1ae5158357b2cff5a834445f45ef7f20c8814eaf2834372c27ba6de8b0", "class_name": "RelatedNodeInfo"}}, "text": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "start_char_idx": 2648, "end_char_idx": 2782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "279e595c-0382-4c62-b08d-5e98db8b7e27": {"__data__": {"id_": "279e595c-0382-4c62-b08d-5e98db8b7e27", "embedding": null, "metadata": {"window": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders. ", "original_text": "our North American businesses continue to generate strong free cash flow. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb64bed6-c105-4fe0-ba2f-ff7d7898978b", "node_type": "1", "metadata": {"window": "Let me conclude my fiscal 2023 outlook remarks with a review of cash flow and capital deployment.  In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "original_text": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a575c557f6d3bd654ebf482e0f36a71e084b9e9ef63bac587e5419562db33e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90aa93d1-5416-427f-b987-3e917d42346e", "node_type": "1", "metadata": {"window": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "original_text": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. "}, "hash": "23302303d00a228e285d88c27d885467593cd1b1cb6d0310e2ebf0a871cceb4a", "class_name": "RelatedNodeInfo"}}, "text": "our North American businesses continue to generate strong free cash flow. ", "start_char_idx": 2782, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90aa93d1-5416-427f-b987-3e917d42346e": {"__data__": {"id_": "90aa93d1-5416-427f-b987-3e917d42346e", "embedding": null, "metadata": {"window": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "original_text": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "279e595c-0382-4c62-b08d-5e98db8b7e27", "node_type": "1", "metadata": {"window": "In fiscal 2023, our cash flows,\nincluding the timing and progression, have been impacted by European divestiture activity and other transactions.  For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders. ", "original_text": "our North American businesses continue to generate strong free cash flow. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c27e34d46ad7fc4ac6c5ab53c9db6255dd2b3ac425d1905192956635b3af3f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b6fb4f3-355d-42be-b9fa-955f9357b46f", "node_type": "1", "metadata": {"window": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "original_text": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n"}, "hash": "490d1bf85e43ba1929386e648f069db8f746e7d675ae20b0ebe823e975d9d8c3", "class_name": "RelatedNodeInfo"}}, "text": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "start_char_idx": 2856, "end_char_idx": 3027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b6fb4f3-355d-42be-b9fa-955f9357b46f": {"__data__": {"id_": "0b6fb4f3-355d-42be-b9fa-955f9357b46f", "embedding": null, "metadata": {"window": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "original_text": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90aa93d1-5416-427f-b987-3e917d42346e", "node_type": "1", "metadata": {"window": "For fiscal 2023, we\ncontinue to anticipate free cash flow of approximately $3.2 billion to $3.6 billion, which is net of property acquisitions and capitalized\nsoftware expenses.\n Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "original_text": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e0ab0ec3c2d45006a66f62b87d460c3af6511dfae7eb589aa26ec6b8e6404fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6199399-174b-4667-b2a5-68fa856b16cc", "node_type": "1", "metadata": {"window": "our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance. ", "original_text": "We also remain committed to returning capital to our shareholders. "}, "hash": "801bf48af0d089e8cf80de48252b0c32b33ce11ebfa95617763a5ac2edc34885", "class_name": "RelatedNodeInfo"}}, "text": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "start_char_idx": 3027, "end_char_idx": 3277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6199399-174b-4667-b2a5-68fa856b16cc": {"__data__": {"id_": "a6199399-174b-4667-b2a5-68fa856b16cc", "embedding": null, "metadata": {"window": "our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance. ", "original_text": "We also remain committed to returning capital to our shareholders. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b6fb4f3-355d-42be-b9fa-955f9357b46f", "node_type": "1", "metadata": {"window": "Our free cash flow guidance includes approximately $900 million of negative impacts from our European operations and divested\nassets.  our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "original_text": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09b3ede2b6cd1a5e24b774b06dd8571011544c2aa7b46cbc70d1f760a4f1caa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98ea4131-fc07-4bc7-a197-e82a225850ef", "node_type": "1", "metadata": {"window": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "original_text": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. "}, "hash": "828fe8cb923bcca4dc75acd14211ee3ff9d95da000a748d15977d536cc095933", "class_name": "RelatedNodeInfo"}}, "text": "We also remain committed to returning capital to our shareholders. ", "start_char_idx": 3277, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98ea4131-fc07-4bc7-a197-e82a225850ef": {"__data__": {"id_": "98ea4131-fc07-4bc7-a197-e82a225850ef", "embedding": null, "metadata": {"window": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "original_text": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6199399-174b-4667-b2a5-68fa856b16cc", "node_type": "1", "metadata": {"window": "our North American businesses continue to generate strong free cash flow.  Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance. ", "original_text": "We also remain committed to returning capital to our shareholders. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21e916b698ca1c963561fc29be69063b1c8f96a26b84ccbae701e5d543a695ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d", "node_type": "1", "metadata": {"window": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "original_text": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n"}, "hash": "d8886a2b47e3ca167e113704673b35cccbe8745c6f123cda8aa7e2eb8c7ad0c4", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "start_char_idx": 3344, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d": {"__data__": {"id_": "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d", "embedding": null, "metadata": {"window": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "original_text": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98ea4131-fc07-4bc7-a197-e82a225850ef", "node_type": "1", "metadata": {"window": "Our capital allocation priorities remain unchanged,\nand our strong balance sheet affords us the flexibility to pursue multiple capital allocation priorities concurrently.  We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "original_text": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c9a90aba13b601f93e529f5db105f098804433d3916d644d7f53bb99b3130c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "773e6222-2f4e-492d-adc5-542cd1c3547e", "node_type": "1", "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "original_text": "In summary, we are pleased with our first half fiscal 2023 performance. "}, "hash": "dfa94a322847304e4bba369a6b61bf51c582e4ff423e2d605a3ffe5a8f4206c5", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "start_char_idx": 3527, "end_char_idx": 3709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "773e6222-2f4e-492d-adc5-542cd1c3547e": {"__data__": {"id_": "773e6222-2f4e-492d-adc5-542cd1c3547e", "embedding": null, "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "original_text": "In summary, we are pleased with our first half fiscal 2023 performance. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d", "node_type": "1", "metadata": {"window": "We will continue\nto prioritize growth, principally in the areas of oncology and biopharma services, as evidenced by our joint venture with the Sarah\nCannon Research Institute, the acquisition of Genospace and the acquisition of Rx Savings Solutions.\n We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "original_text": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4237164cdd4af597b4e28af65b05931d7358e025cf94c3c2c187eed106ecd9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9809b361-864e-4f7c-adf5-a967e2d7f42c", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. "}, "hash": "4e42090cbaa00ddc686d53cbf9b11d232d44ccf10a5895cc9e399047a7761567", "class_name": "RelatedNodeInfo"}}, "text": "In summary, we are pleased with our first half fiscal 2023 performance. ", "start_char_idx": 3709, "end_char_idx": 3781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9809b361-864e-4f7c-adf5-a967e2d7f42c": {"__data__": {"id_": "9809b361-864e-4f7c-adf5-a967e2d7f42c", "embedding": null, "metadata": {"window": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "773e6222-2f4e-492d-adc5-542cd1c3547e", "node_type": "1", "metadata": {"window": "We also remain committed to returning capital to our shareholders.  Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "original_text": "In summary, we are pleased with our first half fiscal 2023 performance. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1577f097030d16a889b7b9dcfbda02b2117ad662c3d7f2b0c3e0c8a2133aba03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a2f41f-b80c-4dca-8a03-874ecbdd2f73", "node_type": "1", "metadata": {"window": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. "}, "hash": "1bf55d2bfdaff4390e67b6dc10e7e389a26dc157b2508a99738759f4d59b47c3", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "start_char_idx": 3781, "end_char_idx": 3974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a2f41f-b80c-4dca-8a03-874ecbdd2f73": {"__data__": {"id_": "64a2f41f-b80c-4dca-8a03-874ecbdd2f73", "embedding": null, "metadata": {"window": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9809b361-864e-4f7c-adf5-a967e2d7f42c", "node_type": "1", "metadata": {"window": "Our outlook incorporates plans to repurchase approximately $3.5\nbillion of shares in fiscal 2023, which we anticipate will be largely complete by the end of our fiscal third quarter.  As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23d0e44bf4337ab0bd205d829dc008563ca81fec5fa56930797752a8bac776a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fb6958f-8ebe-475f-976e-de7763b393a8", "node_type": "1", "metadata": {"window": "In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n"}, "hash": "a4f8389ee6a040c07a3ddc18a141972fc37beeec6e7a82e3b6b7fe62306cb8fc", "class_name": "RelatedNodeInfo"}}, "text": "We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "start_char_idx": 3974, "end_char_idx": 4089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fb6958f-8ebe-475f-976e-de7763b393a8": {"__data__": {"id_": "5fb6958f-8ebe-475f-976e-de7763b393a8", "embedding": null, "metadata": {"window": "In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a2f41f-b80c-4dca-8a03-874ecbdd2f73", "node_type": "1", "metadata": {"window": "As a result of the\nshare repurchase activity, we estimate weighted average diluted shares outstanding for fiscal 2023 to be in the range of approximately\n142 million to 144 million.\n In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ef13e392c2e958bb68663c6e2b6bbc506166440316cf1d722f307046c7c91c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b447c33b-6fd7-4585-86a7-3815397d358c", "node_type": "1", "metadata": {"window": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "And with that, I'll turn the call back over to the operator for Q&A."}, "hash": "989bb2c07b8a822e300a6c1de7e497e2b9da84e1e4ced04c3f41c08604eed9a0", "class_name": "RelatedNodeInfo"}}, "text": "Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "start_char_idx": 4089, "end_char_idx": 4253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b447c33b-6fd7-4585-86a7-3815397d358c": {"__data__": {"id_": "b447c33b-6fd7-4585-86a7-3815397d358c", "embedding": null, "metadata": {"window": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "And with that, I'll turn the call back over to the operator for Q&A.", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b59b0f62-221c-4bbb-a914-c70e8c961380", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47c55bae202246c0898bee7f1d071d3622ea978e21766356f4f7d740e84ba73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fb6958f-8ebe-475f-976e-de7763b393a8", "node_type": "1", "metadata": {"window": "In summary, we are pleased with our first half fiscal 2023 performance.  The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4295e4ea89327d17320867383e16bfb6b063813e325c194c802dc8c62a10e173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc478d1b-3aee-407f-9b34-bb178aae215f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "05d366d9047e0054562a6516619e7fff093112bbc9c0abb9c93ef3bcca10e3b7", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll turn the call back over to the operator for Q&A.", "start_char_idx": 4253, "end_char_idx": 4321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc478d1b-3aee-407f-9b34-bb178aae215f": {"__data__": {"id_": "bc478d1b-3aee-407f-9b34-bb178aae215f", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b447c33b-6fd7-4585-86a7-3815397d358c", "node_type": "1", "metadata": {"window": "The strength of our business model, the value of our products\nand capabilities and the execution of our proven strategies gives us the confidence and visibility to raise our earnings guidance.  We\ncontinue to create value for our share owners through solid growth, cash flow generation and return of capital.  Our strong leadership\nand the tremendous ongoing commitment of our people across McKesson gives us confidence that we will continue to deliver\nsustainable results.\n And with that, I'll turn the call back over to the operator for Q&A.", "original_text": "And with that, I'll turn the call back over to the operator for Q&A.", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd3933e70e34c1642e2e1d1dceae0d1ef630e86979f64a88ea6208502a9a649c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "933bf691-d8f1-436d-81a4-35f8210be68d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "original_text": "All Rights reserved.\n"}, "hash": "b1d446b83eccda1d131e9ae791bb7903699a345adc3d20f89c7f05b09159c2dd", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "933bf691-d8f1-436d-81a4-35f8210be68d": {"__data__": {"id_": "933bf691-d8f1-436d-81a4-35f8210be68d", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "original_text": "All Rights reserved.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc478d1b-3aee-407f-9b34-bb178aae215f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34aed1e5464edaadb0ecbf3da417e602184155fc93c340590f19ab712218475d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f129711-a0c7-4e9c-8cbb-245f9e740cb5", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically? ", "original_text": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n"}, "hash": "8f81a25abcf477986388db327f298cdf21cc410194318f22dc1da431280bac3d", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f129711-a0c7-4e9c-8cbb-245f9e740cb5": {"__data__": {"id_": "8f129711-a0c7-4e9c-8cbb-245f9e740cb5", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically? ", "original_text": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "933bf691-d8f1-436d-81a4-35f8210be68d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "original_text": "All Rights reserved.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d1d132abd40495bdb1ccbeab9b59c6036b76f5204ce44497d3a6cbbba64c73f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64d6f559-c48a-4083-a9a6-4a17a0dc74b4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "original_text": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. "}, "hash": "1dd3d8a603ce602dbff47969d1ca72f40881b406d44ae9e7ec8346382b5eb23f", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n", "start_char_idx": 158, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64d6f559-c48a-4083-a9a6-4a17a0dc74b4": {"__data__": {"id_": "64d6f559-c48a-4083-a9a6-4a17a0dc74b4", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "original_text": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f129711-a0c7-4e9c-8cbb-245f9e740cb5", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically? ", "original_text": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0626bcaf0794dc07ae0ac069f69f0212a4ac575df064e9985513e31ddb704900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b5c0825-6751-4e13-a015-875a0409071e", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes. ", "original_text": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? "}, "hash": "9fb0fc03daec1f299324fb017b872e1da96d6186d7324c2a09b232d7fc1197b5", "class_name": "RelatedNodeInfo"}}, "text": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "start_char_idx": 311, "end_char_idx": 534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b5c0825-6751-4e13-a015-875a0409071e": {"__data__": {"id_": "0b5c0825-6751-4e13-a015-875a0409071e", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes. ", "original_text": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64d6f559-c48a-4083-a9a6-4a17a0dc74b4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "original_text": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9bfd25e8016f5dc7babe4d33ec80a95f71b6d1f2045b7a786639b9856edbda7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3fed86-0ed5-4f17-ad60-8196b8d54b65", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian. ", "original_text": "How much of this is driven by specialty distribution, specifically? "}, "hash": "70a83fd669fa74e7f2977f402e625bddbfdf95a980eb2eb70e3d7e4617ea7623", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "start_char_idx": 534, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3fed86-0ed5-4f17-ad60-8196b8d54b65": {"__data__": {"id_": "dc3fed86-0ed5-4f17-ad60-8196b8d54b65", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian. ", "original_text": "How much of this is driven by specialty distribution, specifically? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b5c0825-6751-4e13-a015-875a0409071e", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes. ", "original_text": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0f4f8f91b2fca6c1a1588d3836cce3a8659c1aac4ebf82483e9a2c69a3903fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4a66be9-066b-44af-a479-06c4c12ca78c", "node_type": "1", "metadata": {"window": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like. ", "original_text": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n"}, "hash": "1d14b3fb4ce60cac54f4a5c014c8d590b22df62267524fd9e961591f552216e4", "class_name": "RelatedNodeInfo"}}, "text": "How much of this is driven by specialty distribution, specifically? ", "start_char_idx": 651, "end_char_idx": 719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4a66be9-066b-44af-a479-06c4c12ca78c": {"__data__": {"id_": "f4a66be9-066b-44af-a479-06c4c12ca78c", "embedding": null, "metadata": {"window": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like. ", "original_text": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3fed86-0ed5-4f17-ad60-8196b8d54b65", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian. ", "original_text": "How much of this is driven by specialty distribution, specifically? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44925d5520141f938666281f4422af5edee7e8c56cb95a2f469c0c0c29a90cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc81a8f-3e72-4750-9e66-afdbcc86130f", "node_type": "1", "metadata": {"window": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "original_text": "Brian S. Tyler\nCEO & Director\nYes. "}, "hash": "929732bc20c6a3d420ea7aeb4b03ac041fea427cb07e8285b4b8a783ee499f7a", "class_name": "RelatedNodeInfo"}}, "text": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "start_char_idx": 719, "end_char_idx": 903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc81a8f-3e72-4750-9e66-afdbcc86130f": {"__data__": {"id_": "0cc81a8f-3e72-4750-9e66-afdbcc86130f", "embedding": null, "metadata": {"window": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "original_text": "Brian S. Tyler\nCEO & Director\nYes. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4a66be9-066b-44af-a479-06c4c12ca78c", "node_type": "1", "metadata": {"window": "Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account.  Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like. ", "original_text": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c4d1538c010da1722ff787469526c7e2c1c6e06c949ec3496b7e56c4ab2c213", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab5b7e2d-a8e8-489d-b77e-6f391b438607", "node_type": "1", "metadata": {"window": "How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "original_text": "Eric, it's Brian. "}, "hash": "329e2eca6b8998a16661db8a31d32420fa8d684a10985f5efa9f74fbea69e962", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nYes. ", "start_char_idx": 903, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab5b7e2d-a8e8-489d-b77e-6f391b438607": {"__data__": {"id_": "ab5b7e2d-a8e8-489d-b77e-6f391b438607", "embedding": null, "metadata": {"window": "How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "original_text": "Eric, it's Brian. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc81a8f-3e72-4750-9e66-afdbcc86130f", "node_type": "1", "metadata": {"window": "Can you give us some sense for what you think is going on with the macro\ntrend if that's continuing to run stronger?  How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "original_text": "Brian S. Tyler\nCEO & Director\nYes. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "895b3cfd9b3e307d47053a9a0cf6d219cab40f9daf55e2eeda23ff7af24861bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a", "node_type": "1", "metadata": {"window": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "original_text": "I'll jump in and then Britt can add any color that he'd like. "}, "hash": "8ec626040169ee8de59f7027910c7a14db660eecce0e45c135ec1473312dd6ef", "class_name": "RelatedNodeInfo"}}, "text": "Eric, it's Brian. ", "start_char_idx": 938, "end_char_idx": 956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a": {"__data__": {"id_": "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a", "embedding": null, "metadata": {"window": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "original_text": "I'll jump in and then Britt can add any color that he'd like. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab5b7e2d-a8e8-489d-b77e-6f391b438607", "node_type": "1", "metadata": {"window": "How much of this is driven by specialty distribution, specifically?  And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "original_text": "Eric, it's Brian. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbb2dd2b9e5fa75ddc68fd5e1f73dd723fc9f418140b32ed6c5d288d4bc2e82f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6983815-d7eb-4ef7-8924-4cc803761c9d", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "original_text": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. "}, "hash": "9e0f6ef6f58dc901e2e5aa5ef37020d39c5d93fee020f8db616e4cfbb24dcd04", "class_name": "RelatedNodeInfo"}}, "text": "I'll jump in and then Britt can add any color that he'd like. ", "start_char_idx": 956, "end_char_idx": 1018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6983815-d7eb-4ef7-8924-4cc803761c9d": {"__data__": {"id_": "f6983815-d7eb-4ef7-8924-4cc803761c9d", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "original_text": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a", "node_type": "1", "metadata": {"window": "And then do you think that\nthere's an element of investments you made in specialty fiscal year '19 to '21 and/or ongoing investments that are also helping generate\nabove-market trend?\n Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "original_text": "I'll jump in and then Britt can add any color that he'd like. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cbcfc0bdbef73c46aa75b6c05a801844bbf87d7324097550d6bce2742dddcb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caee653d-b60b-4ed5-892e-71d6b7f4947c", "node_type": "1", "metadata": {"window": "Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "original_text": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. "}, "hash": "79e1890f1aea95ba06832dd617f9fd78cb466ab909addc9874e7eff1895e32ff", "class_name": "RelatedNodeInfo"}}, "text": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "start_char_idx": 1018, "end_char_idx": 1148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caee653d-b60b-4ed5-892e-71d6b7f4947c": {"__data__": {"id_": "caee653d-b60b-4ed5-892e-71d6b7f4947c", "embedding": null, "metadata": {"window": "Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "original_text": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6983815-d7eb-4ef7-8924-4cc803761c9d", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nYes.  Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "original_text": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8667a004ddcd7e0d9743a200368c6400966e6b0e93ab267ae38dc9e7e99efc0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f24e1d8-03ab-46c2-85d3-c4110d708495", "node_type": "1", "metadata": {"window": "I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "original_text": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n"}, "hash": "2fb13121ec8b8b1afebd356c530f62fb65caef7d16e535331be4fb2c62560f25", "class_name": "RelatedNodeInfo"}}, "text": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "start_char_idx": 1148, "end_char_idx": 1359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f24e1d8-03ab-46c2-85d3-c4110d708495": {"__data__": {"id_": "5f24e1d8-03ab-46c2-85d3-c4110d708495", "embedding": null, "metadata": {"window": "I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "original_text": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caee653d-b60b-4ed5-892e-71d6b7f4947c", "node_type": "1", "metadata": {"window": "Eric, it's Brian.  I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "original_text": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08804d7da7baab692d040e3a5561f1af2c15cce17b6db8c15149491ac7236af2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "deca4694-c872-45a2-9f6d-dc69e276925f", "node_type": "1", "metadata": {"window": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n", "original_text": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. "}, "hash": "2a0cacc04b096df83e7ba2970aa85c426499febe9549e24f0ae6a970599c4220", "class_name": "RelatedNodeInfo"}}, "text": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "start_char_idx": 1359, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "deca4694-c872-45a2-9f6d-dc69e276925f": {"__data__": {"id_": "deca4694-c872-45a2-9f6d-dc69e276925f", "embedding": null, "metadata": {"window": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n", "original_text": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f24e1d8-03ab-46c2-85d3-c4110d708495", "node_type": "1", "metadata": {"window": "I'll jump in and then Britt can add any color that he'd like.  I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "original_text": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dd6edc06ffc3bce5d20e88a724f82be5693b6fdbe4550d7858966462ec392c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41", "node_type": "1", "metadata": {"window": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "original_text": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. "}, "hash": "ac29a8f25dc99f8e5d045b8a03a97ea4de02a674ca3a3b8cd82ddbed5520a354", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "start_char_idx": 1513, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41": {"__data__": {"id_": "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41", "embedding": null, "metadata": {"window": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "original_text": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "deca4694-c872-45a2-9f6d-dc69e276925f", "node_type": "1", "metadata": {"window": "I mean, first off, just in terms of kind of overall market\ntrends and expectations, I think I'd characterize it as pretty stable.  I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n", "original_text": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a83d6166bd0bac70665f801e3a20e3c88a5100ba7bd31c8e3fb38c5de1859d3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f18e1e37-7eb9-4a56-80c5-2dec765e8735", "node_type": "1", "metadata": {"window": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth. ", "original_text": "We have pretty robust value propositions for our community\nproviders and our hospital partners. "}, "hash": "281daf93c579e5a06a226196e7ebe5ad10b128ddc9dd29bc498e57a04dffa957", "class_name": "RelatedNodeInfo"}}, "text": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "start_char_idx": 1716, "end_char_idx": 1858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f18e1e37-7eb9-4a56-80c5-2dec765e8735": {"__data__": {"id_": "f18e1e37-7eb9-4a56-80c5-2dec765e8735", "embedding": null, "metadata": {"window": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth. ", "original_text": "We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41", "node_type": "1", "metadata": {"window": "I think that the volume in terms of prescription transactions that\nwe've been seeing is in line with what we expected at the beginning of the year, probably slightly ahead of where we would have\nbeen pre-COVID.  I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "original_text": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2271af114d7648043d4bc8b8ecab3549fd3f075c94555326c12e7cec1f6dda0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a36b792d-be97-4121-8648-e28b104a77dd", "node_type": "1", "metadata": {"window": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "original_text": "We think we bring them solutions that help them do their business better.\n"}, "hash": "1cbb2ca4e1bd4bcd595b0a16f0198e3992e881b05cc34e5c55afb813b50ce4dc", "class_name": "RelatedNodeInfo"}}, "text": "We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "start_char_idx": 1858, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a36b792d-be97-4121-8648-e28b104a77dd": {"__data__": {"id_": "a36b792d-be97-4121-8648-e28b104a77dd", "embedding": null, "metadata": {"window": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "original_text": "We think we bring them solutions that help them do their business better.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f18e1e37-7eb9-4a56-80c5-2dec765e8735", "node_type": "1", "metadata": {"window": "I mean there are parts of the market that are still recovering, but as a general characterization, I would say it's pretty\nstable and pretty good growth.\n As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth. ", "original_text": "We have pretty robust value propositions for our community\nproviders and our hospital partners. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d177cbcf0c1f08ad282c08f973e9244d4a6f3284d70443b0ea7fe2ea1291be2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "378e410b-a86b-43f6-85c5-d4bd15c1bf3d", "node_type": "1", "metadata": {"window": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "original_text": "And so I would just say it's probably a combination of all of those things that are supporting our growth. "}, "hash": "077e0474d8f821057ebd472e7f756b9908439a29dfdc450212c7fd9c098e9d10", "class_name": "RelatedNodeInfo"}}, "text": "We think we bring them solutions that help them do their business better.\n", "start_char_idx": 1954, "end_char_idx": 2028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "378e410b-a86b-43f6-85c5-d4bd15c1bf3d": {"__data__": {"id_": "378e410b-a86b-43f6-85c5-d4bd15c1bf3d", "embedding": null, "metadata": {"window": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "original_text": "And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a36b792d-be97-4121-8648-e28b104a77dd", "node_type": "1", "metadata": {"window": "As it relates to some of the McKesson-specific assets, we've spent the better part of 15 years building up our differentiated capabilities\nin community distribution with particular strength in oncology.  And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "original_text": "We think we bring them solutions that help them do their business better.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0512514d0ae08f7dd4ddef0bc36bf279c9cf38672494a3413889839a3dcb0dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e12a7cfd-282b-4014-ad46-44a81bc1f6f1", "node_type": "1", "metadata": {"window": "We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments. ", "original_text": "Biosimilars, while still early,\nhas certainly helped support that growth. "}, "hash": "9464bd0502ae02c05a350b90ed8b07aeb18b26a393842f458f0532557116d882", "class_name": "RelatedNodeInfo"}}, "text": "And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "start_char_idx": 2028, "end_char_idx": 2135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e12a7cfd-282b-4014-ad46-44a81bc1f6f1": {"__data__": {"id_": "e12a7cfd-282b-4014-ad46-44a81bc1f6f1", "embedding": null, "metadata": {"window": "We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments. ", "original_text": "Biosimilars, while still early,\nhas certainly helped support that growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "378e410b-a86b-43f6-85c5-d4bd15c1bf3d", "node_type": "1", "metadata": {"window": "And I think as we look at the growth of the oncology pipeline, we\nthink that, that continues to be a strength, certainly supports our growth.  We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "original_text": "And so I would just say it's probably a combination of all of those things that are supporting our growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02ea9791389c48446c1d95d2112cc91a66f1168dd82994635ed254bcd9d12d76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "432653f7-2817-4c99-8f7c-be47f3daf8d8", "node_type": "1", "metadata": {"window": "We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "original_text": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n"}, "hash": "fe35ba22b636fe359a3d1bce1a72bd341b35d42f1d0b9adf0d8776200c7ae5ab", "class_name": "RelatedNodeInfo"}}, "text": "Biosimilars, while still early,\nhas certainly helped support that growth. ", "start_char_idx": 2135, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "432653f7-2817-4c99-8f7c-be47f3daf8d8": {"__data__": {"id_": "432653f7-2817-4c99-8f7c-be47f3daf8d8", "embedding": null, "metadata": {"window": "We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "original_text": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e12a7cfd-282b-4014-ad46-44a81bc1f6f1", "node_type": "1", "metadata": {"window": "We have pretty robust value propositions for our community\nproviders and our hospital partners.  We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments. ", "original_text": "Biosimilars, while still early,\nhas certainly helped support that growth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23899d13e9a1b20d9f0ae761ba768988cba85b97b622c4c97082c6d41b4cca98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70861cc4-88cf-47b0-9023-81dba098f026", "node_type": "1", "metadata": {"window": "And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. "}, "hash": "cf6022f16be0bc541e5299cd8939563bd643079c12879b0e013c40ad099f4d1d", "class_name": "RelatedNodeInfo"}}, "text": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "start_char_idx": 2209, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70861cc4-88cf-47b0-9023-81dba098f026": {"__data__": {"id_": "70861cc4-88cf-47b0-9023-81dba098f026", "embedding": null, "metadata": {"window": "And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "432653f7-2817-4c99-8f7c-be47f3daf8d8", "node_type": "1", "metadata": {"window": "We think we bring them solutions that help them do their business better.\n And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "original_text": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "605325366ecd5edae7d9f9f140c9ddf29cd30b6df38c3725b1793407b128e386", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f", "node_type": "1", "metadata": {"window": "Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology. ", "original_text": "Maybe I'll just make a comment on the investments. "}, "hash": "793f2313769a71f11894f8857017db51a535272e351e742afd2b9a6d9178bd1e", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "start_char_idx": 2302, "end_char_idx": 2360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f": {"__data__": {"id_": "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f", "embedding": null, "metadata": {"window": "Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology. ", "original_text": "Maybe I'll just make a comment on the investments. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70861cc4-88cf-47b0-9023-81dba098f026", "node_type": "1", "metadata": {"window": "And so I would just say it's probably a combination of all of those things that are supporting our growth.  Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25ef15f81362c19b630f2a3955bc91bed70cae728b27a879c9dfde2c57066254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39da514b-4f5c-4ba7-9121-02c1513b7c81", "node_type": "1", "metadata": {"window": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets. ", "original_text": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. "}, "hash": "c631c684b3719040810b3c49d29e750fcc72cd02f0b678fd0794071729377297", "class_name": "RelatedNodeInfo"}}, "text": "Maybe I'll just make a comment on the investments. ", "start_char_idx": 2360, "end_char_idx": 2411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39da514b-4f5c-4ba7-9121-02c1513b7c81": {"__data__": {"id_": "39da514b-4f5c-4ba7-9121-02c1513b7c81", "embedding": null, "metadata": {"window": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets. ", "original_text": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f", "node_type": "1", "metadata": {"window": "Biosimilars, while still early,\nhas certainly helped support that growth.  And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology. ", "original_text": "Maybe I'll just make a comment on the investments. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2067f6298f1833f65f41d8254d239197308a7f1ecb05dd6028a4e075a52c1854", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cda37ce-055b-4ebc-b1af-e7f30c902951", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "original_text": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n"}, "hash": "7a41a896f167986aaba3e040672e300ca795b0914980653ca5f935f53d04150d", "class_name": "RelatedNodeInfo"}}, "text": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "start_char_idx": 2411, "end_char_idx": 2636, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cda37ce-055b-4ebc-b1af-e7f30c902951": {"__data__": {"id_": "8cda37ce-055b-4ebc-b1af-e7f30c902951", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "original_text": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39da514b-4f5c-4ba7-9121-02c1513b7c81", "node_type": "1", "metadata": {"window": "And we think we're well positioned to continue to benefit as that trend continues to unfold.\n Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets. ", "original_text": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59150bcd0543ad1bec98ea8c5e72d35b063052a6c4251f9d8a3e1b66f02303f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3", "node_type": "1", "metadata": {"window": "Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n", "original_text": "And we're just going to continue to do that and lean into oncology. "}, "hash": "a3b39a088a6b0a76668f7ca2801ab0e206e20625403d03c3a7be8b566e48ba3c", "class_name": "RelatedNodeInfo"}}, "text": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "start_char_idx": 2636, "end_char_idx": 2796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3": {"__data__": {"id_": "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3", "embedding": null, "metadata": {"window": "Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n", "original_text": "And we're just going to continue to do that and lean into oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cda37ce-055b-4ebc-b1af-e7f30c902951", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nEric, this is Britt.  Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "original_text": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a96bf2bab7379fb2f55603d60a3c596ca037784ec935f63f8c3db29b570016c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb3c2e08-b2fd-49c7-9062-9d6ae7345339", "node_type": "1", "metadata": {"window": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "original_text": "We think that we have differentiated assets. "}, "hash": "1a81c5d58cf1aaf515d6049bc35d2f9f5eabd03cc7ee40ef9078277eac0e18ec", "class_name": "RelatedNodeInfo"}}, "text": "And we're just going to continue to do that and lean into oncology. ", "start_char_idx": 2796, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb3c2e08-b2fd-49c7-9062-9d6ae7345339": {"__data__": {"id_": "eb3c2e08-b2fd-49c7-9062-9d6ae7345339", "embedding": null, "metadata": {"window": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "original_text": "We think that we have differentiated assets. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3", "node_type": "1", "metadata": {"window": "Maybe I'll just make a comment on the investments.  We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n", "original_text": "And we're just going to continue to do that and lean into oncology. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3792b718ac05a127a9f5c14cc54b2364bf4bca242571356cc9e64f3e184b87a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8f4f225-d8df-467f-99ea-1f573ba67813", "node_type": "1", "metadata": {"window": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "original_text": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n"}, "hash": "ea53b8ea549dfb9483d6b89d9f12bb98d32bc35a509cbe0ed7024cb701ddbcf6", "class_name": "RelatedNodeInfo"}}, "text": "We think that we have differentiated assets. ", "start_char_idx": 2864, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f4f225-d8df-467f-99ea-1f573ba67813": {"__data__": {"id_": "d8f4f225-d8df-467f-99ea-1f573ba67813", "embedding": null, "metadata": {"window": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "original_text": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb3c2e08-b2fd-49c7-9062-9d6ae7345339", "node_type": "1", "metadata": {"window": "We have been investing in this space, and we talked about\ninvestments that we were making specifically in Ontada, which has become a really important part of really the breadth of assets and\ncapabilities we have in oncology.  And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "original_text": "We think that we have differentiated assets. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de4719d8dc0739af943e7c47f2a5ccdb65739044a4478b36d660a60a5777630c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c987e741-6c2f-4f40-b1e7-034c0515dd14", "node_type": "1", "metadata": {"window": "And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question. ", "original_text": "Operator\nAnd next is Michael Cherny with Bank of America.\n"}, "hash": "5c946e662d6826fe51e664b009974339f1d3a9d60664be9fa96a5b71432595cb", "class_name": "RelatedNodeInfo"}}, "text": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "start_char_idx": 2909, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c987e741-6c2f-4f40-b1e7-034c0515dd14": {"__data__": {"id_": "c987e741-6c2f-4f40-b1e7-034c0515dd14", "embedding": null, "metadata": {"window": "And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question. ", "original_text": "Operator\nAnd next is Michael Cherny with Bank of America.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8f4f225-d8df-467f-99ea-1f573ba67813", "node_type": "1", "metadata": {"window": "And Brian referenced today a strategic alliance that we're forming within Ontada with BeiGene,\nwhich is a good example of making investments for future growth.\n And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "original_text": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2e1529760c7fec46b44b51ea9b4b40b83b943a62d3cf7df01f1f581d4bfcddc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11242396-e904-4d80-9c67-657dfe4fa4f9", "node_type": "1", "metadata": {"window": "We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring? ", "original_text": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. "}, "hash": "a8d0ab271480ec9a22974b976668bb623f42388dd16558e8ea897a5b190906a7", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next is Michael Cherny with Bank of America.\n", "start_char_idx": 3158, "end_char_idx": 3216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11242396-e904-4d80-9c67-657dfe4fa4f9": {"__data__": {"id_": "11242396-e904-4d80-9c67-657dfe4fa4f9", "embedding": null, "metadata": {"window": "We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring? ", "original_text": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c987e741-6c2f-4f40-b1e7-034c0515dd14", "node_type": "1", "metadata": {"window": "And we're just going to continue to do that and lean into oncology.  We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question. ", "original_text": "Operator\nAnd next is Michael Cherny with Bank of America.\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "269b81ae6cf58227b6401db73f673b78ba7fead6c4fba10a63c06e0899128b8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56f6870d-6956-4140-be0f-bfe4ad558a3e", "node_type": "1", "metadata": {"window": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n", "original_text": "You talked about some of the hiring that you've done\nrelative to supporting customer actions. "}, "hash": "55249f22a8048ba31c71b63167002bc38d370d634a8d00cc983baed2eff683e7", "class_name": "RelatedNodeInfo"}}, "text": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "start_char_idx": 3216, "end_char_idx": 3355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56f6870d-6956-4140-be0f-bfe4ad558a3e": {"__data__": {"id_": "56f6870d-6956-4140-be0f-bfe4ad558a3e", "embedding": null, "metadata": {"window": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n", "original_text": "You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11242396-e904-4d80-9c67-657dfe4fa4f9", "node_type": "1", "metadata": {"window": "We think that we have differentiated assets.  And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring? ", "original_text": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dd951a1e0b544e468d253dbc8b78e8a0c60c0e516c5161d9f1df5dc045a99e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e34d7623-e1c4-4525-bbdb-920d0e26567b", "node_type": "1", "metadata": {"window": "Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "original_text": "I guess maybe a 2-part question. "}, "hash": "0e1db4721d45dbb70057190917eae360c6698fd7f9361e272a656db9cf48a518", "class_name": "RelatedNodeInfo"}}, "text": "You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "start_char_idx": 3355, "end_char_idx": 3449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e34d7623-e1c4-4525-bbdb-920d0e26567b": {"__data__": {"id_": "e34d7623-e1c4-4525-bbdb-920d0e26567b", "embedding": null, "metadata": {"window": "Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "original_text": "I guess maybe a 2-part question. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56f6870d-6956-4140-be0f-bfe4ad558a3e", "node_type": "1", "metadata": {"window": "And really, the breadth\nof services and capabilities we have from distribution, data and analytics, our Ontada business and now with the Sarah Cannon\nResearch joint venture, we feel well positioned to continue to lean in and make investments there.\n Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n", "original_text": "You talked about some of the hiring that you've done\nrelative to supporting customer actions. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85132795501ecc0f17211feb2333e23b85b37db5c7b4644c4b895ed10144a441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91f0d85a-1f3f-44c7-9663-3a53de628987", "node_type": "1", "metadata": {"window": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "original_text": "One, is that temporary hiring? "}, "hash": "b72eb2a40266b676d29461a0624d93fadab9790991ada89090f86b5b9b7e2bf1", "class_name": "RelatedNodeInfo"}}, "text": "I guess maybe a 2-part question. ", "start_char_idx": 3449, "end_char_idx": 3482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91f0d85a-1f3f-44c7-9663-3a53de628987": {"__data__": {"id_": "91f0d85a-1f3f-44c7-9663-3a53de628987", "embedding": null, "metadata": {"window": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "original_text": "One, is that temporary hiring? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e34d7623-e1c4-4525-bbdb-920d0e26567b", "node_type": "1", "metadata": {"window": "Operator\nAnd next is Michael Cherny with Bank of America.\n Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "original_text": "I guess maybe a 2-part question. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a12b8d6bdff78b092894b1f25fc19051fc738a2f5385376ca4e9d87498112433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6bc943c-8d7d-42a6-9c36-99bf27115c27", "node_type": "1", "metadata": {"window": "You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Or is that people that are going\nto be on your payroll going forward?\n"}, "hash": "85a6033139aeba7ad4a3fd9775421a748534203666abccb1f7cb3fb164f41f1f", "class_name": "RelatedNodeInfo"}}, "text": "One, is that temporary hiring? ", "start_char_idx": 3482, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6bc943c-8d7d-42a6-9c36-99bf27115c27": {"__data__": {"id_": "b6bc943c-8d7d-42a6-9c36-99bf27115c27", "embedding": null, "metadata": {"window": "You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Or is that people that are going\nto be on your payroll going forward?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91f0d85a-1f3f-44c7-9663-3a53de628987", "node_type": "1", "metadata": {"window": "Michael Aaron Cherny\nBofA Securities, Research Division\nI would love to dive into the Prescription Tech Solutions segment a bit, if I can.  You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "original_text": "One, is that temporary hiring? ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d13971f166c0c1866135a0bfc9daa26710de668de08f089574f355bdec10a27a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caff9b0d-66c5-45c3-a22f-055e7745f699", "node_type": "1", "metadata": {"window": "I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. "}, "hash": "b9b593b983b530fc745a55bed6e33da92a9aa2fbe9936a78bca1dd10327fa4ac", "class_name": "RelatedNodeInfo"}}, "text": "Or is that people that are going\nto be on your payroll going forward?\n", "start_char_idx": 3513, "end_char_idx": 3583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caff9b0d-66c5-45c3-a22f-055e7745f699": {"__data__": {"id_": "caff9b0d-66c5-45c3-a22f-055e7745f699", "embedding": null, "metadata": {"window": "I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6bc943c-8d7d-42a6-9c36-99bf27115c27", "node_type": "1", "metadata": {"window": "You talked about some of the hiring that you've done\nrelative to supporting customer actions.  I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Or is that people that are going\nto be on your payroll going forward?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ecb54dd84b82f0e9afb1bd0ec74832152ec464afb344d1afacf8b4e4def8a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d76dd05d-a113-4482-93dc-d29d431aaa00", "node_type": "1", "metadata": {"window": "One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n"}, "hash": "520f009b101a444f1d01159e8237ad97ff7219cdbe235f73d76b710909e53a44", "class_name": "RelatedNodeInfo"}}, "text": "And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "start_char_idx": 3583, "end_char_idx": 3718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d76dd05d-a113-4482-93dc-d29d431aaa00": {"__data__": {"id_": "d76dd05d-a113-4482-93dc-d29d431aaa00", "embedding": null, "metadata": {"window": "One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caff9b0d-66c5-45c3-a22f-055e7745f699", "node_type": "1", "metadata": {"window": "I guess maybe a 2-part question.  One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b20586656c48be12b2936879931075e3901a3c6f3c09fc1e434908e4a7dc8b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6139231-1e63-4d26-afdd-c9225fca96b8", "node_type": "1", "metadata": {"window": "Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Brian S. Tyler"}, "hash": "41b186d35806d0c2aad3311242bcdd5fac7179423b3f53f49aba83509a88022e", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "start_char_idx": 3718, "end_char_idx": 3889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6139231-1e63-4d26-afdd-c9225fca96b8": {"__data__": {"id_": "e6139231-1e63-4d26-afdd-c9225fca96b8", "embedding": null, "metadata": {"window": "Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Brian S. Tyler", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73a74bd265a71f87f4aa16263356f876a8e44a319ee7cf86aa381879ed4e73c3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d76dd05d-a113-4482-93dc-d29d431aaa00", "node_type": "1", "metadata": {"window": "One, is that temporary hiring?  Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99a0d062585aadc0dace7e1669a247368e3f4bbc98b0d138f910ac90aab94bb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d46d928-0be0-460f-8fd8-3377508ca906", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "28229b23a9871ec66322d380d37f4cc69663a880bd6e39074baed22416c8444e", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler", "start_char_idx": 903, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d46d928-0be0-460f-8fd8-3377508ca906": {"__data__": {"id_": "0d46d928-0be0-460f-8fd8-3377508ca906", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6139231-1e63-4d26-afdd-c9225fca96b8", "node_type": "1", "metadata": {"window": "Or is that people that are going\nto be on your payroll going forward?\n And then two, relative to the updated guidance, you took down revenue growth for the segment by 500 basis points but kept EBIT\ngrowth.  Can you give us a sense on what the difference is between those 2 levels and how you're able to generate the sustained EBIT\nperformance despite the slower revenue growth?\n Brian S. Tyler", "original_text": "Brian S. Tyler", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3bb9f5997f1222f1ab275c0fdeefbdd69cd00d4f3e5dbb9b296031412057bc99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea4d9b24-f66e-40d6-9243-e5cb52b555a3", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part. ", "original_text": "All Rights reserved.\n"}, "hash": "5e6472917f5aae6145374bcf0e59f7baad57a7c23fb8dde91776f3eb505f136f", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea4d9b24-f66e-40d6-9243-e5cb52b555a3": {"__data__": {"id_": "ea4d9b24-f66e-40d6-9243-e5cb52b555a3", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part. ", "original_text": "All Rights reserved.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d46d928-0be0-460f-8fd8-3377508ca906", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cc010ae2e7195bc6438926f3222e70c2d11fedec7c7aab4cfb7a9405b13dd55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "original_text": "spglobal.com/marketintelligence 12CEO & Director\nYes. "}, "hash": "3c98608344b91286768edc4eb21b0f7e6c4b0ec2541f2eedc04db1fa0bcb9753", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0": {"__data__": {"id_": "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "original_text": "spglobal.com/marketintelligence 12CEO & Director\nYes. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea4d9b24-f66e-40d6-9243-e5cb52b555a3", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part. ", "original_text": "All Rights reserved.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "936ff834950f35eb6a054d44f136d2b5a32d7e5d8b9d372626c62a4220a42b15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "074f3e11-0102-4891-829a-e7b37cbe5ce9", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "original_text": "Sure, Michael. "}, "hash": "a6029f53ee636fc1b18766e9d48c99084c598a29c83db8bc398d6de94a9fc87e", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 12CEO & Director\nYes. ", "start_char_idx": 158, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "074f3e11-0102-4891-829a-e7b37cbe5ce9": {"__data__": {"id_": "074f3e11-0102-4891-829a-e7b37cbe5ce9", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "original_text": "Sure, Michael. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "original_text": "spglobal.com/marketintelligence 12CEO & Director\nYes. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0911b6c322c5e09c9c6ae1f30cd4a8550f44261966baaa34da43cbf149a4b849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c31f23d-094b-4365-8687-f95bdff9fab7", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary. ", "original_text": "I'll take the first part of that question, and then Britt can take the second part. "}, "hash": "4a69a6cac9948b327f5ca3f2ca994aed964257a43fdf4b2136d122573070d479", "class_name": "RelatedNodeInfo"}}, "text": "Sure, Michael. ", "start_char_idx": 212, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c31f23d-094b-4365-8687-f95bdff9fab7": {"__data__": {"id_": "2c31f23d-094b-4365-8687-f95bdff9fab7", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary. ", "original_text": "I'll take the first part of that question, and then Britt can take the second part. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "074f3e11-0102-4891-829a-e7b37cbe5ce9", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "original_text": "Sure, Michael. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24c257fc7a7283d5534470c707bedf0ec22acda5384474cc676e34a914fa09c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690e948e-bb47-44f3-a629-456d9f63c256", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n", "original_text": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. "}, "hash": "e5726cd84878beae671ca6f18adc19eb6733f189c7586411ea4da3eaeb0515dc", "class_name": "RelatedNodeInfo"}}, "text": "I'll take the first part of that question, and then Britt can take the second part. ", "start_char_idx": 227, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690e948e-bb47-44f3-a629-456d9f63c256": {"__data__": {"id_": "690e948e-bb47-44f3-a629-456d9f63c256", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n", "original_text": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c31f23d-094b-4365-8687-f95bdff9fab7", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary. ", "original_text": "I'll take the first part of that question, and then Britt can take the second part. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7962eb018a2f99b835c9d21dd7f854cd05030c310154f915e2f0d25440099f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e507426-2081-4485-ba8e-508754499e3b", "node_type": "1", "metadata": {"window": "Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "original_text": "And it is, I guess, you could call\nit seasonal or a spike, if you will. "}, "hash": "47f402df618536c59d30bd394df0b5591684454c8c37c8611acbf1f250a814b6", "class_name": "RelatedNodeInfo"}}, "text": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "start_char_idx": 311, "end_char_idx": 450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e507426-2081-4485-ba8e-508754499e3b": {"__data__": {"id_": "5e507426-2081-4485-ba8e-508754499e3b", "embedding": null, "metadata": {"window": "Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "original_text": "And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690e948e-bb47-44f3-a629-456d9f63c256", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n", "original_text": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24c4abd3c0d2d7b881e03e44f143467ab8715f772f580bd2e0062aa636691cba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "651c7e54-3c83-4251-95d7-4e1ac7aa3569", "node_type": "1", "metadata": {"window": "I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want. ", "original_text": "We don't expect it to be temporary. "}, "hash": "6b71bbd5580ad28f2d554d5d8e214d2d3c623003b1a7ae836d37e24788ab41e7", "class_name": "RelatedNodeInfo"}}, "text": "And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "start_char_idx": 450, "end_char_idx": 522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "651c7e54-3c83-4251-95d7-4e1ac7aa3569": {"__data__": {"id_": "651c7e54-3c83-4251-95d7-4e1ac7aa3569", "embedding": null, "metadata": {"window": "I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want. ", "original_text": "We don't expect it to be temporary. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e507426-2081-4485-ba8e-508754499e3b", "node_type": "1", "metadata": {"window": "Sure, Michael.  I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "original_text": "And it is, I guess, you could call\nit seasonal or a spike, if you will. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60556739363699b9ae858890be9d5a41f3e040a18e27f0edd9c9d08fb55c89fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "396104b3-5344-42ee-9df1-20398637dc71", "node_type": "1", "metadata": {"window": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "original_text": "It's recurring every year.\n"}, "hash": "6cb3951f16ef42ccf7855eaa452efa6430d9f6300b0762683b5ec4fdd0c37e04", "class_name": "RelatedNodeInfo"}}, "text": "We don't expect it to be temporary. ", "start_char_idx": 522, "end_char_idx": 558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "396104b3-5344-42ee-9df1-20398637dc71": {"__data__": {"id_": "396104b3-5344-42ee-9df1-20398637dc71", "embedding": null, "metadata": {"window": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "original_text": "It's recurring every year.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "651c7e54-3c83-4251-95d7-4e1ac7aa3569", "node_type": "1", "metadata": {"window": "I'll take the first part of that question, and then Britt can take the second part.  So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want. ", "original_text": "We don't expect it to be temporary. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17fe54a0229680a4812f7ee839ce34e33fa4254fd56799197ca2194dbecdabec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e9c3fba-df23-42de-8b24-86f1347bd783", "node_type": "1", "metadata": {"window": "And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "original_text": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. "}, "hash": "dcff63308518188da7c70c198b533cb7c0e81fc72795fd2991ea5454bf298d5f", "class_name": "RelatedNodeInfo"}}, "text": "It's recurring every year.\n", "start_char_idx": 558, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e9c3fba-df23-42de-8b24-86f1347bd783": {"__data__": {"id_": "5e9c3fba-df23-42de-8b24-86f1347bd783", "embedding": null, "metadata": {"window": "And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "original_text": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "396104b3-5344-42ee-9df1-20398637dc71", "node_type": "1", "metadata": {"window": "So relative to the hiring, there is a\nannual component to some of these programs where we have to reverify patients' eligibility and such.  And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "original_text": "It's recurring every year.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e92e6a5541726ea047f27023d3aa7c395b83e5814dbab820fe53b66728d048e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4b3357b-ad75-4122-ba31-a14d674d92d8", "node_type": "1", "metadata": {"window": "We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "original_text": "And frankly, we didn't attrit as much as we'd want. "}, "hash": "9c10d1603fce4b2d342b093b4338a3d8c4dee4c9eb22b0036b7205815fb90fcf", "class_name": "RelatedNodeInfo"}}, "text": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "start_char_idx": 585, "end_char_idx": 772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4b3357b-ad75-4122-ba31-a14d674d92d8": {"__data__": {"id_": "c4b3357b-ad75-4122-ba31-a14d674d92d8", "embedding": null, "metadata": {"window": "We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "original_text": "And frankly, we didn't attrit as much as we'd want. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e9c3fba-df23-42de-8b24-86f1347bd783", "node_type": "1", "metadata": {"window": "And it is, I guess, you could call\nit seasonal or a spike, if you will.  We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "original_text": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac66947dc22688d5dcb6ccaf9e8c19b81c0e5e842dcb8dbe87ac2e6263d4c3f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13531f0c-456f-45aa-b3d5-17743bfe45f4", "node_type": "1", "metadata": {"window": "It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter. ", "original_text": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. "}, "hash": "396091e8cae8c7ce6b78c9d0eefd5bf31b34cdd94b6f8aea4612496ebd38dbc3", "class_name": "RelatedNodeInfo"}}, "text": "And frankly, we didn't attrit as much as we'd want. ", "start_char_idx": 772, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13531f0c-456f-45aa-b3d5-17743bfe45f4": {"__data__": {"id_": "13531f0c-456f-45aa-b3d5-17743bfe45f4", "embedding": null, "metadata": {"window": "It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter. ", "original_text": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4b3357b-ad75-4122-ba31-a14d674d92d8", "node_type": "1", "metadata": {"window": "We don't expect it to be temporary.  It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "original_text": "And frankly, we didn't attrit as much as we'd want. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b85f5520532a7f3164cea148502071b20189887f81a177fb1e8ba980f6ad93a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7bb97df-6c5f-406d-be32-be85dc3c3657", "node_type": "1", "metadata": {"window": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "original_text": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n"}, "hash": "ddf8eec6fe8b0703e4f1ce2097462458d2806b72fae218b98cac98969900e7f3", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "start_char_idx": 824, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7bb97df-6c5f-406d-be32-be85dc3c3657": {"__data__": {"id_": "c7bb97df-6c5f-406d-be32-be85dc3c3657", "embedding": null, "metadata": {"window": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "original_text": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13531f0c-456f-45aa-b3d5-17743bfe45f4", "node_type": "1", "metadata": {"window": "It's recurring every year.\n Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter. ", "original_text": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2db755b48a59f0ce649e6289ac4e5f9494195b563401acabd74374d77daf0ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2df5f233-4b9e-47a3-a89a-d00ef487de3f", "node_type": "1", "metadata": {"window": "And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. "}, "hash": "cf13f81e2db45e7ccc329611d40a66f8a779ff6fc86cf47efbfe25328b1314be", "class_name": "RelatedNodeInfo"}}, "text": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "start_char_idx": 915, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2df5f233-4b9e-47a3-a89a-d00ef487de3f": {"__data__": {"id_": "2df5f233-4b9e-47a3-a89a-d00ef487de3f", "embedding": null, "metadata": {"window": "And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7bb97df-6c5f-406d-be32-be85dc3c3657", "node_type": "1", "metadata": {"window": "Candidly, as we came into this period with the labor market looking like it was looking, we were probably aggressive in trying to\nmake sure we could secure those resources ahead of time.  And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "original_text": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd8350c163be6965968d1d300634e71b8e31b7838a21202a016b4f0edad5df78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7363960-3c10-40ae-ad8b-162dab04e454", "node_type": "1", "metadata": {"window": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "original_text": "And that business can often be lumpy quarter-to-quarter. "}, "hash": "9ef0554116aa09cc9a5b478d914fe7c4a87cb8eed58baa70b64345b8592725d9", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "start_char_idx": 1009, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7363960-3c10-40ae-ad8b-162dab04e454": {"__data__": {"id_": "a7363960-3c10-40ae-ad8b-162dab04e454", "embedding": null, "metadata": {"window": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "original_text": "And that business can often be lumpy quarter-to-quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2df5f233-4b9e-47a3-a89a-d00ef487de3f", "node_type": "1", "metadata": {"window": "And frankly, we didn't attrit as much as we'd want.  So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c507fd7408dfe79d50f8c5c5cae6bf9c7dbc8bd450b9ff40f5530cdfdaac69e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770", "node_type": "1", "metadata": {"window": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n", "original_text": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. "}, "hash": "c41a0627ec6ebc9fbc468b82669502e7b345337a5395518496796621e458b71b", "class_name": "RelatedNodeInfo"}}, "text": "And that business can often be lumpy quarter-to-quarter. ", "start_char_idx": 1232, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770": {"__data__": {"id_": "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770", "embedding": null, "metadata": {"window": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n", "original_text": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7363960-3c10-40ae-ad8b-162dab04e454", "node_type": "1", "metadata": {"window": "So I think it's a good\nreflection of McKesson as an employer of choice in the marketplace.  But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "original_text": "And that business can often be lumpy quarter-to-quarter. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6f24183d5352e3b8c4d95672d76f29e647ead12900134bdfc434b86b52d9d0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d79a32c9-995b-4f9b-a317-bd131b8100bd", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "original_text": "That is lower-\nmargin business, and we've talked about that mix impact in the past. "}, "hash": "c250d7afe7888ed6eb2dc6c8eb63bffd42b3d13ccddc3bd617e21d15b2193b43", "class_name": "RelatedNodeInfo"}}, "text": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "start_char_idx": 1289, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d79a32c9-995b-4f9b-a317-bd131b8100bd": {"__data__": {"id_": "d79a32c9-995b-4f9b-a317-bd131b8100bd", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "original_text": "That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770", "node_type": "1", "metadata": {"window": "But those 2 things pinched us, but we think we'll work through\nthat over the coming quarters.\n Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n", "original_text": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c4a5a0e8dea6c982ce60098321af1b8dc0a1eb7b8d816f75cf0025c51273552", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5d5b238-be11-4af2-b2d7-6b80628cc93f", "node_type": "1", "metadata": {"window": "And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient. ", "original_text": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n"}, "hash": "5c765bfcf2d6cef44594cb633856c08ecbc71a24d3024e8ab5745045d46ed347", "class_name": "RelatedNodeInfo"}}, "text": "That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "start_char_idx": 1429, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5d5b238-be11-4af2-b2d7-6b80628cc93f": {"__data__": {"id_": "b5d5b238-be11-4af2-b2d7-6b80628cc93f", "embedding": null, "metadata": {"window": "And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient. ", "original_text": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d79a32c9-995b-4f9b-a317-bd131b8100bd", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nAs it relates to the question on revenue, as we've talked about previously, a large component of the revenue, at least within this\nsegment, is related to third-party logistics services.  And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "original_text": "That is lower-\nmargin business, and we've talked about that mix impact in the past. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5abbb7b7cb4a3075e7ecb7ffd6657d60e1d443c1c8f5d2a6ddcffaf1de93908f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5715d32f-3c45-40bf-b72e-6ff87764507a", "node_type": "1", "metadata": {"window": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu? ", "original_text": "Operator\nNext will be Lisa Gill with JPMorgan.\n"}, "hash": "e8d2f92cde323fabe74b3f60a420acaed1b34107f3756ac345e2f2aacfd67872", "class_name": "RelatedNodeInfo"}}, "text": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "start_char_idx": 1513, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5715d32f-3c45-40bf-b72e-6ff87764507a": {"__data__": {"id_": "5715d32f-3c45-40bf-b72e-6ff87764507a", "embedding": null, "metadata": {"window": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu? ", "original_text": "Operator\nNext will be Lisa Gill with JPMorgan.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5d5b238-be11-4af2-b2d7-6b80628cc93f", "node_type": "1", "metadata": {"window": "And that business can often be lumpy quarter-to-quarter.  And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient. ", "original_text": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd502742ae8ca3cfa50da3631a7e2de278e6530e55a503bf111d39e4120572c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a144e3b-4659-40bb-a376-554cc75f80a6", "node_type": "1", "metadata": {"window": "That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason. ", "original_text": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. "}, "hash": "e667c234dbd388c78761142b269ee767e43fde79ce5be452749d8ece7bc45076", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nNext will be Lisa Gill with JPMorgan.\n", "start_char_idx": 1669, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a144e3b-4659-40bb-a376-554cc75f80a6": {"__data__": {"id_": "0a144e3b-4659-40bb-a376-554cc75f80a6", "embedding": null, "metadata": {"window": "That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason. ", "original_text": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5715d32f-3c45-40bf-b72e-6ff87764507a", "node_type": "1", "metadata": {"window": "And so as we think\nabout the third-party logistics business for the full year, that is really a key driver to the reduction in our revenue.  That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu? ", "original_text": "Operator\nNext will be Lisa Gill with JPMorgan.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "492a6fd3d7f306eb52d01419b9685042f0b96b181674d0332d6717505330029f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "352a145a-0f22-49c6-b648-45c931a34d9e", "node_type": "1", "metadata": {"window": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "original_text": "One, you talked about stable utilization and demand\nbeing resilient. "}, "hash": "9c7140cb286d312043cc5cdff46e023a4d25fdcfa9f0cd09ce3eea673a24cc11", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "start_char_idx": 1716, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "352a145a-0f22-49c6-b648-45c931a34d9e": {"__data__": {"id_": "352a145a-0f22-49c6-b648-45c931a34d9e", "embedding": null, "metadata": {"window": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "original_text": "One, you talked about stable utilization and demand\nbeing resilient. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a144e3b-4659-40bb-a376-554cc75f80a6", "node_type": "1", "metadata": {"window": "That is lower-\nmargin business, and we've talked about that mix impact in the past.  And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason. ", "original_text": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4624cc6c94f996acf2462e164f814920dfb215aa14198c2d85b333679d698ac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b", "node_type": "1", "metadata": {"window": "Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "original_text": "I'm just curious, how are you thinking about the impact of flu? "}, "hash": "45ca2995361d8aa85f90add40cac9309ce587e6e7949f7016a3b30da2e37938a", "class_name": "RelatedNodeInfo"}}, "text": "One, you talked about stable utilization and demand\nbeing resilient. ", "start_char_idx": 1853, "end_char_idx": 1922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b": {"__data__": {"id_": "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b", "embedding": null, "metadata": {"window": "Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "original_text": "I'm just curious, how are you thinking about the impact of flu? ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "352a145a-0f22-49c6-b648-45c931a34d9e", "node_type": "1", "metadata": {"window": "And so as we think about the underlying technology services and\nprograms that we run, the revenue there is still strong and the margins remain quite solid.\n Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "original_text": "One, you talked about stable utilization and demand\nbeing resilient. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2aada2e102da94631f1d65a0b0b0b56246917c20110b71995c91fc7c41eaa35e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "202c0eeb-eeb1-40db-b260-beb398bdebe5", "node_type": "1", "metadata": {"window": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "original_text": "It's been a couple of years since we've had a severe flu\nseason. "}, "hash": "bb4b4c178fb5ef3eeaad97a346829a9218ba66bed97b4600b8e857121faabca0", "class_name": "RelatedNodeInfo"}}, "text": "I'm just curious, how are you thinking about the impact of flu? ", "start_char_idx": 1922, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "202c0eeb-eeb1-40db-b260-beb398bdebe5": {"__data__": {"id_": "202c0eeb-eeb1-40db-b260-beb398bdebe5", "embedding": null, "metadata": {"window": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "original_text": "It's been a couple of years since we've had a severe flu\nseason. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b", "node_type": "1", "metadata": {"window": "Operator\nNext will be Lisa Gill with JPMorgan.\n Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "original_text": "I'm just curious, how are you thinking about the impact of flu? ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b1285805079d3509782fbd0b20f9c305c354d5e039817e4f7455e400d8dc746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031654a7-3512-4891-aa46-e7c16a7bae0e", "node_type": "1", "metadata": {"window": "One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "original_text": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n"}, "hash": "e1642f7c2c64071cb62429ba650fb64b5e4af400effa83615a3b5da0617dbbee", "class_name": "RelatedNodeInfo"}}, "text": "It's been a couple of years since we've had a severe flu\nseason. ", "start_char_idx": 1986, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031654a7-3512-4891-aa46-e7c16a7bae0e": {"__data__": {"id_": "031654a7-3512-4891-aa46-e7c16a7bae0e", "embedding": null, "metadata": {"window": "One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "original_text": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "202c0eeb-eeb1-40db-b260-beb398bdebe5", "node_type": "1", "metadata": {"window": "Lisa Christine Gill\nJPMorgan Chase & Co, Research Division\nI just want to go back to a couple of the comments that you made on the call.  One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "original_text": "It's been a couple of years since we've had a severe flu\nseason. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "60dfc94fe64f3779cc051a9105de0d024a5c80e76175c7c0e91a44560a325673", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd", "node_type": "1", "metadata": {"window": "I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "original_text": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. "}, "hash": "4dd573ff7fda8fdc23913109386f8863ca0bab63dd49a15c1a8e3ecfefd1060b", "class_name": "RelatedNodeInfo"}}, "text": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "start_char_idx": 2051, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd": {"__data__": {"id_": "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd", "embedding": null, "metadata": {"window": "I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "original_text": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031654a7-3512-4891-aa46-e7c16a7bae0e", "node_type": "1", "metadata": {"window": "One, you talked about stable utilization and demand\nbeing resilient.  I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "original_text": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a59e897811213400444268d4c4b3cd0bf460dfb0020058f3e673a2057fcf4061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4524d09d-07d7-4936-a583-6e8580da09d4", "node_type": "1", "metadata": {"window": "It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "original_text": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? "}, "hash": "c5cebf67cc898b47bcc73b1fbf5c08458b095b970143193dd90e00e27de07bb3", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "start_char_idx": 2130, "end_char_idx": 2339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4524d09d-07d7-4936-a583-6e8580da09d4": {"__data__": {"id_": "4524d09d-07d7-4936-a583-6e8580da09d4", "embedding": null, "metadata": {"window": "It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "original_text": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd", "node_type": "1", "metadata": {"window": "I'm just curious, how are you thinking about the impact of flu?  It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "original_text": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e0f46f61d40b6824bfd7bb29858a833ad00dfd8a2e05efcd77693b7a2e0a6aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd909664-f408-4af9-8c3c-28ed0be5aebc", "node_type": "1", "metadata": {"window": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship. ", "original_text": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n"}, "hash": "431021030a74cfe65f248fc1ab2fb577585d9945a891fe83eaa45154a811e10c", "class_name": "RelatedNodeInfo"}}, "text": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "start_char_idx": 2339, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd909664-f408-4af9-8c3c-28ed0be5aebc": {"__data__": {"id_": "fd909664-f408-4af9-8c3c-28ed0be5aebc", "embedding": null, "metadata": {"window": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship. ", "original_text": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4524d09d-07d7-4936-a583-6e8580da09d4", "node_type": "1", "metadata": {"window": "It's been a couple of years since we've had a severe flu\nseason.  That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "original_text": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal? ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2633bcd1e8af36d835036f186bd467e9369cbb1848b49925b6763148d75d2798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aebbd7b4-8d40-407b-a321-549e0aeedbf1", "node_type": "1", "metadata": {"window": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS. ", "original_text": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. "}, "hash": "95cb8bd41d2178aa6d5791179d37af140854a54d032bec6933926892b765101a", "class_name": "RelatedNodeInfo"}}, "text": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "start_char_idx": 2427, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aebbd7b4-8d40-407b-a321-549e0aeedbf1": {"__data__": {"id_": "aebbd7b4-8d40-407b-a321-549e0aeedbf1", "embedding": null, "metadata": {"window": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS. ", "original_text": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd909664-f408-4af9-8c3c-28ed0be5aebc", "node_type": "1", "metadata": {"window": "That's expected, at least based on what we've seen in the Southern Hemisphere.\n And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship. ", "original_text": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79e2d2d3bdeb987e97ff03741ed7fa02ddbad876be24df6258733c24d8189cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4e92288-08f6-4769-8668-6fad21635345", "node_type": "1", "metadata": {"window": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged. ", "original_text": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. "}, "hash": "a77fba49af164b7d98617002cd0956abf4eeee4a29b83b5f976c5eaaaa585278", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "start_char_idx": 2544, "end_char_idx": 2610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4e92288-08f6-4769-8668-6fad21635345": {"__data__": {"id_": "e4e92288-08f6-4769-8668-6fad21635345", "embedding": null, "metadata": {"window": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged. ", "original_text": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aebbd7b4-8d40-407b-a321-549e0aeedbf1", "node_type": "1", "metadata": {"window": "And then secondly, when we think about the impact of the CVS renewal, Brian or Britt, one of the things that have stuck out to me\nover the years is that McKesson never calls out a renewal as being a headwind.  But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS. ", "original_text": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26e9064320d054f556f09e5d47d25f02208ebd49637691c92734da8639920e83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf", "node_type": "1", "metadata": {"window": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "original_text": "It's obviously a big relationship. "}, "hash": "c015ac2925bcbffa74954501c84bda6a96e3dc7232bf14f769ae96c96ee31f2f", "class_name": "RelatedNodeInfo"}}, "text": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "start_char_idx": 2610, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf": {"__data__": {"id_": "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf", "embedding": null, "metadata": {"window": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "original_text": "It's obviously a big relationship. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4e92288-08f6-4769-8668-6fad21635345", "node_type": "1", "metadata": {"window": "But I'm just curious, one, is there any impact that\nyou're absorbing from that renewal?  And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged. ", "original_text": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b6a9119349f6339348ecb678db8703adbbb95a9293ca216cb18d32e54cb2e92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8c9e2c3-5352-4a32-84fc-c1a41266a92e", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n", "original_text": "It's a ton of complexity supporting a customer as sophisticated as CVS. "}, "hash": "13852029c0086d2503bf0eaec9561d72a02ada05256b9199619ccdb3f546a97b", "class_name": "RelatedNodeInfo"}}, "text": "It's obviously a big relationship. ", "start_char_idx": 2711, "end_char_idx": 2746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8c9e2c3-5352-4a32-84fc-c1a41266a92e": {"__data__": {"id_": "a8c9e2c3-5352-4a32-84fc-c1a41266a92e", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n", "original_text": "It's a ton of complexity supporting a customer as sophisticated as CVS. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf", "node_type": "1", "metadata": {"window": "And two, are there any incremental services or anything else that you would call out with the\nrelationship with CVS?\n Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "original_text": "It's obviously a big relationship. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "915d5edb24e322f1fdc054257fe06121790faa0f18b8c61b9e72263b6420859f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68090e30-95b8-4342-9d0d-7ba1e0a9694c", "node_type": "1", "metadata": {"window": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "original_text": "The services\nthat we're providing will largely be unchanged. "}, "hash": "21c65868d24b62217634e39602728dcd5180fa2f9667846d89a07751b6db8a36", "class_name": "RelatedNodeInfo"}}, "text": "It's a ton of complexity supporting a customer as sophisticated as CVS. ", "start_char_idx": 2746, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68090e30-95b8-4342-9d0d-7ba1e0a9694c": {"__data__": {"id_": "68090e30-95b8-4342-9d0d-7ba1e0a9694c", "embedding": null, "metadata": {"window": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "original_text": "The services\nthat we're providing will largely be unchanged. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8c9e2c3-5352-4a32-84fc-c1a41266a92e", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLet me take those in reverse order.  So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n", "original_text": "It's a ton of complexity supporting a customer as sophisticated as CVS. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36bc6d1b05711836557a7a3cd2249198716f6eb55d129bad004d43f3ef9a5c28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c353a62-8fe1-47e7-9bd9-28a5b6156d58", "node_type": "1", "metadata": {"window": "It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "original_text": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. "}, "hash": "8807fe6f8e5437b0837c50758d5590ef68818fa655668a560ba27ee068cc83e2", "class_name": "RelatedNodeInfo"}}, "text": "The services\nthat we're providing will largely be unchanged. ", "start_char_idx": 2818, "end_char_idx": 2879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c353a62-8fe1-47e7-9bd9-28a5b6156d58": {"__data__": {"id_": "2c353a62-8fe1-47e7-9bd9-28a5b6156d58", "embedding": null, "metadata": {"window": "It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "original_text": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68090e30-95b8-4342-9d0d-7ba1e0a9694c", "node_type": "1", "metadata": {"window": "So relative to CVS, we're obviously very pleased to extend what's been a long-standing\nrelationship.  It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "original_text": "The services\nthat we're providing will largely be unchanged. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2d1c72327ea74f0e50579b1f428dc2925c961c482b20d7b223503c2e0edf7a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6e7b57a-92a0-4736-8d9a-9013326eced2", "node_type": "1", "metadata": {"window": "It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop. ", "original_text": "So that's largely unchanged.\n"}, "hash": "bd0ded40f07e1f27cd398b1ca8e14863e31cfecd05cac762bc1e50f43e4577ce", "class_name": "RelatedNodeInfo"}}, "text": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "start_char_idx": 2879, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6e7b57a-92a0-4736-8d9a-9013326eced2": {"__data__": {"id_": "d6e7b57a-92a0-4736-8d9a-9013326eced2", "embedding": null, "metadata": {"window": "It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop. ", "original_text": "So that's largely unchanged.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c353a62-8fe1-47e7-9bd9-28a5b6156d58", "node_type": "1", "metadata": {"window": "It's obviously a big relationship.  It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "original_text": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "327bb08c6db2e5812f8e2c1beffbf208fc36b92ebbe09e7596a5fba34e91738b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d562aec2-9f68-4615-8d9b-b2c8d306557c", "node_type": "1", "metadata": {"window": "The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "original_text": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n"}, "hash": "1751cb34fb53a1befed786039e1909c9fa0e6622edb19ebef34f769f44b2dc28", "class_name": "RelatedNodeInfo"}}, "text": "So that's largely unchanged.\n", "start_char_idx": 3012, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d562aec2-9f68-4615-8d9b-b2c8d306557c": {"__data__": {"id_": "d562aec2-9f68-4615-8d9b-b2c8d306557c", "embedding": null, "metadata": {"window": "The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "original_text": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6e7b57a-92a0-4736-8d9a-9013326eced2", "node_type": "1", "metadata": {"window": "It's a ton of complexity supporting a customer as sophisticated as CVS.  The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop. ", "original_text": "So that's largely unchanged.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcac4d83bc0059f6b167858ccb1464dc2780b1bf4f609fcc0a89b0969d725c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b333193a-a600-4089-9de2-3d9b60465eeb", "node_type": "1", "metadata": {"window": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably. ", "original_text": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n"}, "hash": "4c8a63aba9007f92a737d704d786d88fbfa91edd6d38f16b94e39d45022f9345", "class_name": "RelatedNodeInfo"}}, "text": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "start_char_idx": 3041, "end_char_idx": 3176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b333193a-a600-4089-9de2-3d9b60465eeb": {"__data__": {"id_": "b333193a-a600-4089-9de2-3d9b60465eeb", "embedding": null, "metadata": {"window": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably. ", "original_text": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d562aec2-9f68-4615-8d9b-b2c8d306557c", "node_type": "1", "metadata": {"window": "The services\nthat we're providing will largely be unchanged.  We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "original_text": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eb0686e480996634b440bd2ab24860cbebcdcdfdb154e1442dc7649a8dea700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581c4d6a-f07e-4ddb-a182-39064020dfbe", "node_type": "1", "metadata": {"window": "So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves. ", "original_text": "And then as it relates to the flu, we are seeing a flu season develop. "}, "hash": "6a18a531d7d0cb53f38f459a0b1a819cc4d84b7765e7f3fc987ca62a97a0d7c4", "class_name": "RelatedNodeInfo"}}, "text": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "start_char_idx": 3176, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581c4d6a-f07e-4ddb-a182-39064020dfbe": {"__data__": {"id_": "581c4d6a-f07e-4ddb-a182-39064020dfbe", "embedding": null, "metadata": {"window": "So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves. ", "original_text": "And then as it relates to the flu, we are seeing a flu season develop. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b333193a-a600-4089-9de2-3d9b60465eeb", "node_type": "1", "metadata": {"window": "We're still doing the fulfillment for their mail-order pharmacies, for their forward\ndistribution centers, for some of their stores.  So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably. ", "original_text": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46b6e0d7702a68e931244475d92bf800a602ec64d6ee7997745fe71c2e170467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c177a533-546a-478d-ab95-9242b07c432f", "node_type": "1", "metadata": {"window": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu. ", "original_text": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. "}, "hash": "ce986b6510822bc95dcb72bab1733ba2a84151973f74dab400bc52e10e707d26", "class_name": "RelatedNodeInfo"}}, "text": "And then as it relates to the flu, we are seeing a flu season develop. ", "start_char_idx": 3283, "end_char_idx": 3354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c177a533-546a-478d-ab95-9242b07c432f": {"__data__": {"id_": "c177a533-546a-478d-ab95-9242b07c432f", "embedding": null, "metadata": {"window": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu. ", "original_text": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581c4d6a-f07e-4ddb-a182-39064020dfbe", "node_type": "1", "metadata": {"window": "So that's largely unchanged.\n In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves. ", "original_text": "And then as it relates to the flu, we are seeing a flu season develop. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c331a9eed84059f3ab069dd6a4fe54b190affe610673c1fe8b32ff91f404c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74ec2b62-01f0-4c93-be94-b0325099ab06", "node_type": "1", "metadata": {"window": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "original_text": "The impact of flu in general, there's various components, 3 probably. "}, "hash": "562e82cf5ea8953a6dff71b3e45926bfa450cea9aa26d6461b2e1ba53b5943ca", "class_name": "RelatedNodeInfo"}}, "text": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "start_char_idx": 3354, "end_char_idx": 3468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74ec2b62-01f0-4c93-be94-b0325099ab06": {"__data__": {"id_": "74ec2b62-01f0-4c93-be94-b0325099ab06", "embedding": null, "metadata": {"window": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "original_text": "The impact of flu in general, there's various components, 3 probably. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c177a533-546a-478d-ab95-9242b07c432f", "node_type": "1", "metadata": {"window": "In terms of the financials associated, we don't comment on the specific customer financials, as you might expect, for lots of reasons.\n But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu. ", "original_text": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58797f4df88fa6fe6eff2c3080adfc9c32cee9474d633430e178b295b9f396b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "431294c7-e3c4-45de-a202-935eb51e8d84", "node_type": "1", "metadata": {"window": "And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n", "original_text": "There's the flu\nvaccines themselves. "}, "hash": "1b9d3f93e229e56eb2a104daca92bd3763744dcc0cae0af29c36933f5c86ec89", "class_name": "RelatedNodeInfo"}}, "text": "The impact of flu in general, there's various components, 3 probably. ", "start_char_idx": 3468, "end_char_idx": 3538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "431294c7-e3c4-45de-a202-935eb51e8d84": {"__data__": {"id_": "431294c7-e3c4-45de-a202-935eb51e8d84", "embedding": null, "metadata": {"window": "And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n", "original_text": "There's the flu\nvaccines themselves. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74ec2b62-01f0-4c93-be94-b0325099ab06", "node_type": "1", "metadata": {"window": "But I will say that we've contemplated the renewal and the guidance that Britt walked you through earlier.\n And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "original_text": "The impact of flu in general, there's various components, 3 probably. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7f7bad07e287de67926ef94522f90b69f8edb79849b0a6d6beb058bdd82563f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80078a43-26b1-4b14-92b8-beac9a939a00", "node_type": "1", "metadata": {"window": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid. ", "original_text": "There's the flu testing and test kits that go around the flu. "}, "hash": "48d1d6399d7c384dcdb89b9e405bcbb2e330b52378fbc352c34bd7886919aba2", "class_name": "RelatedNodeInfo"}}, "text": "There's the flu\nvaccines themselves. ", "start_char_idx": 3538, "end_char_idx": 3575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80078a43-26b1-4b14-92b8-beac9a939a00": {"__data__": {"id_": "80078a43-26b1-4b14-92b8-beac9a939a00", "embedding": null, "metadata": {"window": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid. ", "original_text": "There's the flu testing and test kits that go around the flu. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "431294c7-e3c4-45de-a202-935eb51e8d84", "node_type": "1", "metadata": {"window": "And then as it relates to the flu, we are seeing a flu season develop.  We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n", "original_text": "There's the flu\nvaccines themselves. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6060f9de2dee803f419353435084dcb0879ec8a2e2eddadbe3f16a37244b5fe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81180d20-2098-483d-8b1f-134518721fa0", "node_type": "1", "metadata": {"window": "The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "original_text": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. "}, "hash": "375027416abf79e4e038cd520909bde5985be793e44225f3a931b23cb4ed3d8f", "class_name": "RelatedNodeInfo"}}, "text": "There's the flu testing and test kits that go around the flu. ", "start_char_idx": 3575, "end_char_idx": 3637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81180d20-2098-483d-8b1f-134518721fa0": {"__data__": {"id_": "81180d20-2098-483d-8b1f-134518721fa0", "embedding": null, "metadata": {"window": "The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "original_text": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80078a43-26b1-4b14-92b8-beac9a939a00", "node_type": "1", "metadata": {"window": "We expect it will probably be more like a pre-COVID flu season\nthan what we've experienced in the last few years.  The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid. ", "original_text": "There's the flu testing and test kits that go around the flu. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9189886adf191bd8e8cf46fe57e2e0e7966f12d72a63c7b7a599b80ff3d481c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd57ab92-9823-410e-be7e-8624a00e40b7", "node_type": "1", "metadata": {"window": "There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "original_text": "So we're well positioned against each of those.\n"}, "hash": "6cfa43dd54bcc19ddcde644d4b3a8f11265e0fad859598edad6b70a5832b390b", "class_name": "RelatedNodeInfo"}}, "text": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "start_char_idx": 3637, "end_char_idx": 3760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd57ab92-9823-410e-be7e-8624a00e40b7": {"__data__": {"id_": "cd57ab92-9823-410e-be7e-8624a00e40b7", "embedding": null, "metadata": {"window": "There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "original_text": "So we're well positioned against each of those.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81180d20-2098-483d-8b1f-134518721fa0", "node_type": "1", "metadata": {"window": "The impact of flu in general, there's various components, 3 probably.  There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "original_text": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eac44091c42fe09a34f16f14964d995b446442f33b7b433910080af3fe18e57c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97bbe544-5f4e-4f8c-9211-22efb42b534d", "node_type": "1", "metadata": {"window": "There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n", "original_text": "The vaccine component is probably not as important as the flu testing, to be quite candid. "}, "hash": "b9ea241c8d211a073627d1267f27f0ba80b44e1b0f54aaefaef0a37a1781f5bb", "class_name": "RelatedNodeInfo"}}, "text": "So we're well positioned against each of those.\n", "start_char_idx": 3760, "end_char_idx": 3808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97bbe544-5f4e-4f8c-9211-22efb42b534d": {"__data__": {"id_": "97bbe544-5f4e-4f8c-9211-22efb42b534d", "embedding": null, "metadata": {"window": "There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n", "original_text": "The vaccine component is probably not as important as the flu testing, to be quite candid. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd57ab92-9823-410e-be7e-8624a00e40b7", "node_type": "1", "metadata": {"window": "There's the flu\nvaccines themselves.  There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "original_text": "So we're well positioned against each of those.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37fce105b7eed95b9617cbf9c15fe2909af537d006f6e5aba6b2d4decc4ae63b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "774a24cf-0763-4768-b8f0-e7eb0d143235", "node_type": "1", "metadata": {"window": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. "}, "hash": "993f72d4bcd4270cf2cfb3941e9a1a884e66792e7f05b625a526b24ee7052898", "class_name": "RelatedNodeInfo"}}, "text": "The vaccine component is probably not as important as the flu testing, to be quite candid. ", "start_char_idx": 3808, "end_char_idx": 3899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "774a24cf-0763-4768-b8f0-e7eb0d143235": {"__data__": {"id_": "774a24cf-0763-4768-b8f0-e7eb0d143235", "embedding": null, "metadata": {"window": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97bbe544-5f4e-4f8c-9211-22efb42b534d", "node_type": "1", "metadata": {"window": "There's the flu testing and test kits that go around the flu.  And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n", "original_text": "The vaccine component is probably not as important as the flu testing, to be quite candid. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "702654e8278023ccb843f4f4cfa8e1fbf3e61881b802b43b964ec78c3be236a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d151cf8-c4b9-4905-afc5-9f0d33361c89", "node_type": "1", "metadata": {"window": "So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n"}, "hash": "25cea85aaf2d83e6a29121b49444f1442affd8c677e6b4eca570efe4b9cef98b", "class_name": "RelatedNodeInfo"}}, "text": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "start_char_idx": 3899, "end_char_idx": 4005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d151cf8-c4b9-4905-afc5-9f0d33361c89": {"__data__": {"id_": "8d151cf8-c4b9-4905-afc5-9f0d33361c89", "embedding": null, "metadata": {"window": "So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "774a24cf-0763-4768-b8f0-e7eb0d143235", "node_type": "1", "metadata": {"window": "And then there's any incremental office visits or front-\nof-store sales associated with cough and cold kinds of medicines.  So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0043afee1c12ce64c45452f10051a52a7ffd553d50644abc071d05bbc9ea80e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f5d30b1-eb8f-4c06-970d-a29f359f2f07", "node_type": "1", "metadata": {"window": "The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Operator\nAnd next will be Steven Valiquette with Barclays.\n"}, "hash": "018fba72b8ff2e0ed62fb026fd30188d0dee8e9efd029f3d6942953cf3d9835d", "class_name": "RelatedNodeInfo"}}, "text": "And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "start_char_idx": 4005, "end_char_idx": 4107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f5d30b1-eb8f-4c06-970d-a29f359f2f07": {"__data__": {"id_": "7f5d30b1-eb8f-4c06-970d-a29f359f2f07", "embedding": null, "metadata": {"window": "The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Operator\nAnd next will be Steven Valiquette with Barclays.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d151cf8-c4b9-4905-afc5-9f0d33361c89", "node_type": "1", "metadata": {"window": "So we're well positioned against each of those.\n The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1b77b061e60e8dd2700ebbd1707bdcaecbf08c3332ee56e3f63101919912e5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e", "node_type": "1", "metadata": {"window": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Steven James Valiquette\nBarclays Bank PLC, Research Division"}, "hash": "a1ee6949f284025168e80656633aab8aead87b1dfbbf7bc8044d3d534db8cb1e", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next will be Steven Valiquette with Barclays.\n", "start_char_idx": 4107, "end_char_idx": 4166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e": {"__data__": {"id_": "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e", "embedding": null, "metadata": {"window": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Steven James Valiquette\nBarclays Bank PLC, Research Division", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029a50c86653c707baaa9e51333877f2aa87a5913d5628a91a410587e0c927fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f5d30b1-eb8f-4c06-970d-a29f359f2f07", "node_type": "1", "metadata": {"window": "The vaccine component is probably not as important as the flu testing, to be quite candid.  But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Operator\nAnd next will be Steven Valiquette with Barclays.\n", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ac428ba771fb09ca0cb0df00c85cf37d579875b092609ded3faae681b777f54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7ac7550-187f-40ab-8769-de5cd5d120ea", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "be319bba4d76a79911b13a87a672bd015db2216ab94ab618ae9551204f5f67ee", "class_name": "RelatedNodeInfo"}}, "text": "Steven James Valiquette\nBarclays Bank PLC, Research Division", "start_char_idx": 4166, "end_char_idx": 4226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7ac7550-187f-40ab-8769-de5cd5d120ea": {"__data__": {"id_": "a7ac7550-187f-40ab-8769-de5cd5d120ea", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e", "node_type": "1", "metadata": {"window": "But as you know, we are a very capable and\nscaled distributor of flu vaccines and, frankly, all vaccines.  And should the flu season continue to materialize, we think we'll be well\npositioned to capture that.\n Operator\nAnd next will be Steven Valiquette with Barclays.\n Steven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "Steven James Valiquette\nBarclays Bank PLC, Research Division", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b879d57cb4c28e9ad7e5bd9a706c02aa839ded7d230d8f95ea166f27020a10f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e77830a5-3ebb-4f68-80d2-2ab1684c87bd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "original_text": "All Rights reserved.\n"}, "hash": "40fdbc4534d8369fd6d2d1dd24142e4759856adc69f3b9531a7642acfc41c3f8", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e77830a5-3ebb-4f68-80d2-2ab1684c87bd": {"__data__": {"id_": "e77830a5-3ebb-4f68-80d2-2ab1684c87bd", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "original_text": "All Rights reserved.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7ac7550-187f-40ab-8769-de5cd5d120ea", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "801fdbc17c8e576e21d1e5bed3126fa7f325917fbdef67e5b5bb7a0210529174", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0ab3463-0b50-48e2-89da-819861606980", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "original_text": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands. "}, "hash": "dd205f6fc60847495365548dc99ca0e9e39d81211b3d15981170bc0a830f63b8", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0ab3463-0b50-48e2-89da-819861606980": {"__data__": {"id_": "b0ab3463-0b50-48e2-89da-819861606980", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "original_text": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e77830a5-3ebb-4f68-80d2-2ab1684c87bd", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "original_text": "All Rights reserved.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6207532f2afaadc3987ab481e774d66eac9fe722cdf1f7b41afe7dcefc556abd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd76b7d-b0de-488b-8986-206dd30850b7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "original_text": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. "}, "hash": "878489d8d2c74bf46dec0a228afa410fc2dca94f26ebc5f58fe94716c28f99a2", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands. ", "start_char_idx": 158, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd76b7d-b0de-488b-8986-206dd30850b7": {"__data__": {"id_": "cbd76b7d-b0de-488b-8986-206dd30850b7", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "original_text": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0ab3463-0b50-48e2-89da-819861606980", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "original_text": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4ccce7a231945d0c10351f0032d80546de729e156f3ec3ba95cad70fcc45896", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "397022e6-2f4a-463f-a2ff-ee2e71f7814a", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "original_text": "So I guess, just to put that to bed, was July just kind of an\nanomaly? "}, "hash": "2db37de2f14d4e84939e09db03128621377de9bcf81e140ad523e845e341d8a1", "class_name": "RelatedNodeInfo"}}, "text": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "start_char_idx": 299, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "397022e6-2f4a-463f-a2ff-ee2e71f7814a": {"__data__": {"id_": "397022e6-2f4a-463f-a2ff-ee2e71f7814a", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "original_text": "So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd76b7d-b0de-488b-8986-206dd30850b7", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "original_text": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98f0ed2fdda5a3b33bbfa89ff6767edfccf2cb980fce5cf01b0ead798842b222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73e01ddb-eabc-4061-9f6b-15a91c3638fa", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question. ", "original_text": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. "}, "hash": "7fc8c801cee9e8b8830347885a09ac16a1a3227b0b7ab21734eeaebb4e2b3a68", "class_name": "RelatedNodeInfo"}}, "text": "So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "start_char_idx": 531, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73e01ddb-eabc-4061-9f6b-15a91c3638fa": {"__data__": {"id_": "73e01ddb-eabc-4061-9f6b-15a91c3638fa", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question. ", "original_text": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "397022e6-2f4a-463f-a2ff-ee2e71f7814a", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "original_text": "So I guess, just to put that to bed, was July just kind of an\nanomaly? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "423a72902f9fd7a51f304d3630b1e2830a8d2274fe138f47d8708ecefdbcab60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5f007da-ecd6-4f3e-869d-1ec40efbc079", "node_type": "1", "metadata": {"window": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct. ", "original_text": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n"}, "hash": "72c845380e0cb23100337fbab564161d8dffed23961109cb1c8ae9db3078f10a", "class_name": "RelatedNodeInfo"}}, "text": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "start_char_idx": 602, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5f007da-ecd6-4f3e-869d-1ec40efbc079": {"__data__": {"id_": "f5f007da-ecd6-4f3e-869d-1ec40efbc079", "embedding": null, "metadata": {"window": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct. ", "original_text": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73e01ddb-eabc-4061-9f6b-15a91c3638fa", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question. ", "original_text": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7022864f64c446d746f4152893cf1db40b88554f682cca7451993504b3b0ea05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e5e18fe-711a-4510-9610-92404d17e35a", "node_type": "1", "metadata": {"window": "So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. "}, "hash": "cea44d4f978f3ca8a7818d8f3cdc7189d1c6dc7dcdb555918c3366d3f289cf27", "class_name": "RelatedNodeInfo"}}, "text": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "start_char_idx": 714, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e5e18fe-711a-4510-9610-92404d17e35a": {"__data__": {"id_": "9e5e18fe-711a-4510-9610-92404d17e35a", "embedding": null, "metadata": {"window": "So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5f007da-ecd6-4f3e-869d-1ec40efbc079", "node_type": "1", "metadata": {"window": "But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend.  So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct. ", "original_text": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "246a2923c9341c9b9bac7607861da1d366fef31e215bd19aa01f4846d532ca76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42b347b1-1ba6-4dae-84f1-41dc8f2e7586", "node_type": "1", "metadata": {"window": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "original_text": "Thanks for the question. "}, "hash": "ede390c9ef7a398d08d4d768f51b08dd31b44398f672040a5c3b6a44c2e74c65", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "start_char_idx": 811, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42b347b1-1ba6-4dae-84f1-41dc8f2e7586": {"__data__": {"id_": "42b347b1-1ba6-4dae-84f1-41dc8f2e7586", "embedding": null, "metadata": {"window": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "original_text": "Thanks for the question. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e5e18fe-711a-4510-9610-92404d17e35a", "node_type": "1", "metadata": {"window": "So I guess, just to put that to bed, was July just kind of an\nanomaly?  Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c81170bdee92fa248b039bdd3747fe76f629f0bbdb26ac1fdb1a2f50af83aefd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c", "node_type": "1", "metadata": {"window": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "original_text": "You are correct. "}, "hash": "5f181f606a84c857f174e9c2f1241b9a83d440981104980104e3e5f296fa229e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 870, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c": {"__data__": {"id_": "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c", "embedding": null, "metadata": {"window": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "original_text": "You are correct. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42b347b1-1ba6-4dae-84f1-41dc8f2e7586", "node_type": "1", "metadata": {"window": "Maybe you could just speak to prescription trends kind of exiting the quarter versus what you saw in that July.  If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "original_text": "Thanks for the question. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39923fd3a051f6a5aeef1151091776d01ded1f68ba1fed90125beceecae19866", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f44a8c3-e203-419d-b5ac-96e30631b588", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "original_text": "We did talk about first quarter prescription volumes on average about\n7% year-over-year. "}, "hash": "e487c8809f1aee60bd3ed2830315b19b26b9578a53b6b6a821b051a4ec72af3f", "class_name": "RelatedNodeInfo"}}, "text": "You are correct. ", "start_char_idx": 895, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f44a8c3-e203-419d-b5ac-96e30631b588": {"__data__": {"id_": "0f44a8c3-e203-419d-b5ac-96e30631b588", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "original_text": "We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c", "node_type": "1", "metadata": {"window": "If July was\njust an anomaly, it'd be good just to kind of address that and just put that to bed.\n Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "original_text": "You are correct. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "771ed9b9bd5b88d2c1b4e3e3277021b3f73cb6460ccf404926c662d0daee4174", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f", "node_type": "1", "metadata": {"window": "Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year. ", "original_text": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. "}, "hash": "4485026c4b243d2df01f34f55a885e869f41a0e42d988658d41bfaa25e9c5dba", "class_name": "RelatedNodeInfo"}}, "text": "We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "start_char_idx": 912, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f": {"__data__": {"id_": "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f", "embedding": null, "metadata": {"window": "Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year. ", "original_text": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f44a8c3-e203-419d-b5ac-96e30631b588", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSteve, this is Britt.  Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "original_text": "We did talk about first quarter prescription volumes on average about\n7% year-over-year. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efa257177d07d2556cee13c9e264ca375e6e654c229640bdeab68d14baaa07b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c3d391f-f477-48c3-96aa-dafe3afc16d6", "node_type": "1", "metadata": {"window": "You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "original_text": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n"}, "hash": "603c50cb1473db5b3c88d323cd77d9188fb4198d95ba11fc5452323ea2f00061", "class_name": "RelatedNodeInfo"}}, "text": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "start_char_idx": 1001, "end_char_idx": 1200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c3d391f-f477-48c3-96aa-dafe3afc16d6": {"__data__": {"id_": "3c3d391f-f477-48c3-96aa-dafe3afc16d6", "embedding": null, "metadata": {"window": "You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "original_text": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f", "node_type": "1", "metadata": {"window": "Thanks for the question.  You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year. ", "original_text": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a19ba987ac341a24713dbd16522c01f1e2e56119239f5553ce065422c557a4c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "904e4ce2-6432-486d-befe-b7b6b62d480c", "node_type": "1", "metadata": {"window": "We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance. ", "original_text": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. "}, "hash": "7f5e5a5f2e74c80f95fcded847fb090a463b8b4b3f2f30461c04b17d794498b0", "class_name": "RelatedNodeInfo"}}, "text": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "start_char_idx": 1200, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "904e4ce2-6432-486d-befe-b7b6b62d480c": {"__data__": {"id_": "904e4ce2-6432-486d-befe-b7b6b62d480c", "embedding": null, "metadata": {"window": "We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance. ", "original_text": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c3d391f-f477-48c3-96aa-dafe3afc16d6", "node_type": "1", "metadata": {"window": "You are correct.  We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "original_text": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6e5800540d1f95ae478cee77d90b231f192d37b5862417c1c4389ff22bd8169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a10c5cf2-8e3b-41c0-bd94-ec32848405bf", "node_type": "1", "metadata": {"window": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger. ", "original_text": "That's well within the range that\nwe had in our guidance at the beginning of the year. "}, "hash": "8107239e843e662cfc2f880b0389dc9faadc62a3b8f56642a99ffb1916c73df8", "class_name": "RelatedNodeInfo"}}, "text": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "start_char_idx": 1312, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a10c5cf2-8e3b-41c0-bd94-ec32848405bf": {"__data__": {"id_": "a10c5cf2-8e3b-41c0-bd94-ec32848405bf", "embedding": null, "metadata": {"window": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger. ", "original_text": "That's well within the range that\nwe had in our guidance at the beginning of the year. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "904e4ce2-6432-486d-befe-b7b6b62d480c", "node_type": "1", "metadata": {"window": "We did talk about first quarter prescription volumes on average about\n7% year-over-year.  When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance. ", "original_text": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885810ab580931637a6e5a1485c83a8add3a2f17708b166fb1af58f5f128eaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93477de0-f52b-476e-ad56-f4a0d3128733", "node_type": "1", "metadata": {"window": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter. ", "original_text": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. "}, "hash": "278c30ea0c39082bc3b0029ff4286c86af4727d0db82b92b42895874fb2d602c", "class_name": "RelatedNodeInfo"}}, "text": "That's well within the range that\nwe had in our guidance at the beginning of the year. ", "start_char_idx": 1412, "end_char_idx": 1499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93477de0-f52b-476e-ad56-f4a0d3128733": {"__data__": {"id_": "93477de0-f52b-476e-ad56-f4a0d3128733", "embedding": null, "metadata": {"window": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter. ", "original_text": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a10c5cf2-8e3b-41c0-bd94-ec32848405bf", "node_type": "1", "metadata": {"window": "When we talked about prescription trends at Morgan Stanley, we were really giving a flash view, and that flash\nview was predominantly our view on July, which did end up being pretty much an anomaly.  It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger. ", "original_text": "That's well within the range that\nwe had in our guidance at the beginning of the year. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c3715131ca49efffd77140f0aa8f35d4cc29644126545f466a2b2398ed0d5ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19939327-62ec-4803-a6a0-0c63c494852e", "node_type": "1", "metadata": {"window": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "original_text": "So it still remains within our guidance. "}, "hash": "c033bd29161ef180f27779ca0c40ad255d89199976f9c25479c03b2b068980bf", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "start_char_idx": 1499, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19939327-62ec-4803-a6a0-0c63c494852e": {"__data__": {"id_": "19939327-62ec-4803-a6a0-0c63c494852e", "embedding": null, "metadata": {"window": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "original_text": "So it still remains within our guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93477de0-f52b-476e-ad56-f4a0d3128733", "node_type": "1", "metadata": {"window": "It was the lowest point that we've seen for\nprescription volume transactions in the first 6 months of the year.\n On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter. ", "original_text": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af1a3f8e0ee2622bc1df8e51103b247349a7b14643d0056ef1510f62be700920", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1708e71f-8728-4abc-a1d6-216e12a3edc8", "node_type": "1", "metadata": {"window": "That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n", "original_text": "And as I talked about, the first quarter was just slightly stronger. "}, "hash": "c6c40ecf9786b3c213ab2e8aabd0fc69467b1e363eaa865c705137ca04027b73", "class_name": "RelatedNodeInfo"}}, "text": "So it still remains within our guidance. ", "start_char_idx": 1594, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1708e71f-8728-4abc-a1d6-216e12a3edc8": {"__data__": {"id_": "1708e71f-8728-4abc-a1d6-216e12a3edc8", "embedding": null, "metadata": {"window": "That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n", "original_text": "And as I talked about, the first quarter was just slightly stronger. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19939327-62ec-4803-a6a0-0c63c494852e", "node_type": "1", "metadata": {"window": "On average, in the second quarter, year-over-year, total prescription volumes increased about 4.5%.  That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "original_text": "So it still remains within our guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbfd67e4a95cff24a829f0f6d4bb1c9d91449694ca1397dedcd48482e4411d64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e28276a0-3d24-4fa9-a486-8ae96ef69763", "node_type": "1", "metadata": {"window": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n", "original_text": "We were seeing\nan illness season extend into that first quarter. "}, "hash": "2f2b372e662715caeb65fac7b505da36a4501b21f901b78262e5128f6809fffd", "class_name": "RelatedNodeInfo"}}, "text": "And as I talked about, the first quarter was just slightly stronger. ", "start_char_idx": 1635, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e28276a0-3d24-4fa9-a486-8ae96ef69763": {"__data__": {"id_": "e28276a0-3d24-4fa9-a486-8ae96ef69763", "embedding": null, "metadata": {"window": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n", "original_text": "We were seeing\nan illness season extend into that first quarter. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1708e71f-8728-4abc-a1d6-216e12a3edc8", "node_type": "1", "metadata": {"window": "That's well within the range that\nwe had in our guidance at the beginning of the year.  As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n", "original_text": "And as I talked about, the first quarter was just slightly stronger. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "968b2a57440c436fa44a18357eacfbb83874e1f861758e6365c1557150bd300c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9279bf2-d9e6-4cad-8af4-3618249b8b82", "node_type": "1", "metadata": {"window": "So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "original_text": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. "}, "hash": "cec3d40b30e4f79024b6ab0b515c844a068ce022f53e3b91e52d2a51d07107d6", "class_name": "RelatedNodeInfo"}}, "text": "We were seeing\nan illness season extend into that first quarter. ", "start_char_idx": 1704, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9279bf2-d9e6-4cad-8af4-3618249b8b82": {"__data__": {"id_": "c9279bf2-d9e6-4cad-8af4-3618249b8b82", "embedding": null, "metadata": {"window": "So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "original_text": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e28276a0-3d24-4fa9-a486-8ae96ef69763", "node_type": "1", "metadata": {"window": "As I mentioned at the conference, we were still seeing transactions in -- within\nour guidance.  So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n", "original_text": "We were seeing\nan illness season extend into that first quarter. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41880678bb3fff14a13a65161efb67df23c8e1db367ceaa70ffc986d499f81b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e3221fb-1b7f-43ad-8a26-49378fc66b33", "node_type": "1", "metadata": {"window": "And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier. ", "original_text": "And July ended up being really the low point that we called out at the conference.\n"}, "hash": "4a46316f4d56427b9d0e0c0b3fd4a2924e28110def84deb1274c692f127e59bd", "class_name": "RelatedNodeInfo"}}, "text": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "start_char_idx": 1769, "end_char_idx": 1873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e3221fb-1b7f-43ad-8a26-49378fc66b33": {"__data__": {"id_": "6e3221fb-1b7f-43ad-8a26-49378fc66b33", "embedding": null, "metadata": {"window": "And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier. ", "original_text": "And July ended up being really the low point that we called out at the conference.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9279bf2-d9e6-4cad-8af4-3618249b8b82", "node_type": "1", "metadata": {"window": "So it still remains within our guidance.  And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "original_text": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4f3e093aef8146d0746bd21ed167c36eb8ebfadf1d74beea567037a8339c012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99056860-1a3b-4a11-8345-49aefa77cdeb", "node_type": "1", "metadata": {"window": "We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us? ", "original_text": "Operator\nNext will be Charles Rhyee with Cowen.\n"}, "hash": "dfba3152255befc73ea6539c0220d969edc1f24ebc4642b07016fe5a7cca549c", "class_name": "RelatedNodeInfo"}}, "text": "And July ended up being really the low point that we called out at the conference.\n", "start_char_idx": 1873, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99056860-1a3b-4a11-8345-49aefa77cdeb": {"__data__": {"id_": "99056860-1a3b-4a11-8345-49aefa77cdeb", "embedding": null, "metadata": {"window": "We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us? ", "original_text": "Operator\nNext will be Charles Rhyee with Cowen.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e3221fb-1b7f-43ad-8a26-49378fc66b33", "node_type": "1", "metadata": {"window": "And as I talked about, the first quarter was just slightly stronger.  We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier. ", "original_text": "And July ended up being really the low point that we called out at the conference.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96cdefc1af3a799c85c303f8640e1442def8b95582cc278e269a76d9c1979c4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2ec3475-8afe-4878-ab0b-67affdb1048d", "node_type": "1", "metadata": {"window": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "original_text": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. "}, "hash": "2f063aba542bb73c0f00a0b5c7b8922ddbc1b9d5ddf52628e13b05c8f2f0f873", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nNext will be Charles Rhyee with Cowen.\n", "start_char_idx": 1956, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2ec3475-8afe-4878-ab0b-67affdb1048d": {"__data__": {"id_": "c2ec3475-8afe-4878-ab0b-67affdb1048d", "embedding": null, "metadata": {"window": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "original_text": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99056860-1a3b-4a11-8345-49aefa77cdeb", "node_type": "1", "metadata": {"window": "We were seeing\nan illness season extend into that first quarter.  So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us? ", "original_text": "Operator\nNext will be Charles Rhyee with Cowen.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4866c66d6cb8212288654b7e37887f96e9999c9aacbe22f56d65f429166bb83a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32480dbd-b40d-48ae-b07a-127dfd10cf57", "node_type": "1", "metadata": {"window": "And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline? ", "original_text": "Just to -- maybe I missed it earlier. "}, "hash": "ea9b0fc6754141b20ad2066ca8945cc22b1728ea1796913c16e70076656322be", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "start_char_idx": 2004, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32480dbd-b40d-48ae-b07a-127dfd10cf57": {"__data__": {"id_": "32480dbd-b40d-48ae-b07a-127dfd10cf57", "embedding": null, "metadata": {"window": "And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline? ", "original_text": "Just to -- maybe I missed it earlier. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2ec3475-8afe-4878-ab0b-67affdb1048d", "node_type": "1", "metadata": {"window": "So 7% on average year-over-year in the first quarter and the second quarter on average,\nabout 4% to 5%.  And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "original_text": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dfb4a595ba0bf4cd5e008ab76aa7836207207ac3d85d29581d2b41ca603e5d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75eed641-28e3-498a-bf6d-148e83959d1f", "node_type": "1", "metadata": {"window": "Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related? ", "original_text": "Just -- can you just remind us? "}, "hash": "2e72a4bf70fdb4b5af266f683cad28fad5ad3417c898c36e877386c90a59ead6", "class_name": "RelatedNodeInfo"}}, "text": "Just to -- maybe I missed it earlier. ", "start_char_idx": 2120, "end_char_idx": 2158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75eed641-28e3-498a-bf6d-148e83959d1f": {"__data__": {"id_": "75eed641-28e3-498a-bf6d-148e83959d1f", "embedding": null, "metadata": {"window": "Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related? ", "original_text": "Just -- can you just remind us? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32480dbd-b40d-48ae-b07a-127dfd10cf57", "node_type": "1", "metadata": {"window": "And July ended up being really the low point that we called out at the conference.\n Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline? ", "original_text": "Just to -- maybe I missed it earlier. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47ffd6f6d0022120ef970c29b1cd8c2be180664449cb263803ad9de2a560b129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04681c60-750f-48a7-bc4c-bd34938ce88f", "node_type": "1", "metadata": {"window": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n", "original_text": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. "}, "hash": "a14809a7d92f4ef41d7eb6f46563d7bdcfb9bb3b718be9044b87231f10feb388", "class_name": "RelatedNodeInfo"}}, "text": "Just -- can you just remind us? ", "start_char_idx": 2158, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04681c60-750f-48a7-bc4c-bd34938ce88f": {"__data__": {"id_": "04681c60-750f-48a7-bc4c-bd34938ce88f", "embedding": null, "metadata": {"window": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n", "original_text": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75eed641-28e3-498a-bf6d-148e83959d1f", "node_type": "1", "metadata": {"window": "Operator\nNext will be Charles Rhyee with Cowen.\n Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related? ", "original_text": "Just -- can you just remind us? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a690bb8c197a189bf4e40f842288bf9649b37c2219465e38ea0a07e1ad583521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddf6aa5c-0941-4971-9aa1-2028d5c75443", "node_type": "1", "metadata": {"window": "Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "original_text": "What were the\nfactors for the decline? "}, "hash": "ceef44fa48de8eb0b5fb4dcfe0aee1cade20d0029fe8fb28ed51a516767da84a", "class_name": "RelatedNodeInfo"}}, "text": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "start_char_idx": 2190, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddf6aa5c-0941-4971-9aa1-2028d5c75443": {"__data__": {"id_": "ddf6aa5c-0941-4971-9aa1-2028d5c75443", "embedding": null, "metadata": {"window": "Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "original_text": "What were the\nfactors for the decline? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04681c60-750f-48a7-bc4c-bd34938ce88f", "node_type": "1", "metadata": {"window": "Charles Rhyee\nCowen and Company, LLC, Research Division\nJust a point of clarity on the Med-Surg Solutions guidance.  Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n", "original_text": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "297daff4a1c5271b629152c1ff924dc8d540af7bb8ada3726d306f94c03146ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "209521b5-aedd-4cdc-a4e1-9efe9abd7b81", "node_type": "1", "metadata": {"window": "Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP. ", "original_text": "Is that just FX-related? "}, "hash": "b00bf6894cf0defbc1d543e8f528c13b5437090e6b914f77c63aa4f1a99b5e1b", "class_name": "RelatedNodeInfo"}}, "text": "What were the\nfactors for the decline? ", "start_char_idx": 2313, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "209521b5-aedd-4cdc-a4e1-9efe9abd7b81": {"__data__": {"id_": "209521b5-aedd-4cdc-a4e1-9efe9abd7b81", "embedding": null, "metadata": {"window": "Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP. ", "original_text": "Is that just FX-related? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddf6aa5c-0941-4971-9aa1-2028d5c75443", "node_type": "1", "metadata": {"window": "Just to -- maybe I missed it earlier.  Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "original_text": "What were the\nfactors for the decline? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3a5b15c7ca487de278373ca906836d6691b526db957c732d4e62f52f36e7654", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4", "node_type": "1", "metadata": {"window": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n", "original_text": "Or can you just remind -- maybe I just missed it, I apologize.\n"}, "hash": "8a892172c86af82093b304fcc6ae44769c89caa079be93b7afbd8f3a468a3aab", "class_name": "RelatedNodeInfo"}}, "text": "Is that just FX-related? ", "start_char_idx": 2352, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4": {"__data__": {"id_": "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4", "embedding": null, "metadata": {"window": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n", "original_text": "Or can you just remind -- maybe I just missed it, I apologize.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "209521b5-aedd-4cdc-a4e1-9efe9abd7b81", "node_type": "1", "metadata": {"window": "Just -- can you just remind us?  You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP. ", "original_text": "Is that just FX-related? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dc40147152e2ca0651450707adc8a72762a6465cc10cf6471907852868717cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91f60cc5-bab8-4dcd-979a-dc7603cdc937", "node_type": "1", "metadata": {"window": "What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. "}, "hash": "d1d32b8a0fd41329badcb246c7bd95b7ba99a60a694eac6b8a03ee49c529ce04", "class_name": "RelatedNodeInfo"}}, "text": "Or can you just remind -- maybe I just missed it, I apologize.\n", "start_char_idx": 2377, "end_char_idx": 2440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91f60cc5-bab8-4dcd-979a-dc7603cdc937": {"__data__": {"id_": "91f60cc5-bab8-4dcd-979a-dc7603cdc937", "embedding": null, "metadata": {"window": "What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4", "node_type": "1", "metadata": {"window": "You\ntalked about upping the guidance related to the kitting part, the one we look at the -- obviously, top line is better.  What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n", "original_text": "Or can you just remind -- maybe I just missed it, I apologize.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edd244c337d259869c2ea6dd9e4ab6e79d7bb70f3fb6c99b8b38dc26c0cc33a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81a46807-6a44-4a86-80cc-82a71207ab86", "node_type": "1", "metadata": {"window": "Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "original_text": "The decline is in our AOP. "}, "hash": "5c02d49aa4c031d16179e3533fc67a7aeedbb6b20f0da7155f7e5aa6cf6cfc51", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "start_char_idx": 2440, "end_char_idx": 2534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81a46807-6a44-4a86-80cc-82a71207ab86": {"__data__": {"id_": "81a46807-6a44-4a86-80cc-82a71207ab86", "embedding": null, "metadata": {"window": "Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "original_text": "The decline is in our AOP. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91f60cc5-bab8-4dcd-979a-dc7603cdc937", "node_type": "1", "metadata": {"window": "What were the\nfactors for the decline?  Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a05ba504761bdce739c6ee27985fa18fc2bc362b7d99caa07f7e023cb71180ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11790c17-1ebc-40b2-9958-f3d82d391deb", "node_type": "1", "metadata": {"window": "Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n", "original_text": "It's a very modest decline from the previous guidance.\n"}, "hash": "d8381ffe49739936feee056aff8d02472f338db62a650782971548739d3bdf07", "class_name": "RelatedNodeInfo"}}, "text": "The decline is in our AOP. ", "start_char_idx": 2534, "end_char_idx": 2561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11790c17-1ebc-40b2-9958-f3d82d391deb": {"__data__": {"id_": "11790c17-1ebc-40b2-9958-f3d82d391deb", "embedding": null, "metadata": {"window": "Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n", "original_text": "It's a very modest decline from the previous guidance.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81a46807-6a44-4a86-80cc-82a71207ab86", "node_type": "1", "metadata": {"window": "Is that just FX-related?  Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "original_text": "The decline is in our AOP. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4672aa98b0b12d358175337049a25c4cec6bceef7d89f69fa8fb60f3b52cb199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d6e6902-dc76-4a84-a04e-764d1d3eb09d", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment. ", "original_text": "We're still showing 11% to 15% growth excluding COVID-related items. "}, "hash": "0667c6dc16a5d5fa2a7f42281998be5cd7f0ec715a245113a16b23493228b290", "class_name": "RelatedNodeInfo"}}, "text": "It's a very modest decline from the previous guidance.\n", "start_char_idx": 2561, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d6e6902-dc76-4a84-a04e-764d1d3eb09d": {"__data__": {"id_": "8d6e6902-dc76-4a84-a04e-764d1d3eb09d", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment. ", "original_text": "We're still showing 11% to 15% growth excluding COVID-related items. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11790c17-1ebc-40b2-9958-f3d82d391deb", "node_type": "1", "metadata": {"window": "Or can you just remind -- maybe I just missed it, I apologize.\n Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n", "original_text": "It's a very modest decline from the previous guidance.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "081d13ffca2bf679bab71bab857cd209814ab603f8f3159b4cf8c195bb54ae8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4", "node_type": "1", "metadata": {"window": "The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid. ", "original_text": "So that's well above the long-term guidance range that we\ngave at our Investor Day. "}, "hash": "b285ffda7b94a41bf3e0a3bcd7720cb3f35df8ec340e3b4dcc9c124c4fc4fe4b", "class_name": "RelatedNodeInfo"}}, "text": "We're still showing 11% to 15% growth excluding COVID-related items. ", "start_char_idx": 2616, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4": {"__data__": {"id_": "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4", "embedding": null, "metadata": {"window": "The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid. ", "original_text": "So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d6e6902-dc76-4a84-a04e-764d1d3eb09d", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nSo let me just see if I can translate this a little bit.  The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment. ", "original_text": "We're still showing 11% to 15% growth excluding COVID-related items. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "287a94feb36c244ad59dbccb5f81b804a737fe00448beabec79464b3403d87d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ccfbd03-8217-4349-9080-dec979c4996b", "node_type": "1", "metadata": {"window": "It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "original_text": "So we feel very comfortable with that.\n"}, "hash": "98c67531e2147805378d9f6854389ea8585cd187329e76c9470b97897d7dda26", "class_name": "RelatedNodeInfo"}}, "text": "So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "start_char_idx": 2685, "end_char_idx": 2769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ccfbd03-8217-4349-9080-dec979c4996b": {"__data__": {"id_": "9ccfbd03-8217-4349-9080-dec979c4996b", "embedding": null, "metadata": {"window": "It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "original_text": "So we feel very comfortable with that.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4", "node_type": "1", "metadata": {"window": "The decline is in our AOP.  It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid. ", "original_text": "So that's well above the long-term guidance range that we\ngave at our Investor Day. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70af349c503c1107d563f0f60bf6eeb1ff9f197b26c4ade2596df55a4e903f19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bea3295d-43b1-464d-ab6d-516f3194b96d", "node_type": "1", "metadata": {"window": "We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n", "original_text": "There is no FX that runs through the medical segment. "}, "hash": "c3d566a610c2950c43660871c696fd74255eaa53980cddb507cd4a5db19c5af9", "class_name": "RelatedNodeInfo"}}, "text": "So we feel very comfortable with that.\n", "start_char_idx": 2769, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bea3295d-43b1-464d-ab6d-516f3194b96d": {"__data__": {"id_": "bea3295d-43b1-464d-ab6d-516f3194b96d", "embedding": null, "metadata": {"window": "We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n", "original_text": "There is no FX that runs through the medical segment. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ccfbd03-8217-4349-9080-dec979c4996b", "node_type": "1", "metadata": {"window": "It's a very modest decline from the previous guidance.\n We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "original_text": "So we feel very comfortable with that.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d37d962a1a421854a7794974485cf914d5ef6607723fb94d564609806b112d69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3", "node_type": "1", "metadata": {"window": "So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "original_text": "So our guidance still remains very solid. "}, "hash": "ab120bc31ee2a2769eab9643a322cdd610cf7d7c8f6413be66f3b05c2e59cb88", "class_name": "RelatedNodeInfo"}}, "text": "There is no FX that runs through the medical segment. ", "start_char_idx": 2808, "end_char_idx": 2862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3": {"__data__": {"id_": "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3", "embedding": null, "metadata": {"window": "So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "original_text": "So our guidance still remains very solid. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bea3295d-43b1-464d-ab6d-516f3194b96d", "node_type": "1", "metadata": {"window": "We're still showing 11% to 15% growth excluding COVID-related items.  So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n", "original_text": "There is no FX that runs through the medical segment. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd98fed0162313cc841b7bef227bd323a4497245dca186d5bcbee2c551ac1925", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99dd90b0-9671-4399-99ee-ec236f52122b", "node_type": "1", "metadata": {"window": "So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there? ", "original_text": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n"}, "hash": "92b59058bc832d00d6f06e05e704dbb58a87c1ff5aa0e4fcec5ab4bb71d2efc3", "class_name": "RelatedNodeInfo"}}, "text": "So our guidance still remains very solid. ", "start_char_idx": 2862, "end_char_idx": 2904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99dd90b0-9671-4399-99ee-ec236f52122b": {"__data__": {"id_": "99dd90b0-9671-4399-99ee-ec236f52122b", "embedding": null, "metadata": {"window": "So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there? ", "original_text": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3", "node_type": "1", "metadata": {"window": "So that's well above the long-term guidance range that we\ngave at our Investor Day.  So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "original_text": "So our guidance still remains very solid. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a018e2cb81b4535d448c3386a1020018ab1d12a8022d223954b8e317c9154725", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73bf4cf6-1ce3-44d8-9525-b52910ab0433", "node_type": "1", "metadata": {"window": "There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits? ", "original_text": "Operator\nNext will be Kevin Caliendo with UBS.\n"}, "hash": "b04d1dd3ea880c1d92edda32012174d2b28fa0a2a8de4446ec51b8cead29082c", "class_name": "RelatedNodeInfo"}}, "text": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "start_char_idx": 2904, "end_char_idx": 3026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73bf4cf6-1ce3-44d8-9525-b52910ab0433": {"__data__": {"id_": "73bf4cf6-1ce3-44d8-9525-b52910ab0433", "embedding": null, "metadata": {"window": "There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits? ", "original_text": "Operator\nNext will be Kevin Caliendo with UBS.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99dd90b0-9671-4399-99ee-ec236f52122b", "node_type": "1", "metadata": {"window": "So we feel very comfortable with that.\n There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there? ", "original_text": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1553aa96dcf32e667c089ff447df752ea915270eacd22e1e31fdfb3347779a39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77089489-ac61-4d86-b086-97973cced48b", "node_type": "1", "metadata": {"window": "So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care? ", "original_text": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. "}, "hash": "1c6f136006aa050fffb685d6ae4e30fda89275bc898c053f925a1e6f84cea21d", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nNext will be Kevin Caliendo with UBS.\n", "start_char_idx": 3026, "end_char_idx": 3073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77089489-ac61-4d86-b086-97973cced48b": {"__data__": {"id_": "77089489-ac61-4d86-b086-97973cced48b", "embedding": null, "metadata": {"window": "So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care? ", "original_text": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73bf4cf6-1ce3-44d8-9525-b52910ab0433", "node_type": "1", "metadata": {"window": "There is no FX that runs through the medical segment.  So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits? ", "original_text": "Operator\nNext will be Kevin Caliendo with UBS.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6b637a517a51ed3461d684918bff7be67aa1108c6c534b194daaf9c4c972669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9", "node_type": "1", "metadata": {"window": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue? ", "original_text": "Can you call out like what's happening there? "}, "hash": "132962d797fc4df9c21cca9474978acc696cfe0aae03324b0b28c977fa49eb8d", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "start_char_idx": 3073, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9": {"__data__": {"id_": "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9", "embedding": null, "metadata": {"window": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue? ", "original_text": "Can you call out like what's happening there? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77089489-ac61-4d86-b086-97973cced48b", "node_type": "1", "metadata": {"window": "So our guidance still remains very solid.  Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care? ", "original_text": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a6e3688b951e8f75baf9b4ba7d7f059187a5f5b447c84d919f9b3f6633eedcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3695140-2646-44e9-9629-2eeb138d680c", "node_type": "1", "metadata": {"window": "Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n", "original_text": "Is that a change\nin doc visits? "}, "hash": "63a604c800b6ccb3eee3754fcb559bba80b0d7c5028f35e1b0ad85f7ed1472f7", "class_name": "RelatedNodeInfo"}}, "text": "Can you call out like what's happening there? ", "start_char_idx": 3196, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3695140-2646-44e9-9629-2eeb138d680c": {"__data__": {"id_": "e3695140-2646-44e9-9629-2eeb138d680c", "embedding": null, "metadata": {"window": "Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n", "original_text": "Is that a change\nin doc visits? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9", "node_type": "1", "metadata": {"window": "Our AOP guidance, excluding\nCOVID-related programs, 11% to 15% is still above our long-term targets that we provided you.\n Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue? ", "original_text": "Can you call out like what's happening there? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dd67970305dc8c7e2b9ce2f93c5cf8edf2750c23a692676317f706421f9afb8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56433d6c-f851-4205-8885-be8b300cbe8d", "node_type": "1", "metadata": {"window": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "original_text": "Is it you're able to generate more revenue from primary care? "}, "hash": "57f84b8de9ae27c94f75b31a21167e00e903ff76f7b8ac83ba876b3ed4946a95", "class_name": "RelatedNodeInfo"}}, "text": "Is that a change\nin doc visits? ", "start_char_idx": 3242, "end_char_idx": 3274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56433d6c-f851-4205-8885-be8b300cbe8d": {"__data__": {"id_": "56433d6c-f851-4205-8885-be8b300cbe8d", "embedding": null, "metadata": {"window": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "original_text": "Is it you're able to generate more revenue from primary care? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3695140-2646-44e9-9629-2eeb138d680c", "node_type": "1", "metadata": {"window": "Operator\nNext will be Kevin Caliendo with UBS.\n Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n", "original_text": "Is that a change\nin doc visits? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4344214cc790d4c847d37c0dc927060c96f187184f3a1dbf48065e9128711e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91a0a40f-a4f5-4ad6-9353-140efc21c877", "node_type": "1", "metadata": {"window": "Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "original_text": "Is it a mix issue? "}, "hash": "91ad6f6d70371804d6d8584b23c06c62a553653e0b7f9f28a9e244f938f83490", "class_name": "RelatedNodeInfo"}}, "text": "Is it you're able to generate more revenue from primary care? ", "start_char_idx": 3274, "end_char_idx": 3336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91a0a40f-a4f5-4ad6-9353-140efc21c877": {"__data__": {"id_": "91a0a40f-a4f5-4ad6-9353-140efc21c877", "embedding": null, "metadata": {"window": "Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "original_text": "Is it a mix issue? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56433d6c-f851-4205-8885-be8b300cbe8d", "node_type": "1", "metadata": {"window": "Kevin Caliendo\nUBS Investment Bank, Research Division\nIn the Med-Surg side, you noted growth in the primary care business.  Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "original_text": "Is it you're able to generate more revenue from primary care? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "287a952598d9c6ddfecbb5a7529464b63b1e94e40021d67f1f735ce3ea9324cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17486a67-e343-4fe6-9658-2901a6e68bb0", "node_type": "1", "metadata": {"window": "Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there. ", "original_text": "Just any more color on what's happening\nthere would be interesting.\n"}, "hash": "a60673b38917ef7371a7842e1dfc60a6b6518163620a01d5b69f496c4e29575a", "class_name": "RelatedNodeInfo"}}, "text": "Is it a mix issue? ", "start_char_idx": 3336, "end_char_idx": 3355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17486a67-e343-4fe6-9658-2901a6e68bb0": {"__data__": {"id_": "17486a67-e343-4fe6-9658-2901a6e68bb0", "embedding": null, "metadata": {"window": "Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there. ", "original_text": "Just any more color on what's happening\nthere would be interesting.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91a0a40f-a4f5-4ad6-9353-140efc21c877", "node_type": "1", "metadata": {"window": "Can you call out like what's happening there?  Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "original_text": "Is it a mix issue? ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f813c74febf02a9471080911720a1844f2337ba6bcc6d35c99e47ec26e7877c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc", "node_type": "1", "metadata": {"window": "Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "original_text": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. "}, "hash": "9643e6e27d6d57b089b4f4287096b3a4971d7816414f5b4bcd8e3b1047665445", "class_name": "RelatedNodeInfo"}}, "text": "Just any more color on what's happening\nthere would be interesting.\n", "start_char_idx": 3355, "end_char_idx": 3423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc": {"__data__": {"id_": "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc", "embedding": null, "metadata": {"window": "Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "original_text": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17486a67-e343-4fe6-9658-2901a6e68bb0", "node_type": "1", "metadata": {"window": "Is that a change\nin doc visits?  Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there. ", "original_text": "Just any more color on what's happening\nthere would be interesting.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06ff8f92a4bed38ebd4f3d21f9fc8b3db82027b45ea3838607dcc7f832151f28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1", "node_type": "1", "metadata": {"window": "Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business. ", "original_text": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. "}, "hash": "0edb6e5d806e034ef6899e7d32d34afa78dd372916fe0e461814b0a22646794d", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "start_char_idx": 3423, "end_char_idx": 3520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1": {"__data__": {"id_": "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1", "embedding": null, "metadata": {"window": "Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business. ", "original_text": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc", "node_type": "1", "metadata": {"window": "Is it you're able to generate more revenue from primary care?  Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "original_text": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bc0ee84daabbabebd2a949a510760483a1847cc102c3608174d757825c478c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "113badde-7340-4a99-974a-0f04fc6aedec", "node_type": "1", "metadata": {"window": "Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets. ", "original_text": "That certainly helped support the growth there. "}, "hash": "f254c81186fb29b398f5a381ca57ffce9874352d2098c5b22f7b55354abeeb1c", "class_name": "RelatedNodeInfo"}}, "text": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "start_char_idx": 3520, "end_char_idx": 3614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "113badde-7340-4a99-974a-0f04fc6aedec": {"__data__": {"id_": "113badde-7340-4a99-974a-0f04fc6aedec", "embedding": null, "metadata": {"window": "Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets. ", "original_text": "That certainly helped support the growth there. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1", "node_type": "1", "metadata": {"window": "Is it a mix issue?  Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business. ", "original_text": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6667e8bf2fc9a885d863f7d65a6627842bd6806af091a2ad1ab0cae81dca0edf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a28dc81-32c2-4084-8427-3f46528fb623", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined. ", "original_text": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n"}, "hash": "600fd6e83931b452e6780acfc753ce097ff5c786408a1db6dacfb66012eaf789", "class_name": "RelatedNodeInfo"}}, "text": "That certainly helped support the growth there. ", "start_char_idx": 3614, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a28dc81-32c2-4084-8427-3f46528fb623": {"__data__": {"id_": "5a28dc81-32c2-4084-8427-3f46528fb623", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined. ", "original_text": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "113badde-7340-4a99-974a-0f04fc6aedec", "node_type": "1", "metadata": {"window": "Just any more color on what's happening\nthere would be interesting.\n Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets. ", "original_text": "That certainly helped support the growth there. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac00ecdd497e1021c750482657b6cc99fc3d0bf750dedb82a6c0a9efb5c5c115", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66874581-eb42-4e1b-ade7-bba8478d8095", "node_type": "1", "metadata": {"window": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "original_text": "What I would point you to is that the medical business is a very broad business. "}, "hash": "3a8dffa42c62f2e0dae6edf243f081cc7042d4de7b983a3608cdb265bf9670c6", "class_name": "RelatedNodeInfo"}}, "text": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "start_char_idx": 3662, "end_char_idx": 3819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66874581-eb42-4e1b-ade7-bba8478d8095": {"__data__": {"id_": "66874581-eb42-4e1b-ade7-bba8478d8095", "embedding": null, "metadata": {"window": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "original_text": "What I would point you to is that the medical business is a very broad business. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a28dc81-32c2-4084-8427-3f46528fb623", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nWell, I think it's probably the confluence of all of those things.  We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined. ", "original_text": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24adc979e9d6baf91ff2c4ebf1ebb829ee61d8766c700870bec06b9a0ebdaa35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d880a5c-9e1c-4381-8f10-ac551905375a", "node_type": "1", "metadata": {"window": "That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "We have reached into all the alternate site markets. "}, "hash": "e8b519a28839df76c39d0a9d7ce1e4d140fd458701a9a16947284ecf1017cdb5", "class_name": "RelatedNodeInfo"}}, "text": "What I would point you to is that the medical business is a very broad business. ", "start_char_idx": 3819, "end_char_idx": 3900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d880a5c-9e1c-4381-8f10-ac551905375a": {"__data__": {"id_": "7d880a5c-9e1c-4381-8f10-ac551905375a", "embedding": null, "metadata": {"window": "That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "We have reached into all the alternate site markets. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66874581-eb42-4e1b-ade7-bba8478d8095", "node_type": "1", "metadata": {"window": "We talked earlier about the presence of flu in the marketplace for\nthe first time in a while.  That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "original_text": "What I would point you to is that the medical business is a very broad business. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c444b03fbdd260977c32423c9d73353d7d9198d4efa621736d1d59e9442a967d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc7438b-9ddf-431e-b16a-c229d8802fa0", "node_type": "1", "metadata": {"window": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "So\nit's not just physician office narrowly defined. "}, "hash": "a12a1288e49a948497f18c0927c99ec4b94e5230aa0be0fcffd75ea3b86d4c97", "class_name": "RelatedNodeInfo"}}, "text": "We have reached into all the alternate site markets. ", "start_char_idx": 3900, "end_char_idx": 3953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc7438b-9ddf-431e-b16a-c229d8802fa0": {"__data__": {"id_": "adc7438b-9ddf-431e-b16a-c229d8802fa0", "embedding": null, "metadata": {"window": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "So\nit's not just physician office narrowly defined. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d880a5c-9e1c-4381-8f10-ac551905375a", "node_type": "1", "metadata": {"window": "That certainly helped support the growth there.  There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "We have reached into all the alternate site markets. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90105b412c7a3e6d630e5316233f8b60af5a6e2dc6e8aabe38c8f33738c1293e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f70de659-895f-4f23-a202-0f6de42891ce", "node_type": "1", "metadata": {"window": "What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n"}, "hash": "0a705ad3c978fa957b511606ec2cd4e5fe8f28cc8f361c214deb7f88cfe19c1e", "class_name": "RelatedNodeInfo"}}, "text": "So\nit's not just physician office narrowly defined. ", "start_char_idx": 3953, "end_char_idx": 4005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f70de659-895f-4f23-a202-0f6de42891ce": {"__data__": {"id_": "f70de659-895f-4f23-a202-0f6de42891ce", "embedding": null, "metadata": {"window": "What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc7438b-9ddf-431e-b16a-c229d8802fa0", "node_type": "1", "metadata": {"window": "There's -- the last several years have been quite dynamic,\nobviously, in terms of missed procedures, electric -- elective procedures, things of that nature.\n What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "So\nit's not just physician office narrowly defined. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73b587bdc8d39441f451129e57deb9b4e100a6fd07259a52412be19e5ca4cee4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f", "node_type": "1", "metadata": {"window": "We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer"}, "hash": "e4b214c7d88f9ae68ef319036dcdeca229ccd1c486114180987e3f1230332fc6", "class_name": "RelatedNodeInfo"}}, "text": "It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "start_char_idx": 4005, "end_char_idx": 4100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f": {"__data__": {"id_": "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f", "embedding": null, "metadata": {"window": "We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2718f319-ebcd-4a04-81f5-8753264a92fc", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53ea56d1af7c60a5c299f9bbbf7a30d537c1b969ce492933ffa9579d5382c7fe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f70de659-895f-4f23-a202-0f6de42891ce", "node_type": "1", "metadata": {"window": "What I would point you to is that the medical business is a very broad business.  We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54fef09c6cf2433a71d312f4fcb6a748f76b749d8a6096da2947beedc39a0956", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7dbc76f-3f1c-4300-ba91-60a153e8e3e2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "1457600aaee27e04db091430609db6f7a02bb42ce0d9ea06b16c1c20faeb9c35", "class_name": "RelatedNodeInfo"}}, "text": "Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "start_char_idx": 4100, "end_char_idx": 4226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7dbc76f-3f1c-4300-ba91-60a153e8e3e2": {"__data__": {"id_": "b7dbc76f-3f1c-4300-ba91-60a153e8e3e2", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f", "node_type": "1", "metadata": {"window": "We have reached into all the alternate site markets.  So\nit's not just physician office narrowly defined.  It's urgent care clinics, it's retail pharmacy-based clinics, it's ambulatory surgery centers.\n Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "original_text": "Really anywhere a patient might present in the community to consume medical care, we have reach and support into that customer", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7d7c202e2f5f0446a939c36a3cf1b14943c3c903c471fa0b141384a5ccfc59d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2db61508-99bd-4416-b03e-ab20e30d0839", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "original_text": "All Rights reserved.\n"}, "hash": "334a3fb7b1c53993cef6cca1a7e2a9b71d66eb473b67c71b0aee6551615e4de7", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2db61508-99bd-4416-b03e-ab20e30d0839": {"__data__": {"id_": "2db61508-99bd-4416-b03e-ab20e30d0839", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "original_text": "All Rights reserved.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7dbc76f-3f1c-4300-ba91-60a153e8e3e2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0ba4a01b562b453afe6f89a8963a5932bbb12e06feaa3fd8dc1f831f485e7be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30124779-9ce8-4531-bdf7-eda40765208f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n", "original_text": "spglobal.com/marketintelligence 14base. "}, "hash": "0b2b60a6b8ba23613068b0c7cc03181f1294d9fa75a21afe552bb1e2e3375037", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30124779-9ce8-4531-bdf7-eda40765208f": {"__data__": {"id_": "30124779-9ce8-4531-bdf7-eda40765208f", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n", "original_text": "spglobal.com/marketintelligence 14base. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2db61508-99bd-4416-b03e-ab20e30d0839", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "original_text": "All Rights reserved.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "989476071dbffc9c81bc59010ebf7e2341de137a132d2ca63ad168d751dd0f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "354f7254-dbe1-40ac-b3de-8fa2e3a3f946", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "original_text": "So it's kind of a follow-the-patient kind of strategy. "}, "hash": "9dd4cf595488ad8945cf2e020332d23f8d94dc537634dd3df13b2508e18f9fe7", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 14base. ", "start_char_idx": 158, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "354f7254-dbe1-40ac-b3de-8fa2e3a3f946": {"__data__": {"id_": "354f7254-dbe1-40ac-b3de-8fa2e3a3f946", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "original_text": "So it's kind of a follow-the-patient kind of strategy. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30124779-9ce8-4531-bdf7-eda40765208f", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n", "original_text": "spglobal.com/marketintelligence 14base. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d75e9969497e8ef60f7a8d10d5541f8ec2dbebd610a5f3e999efbda7f1650a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c77e065c-e67c-4e1f-a595-da6b20d6e25c", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "original_text": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n"}, "hash": "5f4f5015264b1029e1bece78017d375db517a4c6a8bbcfb546e3e81ed0b8bd1c", "class_name": "RelatedNodeInfo"}}, "text": "So it's kind of a follow-the-patient kind of strategy. ", "start_char_idx": 198, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c77e065c-e67c-4e1f-a595-da6b20d6e25c": {"__data__": {"id_": "c77e065c-e67c-4e1f-a595-da6b20d6e25c", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "original_text": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "354f7254-dbe1-40ac-b3de-8fa2e3a3f946", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "original_text": "So it's kind of a follow-the-patient kind of strategy. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad0bc0f5dc607a8a9c34aea02255993307e36a3ae61ef18dd44780ec822881c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "original_text": "Operator\nAnd next will be George Hill with Deutsche Bank.\n"}, "hash": "57505c676c1ce18782a717319b4139cbb341e742f4ae9fe65816883df07d1f19", "class_name": "RelatedNodeInfo"}}, "text": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "start_char_idx": 253, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a": {"__data__": {"id_": "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "original_text": "Operator\nAnd next will be George Hill with Deutsche Bank.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c77e065c-e67c-4e1f-a595-da6b20d6e25c", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "original_text": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8787a0262f016c9f3617f387f7b0097dad70fb552495a9e5b374cef225f9fc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1112aea4-d10d-4025-908a-26a648bcc59b", "node_type": "1", "metadata": {"window": "So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "original_text": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. "}, "hash": "9bbcd3256a832a6562f74d84903b3263f2f4291bc54f55acb1da7a74d8e31068", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next will be George Hill with Deutsche Bank.\n", "start_char_idx": 354, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1112aea4-d10d-4025-908a-26a648bcc59b": {"__data__": {"id_": "1112aea4-d10d-4025-908a-26a648bcc59b", "embedding": null, "metadata": {"window": "So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "original_text": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "original_text": "Operator\nAnd next will be George Hill with Deutsche Bank.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "417b2f4dc0840f0708989ac4e0497e6987fd4a8a9280315ece711e73f74741df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "176676c0-0e81-48fb-bac6-b23267e00634", "node_type": "1", "metadata": {"window": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "original_text": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. "}, "hash": "c26b8082a0195ebd659279cad43bbdd5b01e538adb6d0b7d8342a894d14101dd", "class_name": "RelatedNodeInfo"}}, "text": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "start_char_idx": 412, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "176676c0-0e81-48fb-bac6-b23267e00634": {"__data__": {"id_": "176676c0-0e81-48fb-bac6-b23267e00634", "embedding": null, "metadata": {"window": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "original_text": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1112aea4-d10d-4025-908a-26a648bcc59b", "node_type": "1", "metadata": {"window": "So it's kind of a follow-the-patient kind of strategy.  And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "original_text": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "496a7236c8f9c4ff22b8d2fcd8981cd13e11902e6321d2bf3c92c5f1d819ab8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a0ebe08-8b68-40ea-8943-1adb1cf9712b", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable. ", "original_text": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? "}, "hash": "432f59d61c3049ae8c2ab34470db2d1acbbc6e58939d82a027ba6606f56b5276", "class_name": "RelatedNodeInfo"}}, "text": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "start_char_idx": 525, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a0ebe08-8b68-40ea-8943-1adb1cf9712b": {"__data__": {"id_": "2a0ebe08-8b68-40ea-8943-1adb1cf9712b", "embedding": null, "metadata": {"window": "Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable. ", "original_text": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "176676c0-0e81-48fb-bac6-b23267e00634", "node_type": "1", "metadata": {"window": "And obviously, as illnesses circulate in the community, that tends to support\nthat business segment.\n Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "original_text": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ecc93c11ccfee4673e0f001e731bfdcb7991849547a0ceca1eefa1681adbe32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1da66dbd-f93f-46c8-b822-f865eeb17190", "node_type": "1", "metadata": {"window": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong. ", "original_text": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n"}, "hash": "046e7d7dd3ce6ea291a11e2382904895800a33580cd601c26167f0159737dfa4", "class_name": "RelatedNodeInfo"}}, "text": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "start_char_idx": 672, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1da66dbd-f93f-46c8-b822-f865eeb17190": {"__data__": {"id_": "1da66dbd-f93f-46c8-b822-f865eeb17190", "embedding": null, "metadata": {"window": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong. ", "original_text": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a0ebe08-8b68-40ea-8943-1adb1cf9712b", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be George Hill with Deutsche Bank.\n George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable. ", "original_text": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness? ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5781392213e3ea2c1ef8c444292d57425be733f5231cee5159fcdac8ccc76af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b1d88da-590b-4d88-a671-f0115a317e7b", "node_type": "1", "metadata": {"window": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID. ", "original_text": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. "}, "hash": "36cb51165edc173a90bcc41284844029de032a6cb1b9d4f21b5c7f8108008bea", "class_name": "RelatedNodeInfo"}}, "text": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "start_char_idx": 829, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b1d88da-590b-4d88-a671-f0115a317e7b": {"__data__": {"id_": "6b1d88da-590b-4d88-a671-f0115a317e7b", "embedding": null, "metadata": {"window": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID. ", "original_text": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1da66dbd-f93f-46c8-b822-f865eeb17190", "node_type": "1", "metadata": {"window": "George Robert Hill\nDeutsche Bank AG, Research Division\nI guess I'm going to ask one more on the medical segment.  I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong. ", "original_text": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f261861c49b1ab5a2b68d30acc876ab2939ea84948ab26fa92ffd8b148821cca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99da7da1-730e-4acf-9fbd-6353e297bf8d", "node_type": "1", "metadata": {"window": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n", "original_text": "I would say, generally, we think that's been pretty stable. "}, "hash": "224750802a47821a9b6787a576d86a7fcfe2a23cd22d910dafacac589a9805dd", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "start_char_idx": 980, "end_char_idx": 1065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99da7da1-730e-4acf-9fbd-6353e297bf8d": {"__data__": {"id_": "99da7da1-730e-4acf-9fbd-6353e297bf8d", "embedding": null, "metadata": {"window": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n", "original_text": "I would say, generally, we think that's been pretty stable. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b1d88da-590b-4d88-a671-f0115a317e7b", "node_type": "1", "metadata": {"window": "I guess I would expect that we're starting to see a decline in utilization as\nit relates to PPE, which probably is reflected in the updated guide.  I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID. ", "original_text": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "262c5fd52ec2930688b0d5f4e8d2a8e5122cd2bd10acdca68edda034a1b36d4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9956172-0b89-40d0-8e3b-4a33823d6b42", "node_type": "1", "metadata": {"window": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products. ", "original_text": "Britt, correct me if\nI'm wrong. "}, "hash": "8802cf47c7879174eb3062d6e7e74937ec45025d656f853d189f18c86315b537", "class_name": "RelatedNodeInfo"}}, "text": "I would say, generally, we think that's been pretty stable. ", "start_char_idx": 1065, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9956172-0b89-40d0-8e3b-4a33823d6b42": {"__data__": {"id_": "b9956172-0b89-40d0-8e3b-4a33823d6b42", "embedding": null, "metadata": {"window": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products. ", "original_text": "Britt, correct me if\nI'm wrong. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99da7da1-730e-4acf-9fbd-6353e297bf8d", "node_type": "1", "metadata": {"window": "I guess could you talk, Brian, a little bit about product categories\nwhere you're seeing strength and product categories where you might be seeing weakness?  Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n", "original_text": "I would say, generally, we think that's been pretty stable. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff0a00c1c110aca5190bbd8b957ed6dbea420d9797654862706e6031adcecb43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80241cda-8046-4b8c-8e03-59f690db0c85", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "original_text": "I think we're well into the kind of the massive spikes in the presence of COVID. "}, "hash": "05626f8c8b3fa3029c5308ffb63ed8a6fbeb5f086533c9b5f4bc710d63fb71d8", "class_name": "RelatedNodeInfo"}}, "text": "Britt, correct me if\nI'm wrong. ", "start_char_idx": 1125, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80241cda-8046-4b8c-8e03-59f690db0c85": {"__data__": {"id_": "80241cda-8046-4b8c-8e03-59f690db0c85", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "original_text": "I think we're well into the kind of the massive spikes in the presence of COVID. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9956172-0b89-40d0-8e3b-4a33823d6b42", "node_type": "1", "metadata": {"window": "Just probably focusing a little less on site\nof care but just would like to know which product categories are reflecting positively versus negatively.\n Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products. ", "original_text": "Britt, correct me if\nI'm wrong. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81011e4d31b6eae25d41fd883074d8409ad652743addce5c504cb62f59261032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac43f16b-cba7-4981-82e0-ecf6178bccf6", "node_type": "1", "metadata": {"window": "I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "original_text": "And so I think that that's been relatively\nstable.\n"}, "hash": "b0dcf3cad0760672247e9835cbfe7709fad6753afd2d14fb2bc4599d58d8cf79", "class_name": "RelatedNodeInfo"}}, "text": "I think we're well into the kind of the massive spikes in the presence of COVID. ", "start_char_idx": 1157, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac43f16b-cba7-4981-82e0-ecf6178bccf6": {"__data__": {"id_": "ac43f16b-cba7-4981-82e0-ecf6178bccf6", "embedding": null, "metadata": {"window": "I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "original_text": "And so I think that that's been relatively\nstable.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80241cda-8046-4b8c-8e03-59f690db0c85", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nI mean, generally, I would say -- you asked about PPE.  I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "original_text": "I think we're well into the kind of the massive spikes in the presence of COVID. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "437963dfe31443cca0d619716d2686b3e5063013d9bfd92d41d479f9637047ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3932b089-6f80-4f9b-bf67-acbb3afc84f6", "node_type": "1", "metadata": {"window": "Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n", "original_text": "I think it's definitely a portfolio of products. "}, "hash": "0e170fda2916c9a47d677725a4af32f44b4c5bf17f55d5488836d7837b104cf1", "class_name": "RelatedNodeInfo"}}, "text": "And so I think that that's been relatively\nstable.\n", "start_char_idx": 1238, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3932b089-6f80-4f9b-bf67-acbb3afc84f6": {"__data__": {"id_": "3932b089-6f80-4f9b-bf67-acbb3afc84f6", "embedding": null, "metadata": {"window": "Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n", "original_text": "I think it's definitely a portfolio of products. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac43f16b-cba7-4981-82e0-ecf6178bccf6", "node_type": "1", "metadata": {"window": "I would say, generally, we think that's been pretty stable.  Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "original_text": "And so I think that that's been relatively\nstable.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de9b579f813d931ca60d9e0b47faecb8cfd2f212ba1d5693cb42fd992e6c67f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60929aa6-f81a-4feb-9935-7f364f2b7c8a", "node_type": "1", "metadata": {"window": "I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "original_text": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. "}, "hash": "5ae8d7dd8803172ccadc558ef53ba69b958406c1c7dcebb5a9ddfe2b082bda56", "class_name": "RelatedNodeInfo"}}, "text": "I think it's definitely a portfolio of products. ", "start_char_idx": 1289, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60929aa6-f81a-4feb-9935-7f364f2b7c8a": {"__data__": {"id_": "60929aa6-f81a-4feb-9935-7f364f2b7c8a", "embedding": null, "metadata": {"window": "I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "original_text": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3932b089-6f80-4f9b-bf67-acbb3afc84f6", "node_type": "1", "metadata": {"window": "Britt, correct me if\nI'm wrong.  I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n", "original_text": "I think it's definitely a portfolio of products. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c44fc2f7ce00e318d53cfddde68b8c7742062b358bcb088dfa5ed19e02cce285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bedbaaf1-96e0-4daa-ba4b-05f114c512de", "node_type": "1", "metadata": {"window": "And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "original_text": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. "}, "hash": "c41f1a8ed475497102e7c30467f6b8499ceebc2ceb23a4d6c2352a236f66fc20", "class_name": "RelatedNodeInfo"}}, "text": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "start_char_idx": 1338, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bedbaaf1-96e0-4daa-ba4b-05f114c512de": {"__data__": {"id_": "bedbaaf1-96e0-4daa-ba4b-05f114c512de", "embedding": null, "metadata": {"window": "And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "original_text": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60929aa6-f81a-4feb-9935-7f364f2b7c8a", "node_type": "1", "metadata": {"window": "I think we're well into the kind of the massive spikes in the presence of COVID.  And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "original_text": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d139b99916e43bef6e60bc2c8ae066a1ed9ec17fe06063f437e72f8b6fe14b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9f9690e-addb-4a05-8224-47f68758dd4e", "node_type": "1", "metadata": {"window": "I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "original_text": "So I think it's probably all of those factors, no single factor.\n"}, "hash": "8170c618cd81c7d2b56fc86ca2955da6185c15184beceecf6b18b54601162605", "class_name": "RelatedNodeInfo"}}, "text": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "start_char_idx": 1446, "end_char_idx": 1589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f9690e-addb-4a05-8224-47f68758dd4e": {"__data__": {"id_": "f9f9690e-addb-4a05-8224-47f68758dd4e", "embedding": null, "metadata": {"window": "I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "original_text": "So I think it's probably all of those factors, no single factor.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bedbaaf1-96e0-4daa-ba4b-05f114c512de", "node_type": "1", "metadata": {"window": "And so I think that that's been relatively\nstable.\n I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "original_text": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f515cb7d83f9bf8eb2d08928d2bd6de6896a522dd5209f4ad123eb17c8706c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f17383-18af-4f23-9561-63b9e9c8fcaf", "node_type": "1", "metadata": {"window": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "original_text": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n"}, "hash": "8005bbb728f25dbb388bab9f4e29b1e918c9d90fc47ec4d515766572d30af479", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's probably all of those factors, no single factor.\n", "start_char_idx": 1589, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f17383-18af-4f23-9561-63b9e9c8fcaf": {"__data__": {"id_": "74f17383-18af-4f23-9561-63b9e9c8fcaf", "embedding": null, "metadata": {"window": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "original_text": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f9690e-addb-4a05-8224-47f68758dd4e", "node_type": "1", "metadata": {"window": "I think it's definitely a portfolio of products.  I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "original_text": "So I think it's probably all of those factors, no single factor.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "023dd0e811b5fb31d3422ff2d69b0fb2d91e410c4b8dfda28024e3c001109f1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2adfcf9-4c99-400f-a1f7-e35768cd22ff", "node_type": "1", "metadata": {"window": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "original_text": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. "}, "hash": "d2501b8dbf835c3fdd307e9707a023ec697febc53370cba91f06e2c9313d978a", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "start_char_idx": 1654, "end_char_idx": 1712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2adfcf9-4c99-400f-a1f7-e35768cd22ff": {"__data__": {"id_": "d2adfcf9-4c99-400f-a1f7-e35768cd22ff", "embedding": null, "metadata": {"window": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "original_text": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f17383-18af-4f23-9561-63b9e9c8fcaf", "node_type": "1", "metadata": {"window": "I mean we're supporting pharmaceuticals, we're supporting lab, we're supporting\ncommodity medical supplies.  We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "original_text": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86e0afd65145ed6b1d84e808a872f21c4726cce5db8668af973c2acd16eec562", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97243f8b-8294-4321-af81-668412c5538b", "node_type": "1", "metadata": {"window": "So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question. ", "original_text": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. "}, "hash": "0f8aeef4542ae2b63390d0585c0625686a36e5c2fe68c1c71b4f0b59e55c6eb8", "class_name": "RelatedNodeInfo"}}, "text": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "start_char_idx": 1712, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97243f8b-8294-4321-af81-668412c5538b": {"__data__": {"id_": "97243f8b-8294-4321-af81-668412c5538b", "embedding": null, "metadata": {"window": "So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question. ", "original_text": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2adfcf9-4c99-400f-a1f7-e35768cd22ff", "node_type": "1", "metadata": {"window": "We obviously have a large mature private brand program, which helps underpin and support our growth\nas we continue to grow and penetrate that.  So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "original_text": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "519591b51b71678466255673d09bcee9b5a050ecf02e083b1da6a16c57a1e218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90458ae8-c023-4906-9930-106af6ddd9b8", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "original_text": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n"}, "hash": "bc40d004b67dd5545cdb0f3eab29499381c39c4f54da36a590118d6096c950f5", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "start_char_idx": 1842, "end_char_idx": 1933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90458ae8-c023-4906-9930-106af6ddd9b8": {"__data__": {"id_": "90458ae8-c023-4906-9930-106af6ddd9b8", "embedding": null, "metadata": {"window": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "original_text": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97243f8b-8294-4321-af81-668412c5538b", "node_type": "1", "metadata": {"window": "So I think it's probably all of those factors, no single factor.\n Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question. ", "original_text": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "897b9f890f263ff76185923ea574a4f64b771f2617f4a799978a12c97bc9cfd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2f227d6-221e-4ffa-89e4-c434ac9ec29b", "node_type": "1", "metadata": {"window": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nYes. "}, "hash": "f8fa6cf9d1f5d50180ef592acb6c2bfd33818614dea31d4c1451c220c9ca51f9", "class_name": "RelatedNodeInfo"}}, "text": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "start_char_idx": 1933, "end_char_idx": 2034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2f227d6-221e-4ffa-89e4-c434ac9ec29b": {"__data__": {"id_": "a2f227d6-221e-4ffa-89e4-c434ac9ec29b", "embedding": null, "metadata": {"window": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90458ae8-c023-4906-9930-106af6ddd9b8", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be Brian Tanquilut with Jefferies.\n Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "original_text": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72c7a06103252f19ceb9e95927bc6d2895741a65897a46e790ff294eb8fb7cd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d50d9b9-1140-4587-bc76-a36723646e5d", "node_type": "1", "metadata": {"window": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case. ", "original_text": "Thanks for the question. "}, "hash": "02c380e7617ccaddf7125417e690cfa82a363387eee767c1745df4073dfc9532", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "start_char_idx": 2034, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d50d9b9-1140-4587-bc76-a36723646e5d": {"__data__": {"id_": "8d50d9b9-1140-4587-bc76-a36723646e5d", "embedding": null, "metadata": {"window": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case. ", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2f227d6-221e-4ffa-89e4-c434ac9ec29b", "node_type": "1", "metadata": {"window": "Brian Gil Tanquilut\nJefferies LLC, Research Division\nBritt, just a question on the guidance rate on the vaccine and kitting side.  Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nYes. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04ece70a876ad1b61dbe5e9dad51fc47d740b5a6ebc3f53be298e72d147711d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d", "node_type": "1", "metadata": {"window": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "original_text": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. "}, "hash": "00acac7dc86edff97d0f7fc58025594f421ad750d2a5bce6e5ef854dcd193285", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2076, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d": {"__data__": {"id_": "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d", "embedding": null, "metadata": {"window": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "original_text": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d50d9b9-1140-4587-bc76-a36723646e5d", "node_type": "1", "metadata": {"window": "Obviously, there's a lot of discussion about how the uptake in\nthe vaccine is pretty slow.  So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case. ", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca3b74d9b21adb7ebe9f17f74f5f523732d46ca10db49e720b30c762e1f9aeae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n", "original_text": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n"}, "hash": "533a40cbb6df2dfa3a6def5ae3ef8db29635b6fed7a67548a77b4625aceb462f", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "start_char_idx": 2101, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d": {"__data__": {"id_": "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n", "original_text": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d", "node_type": "1", "metadata": {"window": "So just curious what your assumptions are that prompted you to raise that guidance for vaccinations.\n Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "original_text": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "879bd4765a1dc1c9503a9c88661f166fef09843e478adf324c9c76c4f385573e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6", "node_type": "1", "metadata": {"window": "Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "original_text": "That is, in fact, the case. "}, "hash": "18fa16ee3110bface8092ae5608b991a8d88637062e8e13a46d6f479079c217c", "class_name": "RelatedNodeInfo"}}, "text": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "start_char_idx": 2307, "end_char_idx": 2463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6": {"__data__": {"id_": "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6", "embedding": null, "metadata": {"window": "Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "original_text": "That is, in fact, the case. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nYes.  Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n", "original_text": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f51f35b5c85d82fc9dfe9e1cf6f68e588c396418b31e99edcd985aa4693797a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "707310e8-eb6c-4771-9c3c-3fa1b566a7fd", "node_type": "1", "metadata": {"window": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down. ", "original_text": "They haven't declined as fast as we had anticipated, but they are down year-over-year. "}, "hash": "3342d0523ee2b6f4a96a4ccb3ffd0fcb2814ffaa0465fb5616f99e91a38446f4", "class_name": "RelatedNodeInfo"}}, "text": "That is, in fact, the case. ", "start_char_idx": 2463, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "707310e8-eb6c-4771-9c3c-3fa1b566a7fd": {"__data__": {"id_": "707310e8-eb6c-4771-9c3c-3fa1b566a7fd", "embedding": null, "metadata": {"window": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down. ", "original_text": "They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6", "node_type": "1", "metadata": {"window": "Thanks for the question.  As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "original_text": "That is, in fact, the case. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62dfd41653e52f44575431394b6d4353766e33a5de4b7886f85bbb6f6fd3bda4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e2409fa-b22f-49ec-93d3-a46b0d955e5f", "node_type": "1", "metadata": {"window": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "original_text": "They are continuing to\ncome down from prior -- from the fourth quarter.\n"}, "hash": "73a2908b1a7be1c66273ad63ce51e9e5f3a5ae80e642bb478783466cf8c5ee7a", "class_name": "RelatedNodeInfo"}}, "text": "They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "start_char_idx": 2491, "end_char_idx": 2578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e2409fa-b22f-49ec-93d3-a46b0d955e5f": {"__data__": {"id_": "4e2409fa-b22f-49ec-93d3-a46b0d955e5f", "embedding": null, "metadata": {"window": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "original_text": "They are continuing to\ncome down from prior -- from the fourth quarter.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "707310e8-eb6c-4771-9c3c-3fa1b566a7fd", "node_type": "1", "metadata": {"window": "As we've talked about from the beginning, we take our guidance really from the government, and we\nfactor that in both from a vaccine perspective and as how we support the building of ancillary supply kits.  And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down. ", "original_text": "They haven't declined as fast as we had anticipated, but they are down year-over-year. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77b577ef42984027d6b94c6d5e35e716214f46906e54f115b693d2bf935d10a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c46f537e-6939-442a-a57c-0abe0ad822d2", "node_type": "1", "metadata": {"window": "That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J. ", "original_text": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. "}, "hash": "11abaaeef6a1841137e7e1ed909a3dcc87f52543b8f961d21a2c54d5e73911c1", "class_name": "RelatedNodeInfo"}}, "text": "They are continuing to\ncome down from prior -- from the fourth quarter.\n", "start_char_idx": 2578, "end_char_idx": 2650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c46f537e-6939-442a-a57c-0abe0ad822d2": {"__data__": {"id_": "c46f537e-6939-442a-a57c-0abe0ad822d2", "embedding": null, "metadata": {"window": "That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J. ", "original_text": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e2409fa-b22f-49ec-93d3-a46b0d955e5f", "node_type": "1", "metadata": {"window": "And so as we've talked\nabout at the beginning of the year, we anticipated that the volumes for the program would continue to decline versus the prior year.\n That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "original_text": "They are continuing to\ncome down from prior -- from the fourth quarter.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e1c4bb11845b6c670832cb6fc06853321ed5a78096cfec26e2f018fd12cfa14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "690b2419-093d-4f29-bc05-a01b6e9b5346", "node_type": "1", "metadata": {"window": "They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n", "original_text": "So we are\nseeing that the centralized program is beginning to slow down. "}, "hash": "610be12cb45232254df72f72aba3c5de23b2c22a037945184e5473468e968fa7", "class_name": "RelatedNodeInfo"}}, "text": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "start_char_idx": 2650, "end_char_idx": 2775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "690b2419-093d-4f29-bc05-a01b6e9b5346": {"__data__": {"id_": "690b2419-093d-4f29-bc05-a01b6e9b5346", "embedding": null, "metadata": {"window": "They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n", "original_text": "So we are\nseeing that the centralized program is beginning to slow down. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c46f537e-6939-442a-a57c-0abe0ad822d2", "node_type": "1", "metadata": {"window": "That is, in fact, the case.  They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J. ", "original_text": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55fd94d488f5eb284999ca41ea675cb5fead197362abaf957c15fd8276c93112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "682a0237-2f42-47dc-8a44-f2672cde7fd7", "node_type": "1", "metadata": {"window": "They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "original_text": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n"}, "hash": "f576f684d7672445ee3b96e27bf0fe9e24e087e65337de368c2230ace19b486a", "class_name": "RelatedNodeInfo"}}, "text": "So we are\nseeing that the centralized program is beginning to slow down. ", "start_char_idx": 2775, "end_char_idx": 2848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "682a0237-2f42-47dc-8a44-f2672cde7fd7": {"__data__": {"id_": "682a0237-2f42-47dc-8a44-f2672cde7fd7", "embedding": null, "metadata": {"window": "They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "original_text": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "690b2419-093d-4f29-bc05-a01b6e9b5346", "node_type": "1", "metadata": {"window": "They haven't declined as fast as we had anticipated, but they are down year-over-year.  They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n", "original_text": "So we are\nseeing that the centralized program is beginning to slow down. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30d9aec91b78f875df3c820d390f1c122a3e3b04ea955db8e1438ad724a7c933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b", "node_type": "1", "metadata": {"window": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting? ", "original_text": "Operator\nAnd next will be A.J. "}, "hash": "5922046199a4db2ae38003cc180e4d3e8855151542b48103b511cee8ab5e9d7f", "class_name": "RelatedNodeInfo"}}, "text": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "start_char_idx": 2848, "end_char_idx": 3093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b": {"__data__": {"id_": "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b", "embedding": null, "metadata": {"window": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting? ", "original_text": "Operator\nAnd next will be A.J. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "682a0237-2f42-47dc-8a44-f2672cde7fd7", "node_type": "1", "metadata": {"window": "They are continuing to\ncome down from prior -- from the fourth quarter.\n And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "original_text": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87eab32b19a66d3785e5a390c4ef4af4988a7a0acec4268a1b4b62673da0eea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e891dd-7e29-40fe-961f-d0ab61a1bebf", "node_type": "1", "metadata": {"window": "So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "original_text": "Rice with Credit Suisse.\n"}, "hash": "ef9ae2744619a61304247554f369ab4f0f4f109018fa745d21d731909b66a977", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next will be A.J. ", "start_char_idx": 3093, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e891dd-7e29-40fe-961f-d0ab61a1bebf": {"__data__": {"id_": "85e891dd-7e29-40fe-961f-d0ab61a1bebf", "embedding": null, "metadata": {"window": "So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "original_text": "Rice with Credit Suisse.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b", "node_type": "1", "metadata": {"window": "And in our guidance for the rest of the year, we anticipate that the second half will actually be lower than the first half.  So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting? ", "original_text": "Operator\nAnd next will be A.J. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c047143c955e7ab931705c31d0cff7fe5765921c6df163bb5918a24a3a5f6326", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cd136b3-ac98-4732-b165-1676cd91bf4c", "node_type": "1", "metadata": {"window": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n", "original_text": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. "}, "hash": "41bf9af62e9e75a830ddd745e2af7588a497ce44cd49db1c28b92bba61321852", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse.\n", "start_char_idx": 3124, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cd136b3-ac98-4732-b165-1676cd91bf4c": {"__data__": {"id_": "4cd136b3-ac98-4732-b165-1676cd91bf4c", "embedding": null, "metadata": {"window": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n", "original_text": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e891dd-7e29-40fe-961f-d0ab61a1bebf", "node_type": "1", "metadata": {"window": "So we are\nseeing that the centralized program is beginning to slow down.  And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "original_text": "Rice with Credit Suisse.\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "843bb82806c6919b0a6f7c51d098701c42401b70b256362bd7494ed94cd7072c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1676ac87-02c9-4839-8a3a-bb6796ccbab1", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Is it fee-based compensation shared results somehow that you're getting? "}, "hash": "105d475699f65e48417764768d8f58ca369a22ee1a558a795b2c611f20087468", "class_name": "RelatedNodeInfo"}}, "text": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "start_char_idx": 3149, "end_char_idx": 3389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1676ac87-02c9-4839-8a3a-bb6796ccbab1": {"__data__": {"id_": "1676ac87-02c9-4839-8a3a-bb6796ccbab1", "embedding": null, "metadata": {"window": "Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Is it fee-based compensation shared results somehow that you're getting? ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cd136b3-ac98-4732-b165-1676cd91bf4c", "node_type": "1", "metadata": {"window": "And we would expect that as our contracts expire, our medical contract\nexpires in January and the vaccine distribution expires in June, that, that will return at that point to the -- not from a centralized\nprogram back into a distributor model.\n Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n", "original_text": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "229ad444e6d8256a5587a999cc524c02fabbff7017aa78425b44bfcc64cf36c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cffa5d60-2ba3-475b-8617-6fdeb1221144", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. "}, "hash": "dff9124b2ec92db85c8e9111505b1dabf7d62c9c26ca4a2860419e60d80f790c", "class_name": "RelatedNodeInfo"}}, "text": "Is it fee-based compensation shared results somehow that you're getting? ", "start_char_idx": 3389, "end_char_idx": 3462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cffa5d60-2ba3-475b-8617-6fdeb1221144": {"__data__": {"id_": "cffa5d60-2ba3-475b-8617-6fdeb1221144", "embedding": null, "metadata": {"window": "Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1676ac87-02c9-4839-8a3a-bb6796ccbab1", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be A.J.  Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Is it fee-based compensation shared results somehow that you're getting? ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6d7a9bfaeb6697b620e4b35fcf7fc18c54562316cdb7612ed53d87a64b8564a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe54c565-ae8f-4646-bc4f-16b808ee1509", "node_type": "1", "metadata": {"window": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "What are the milestones to\nget to that accretion target?\n"}, "hash": "525f59775d50e4320105fe4a7ee8f05182cd14247a92df4f56ba401fcb8f6e73", "class_name": "RelatedNodeInfo"}}, "text": "And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "start_char_idx": 3462, "end_char_idx": 3581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe54c565-ae8f-4646-bc4f-16b808ee1509": {"__data__": {"id_": "fe54c565-ae8f-4646-bc4f-16b808ee1509", "embedding": null, "metadata": {"window": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "What are the milestones to\nget to that accretion target?\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cffa5d60-2ba3-475b-8617-6fdeb1221144", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.\n Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51ed9e2d744adfc9a847732ca67da7a856b137a9292b010144e785fbaa65bf8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f0bca8-3ef9-414c-8301-5df968d976dd", "node_type": "1", "metadata": {"window": "Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Brian S. Tyler"}, "hash": "0d3e027ad9db77ffb5f0c67fea7844694c46154fef2004d86b6ecdf740173e8a", "class_name": "RelatedNodeInfo"}}, "text": "What are the milestones to\nget to that accretion target?\n", "start_char_idx": 3581, "end_char_idx": 3638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f0bca8-3ef9-414c-8301-5df968d976dd": {"__data__": {"id_": "65f0bca8-3ef9-414c-8301-5df968d976dd", "embedding": null, "metadata": {"window": "Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Brian S. Tyler", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e73dbbdaf0a3d6843fde7289fa8a5beb80311b549a138169c412d01258deff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe54c565-ae8f-4646-bc4f-16b808ee1509", "node_type": "1", "metadata": {"window": "Albert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nJust on your initiative around its access, adherence and affordability in the biopharma segment, I wonder if you could just walk us\nthrough the economic model associated with that.  Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "What are the milestones to\nget to that accretion target?\n", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdac17ce0bd8c859ea244144f1d1b668eb6eb6e109c5769f3976bb8685ba10f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0c8a836-e87f-4a34-82a4-eee1918bef42", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "99bff045ace8b7bdb919af56829d76102210b07f0b88af60283f16406fb07ac8", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler", "start_char_idx": 980, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0c8a836-e87f-4a34-82a4-eee1918bef42": {"__data__": {"id_": "d0c8a836-e87f-4a34-82a4-eee1918bef42", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f0bca8-3ef9-414c-8301-5df968d976dd", "node_type": "1", "metadata": {"window": "Is it fee-based compensation shared results somehow that you're getting?  And then\nyou say the step-up -- you offered the step-up in Rx Savings accretion over the next year is pretty dramatic.  What are the milestones to\nget to that accretion target?\n Brian S. Tyler", "original_text": "Brian S. Tyler", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1050e5976db95dbec6a13700a85ad526ed79e6b38e800f728956325dac47e3ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de123c69-78bf-47c6-bdbe-90a09088a7ec", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n", "original_text": "All Rights reserved.\n"}, "hash": "9f35992a5bc4097e2afe2548fc65e1e55c1ab9dd8502b039fede72a1f61ac244", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de123c69-78bf-47c6-bdbe-90a09088a7ec": {"__data__": {"id_": "de123c69-78bf-47c6-bdbe-90a09088a7ec", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n", "original_text": "All Rights reserved.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0c8a836-e87f-4a34-82a4-eee1918bef42", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31b805e1ab102c5d4fd63e38abd8f0b546a591d4ae492b6e0e211b5b70209f44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48491696-0e59-4fc3-b0f2-3bb172fb89e4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "original_text": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model. "}, "hash": "b1f1dcada0c4b374103c045f52d95972645bef650b264e2ec438e24af5c9bf18", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48491696-0e59-4fc3-b0f2-3bb172fb89e4": {"__data__": {"id_": "48491696-0e59-4fc3-b0f2-3bb172fb89e4", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "original_text": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de123c69-78bf-47c6-bdbe-90a09088a7ec", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n", "original_text": "All Rights reserved.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edf9edb60870155aeb7b0f05bf1f957854c4a38db05a3aaa7e84d9ff6ae595e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "224658ff-a24f-4083-a359-ac1b39a4a2c0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "original_text": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. "}, "hash": "1fc35b548871f24b00bd2869d36eb0a4131853e117979547756bc4b0c970d802", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model. ", "start_char_idx": 158, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "224658ff-a24f-4083-a359-ac1b39a4a2c0": {"__data__": {"id_": "224658ff-a24f-4083-a359-ac1b39a4a2c0", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "original_text": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48491696-0e59-4fc3-b0f2-3bb172fb89e4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "original_text": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "744bbdc35fa9739b8c492962ec63598474e77e66832ac7096dab745503fc629f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf947523-ad7a-478b-9eff-55f43264786f", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "original_text": "We have more programmatic models, where you pay for a service over a period of time.\n"}, "hash": "4393fc07bc33f58a86558f3852db3706b7e5b9d887997276107617e57421ecef", "class_name": "RelatedNodeInfo"}}, "text": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "start_char_idx": 254, "end_char_idx": 392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf947523-ad7a-478b-9eff-55f43264786f": {"__data__": {"id_": "cf947523-ad7a-478b-9eff-55f43264786f", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "original_text": "We have more programmatic models, where you pay for a service over a period of time.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "224658ff-a24f-4083-a359-ac1b39a4a2c0", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "original_text": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6f1f0e9f12a164bb8bda6d885c067236ce092afe9bd633fe3be046dd72ce442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "344ddd36-3a22-48e7-aef6-86ad860d91d0", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients. ", "original_text": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n"}, "hash": "d078b58945cc07cc028f3d4d3e9b7ba8034b28e34188a54fd681540af3c28bfa", "class_name": "RelatedNodeInfo"}}, "text": "We have more programmatic models, where you pay for a service over a period of time.\n", "start_char_idx": 392, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344ddd36-3a22-48e7-aef6-86ad860d91d0": {"__data__": {"id_": "344ddd36-3a22-48e7-aef6-86ad860d91d0", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients. ", "original_text": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf947523-ad7a-478b-9eff-55f43264786f", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "original_text": "We have more programmatic models, where you pay for a service over a period of time.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ffe7123e6009372a32a255c5764f82980e5476282bf45fcdd386172b0c763979", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d051edaa-d12c-4b29-b5f4-8479a4e5d30a", "node_type": "1", "metadata": {"window": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n", "original_text": "So we really got a nice mix across the segment, and we're quite pleased with that mix. "}, "hash": "0d156ee28f3231af3e37d525aa6181e2bfca9346ded8f63d92766111f5139991", "class_name": "RelatedNodeInfo"}}, "text": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "start_char_idx": 477, "end_char_idx": 568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d051edaa-d12c-4b29-b5f4-8479a4e5d30a": {"__data__": {"id_": "d051edaa-d12c-4b29-b5f4-8479a4e5d30a", "embedding": null, "metadata": {"window": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n", "original_text": "So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344ddd36-3a22-48e7-aef6-86ad860d91d0", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients. ", "original_text": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af5860207fddf49e4951555db4da0c29b1270299ddc0bb61e1560f255549285a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a06e42d8-cd8f-4595-a6bb-52b73a31d876", "node_type": "1", "metadata": {"window": "We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "original_text": "We're really excited about adding the Rx\nSavings Solutions to our portfolio. "}, "hash": "25417b66b4647bdfc5c7c8e1380d77d458519274da194d1c49b5de2b601e7c31", "class_name": "RelatedNodeInfo"}}, "text": "So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "start_char_idx": 568, "end_char_idx": 655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a06e42d8-cd8f-4595-a6bb-52b73a31d876": {"__data__": {"id_": "a06e42d8-cd8f-4595-a6bb-52b73a31d876", "embedding": null, "metadata": {"window": "We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "original_text": "We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d051edaa-d12c-4b29-b5f4-8479a4e5d30a", "node_type": "1", "metadata": {"window": "I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through.  We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n", "original_text": "So we really got a nice mix across the segment, and we're quite pleased with that mix. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b374b84245c5435d56d87b52c35cb428d9753a36259247cb5f5346a5d1eebe0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2e2d9ce-4817-410d-b498-ccfa960a4eb6", "node_type": "1", "metadata": {"window": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n", "original_text": "They serve about 17 million patients. "}, "hash": "57028e16a43aed9b3c13e9fd993a01e0b8430b37363df74cb52e8f9a150a5967", "class_name": "RelatedNodeInfo"}}, "text": "We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "start_char_idx": 655, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2e2d9ce-4817-410d-b498-ccfa960a4eb6": {"__data__": {"id_": "b2e2d9ce-4817-410d-b498-ccfa960a4eb6", "embedding": null, "metadata": {"window": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n", "original_text": "They serve about 17 million patients. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a06e42d8-cd8f-4595-a6bb-52b73a31d876", "node_type": "1", "metadata": {"window": "We have more programmatic models, where you pay for a service over a period of time.\n And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "original_text": "We're really excited about adding the Rx\nSavings Solutions to our portfolio. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07f003656b70cce17d2db7056be5d194189d90d48f7275155d6ecb76e6efa2c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "623eb302-b0a1-4092-aa41-0b82f4d5067b", "node_type": "1", "metadata": {"window": "So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "original_text": "It's really on point for access and affordability for patients.\n"}, "hash": "a34747132a1e313bcdae3d4e307b64c2d2b85fc3447243a0cd2239dcd1990c86", "class_name": "RelatedNodeInfo"}}, "text": "They serve about 17 million patients. ", "start_char_idx": 732, "end_char_idx": 770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "623eb302-b0a1-4092-aa41-0b82f4d5067b": {"__data__": {"id_": "623eb302-b0a1-4092-aa41-0b82f4d5067b", "embedding": null, "metadata": {"window": "So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "original_text": "It's really on point for access and affordability for patients.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2e2d9ce-4817-410d-b498-ccfa960a4eb6", "node_type": "1", "metadata": {"window": "And then the Rx Savings Solutions model specifically is more of a subscription-type model.\n So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n", "original_text": "They serve about 17 million patients. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "953ca352160594ecb6197a77660285d1208808748d839564ae1633eacc1dcc44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "194e81d8-3863-4eb1-828e-f900ef9f33a7", "node_type": "1", "metadata": {"window": "We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "original_text": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. "}, "hash": "24fb27ddac101bd55c419b905342e236a2ca94dc25c2fc6fafbed2fc7601bb16", "class_name": "RelatedNodeInfo"}}, "text": "It's really on point for access and affordability for patients.\n", "start_char_idx": 770, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "194e81d8-3863-4eb1-828e-f900ef9f33a7": {"__data__": {"id_": "194e81d8-3863-4eb1-828e-f900ef9f33a7", "embedding": null, "metadata": {"window": "We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "original_text": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "623eb302-b0a1-4092-aa41-0b82f4d5067b", "node_type": "1", "metadata": {"window": "So we really got a nice mix across the segment, and we're quite pleased with that mix.  We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "original_text": "It's really on point for access and affordability for patients.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "614f892d858382281a3873162a3ac33093d02c45e9e09890f572d4a859a95f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35504a88-2f74-4416-b87f-a0d1f111dc10", "node_type": "1", "metadata": {"window": "They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "original_text": "So we're super excited about that, of bringing these assets together.\n"}, "hash": "77aec08a6106b9d9e05403f214bf0d20fd45213ea2cb59c923c5ac64602c6a9f", "class_name": "RelatedNodeInfo"}}, "text": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "start_char_idx": 834, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35504a88-2f74-4416-b87f-a0d1f111dc10": {"__data__": {"id_": "35504a88-2f74-4416-b87f-a0d1f111dc10", "embedding": null, "metadata": {"window": "They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "original_text": "So we're super excited about that, of bringing these assets together.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "194e81d8-3863-4eb1-828e-f900ef9f33a7", "node_type": "1", "metadata": {"window": "We're really excited about adding the Rx\nSavings Solutions to our portfolio.  They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "original_text": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4826fd99a15425b3fa2a756a54efd561af7eb59d23e9d2d503e54c9a6263ae03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db71ce6c-5402-4c62-8803-73a68dbadee8", "node_type": "1", "metadata": {"window": "It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "original_text": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n"}, "hash": "5ef5c3608fddbadb66c29445e43a449825d8342e40bfe08a5205be9960b1394b", "class_name": "RelatedNodeInfo"}}, "text": "So we're super excited about that, of bringing these assets together.\n", "start_char_idx": 1152, "end_char_idx": 1222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db71ce6c-5402-4c62-8803-73a68dbadee8": {"__data__": {"id_": "db71ce6c-5402-4c62-8803-73a68dbadee8", "embedding": null, "metadata": {"window": "It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "original_text": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35504a88-2f74-4416-b87f-a0d1f111dc10", "node_type": "1", "metadata": {"window": "They serve about 17 million patients.  It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "original_text": "So we're super excited about that, of bringing these assets together.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71e5b9bdfdc45aa8897012cd1d8037ced29685c7d7672dc6fd8ea8d9e8f2b11c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1", "node_type": "1", "metadata": {"window": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "original_text": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. "}, "hash": "01bbc941f5f4a5e75e735bac82c9c15fe59d2dfa76367f3d53d56de4eac92402", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "start_char_idx": 1222, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1": {"__data__": {"id_": "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1", "embedding": null, "metadata": {"window": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "original_text": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db71ce6c-5402-4c62-8803-73a68dbadee8", "node_type": "1", "metadata": {"window": "It's really on point for access and affordability for patients.\n And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "original_text": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed268e3aedf2397878667553c2be574e0e229daa69cb9dfdb8e3b4a072d3920d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c9726d0-9f51-43ae-ab46-acdb6747ca4c", "node_type": "1", "metadata": {"window": "So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "original_text": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n"}, "hash": "0fd469d2c22c717a1a0aa86b62b7a56321aa20d775ab5cda66ad6086fab68537", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "start_char_idx": 1282, "end_char_idx": 1481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c9726d0-9f51-43ae-ab46-acdb6747ca4c": {"__data__": {"id_": "7c9726d0-9f51-43ae-ab46-acdb6747ca4c", "embedding": null, "metadata": {"window": "So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "original_text": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1", "node_type": "1", "metadata": {"window": "And we think there's a high complementarity between some of the programs and services that we offer in the legacy business that we\ncan use to augment the value proposition Rx Savings Solutions has and use their technology and AI and their really analytics to help\nsupport some of the legacy McKesson programs as well.  So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "original_text": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92d81c0ea4e7c392e7a6bb91cf8cbe347ebaf140e021cbad92d1c558ffefd425", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a32c3b7-613c-473e-8a10-2de942b3bc64", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business. ", "original_text": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. "}, "hash": "b062686912a2e858a8d745e1445d9aa5d33e23e8e0527bd679f072d883d39eba", "class_name": "RelatedNodeInfo"}}, "text": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "start_char_idx": 1481, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a32c3b7-613c-473e-8a10-2de942b3bc64": {"__data__": {"id_": "1a32c3b7-613c-473e-8a10-2de942b3bc64", "embedding": null, "metadata": {"window": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business. ", "original_text": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c9726d0-9f51-43ae-ab46-acdb6747ca4c", "node_type": "1", "metadata": {"window": "So we're super excited about that, of bringing these assets together.\n Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "original_text": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6235da94807496be3bbd10e5fb261a3a862db94e1bade7568363071ffe4fbfaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d", "node_type": "1", "metadata": {"window": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand. ", "original_text": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n"}, "hash": "aacd6fadc5fb1ab87cd5b6799d667b60d8970f254abe6c8549a831aea8ca6a70", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "start_char_idx": 1759, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d": {"__data__": {"id_": "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d", "embedding": null, "metadata": {"window": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand. ", "original_text": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a32c3b7-613c-473e-8a10-2de942b3bc64", "node_type": "1", "metadata": {"window": "Operator\nAnd next will be Elizabeth Anderson with Evercore.\n Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business. ", "original_text": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8d57552ce1bb66f2fed64fb0a91204fbc400a4bf494963a533155b0a2cf7eb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6febd76-10df-4270-8ce5-61dfd05d9ba4", "node_type": "1", "metadata": {"window": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there. ", "original_text": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. "}, "hash": "b3b8aaad0f31273509f03589569edd6a90eb5653d03a629a9a182ce0c8c47d4c", "class_name": "RelatedNodeInfo"}}, "text": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "start_char_idx": 1956, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6febd76-10df-4270-8ce5-61dfd05d9ba4": {"__data__": {"id_": "e6febd76-10df-4270-8ce5-61dfd05d9ba4", "embedding": null, "metadata": {"window": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there. ", "original_text": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d", "node_type": "1", "metadata": {"window": "Elizabeth Hammell Anderson\nEvercore ISI Institutional Equities, Research Division\nI appreciate the update you gave us on sort of the pieces -- moving pieces in the Prescription Technology Solutions.  Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand. ", "original_text": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "323c316292ec03779ffede57ecf39abe59296e4e8b4869bff81b1328bbad298f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b914c218-5275-4794-806b-52c43dbf1632", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "original_text": "There is some lumpiness in that business. "}, "hash": "dbbe989596e45f28a9a7a3b6184c1bd1fc934c3195ebfacc46b88f6ac350db94", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "start_char_idx": 2025, "end_char_idx": 2108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b914c218-5275-4794-806b-52c43dbf1632": {"__data__": {"id_": "b914c218-5275-4794-806b-52c43dbf1632", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "original_text": "There is some lumpiness in that business. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6febd76-10df-4270-8ce5-61dfd05d9ba4", "node_type": "1", "metadata": {"window": "Ex what you were\ntalking about in terms of the guidance step-down for the logistics business, can you talk about how sort of some of those other core\nbusinesses in that segment are doing in terms of CoverMyMeds or some of the others that we've heard have contributed over time?\n Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there. ", "original_text": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d528a6369c33f8f14b0fc382f1861b312b2d40f3f08c50f87ed2a73388796fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7073653-97fe-43aa-bfca-3d056ee939dd", "node_type": "1", "metadata": {"window": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "original_text": "When we look at that business, it's really\ndriven in large part by underlying script demand. "}, "hash": "3cfadf73090079ee3cc88e05a8e5da41d56e1161706e1d2efedb39a6d19de21d", "class_name": "RelatedNodeInfo"}}, "text": "There is some lumpiness in that business. ", "start_char_idx": 2108, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7073653-97fe-43aa-bfca-3d056ee939dd": {"__data__": {"id_": "a7073653-97fe-43aa-bfca-3d056ee939dd", "embedding": null, "metadata": {"window": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "original_text": "When we look at that business, it's really\ndriven in large part by underlying script demand. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b914c218-5275-4794-806b-52c43dbf1632", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nSo I'd say that Britt talked about the mix with 3PL, and I think he rightly characterized that as there's some -- I don't know the word he\nused, it wasn't volatility.  But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "original_text": "There is some lumpiness in that business. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e21b20ec7f91f7f9fb13914c1d9797d802d13456fef2fd9ce64850c64c91340", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dd4513c-5672-4f14-803c-e3fea7872e36", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing. ", "original_text": "So we're happy to see growth come back there. "}, "hash": "54f8a266db7f85deefdcb303ea3e9c4b47b7f0ea3cc29b7d26aa2c502457f50c", "class_name": "RelatedNodeInfo"}}, "text": "When we look at that business, it's really\ndriven in large part by underlying script demand. ", "start_char_idx": 2150, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dd4513c-5672-4f14-803c-e3fea7872e36": {"__data__": {"id_": "3dd4513c-5672-4f14-803c-e3fea7872e36", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing. ", "original_text": "So we're happy to see growth come back there. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7073653-97fe-43aa-bfca-3d056ee939dd", "node_type": "1", "metadata": {"window": "But there is some...\nBritt J. Vitalone\nExecutive VP & CFO\nLumpiness.\n Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "original_text": "When we look at that business, it's really\ndriven in large part by underlying script demand. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75289ac747744e1672e1d405fc628ede9de39e532fa655ee73f5a8be2f82e891", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c956c3ee-1ab8-42df-9db7-8e09e07e9941", "node_type": "1", "metadata": {"window": "There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "original_text": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n"}, "hash": "0b0b155bc641cb21dacb16ea974bbbbfbb096f0bd351b7784bb63d91dc7bfac4", "class_name": "RelatedNodeInfo"}}, "text": "So we're happy to see growth come back there. ", "start_char_idx": 2243, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c956c3ee-1ab8-42df-9db7-8e09e07e9941": {"__data__": {"id_": "c956c3ee-1ab8-42df-9db7-8e09e07e9941", "embedding": null, "metadata": {"window": "There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "original_text": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dd4513c-5672-4f14-803c-e3fea7872e36", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nLumpiness, yes, that's the right way to describe it.  There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing. ", "original_text": "So we're happy to see growth come back there. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55ae89280524b9dda158079ab94d9b457236d70947599bd285d22a1f88b0a0ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a68eff2a-bd3c-4c58-89b2-0b0ef090218f", "node_type": "1", "metadata": {"window": "When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n", "original_text": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. "}, "hash": "ee317dcb061b64fdc603b0e373118e6bc0169f918ad62f8433902af014d2bac6", "class_name": "RelatedNodeInfo"}}, "text": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "start_char_idx": 2289, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a68eff2a-bd3c-4c58-89b2-0b0ef090218f": {"__data__": {"id_": "a68eff2a-bd3c-4c58-89b2-0b0ef090218f", "embedding": null, "metadata": {"window": "When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n", "original_text": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c956c3ee-1ab8-42df-9db7-8e09e07e9941", "node_type": "1", "metadata": {"window": "There is some lumpiness in that business.  When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "original_text": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb117656b5148ffcfe03cc50e4dfa04e5629f5becc6df9f1cc1c5c921fd5ad4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563", "node_type": "1", "metadata": {"window": "So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly. ", "original_text": "So that's\nan important component of that business to keep that growing. "}, "hash": "8a0dab7b73ac0ab800b715ff857b4775f0ec9b0ee1cc5e18fa85c59371fdef2c", "class_name": "RelatedNodeInfo"}}, "text": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "start_char_idx": 2575, "end_char_idx": 2700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563": {"__data__": {"id_": "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563", "embedding": null, "metadata": {"window": "So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly. ", "original_text": "So that's\nan important component of that business to keep that growing. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a68eff2a-bd3c-4c58-89b2-0b0ef090218f", "node_type": "1", "metadata": {"window": "When we look at that business, it's really\ndriven in large part by underlying script demand.  So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n", "original_text": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "127673d9a086e702e52dcc43d0e0466b3a8c0526ee93fb37900efe57438b7e18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20aa7af4-aee7-44a8-aff3-c18698938d22", "node_type": "1", "metadata": {"window": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n", "original_text": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n"}, "hash": "646ff6507daf7a211a12b4671be3c6bae7aec3d34477377df55ce1e08bac9cb5", "class_name": "RelatedNodeInfo"}}, "text": "So that's\nan important component of that business to keep that growing. ", "start_char_idx": 2700, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20aa7af4-aee7-44a8-aff3-c18698938d22": {"__data__": {"id_": "20aa7af4-aee7-44a8-aff3-c18698938d22", "embedding": null, "metadata": {"window": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n", "original_text": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563", "node_type": "1", "metadata": {"window": "So we're happy to see growth come back there.  It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly. ", "original_text": "So that's\nan important component of that business to keep that growing. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00c887e75f42e99e5798f4d9fbfdb3ddb1fb0571942dff67fb87f9ebcc2aefcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc", "node_type": "1", "metadata": {"window": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "original_text": "Rachel Rodriguez\nAnd we have time for one more question, please.\n"}, "hash": "e9c0f7da899095675f79fd1b643ff7d1dcf50f69b57e3e0b048b12cf40ca0cc8", "class_name": "RelatedNodeInfo"}}, "text": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "start_char_idx": 2772, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc": {"__data__": {"id_": "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc", "embedding": null, "metadata": {"window": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "original_text": "Rachel Rodriguez\nAnd we have time for one more question, please.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20aa7af4-aee7-44a8-aff3-c18698938d22", "node_type": "1", "metadata": {"window": "It's driven by, in some cases, brand\nlaunches and our ability to convince brands that the value propositions we have to help them find patients break down the barriers to\nget those patients started on therapy and then to keep those patients on therapy, we think has a really great ROI.\n So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n", "original_text": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb8db3e6defd03c74c492b63a35b260cf549136ad01078752174648375ec068b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cb0ad33-f21d-4d11-a57b-a955cd544fc9", "node_type": "1", "metadata": {"window": "So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal? ", "original_text": "Operator\nCertainly. "}, "hash": "ec46212709ff922bb4cbc30ed1c9ba8413767bc8c41cbd1430010ff07e516c3a", "class_name": "RelatedNodeInfo"}}, "text": "Rachel Rodriguez\nAnd we have time for one more question, please.\n", "start_char_idx": 3041, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb0ad33-f21d-4d11-a57b-a955cd544fc9": {"__data__": {"id_": "4cb0ad33-f21d-4d11-a57b-a955cd544fc9", "embedding": null, "metadata": {"window": "So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal? ", "original_text": "Operator\nCertainly. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc", "node_type": "1", "metadata": {"window": "So historically, we've been able to grow our portfolio of brands and relationships and it's multiple, multiple hundreds now.  So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "original_text": "Rachel Rodriguez\nAnd we have time for one more question, please.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a53e0687245b3d0dc66e0ee15d1a62313469d8c609dfc19d55919310b84384ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50b472ab-c98b-461f-9c64-7d461c7bcf7b", "node_type": "1", "metadata": {"window": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "original_text": "That question will come from Erin Wright with Morgan Stanley.\n"}, "hash": "4adef82b519f212f9ba1534682478e9bc9ab12ff4248ee162a1cc565ed8ebe73", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nCertainly. ", "start_char_idx": 3106, "end_char_idx": 3126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50b472ab-c98b-461f-9c64-7d461c7bcf7b": {"__data__": {"id_": "50b472ab-c98b-461f-9c64-7d461c7bcf7b", "embedding": null, "metadata": {"window": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "original_text": "That question will come from Erin Wright with Morgan Stanley.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cb0ad33-f21d-4d11-a57b-a955cd544fc9", "node_type": "1", "metadata": {"window": "So that's\nan important component of that business to keep that growing.  And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal? ", "original_text": "Operator\nCertainly. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "689e586f25f71e38740dc1946fb7870bc8f8986f3dae432e68db92837a943243", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89580ff6-7d77-4236-8b76-26b94fc44bcb", "node_type": "1", "metadata": {"window": "Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? "}, "hash": "4d58eb5b154625f6972d20c0645554168b7ac205aaeebd4cfb7b67a0e319ac90", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Erin Wright with Morgan Stanley.\n", "start_char_idx": 3126, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89580ff6-7d77-4236-8b76-26b94fc44bcb": {"__data__": {"id_": "89580ff6-7d77-4236-8b76-26b94fc44bcb", "embedding": null, "metadata": {"window": "Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50b472ab-c98b-461f-9c64-7d461c7bcf7b", "node_type": "1", "metadata": {"window": "And now with Rx Savings Solutions, we think we've got a chance to\ncontinue to grow the population or the number of people accessing that platform through expanding relationships with payers and\nexpanding relationships with manufacturers to run more sponsored programs.\n Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "original_text": "That question will come from Erin Wright with Morgan Stanley.\n", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "569057c75cab4db8c51e9f702a0adfc63e1efbcc63cb60d7dce02739814fb4b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68666d57-b033-48bf-ae1a-3bde602e636c", "node_type": "1", "metadata": {"window": "Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And can you speak to the financials of the\ndeal? "}, "hash": "47be8c0b697ca72e664c3df93877130f3f5964337ce8ecb310b42bf1481173ae", "class_name": "RelatedNodeInfo"}}, "text": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "start_char_idx": 3188, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68666d57-b033-48bf-ae1a-3bde602e636c": {"__data__": {"id_": "68666d57-b033-48bf-ae1a-3bde602e636c", "embedding": null, "metadata": {"window": "Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And can you speak to the financials of the\ndeal? ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89580ff6-7d77-4236-8b76-26b94fc44bcb", "node_type": "1", "metadata": {"window": "Rachel Rodriguez\nAnd we have time for one more question, please.\n Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena? ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f43ed0f9e43504f503684da7eb8e4d50d2695fdd0219976fdbeb444d0f8db4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83", "node_type": "1", "metadata": {"window": "That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. "}, "hash": "2279cb8bf31317831c3aa9c8f46fb27747f06e00428fcba434a1d8092e261529", "class_name": "RelatedNodeInfo"}}, "text": "And can you speak to the financials of the\ndeal? ", "start_char_idx": 3341, "end_char_idx": 3390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83": {"__data__": {"id_": "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83", "embedding": null, "metadata": {"window": "That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68666d57-b033-48bf-ae1a-3bde602e636c", "node_type": "1", "metadata": {"window": "Operator\nCertainly.  That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And can you speak to the financials of the\ndeal? ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c2289563ee6826b4e343a042aaff7dc766234f6e7d69cf9fd463dae398130a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7c94438-88d1-4612-b9c1-aef4a1cbf416", "node_type": "1", "metadata": {"window": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?"}, "hash": "c5cb987859575d66f7327c59cc07841ac37144e3fe20f10c55513d31d217fd0b", "class_name": "RelatedNodeInfo"}}, "text": "I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "start_char_idx": 3390, "end_char_idx": 3522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7c94438-88d1-4612-b9c1-aef4a1cbf416": {"__data__": {"id_": "f7c94438-88d1-4612-b9c1-aef4a1cbf416", "embedding": null, "metadata": {"window": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f1abd9-ed46-4209-a100-85962b57e625", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00396f00f48a69844879956a49ab1e522fba92e2815ff2f4d7104b9ad71b0983", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83", "node_type": "1", "metadata": {"window": "That question will come from Erin Wright with Morgan Stanley.\n Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d29cd7cf366f6b0cb3454ce75f18dfdd354f69e5c2e9f5f831dcb49d373d7ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "13e08bb4111a597954d265f6efacc5d4250f045ee0f4b4030d37b06fe969ef87", "class_name": "RelatedNodeInfo"}}, "text": "And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "start_char_idx": 3522, "end_char_idx": 3723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48": {"__data__": {"id_": "ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7c94438-88d1-4612-b9c1-aef4a1cbf416", "node_type": "1", "metadata": {"window": "Erin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nSo on the HCA JV, I guess, can you speak to how this positions you in the oncology arena?  And can you speak to the financials of the\ndeal?  I think from a longer-term perspective, you mentioned some 2026 contributions, but maybe some of the near-term contributions\nthere.  And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "original_text": "And will this help to explain the types of deals that you'll be focused on kind of going forward in terms of partnerships and JVs\nthat are relatively open in terms of that versus outright acquisitions?", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e16623c91fd0a9acaa78b897d432f75afe136a18d9badac3daae6098c816d7b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a85b429-e537-44b2-86e9-ce221001df87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "original_text": "All Rights reserved.\n"}, "hash": "3d2ccd09473d0156742f56ef52cc6f58990d69dfacb65cf11dc77107df41304b", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a85b429-e537-44b2-86e9-ce221001df87": {"__data__": {"id_": "3a85b429-e537-44b2-86e9-ce221001df87", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "original_text": "All Rights reserved.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e05c89df09c080a04c808b328b3f2260239b79a19262d79ab64817f6e73eb461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "original_text": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question. "}, "hash": "2c72b581de8a776428f002ebbc6de482beaa94d67470d675d256f418a219d96e", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4": {"__data__": {"id_": "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "original_text": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a85b429-e537-44b2-86e9-ce221001df87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "original_text": "All Rights reserved.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85b0abc2768b36d087465414c39124292a57b635a2fdb2494985d75fe55b40d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a75dee-3d41-4fe6-b073-e767a2f1899d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "original_text": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. "}, "hash": "108a3e1402d4dc5b14dbf33b9b1ed7666be8979b866f8c4def03b358ca460aa4", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question. ", "start_char_idx": 158, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a75dee-3d41-4fe6-b073-e767a2f1899d": {"__data__": {"id_": "b4a75dee-3d41-4fe6-b073-e767a2f1899d", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "original_text": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "original_text": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1a33a226cb819d44d143bce3589bbadcaca5e189f76c72b0435f9b07006e98e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1cbaaac-c993-4fb8-81a8-a8b9508d706f", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower. ", "original_text": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n"}, "hash": "682b224288d83f777f6de7c13a9225c5899d39ca6fbb66ef8b694f3a1f42aba6", "class_name": "RelatedNodeInfo"}}, "text": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "start_char_idx": 250, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1cbaaac-c993-4fb8-81a8-a8b9508d706f": {"__data__": {"id_": "c1cbaaac-c993-4fb8-81a8-a8b9508d706f", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower. ", "original_text": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4a75dee-3d41-4fe6-b073-e767a2f1899d", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "original_text": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "828e8610d0e8bc94737432d529de0af002590c4166fa89429b1ec513198067b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b15209b5-a242-442f-a89d-54510864a65f", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "original_text": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. "}, "hash": "9ea4d8e32e4d7cc5da46272fbcd4d9a66f5c330ca359813c63364048948ce8a7", "class_name": "RelatedNodeInfo"}}, "text": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "start_char_idx": 407, "end_char_idx": 630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b15209b5-a242-442f-a89d-54510864a65f": {"__data__": {"id_": "b15209b5-a242-442f-a89d-54510864a65f", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "original_text": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1cbaaac-c993-4fb8-81a8-a8b9508d706f", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower. ", "original_text": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9af9ff08b5a802f4beefa9b209fe9d1bc0ea24cf807add7a81bcfb0359ce920e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8539d0c9-7197-482e-9aea-e0a41480ace0", "node_type": "1", "metadata": {"window": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "original_text": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. "}, "hash": "6bb0b4ad85ee63da6f10e3b6e7e16c05a3f9277133e8d692fe2f3ae8c4d997c1", "class_name": "RelatedNodeInfo"}}, "text": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "start_char_idx": 630, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8539d0c9-7197-482e-9aea-e0a41480ace0": {"__data__": {"id_": "8539d0c9-7197-482e-9aea-e0a41480ace0", "embedding": null, "metadata": {"window": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "original_text": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b15209b5-a242-442f-a89d-54510864a65f", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "original_text": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14acf23be24281fb7bbfd25dcfb6acdc652ba5a6633aac54a464fa9f06715cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4772c5ec-dee2-417e-8561-32fbd75e740f", "node_type": "1", "metadata": {"window": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "original_text": "We know the uptake in the community setting is much lower. "}, "hash": "76a8a6637eaa47b85c893e089b0f4641455eac7713ab234f9e6bf363fd6167ab", "class_name": "RelatedNodeInfo"}}, "text": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "start_char_idx": 740, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4772c5ec-dee2-417e-8561-32fbd75e740f": {"__data__": {"id_": "4772c5ec-dee2-417e-8561-32fbd75e740f", "embedding": null, "metadata": {"window": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "original_text": "We know the uptake in the community setting is much lower. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8539d0c9-7197-482e-9aea-e0a41480ace0", "node_type": "1", "metadata": {"window": "We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology.  We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "original_text": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d654e7e774c8bd5df0a0bb04054a729841c3678b22abb15a6ef177bc0f84ff01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68d51fd1-b524-444e-837f-072ff64ef8a8", "node_type": "1", "metadata": {"window": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this. ", "original_text": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n"}, "hash": "0c79cddcae3228cd8cf39c71297655e9ab95c024811c776b58171530a75dcc3a", "class_name": "RelatedNodeInfo"}}, "text": "We know the uptake in the community setting is much lower. ", "start_char_idx": 946, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68d51fd1-b524-444e-837f-072ff64ef8a8": {"__data__": {"id_": "68d51fd1-b524-444e-837f-072ff64ef8a8", "embedding": null, "metadata": {"window": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this. ", "original_text": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4772c5ec-dee2-417e-8561-32fbd75e740f", "node_type": "1", "metadata": {"window": "We think through the combination of these 2 clinical research networks and\nreally their underlying data and analytic capabilities that this is going to enable us to bring greater efficiency to the drug development\nprocess.\n And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "original_text": "We know the uptake in the community setting is much lower. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdefe0a51a185521e317ae58107c3e84946d919345aaf0b4343329f16b79e5e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbcc26e6-84f7-41b6-a415-04c9b6129e2e", "node_type": "1", "metadata": {"window": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "original_text": "So we think this is about enhancing the quality of care by increasing access to novel treatment options. "}, "hash": "26df695ca10bc0f436582614c66f4fedec8fbe833431297ae24f3ac0678802e9", "class_name": "RelatedNodeInfo"}}, "text": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "start_char_idx": 1005, "end_char_idx": 1214, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbcc26e6-84f7-41b6-a415-04c9b6129e2e": {"__data__": {"id_": "cbcc26e6-84f7-41b6-a415-04c9b6129e2e", "embedding": null, "metadata": {"window": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "original_text": "So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68d51fd1-b524-444e-837f-072ff64ef8a8", "node_type": "1", "metadata": {"window": "And we also think, importantly, it's going to help more cancer patients access newer life-saving medications.  And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this. ", "original_text": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cad8a90299c6e8d2743bd3765c8e247defc522d0da8927d4f0ae6760437ec8e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "744c623d-05d2-4e0e-89ca-5b0042fa09d8", "node_type": "1", "metadata": {"window": "We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy. ", "original_text": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. "}, "hash": "10f19d457ee9e8d12615b9fdec617988ea2411df2dc209297b75c1bde23425b7", "class_name": "RelatedNodeInfo"}}, "text": "So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "start_char_idx": 1214, "end_char_idx": 1319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "744c623d-05d2-4e0e-89ca-5b0042fa09d8": {"__data__": {"id_": "744c623d-05d2-4e0e-89ca-5b0042fa09d8", "embedding": null, "metadata": {"window": "We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy. ", "original_text": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbcc26e6-84f7-41b6-a415-04c9b6129e2e", "node_type": "1", "metadata": {"window": "And oftentimes, in\nabsence of a JV like this in the community setting, it's hard for people to find out they're eligible for a clinical trial and they might be\nable to benefit from a trial that's going on.  We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "original_text": "So we think this is about enhancing the quality of care by increasing access to novel treatment options. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ad706518f5939b865c0b85639a42a26b7e3ab41c9886c92281191dc99ebb190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e961f0b5-13d4-4417-b343-762c83a9a8e8", "node_type": "1", "metadata": {"window": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "original_text": "And we're excited to have a JV and a relationship\nwith HCA around this. "}, "hash": "765b090d2dfd366dd0093e3e50f49d8c0c0ad709fea7775962e045bb2c380c27", "class_name": "RelatedNodeInfo"}}, "text": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "start_char_idx": 1319, "end_char_idx": 1425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e961f0b5-13d4-4417-b343-762c83a9a8e8": {"__data__": {"id_": "e961f0b5-13d4-4417-b343-762c83a9a8e8", "embedding": null, "metadata": {"window": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "original_text": "And we're excited to have a JV and a relationship\nwith HCA around this. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "744c623d-05d2-4e0e-89ca-5b0042fa09d8", "node_type": "1", "metadata": {"window": "We know the uptake in the community setting is much lower.  And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy. ", "original_text": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1cfb8b73fed46cfd56dd8e078180f221d6c00283e14d8fd134d2d873c049606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4", "node_type": "1", "metadata": {"window": "So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility. ", "original_text": "I think one of the things that we would signal to everybody is we've got a very clear strategy. "}, "hash": "af0eb725fc352e5cc36dadd1f0597641b7d8138a0e64f4fdd937e5122870a1ed", "class_name": "RelatedNodeInfo"}}, "text": "And we're excited to have a JV and a relationship\nwith HCA around this. ", "start_char_idx": 1425, "end_char_idx": 1497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4": {"__data__": {"id_": "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4", "embedding": null, "metadata": {"window": "So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility. ", "original_text": "I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e961f0b5-13d4-4417-b343-762c83a9a8e8", "node_type": "1", "metadata": {"window": "And so we're really excited\nwhen we think about the impact this can have on people's lives and helping get communities that are often underserved communities\nand get those patients enrolled in these programs.\n So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "original_text": "And we're excited to have a JV and a relationship\nwith HCA around this. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f20031eed55a8afc677668bf5988f027823b495ac1e7ada102131ef3d1dccec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87c8a345-f07d-4d01-b708-9ee8412aff7c", "node_type": "1", "metadata": {"window": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "original_text": "There will be\ntimes where we're going to invest organically to activate that strategy. "}, "hash": "7652f3a13ea283daec4def99e8e2562cad4d7f033beea171716969d6ff797313", "class_name": "RelatedNodeInfo"}}, "text": "I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "start_char_idx": 1497, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87c8a345-f07d-4d01-b708-9ee8412aff7c": {"__data__": {"id_": "87c8a345-f07d-4d01-b708-9ee8412aff7c", "embedding": null, "metadata": {"window": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "original_text": "There will be\ntimes where we're going to invest organically to activate that strategy. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4", "node_type": "1", "metadata": {"window": "So we think this is about enhancing the quality of care by increasing access to novel treatment options.  We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility. ", "original_text": "I think one of the things that we would signal to everybody is we've got a very clear strategy. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3a63023b59c334ea6e09fe1e506233091dd0dfc69114f1e9584e6a5460845e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ea91b0c-388b-4780-8608-219e0fa2d417", "node_type": "1", "metadata": {"window": "And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "original_text": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n"}, "hash": "89c84b1eaffed526d65e65f367330f761f45989de38b22d1f971fecf60f06e13", "class_name": "RelatedNodeInfo"}}, "text": "There will be\ntimes where we're going to invest organically to activate that strategy. ", "start_char_idx": 1593, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ea91b0c-388b-4780-8608-219e0fa2d417": {"__data__": {"id_": "6ea91b0c-388b-4780-8608-219e0fa2d417", "embedding": null, "metadata": {"window": "And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "original_text": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87c8a345-f07d-4d01-b708-9ee8412aff7c", "node_type": "1", "metadata": {"window": "We think it's about helping\naccelerate the commercial or getting these new exciting oncolytics to market.  And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "original_text": "There will be\ntimes where we're going to invest organically to activate that strategy. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c98ab25578340c597b9e67188b10990c54fc4aa4fbcc9ee31789fd174e4e85dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "619bfc41-3a87-49a2-a9b1-1f23770867dc", "node_type": "1", "metadata": {"window": "I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n", "original_text": "And so we'll have flexibility. "}, "hash": "7c88f91c9aa767da0d8271286978014975de6fdaa28864b4d2296cdfb36df4d0", "class_name": "RelatedNodeInfo"}}, "text": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "start_char_idx": 1680, "end_char_idx": 1879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "619bfc41-3a87-49a2-a9b1-1f23770867dc": {"__data__": {"id_": "619bfc41-3a87-49a2-a9b1-1f23770867dc", "embedding": null, "metadata": {"window": "I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n", "original_text": "And so we'll have flexibility. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ea91b0c-388b-4780-8608-219e0fa2d417", "node_type": "1", "metadata": {"window": "And we're excited to have a JV and a relationship\nwith HCA around this.  I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "original_text": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58f588f92a7c43e34bb299ff9c028a3084c2c024b5372a3ca7438ce040674bbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7030e0eb-d563-43d4-ae24-cdd3ee348361", "node_type": "1", "metadata": {"window": "There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "original_text": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. "}, "hash": "7678858b7faa60f26eb9bf8e5727e36ac82596aa92d66b0730d8e84f58c66c66", "class_name": "RelatedNodeInfo"}}, "text": "And so we'll have flexibility. ", "start_char_idx": 1879, "end_char_idx": 1910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7030e0eb-d563-43d4-ae24-cdd3ee348361": {"__data__": {"id_": "7030e0eb-d563-43d4-ae24-cdd3ee348361", "embedding": null, "metadata": {"window": "There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "original_text": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "619bfc41-3a87-49a2-a9b1-1f23770867dc", "node_type": "1", "metadata": {"window": "I think one of the things that we would signal to everybody is we've got a very clear strategy.  There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n", "original_text": "And so we'll have flexibility. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fff48b1b3839f7e7299c423d1f31ee037db65e626c7c33996a3c2396ae1e5053", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84b0b7a9-dd9d-4009-9958-ace73cfa3659", "node_type": "1", "metadata": {"window": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that. ", "original_text": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. "}, "hash": "054e585355ac33a9af70792bbb6dd0b07a9082141dfb301af9311ed9c0592e67", "class_name": "RelatedNodeInfo"}}, "text": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "start_char_idx": 1910, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84b0b7a9-dd9d-4009-9958-ace73cfa3659": {"__data__": {"id_": "84b0b7a9-dd9d-4009-9958-ace73cfa3659", "embedding": null, "metadata": {"window": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that. ", "original_text": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7030e0eb-d563-43d4-ae24-cdd3ee348361", "node_type": "1", "metadata": {"window": "There will be\ntimes where we're going to invest organically to activate that strategy.  There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "original_text": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cefbb09e6379adc592b80bde2958ce2a008e9824bc36342482d403cff3c5b39c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "811dacea-9fc8-40b7-a89d-d7c93b62472f", "node_type": "1", "metadata": {"window": "And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "original_text": "Oncology Research Network.\n"}, "hash": "12b62cd42f4bdf33a66591ee1b35ae555a49755ee7820c19eacbaa28a17a441e", "class_name": "RelatedNodeInfo"}}, "text": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "start_char_idx": 2084, "end_char_idx": 2170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "811dacea-9fc8-40b7-a89d-d7c93b62472f": {"__data__": {"id_": "811dacea-9fc8-40b7-a89d-d7c93b62472f", "embedding": null, "metadata": {"window": "And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "original_text": "Oncology Research Network.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84b0b7a9-dd9d-4009-9958-ace73cfa3659", "node_type": "1", "metadata": {"window": "There will be times where we'll do acquisition to activate that\nstrategy, and there are times where combinations like this become, we think, the most effective way to get at activating our strategy.\n And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that. ", "original_text": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6d2ace54716f195ee9843be5105f1424a5ab87d8a181cdd078b6134caa2d850", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e20a916-deef-4e1c-9728-81fd0561cd43", "node_type": "1", "metadata": {"window": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. "}, "hash": "722cb9635ea162e19e48c7c5ad62ff4415ba182063f5e26c37075e3fb1073127", "class_name": "RelatedNodeInfo"}}, "text": "Oncology Research Network.\n", "start_char_idx": 2170, "end_char_idx": 2197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e20a916-deef-4e1c-9728-81fd0561cd43": {"__data__": {"id_": "2e20a916-deef-4e1c-9728-81fd0561cd43", "embedding": null, "metadata": {"window": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "811dacea-9fc8-40b7-a89d-d7c93b62472f", "node_type": "1", "metadata": {"window": "And so we'll have flexibility.  We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "original_text": "Oncology Research Network.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98ae7af46038e43a3425f67b61aad66e746927b9e9275a47f1dc009f09233a87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea3280f1-ee14-4e3b-9e3a-a2241293506d", "node_type": "1", "metadata": {"window": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "original_text": "And so we'll\nbe recording that. "}, "hash": "00f13ea2f5bc2d854f8e53cbd6bbe1e2951063ea222f7225e1d113d5df67efd8", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "start_char_idx": 2197, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea3280f1-ee14-4e3b-9e3a-a2241293506d": {"__data__": {"id_": "ea3280f1-ee14-4e3b-9e3a-a2241293506d", "embedding": null, "metadata": {"window": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "original_text": "And so we'll\nbe recording that. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e20a916-deef-4e1c-9728-81fd0561cd43", "node_type": "1", "metadata": {"window": "We look at every deal on its own and its own merits in terms of its alignment to our strategy and our\nfinancial expectations before we decide to move forward with something.  In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this. ", "original_text": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b7b2895823f49642c23c9c0daa11f1374e18a30d5640dc9c1468d86790d6fe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edf7e525-e581-4ffe-a3b7-6a66865f690a", "node_type": "1", "metadata": {"window": "Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "original_text": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. "}, "hash": "a067fa70a9fca88942bf2ef5ba14b5f0004d7d231818f9830b11df887c39f76b", "class_name": "RelatedNodeInfo"}}, "text": "And so we'll\nbe recording that. ", "start_char_idx": 2354, "end_char_idx": 2386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edf7e525-e581-4ffe-a3b7-6a66865f690a": {"__data__": {"id_": "edf7e525-e581-4ffe-a3b7-6a66865f690a", "embedding": null, "metadata": {"window": "Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "original_text": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea3280f1-ee14-4e3b-9e3a-a2241293506d", "node_type": "1", "metadata": {"window": "In this case, we feel really excited about the partnership with\nSarah Cannon and U.S.  Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "original_text": "And so we'll\nbe recording that. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1605d55a542af23112ea95d961e613069217f41c9cf366ad45e05e9e902cbb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0feaa758-97dd-46d6-8145-5ab05833f784", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "original_text": "There are probably a number of synergies that are unrelated to this. "}, "hash": "3958bc0d333a44d25350c502dd2744257b6b1ab3f6116e5bee3ab3dee1fe5cf1", "class_name": "RelatedNodeInfo"}}, "text": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "start_char_idx": 2386, "end_char_idx": 2553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0feaa758-97dd-46d6-8145-5ab05833f784": {"__data__": {"id_": "0feaa758-97dd-46d6-8145-5ab05833f784", "embedding": null, "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "original_text": "There are probably a number of synergies that are unrelated to this. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edf7e525-e581-4ffe-a3b7-6a66865f690a", "node_type": "1", "metadata": {"window": "Oncology Research Network.\n Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "original_text": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "609e2b045b44ce2611658e5fe6b335b34886c9c3a624c977e8e542be89d0f00d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1e14c25-bacc-4072-a369-c03399893401", "node_type": "1", "metadata": {"window": "And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n", "original_text": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n"}, "hash": "62dfa492d1619e95b12c624eb52bfa6d01a0809dbdf20184797334ea10db6c11", "class_name": "RelatedNodeInfo"}}, "text": "There are probably a number of synergies that are unrelated to this. ", "start_char_idx": 2553, "end_char_idx": 2622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1e14c25-bacc-4072-a369-c03399893401": {"__data__": {"id_": "f1e14c25-bacc-4072-a369-c03399893401", "embedding": null, "metadata": {"window": "And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n", "original_text": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0feaa758-97dd-46d6-8145-5ab05833f784", "node_type": "1", "metadata": {"window": "Britt J. Vitalone\nExecutive VP & CFO\nThe one other thing maybe that I would add, just as a reminder for this JV, we will have 51% of the earnings of the JV.  And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "original_text": "There are probably a number of synergies that are unrelated to this. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9b4eb5e574acb1af855261c95234263dc08facc9e167cb0a399d9803c4015ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39c4117b-2ecf-496b-8bb5-74ea610170ba", "node_type": "1", "metadata": {"window": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n", "original_text": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n"}, "hash": "78346ae1cc97bb9f544c6ac20559a8eff55c6ef4828c75d952de6ada8ddf1aa8", "class_name": "RelatedNodeInfo"}}, "text": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "start_char_idx": 2622, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39c4117b-2ecf-496b-8bb5-74ea610170ba": {"__data__": {"id_": "39c4117b-2ecf-496b-8bb5-74ea610170ba", "embedding": null, "metadata": {"window": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n", "original_text": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1e14c25-bacc-4072-a369-c03399893401", "node_type": "1", "metadata": {"window": "And so we'll\nbe recording that.  The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n", "original_text": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db8549b66c1e3dcd8a5d52b99f873761331cbb0217b12b916d6e65881c380f95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c88a823-894a-4df3-a2cd-6346ad415a4c", "node_type": "1", "metadata": {"window": "There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "original_text": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. "}, "hash": "221382a5be306d9583f2c54a1cdad5704187e337ca673b8b792bda86c9096ab6", "class_name": "RelatedNodeInfo"}}, "text": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "start_char_idx": 2759, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c88a823-894a-4df3-a2cd-6346ad415a4c": {"__data__": {"id_": "5c88a823-894a-4df3-a2cd-6346ad415a4c", "embedding": null, "metadata": {"window": "There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "original_text": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39c4117b-2ecf-496b-8bb5-74ea610170ba", "node_type": "1", "metadata": {"window": "The $0.10 to $0.20 accretion that I referenced is related to that 51% ownership that we have, and it's specific to the\ncombination of this JV and the JV's activities.  There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n", "original_text": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59dfc5f1a0226db0c1d4d539e579cafd0b1fbda52fc98d7621a91f547dc3bba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d7ba98-5c21-4c17-b4b2-25d836d54f5c", "node_type": "1", "metadata": {"window": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "original_text": "Appreciate the thoughtful questions and your support of McKesson.\n"}, "hash": "705f0e5a163172092c412a63a388873ab7a3a0ad8022f60686b5d800d70ef4a1", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "start_char_idx": 2982, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d7ba98-5c21-4c17-b4b2-25d836d54f5c": {"__data__": {"id_": "93d7ba98-5c21-4c17-b4b2-25d836d54f5c", "embedding": null, "metadata": {"window": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "original_text": "Appreciate the thoughtful questions and your support of McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c88a823-894a-4df3-a2cd-6346ad415a4c", "node_type": "1", "metadata": {"window": "There are probably a number of synergies that are unrelated to this.  There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "original_text": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3f2b437ff4e4d170f12670f88d5bb3a1928846f2e703ac748995ac3ebc0dd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc87f15-d6d0-4587-bfd8-42cc5612ad22", "node_type": "1", "metadata": {"window": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "original_text": "And thanks to Jenny, our operator, for facilitating the call.\n"}, "hash": "2a2dc2939c17240179747257ef56c8cd5a53ea8f3fd1414286406d8d979caea3", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate the thoughtful questions and your support of McKesson.\n", "start_char_idx": 3080, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc87f15-d6d0-4587-bfd8-42cc5612ad22": {"__data__": {"id_": "afc87f15-d6d0-4587-bfd8-42cc5612ad22", "embedding": null, "metadata": {"window": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "original_text": "And thanks to Jenny, our operator, for facilitating the call.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d7ba98-5c21-4c17-b4b2-25d836d54f5c", "node_type": "1", "metadata": {"window": "There's a flywheel\neffect of having it and combining it as part of the overall oncology ecosystem that we're not including at this time.\n So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "original_text": "Appreciate the thoughtful questions and your support of McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c10c22f4a06088178408f61df9a72f6441ffbea7a2b8db9d55b00c419da36b53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab3c5d10-35b5-4632-b70d-7b0911e1709c", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "original_text": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. "}, "hash": "c8bc80517c3a2a8927fffffcb4dcb8d4ebcb3638839163aac02329098bb62f28", "class_name": "RelatedNodeInfo"}}, "text": "And thanks to Jenny, our operator, for facilitating the call.\n", "start_char_idx": 3146, "end_char_idx": 3208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab3c5d10-35b5-4632-b70d-7b0911e1709c": {"__data__": {"id_": "ab3c5d10-35b5-4632-b70d-7b0911e1709c", "embedding": null, "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "original_text": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc87f15-d6d0-4587-bfd8-42cc5612ad22", "node_type": "1", "metadata": {"window": "So we'll continue to watch this over time as the JV comes together and forms and some of these synergies really come into play, but\nwe're excited about what it's going to bring to the overall oncology business at McKesson.\n Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "original_text": "And thanks to Jenny, our operator, for facilitating the call.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0fc0a0f7c516b7ba3510a37f01ee08ed32b7c31024021aabbd57df2d549dc6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aaf667a-0c44-4009-ba15-45a9687914fa", "node_type": "1", "metadata": {"window": "Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n", "original_text": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n"}, "hash": "cf0d82f0ff1ef9a8bb2b238d945ebf1e62ae39accb97ff955e541b0695196340", "class_name": "RelatedNodeInfo"}}, "text": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "start_char_idx": 3208, "end_char_idx": 3317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aaf667a-0c44-4009-ba15-45a9687914fa": {"__data__": {"id_": "0aaf667a-0c44-4009-ba15-45a9687914fa", "embedding": null, "metadata": {"window": "Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n", "original_text": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab3c5d10-35b5-4632-b70d-7b0911e1709c", "node_type": "1", "metadata": {"window": "Brian S. Tyler\nCEO & Director\nThank you, Britt, and thanks, everyone, for joining our call today.  Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "original_text": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56890d65326464114c10fe729639c1a185d675f7304e39783cc52fc4dbd21f15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea9615d2-c969-4402-8134-5a6cd14040b0", "node_type": "1", "metadata": {"window": "And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call. ", "original_text": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. "}, "hash": "51b3e08840d387970532fc45d45ecad88759be540eb1aca04e4a539ae3f9a752", "class_name": "RelatedNodeInfo"}}, "text": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "start_char_idx": 3317, "end_char_idx": 3440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea9615d2-c969-4402-8134-5a6cd14040b0": {"__data__": {"id_": "ea9615d2-c969-4402-8134-5a6cd14040b0", "embedding": null, "metadata": {"window": "And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call. ", "original_text": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aaf667a-0c44-4009-ba15-45a9687914fa", "node_type": "1", "metadata": {"window": "Appreciate the thoughtful questions and your support of McKesson.\n And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n", "original_text": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49ec6aaf0ebe02bec4f9aa33de33d6096f45128550ab061bf926e6272b62ae0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d371c34e-af46-4582-a2d1-48135a41e0dc", "node_type": "1", "metadata": {"window": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n", "original_text": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. "}, "hash": "9b43cb83640d03bc494bcd2794d15de344e29c64acde3ef5cc4bbd09e765811a", "class_name": "RelatedNodeInfo"}}, "text": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "start_char_idx": 3440, "end_char_idx": 3542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d371c34e-af46-4582-a2d1-48135a41e0dc": {"__data__": {"id_": "d371c34e-af46-4582-a2d1-48135a41e0dc", "embedding": null, "metadata": {"window": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n", "original_text": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea9615d2-c969-4402-8134-5a6cd14040b0", "node_type": "1", "metadata": {"window": "And thanks to Jenny, our operator, for facilitating the call.\n McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call. ", "original_text": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04ce58d3a5f56ae381819c79a905356b212f016c9676df5d247224f4b270b192", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "154163cb-b262-47c4-8822-eb9195763afd", "node_type": "1", "metadata": {"window": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call. ", "original_text": "I'm really proud to be a member and the\nleader of Team McKesson.\n"}, "hash": "1567badc9f8fdc5c6a3f2333aa68f9c0c4b9d2f55754e351fd0d100830cfcdc8", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "start_char_idx": 3542, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "154163cb-b262-47c4-8822-eb9195763afd": {"__data__": {"id_": "154163cb-b262-47c4-8822-eb9195763afd", "embedding": null, "metadata": {"window": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call. ", "original_text": "I'm really proud to be a member and the\nleader of Team McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d371c34e-af46-4582-a2d1-48135a41e0dc", "node_type": "1", "metadata": {"window": "McKesson delivered a solid second quarter, really driven by continued momentum in our underlying businesses.  I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n", "original_text": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a1fc293812c77037366bfca9ff0e0dd27f5567cfeea8f54e4b8da327d501fdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4960b150-5134-484a-a6a2-6c29a7e61d27", "node_type": "1", "metadata": {"window": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Thanks again for joining our call. "}, "hash": "a35222f319618793cb8e47b9534162b0cc914f5d318a448d3c93c7326dd42941", "class_name": "RelatedNodeInfo"}}, "text": "I'm really proud to be a member and the\nleader of Team McKesson.\n", "start_char_idx": 3662, "end_char_idx": 3727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4960b150-5134-484a-a6a2-6c29a7e61d27": {"__data__": {"id_": "4960b150-5134-484a-a6a2-6c29a7e61d27", "embedding": null, "metadata": {"window": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Thanks again for joining our call. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "154163cb-b262-47c4-8822-eb9195763afd", "node_type": "1", "metadata": {"window": "I remain confident in\nour ability to consistently execute on company priorities and to drive sustainable long-term growth.\n I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call. ", "original_text": "I'm really proud to be a member and the\nleader of Team McKesson.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26e319d1ee2006dbebcbb6cedeed30f016a25a8b81fa64007bcd996a628d9403", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e089a9a6-509d-40b4-9882-40f3c8f236e5", "node_type": "1", "metadata": {"window": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "I hope you all have a terrific evening.\n"}, "hash": "c6d1954243492503a8e7431655e407e1cd17ba17a7508dfb5548802342339b27", "class_name": "RelatedNodeInfo"}}, "text": "Thanks again for joining our call. ", "start_char_idx": 3727, "end_char_idx": 3762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e089a9a6-509d-40b4-9882-40f3c8f236e5": {"__data__": {"id_": "e089a9a6-509d-40b4-9882-40f3c8f236e5", "embedding": null, "metadata": {"window": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "I hope you all have a terrific evening.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4960b150-5134-484a-a6a2-6c29a7e61d27", "node_type": "1", "metadata": {"window": "I want to conclude today's call by once again just acknowledging all the great work of Team McKesson.  I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Thanks again for joining our call. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02016d6a3c161131b8b5c84eeac716c6e9ce3755c936771c21df3a199c7c3ac1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8535769d-a71c-4177-b70a-d817871d6baa", "node_type": "1", "metadata": {"window": "I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Operator\nAnd thank you for joining today's conference call. "}, "hash": "9e92e8a8638e05d478a8711f668d3e94a09d89fe1c00634d59b714bf4b251578", "class_name": "RelatedNodeInfo"}}, "text": "I hope you all have a terrific evening.\n", "start_char_idx": 3762, "end_char_idx": 3802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8535769d-a71c-4177-b70a-d817871d6baa": {"__data__": {"id_": "8535769d-a71c-4177-b70a-d817871d6baa", "embedding": null, "metadata": {"window": "I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Operator\nAnd thank you for joining today's conference call. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e089a9a6-509d-40b4-9882-40f3c8f236e5", "node_type": "1", "metadata": {"window": "I want to thank each of you\nfor your dedication and what you do every day to help our customers, partners and patients.  I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "I hope you all have a terrific evening.\n", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a6be00011f6754f324a440f40396e890a22faea62bda4094d78b485b8797f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aad46357-8aa4-4800-93de-660e841f6bc8", "node_type": "1", "metadata": {"window": "Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "You may now disconnect, and have a great day."}, "hash": "6883c6bbe09f0ea7c8171786eb984406633985fd22d1ec2cc1dcf5f1c697c211", "class_name": "RelatedNodeInfo"}}, "text": "Operator\nAnd thank you for joining today's conference call. ", "start_char_idx": 3802, "end_char_idx": 3862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aad46357-8aa4-4800-93de-660e841f6bc8": {"__data__": {"id_": "aad46357-8aa4-4800-93de-660e841f6bc8", "embedding": null, "metadata": {"window": "Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "You may now disconnect, and have a great day.", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edc5e377a46537859b41c3b4d00d118bc59b1ce7c9f484d4e7c55cd8ebe37d9f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8535769d-a71c-4177-b70a-d817871d6baa", "node_type": "1", "metadata": {"window": "I'm really proud to be a member and the\nleader of Team McKesson.\n Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "Operator\nAnd thank you for joining today's conference call. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e34d2f6cf366e7515ed3bafccd0350df9a396ad5a1921408a96196e5170629e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31b0d495-c882-462a-93ec-1f71dc350367", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "ecfe11f42037d690f1fc7ade99609f4a48d71b4392358389384db793cc61f647", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect, and have a great day.", "start_char_idx": 3862, "end_char_idx": 3907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31b0d495-c882-462a-93ec-1f71dc350367": {"__data__": {"id_": "31b0d495-c882-462a-93ec-1f71dc350367", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aad46357-8aa4-4800-93de-660e841f6bc8", "node_type": "1", "metadata": {"window": "Thanks again for joining our call.  I hope you all have a terrific evening.\n Operator\nAnd thank you for joining today's conference call.  You may now disconnect, and have a great day.", "original_text": "You may now disconnect, and have a great day.", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e541e1ddd10a88dfe0280fa01119cf3568df0f12090689261f84efe6f549682c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "original_text": "All Rights reserved.\n"}, "hash": "a3696e3b1eb23afc5ee7790f1e06f836a911a9af05a87598f133d3ff4a0d458d", "class_name": "RelatedNodeInfo"}}, "text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 0, "end_char_idx": 137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2": {"__data__": {"id_": "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "original_text": "All Rights reserved.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31b0d495-c882-462a-93ec-1f71dc350367", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a61159568ba659666ce8ad988e9155d91f0006661437e9d2ab4ec42289bf664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c219f05-b668-4615-a527-ffb10c8dec07", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "original_text": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc. "}, "hash": "466eb85277ac6df9312c937844a23e0bd077a831f9590e331e820c1aaa090ec9", "class_name": "RelatedNodeInfo"}}, "text": "All Rights reserved.\n", "start_char_idx": 137, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c219f05-b668-4615-a527-ffb10c8dec07": {"__data__": {"id_": "4c219f05-b668-4615-a527-ffb10c8dec07", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "original_text": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "original_text": "All Rights reserved.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95b5a6d14870cfc20d3cea274cae0bd1a71055563b6510871e6b6c2e6cdad49f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee5b1af3-c1c7-40ff-93fd-991745d4ec87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes. ", "original_text": "All rights reserved.\n"}, "hash": "9d8d29e7c81233cc8ce0dd8e7c3e1b27a3d050a4e527c284f0b7732504c05689", "class_name": "RelatedNodeInfo"}}, "text": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc. ", "start_char_idx": 158, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee5b1af3-c1c7-40ff-93fd-991745d4ec87": {"__data__": {"id_": "ee5b1af3-c1c7-40ff-93fd-991745d4ec87", "embedding": null, "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes. ", "original_text": "All rights reserved.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c219f05-b668-4615-a527-ffb10c8dec07", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "original_text": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7822262e8ed2385b7846f843038319fc7bdd6ea23ce9deba8f5b8ea3e0ffeb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a1bf48-a802-4f2f-86b0-30942cbf6349", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "original_text": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n"}, "hash": "97b8fdb49aa617e9bce2cda88995bc3bc579f3c4677241bc9ac2237ccac5fe4a", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.\n", "start_char_idx": 274, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a1bf48-a802-4f2f-86b0-30942cbf6349": {"__data__": {"id_": "f2a1bf48-a802-4f2f-86b0-30942cbf6349", "embedding": null, "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "original_text": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee5b1af3-c1c7-40ff-93fd-991745d4ec87", "node_type": "1", "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes. ", "original_text": "All rights reserved.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fdc75f591995745cb9191245e78dd78a0c78b6353b7c0807d21bb9e7afb4422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ebdee50-c897-421f-bd06-5394a739f231", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "original_text": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). "}, "hash": "a86c076eb9aa4f4c91823ad30be979ae210536bc59280a99851bb2784a61903c", "class_name": "RelatedNodeInfo"}}, "text": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "start_char_idx": 295, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ebdee50-c897-421f-bd06-5394a739f231": {"__data__": {"id_": "3ebdee50-c897-421f-bd06-5394a739f231", "embedding": null, "metadata": {"window": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "original_text": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a1bf48-a802-4f2f-86b0-30942cbf6349", "node_type": "1", "metadata": {"window": "All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "original_text": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3971245e66b617e4d82dd6b32096cd118c214a3ac9de148f605005ce4032f04c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8a6093-fe5c-4cd7-a634-49e35d4844f3", "node_type": "1", "metadata": {"window": "All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "original_text": "The Content shall not be used for any unlawful or unauthorized\npurposes. "}, "hash": "805ee0fce5287b489f7d149b1deecae575393159d0807432995d8372fa4d3d91", "class_name": "RelatedNodeInfo"}}, "text": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "start_char_idx": 461, "end_char_idx": 887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8a6093-fe5c-4cd7-a634-49e35d4844f3": {"__data__": {"id_": "1d8a6093-fe5c-4cd7-a634-49e35d4844f3", "embedding": null, "metadata": {"window": "All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "original_text": "The Content shall not be used for any unlawful or unauthorized\npurposes. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ebdee50-c897-421f-bd06-5394a739f231", "node_type": "1", "metadata": {"window": "spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "original_text": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d60602b6d497352510e7e4b47aecfd08793b59f68c634bd4c29062b888cff30d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "169774b1-e835-49f4-a7bb-babb079fbe4d", "node_type": "1", "metadata": {"window": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "original_text": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. "}, "hash": "c082320b8650a2e6436f6289a2c3a201b087f2cbea945ccf18efe432956194fb", "class_name": "RelatedNodeInfo"}}, "text": "The Content shall not be used for any unlawful or unauthorized\npurposes. ", "start_char_idx": 887, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "169774b1-e835-49f4-a7bb-babb079fbe4d": {"__data__": {"id_": "169774b1-e835-49f4-a7bb-babb079fbe4d", "embedding": null, "metadata": {"window": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "original_text": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8a6093-fe5c-4cd7-a634-49e35d4844f3", "node_type": "1", "metadata": {"window": "All rights reserved.\n These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "original_text": "The Content shall not be used for any unlawful or unauthorized\npurposes. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbc02cad8b8bcf967e3d50c09888969142fa86dbc305d47840d3ed9e00bd4b4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a3aa474-462a-4b21-982b-6ae1313080ca", "node_type": "1", "metadata": {"window": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "original_text": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. "}, "hash": "8b8c52bf190db6d9ef327b0aa4ac9d7729c8aeebb4ec98cea35541f6db64949e", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "start_char_idx": 960, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a3aa474-462a-4b21-982b-6ae1313080ca": {"__data__": {"id_": "0a3aa474-462a-4b21-982b-6ae1313080ca", "embedding": null, "metadata": {"window": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "original_text": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "169774b1-e835-49f4-a7bb-babb079fbe4d", "node_type": "1", "metadata": {"window": "These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable.\n No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "original_text": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7115a06bf27f543bf0fde9cb9b6e9905ee65498974bc45ffa21d422fc94734b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0efd9b54-c1d5-46a7-8f30-db3f08a314f8", "node_type": "1", "metadata": {"window": "The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "original_text": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. "}, "hash": "afa8b8f6a4126f26c1a2bfc9d126782c484af90c451d4568b6075796538509c5", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "start_char_idx": 1124, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0efd9b54-c1d5-46a7-8f30-db3f08a314f8": {"__data__": {"id_": "0efd9b54-c1d5-46a7-8f30-db3f08a314f8", "embedding": null, "metadata": {"window": "The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "original_text": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a3aa474-462a-4b21-982b-6ae1313080ca", "node_type": "1", "metadata": {"window": "No content (including index data, ratings, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof\n(Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior\nwritten permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global).  The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "original_text": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8e7b8041f7bc89e527574fc7985c3b792c37bb255f6e0baa0d05d1df80025b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f", "node_type": "1", "metadata": {"window": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data. ", "original_text": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. "}, "hash": "5cc79dfb5982d37a105b82148b36235a64f4b02a33a3ce222c6d732db52c33dc", "class_name": "RelatedNodeInfo"}}, "text": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "start_char_idx": 1271, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f": {"__data__": {"id_": "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f", "embedding": null, "metadata": {"window": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data. ", "original_text": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0efd9b54-c1d5-46a7-8f30-db3f08a314f8", "node_type": "1", "metadata": {"window": "The Content shall not be used for any unlawful or unauthorized\npurposes.  S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "original_text": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c615cf8b1af485733fabab65043297313d28976f3b88c50d1630db48ee257cf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "950475a7-08d2-4cef-b008-1906ac898ce1", "node_type": "1", "metadata": {"window": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible. ", "original_text": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. "}, "hash": "f8a809740dd01c4e1725fdc14c7e97ec3221d7a5c2b35526bc22549cdd355236", "class_name": "RelatedNodeInfo"}}, "text": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "start_char_idx": 1313, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "950475a7-08d2-4cef-b008-1906ac898ce1": {"__data__": {"id_": "950475a7-08d2-4cef-b008-1906ac898ce1", "embedding": null, "metadata": {"window": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible. ", "original_text": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f", "node_type": "1", "metadata": {"window": "S&P Global and any third-party providers, (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of\nthe Content.  S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data. ", "original_text": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a543838f155006811b0bc5ca8bf4d48a09825945982016f870ed24cef63dbc87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b783b52d-b39a-4594-86d9-73bceba2c07b", "node_type": "1", "metadata": {"window": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "original_text": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. "}, "hash": "b35d6788d63ce87d8b023377558d18c4438aadd91dceee6981f139cd4d7ed45e", "class_name": "RelatedNodeInfo"}}, "text": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "start_char_idx": 1671, "end_char_idx": 2085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b783b52d-b39a-4594-86d9-73bceba2c07b": {"__data__": {"id_": "b783b52d-b39a-4594-86d9-73bceba2c07b", "embedding": null, "metadata": {"window": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "original_text": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "950475a7-08d2-4cef-b008-1906ac898ce1", "node_type": "1", "metadata": {"window": "S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content.  THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible. ", "original_text": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6175f1c4a6581f5ab92fe7c1f33c5f6860e3be512b74fb0b1510063db4eb336", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88191f82-0498-4581-91f7-2612b875e66f", "node_type": "1", "metadata": {"window": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "original_text": "S&P Global Market\nIntelligence may provide index data. "}, "hash": "97bd0a93fd89ea1677edf4759ff803c901acadb1f6b546baecf778a596134287", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "start_char_idx": 2085, "end_char_idx": 2410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88191f82-0498-4581-91f7-2612b875e66f": {"__data__": {"id_": "88191f82-0498-4581-91f7-2612b875e66f", "embedding": null, "metadata": {"window": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "original_text": "S&P Global Market\nIntelligence may provide index data. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b783b52d-b39a-4594-86d9-73bceba2c07b", "node_type": "1", "metadata": {"window": "THE\nCONTENT IS PROVIDED ON \"AS IS\" BASIS.  S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "original_text": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bc771a46590b155279a4c28ab913f80f86bcaa1d2d4e768229dbf25c072e11b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb136063-9d44-42d2-8060-e653932f19a5", "node_type": "1", "metadata": {"window": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "original_text": "Direct investment in an index is not possible. "}, "hash": "75faa9f4a1675fe29d94b9016a30744a95605c4b5f87a1a060be342cce2e7eca", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global Market\nIntelligence may provide index data. ", "start_char_idx": 2410, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb136063-9d44-42d2-8060-e653932f19a5": {"__data__": {"id_": "bb136063-9d44-42d2-8060-e653932f19a5", "embedding": null, "metadata": {"window": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "original_text": "Direct investment in an index is not possible. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88191f82-0498-4581-91f7-2612b875e66f", "node_type": "1", "metadata": {"window": "S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING,\nBUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS,\nSOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE\nWITH ANY SOFTWARE OR HARDWARE CONFIGURATION.  In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "original_text": "S&P Global Market\nIntelligence may provide index data. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26f40f1803db91a415c1568a67ce81a8cd7e5d63179354f656b26371fcc54e26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a182e5b1-5dec-4102-ab79-c246973e9368", "node_type": "1", "metadata": {"window": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "original_text": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. "}, "hash": "c2f0d52d9daf0d1bd1cd92bc98299e3143e55c6e5904bb60b6c9ad86c90f681a", "class_name": "RelatedNodeInfo"}}, "text": "Direct investment in an index is not possible. ", "start_char_idx": 2465, "end_char_idx": 2512, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a182e5b1-5dec-4102-ab79-c246973e9368": {"__data__": {"id_": "a182e5b1-5dec-4102-ab79-c246973e9368", "embedding": null, "metadata": {"window": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "original_text": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb136063-9d44-42d2-8060-e653932f19a5", "node_type": "1", "metadata": {"window": "In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental,\nexemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits\nand opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.  S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "original_text": "Direct investment in an index is not possible. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "227ad80148c27df3708b29b20f92c031b41b665f0a38df222f9e35b34790b323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60b2a29d-8b44-434d-8e27-7cbac0d4f62c", "node_type": "1", "metadata": {"window": "S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "original_text": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. "}, "hash": "49d4a8ebe3aed8048cbd51133ba045a13444d2c76bcfb36576c08739deda3343", "class_name": "RelatedNodeInfo"}}, "text": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "start_char_idx": 2512, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60b2a29d-8b44-434d-8e27-7cbac0d4f62c": {"__data__": {"id_": "60b2a29d-8b44-434d-8e27-7cbac0d4f62c", "embedding": null, "metadata": {"window": "S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "original_text": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a182e5b1-5dec-4102-ab79-c246973e9368", "node_type": "1", "metadata": {"window": "S&P Global\nMarket Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or\nrecommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security.  S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "original_text": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "273a0f2f87ebeefe9b5e4fbf29f209ee66d8b3a7f69f79deef40b740a19c3619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e597f3d-1904-40bd-bec0-06c95a0b3237", "node_type": "1", "metadata": {"window": "Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "original_text": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. "}, "hash": "d259f06a93639c9a26ece9f8699688dae4a83ab0dca41520e49bef9215e54bd3", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "start_char_idx": 2628, "end_char_idx": 2748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e597f3d-1904-40bd-bec0-06c95a0b3237": {"__data__": {"id_": "8e597f3d-1904-40bd-bec0-06c95a0b3237", "embedding": null, "metadata": {"window": "Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "original_text": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60b2a29d-8b44-434d-8e27-7cbac0d4f62c", "node_type": "1", "metadata": {"window": "S&P Global Market\nIntelligence may provide index data.  Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "original_text": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa93cdf8d75667527bbefd09956ea0811f7c2e28cc3e84678a63b6f721cc0184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c40aba76-1b6a-414e-b03a-d6b4cb62340d", "node_type": "1", "metadata": {"window": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "original_text": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. "}, "hash": "75f5c1699aac09c729c22e75f47506ef4737f474794111861ae48a7f3f674f06", "class_name": "RelatedNodeInfo"}}, "text": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "start_char_idx": 2748, "end_char_idx": 2964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c40aba76-1b6a-414e-b03a-d6b4cb62340d": {"__data__": {"id_": "c40aba76-1b6a-414e-b03a-d6b4cb62340d", "embedding": null, "metadata": {"window": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "original_text": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e597f3d-1904-40bd-bec0-06c95a0b3237", "node_type": "1", "metadata": {"window": "Direct investment in an index is not possible.  Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "original_text": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1d8ab76b05efcce6b47d7dff923cd708b654f9d6818b58e2da5b860074ec2f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db", "node_type": "1", "metadata": {"window": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "original_text": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. "}, "hash": "40cd81a08c82873eca51188b87e6353f925900dd9d6354cac3359413bdac7510", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "start_char_idx": 2964, "end_char_idx": 3081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db": {"__data__": {"id_": "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db", "embedding": null, "metadata": {"window": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "original_text": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c40aba76-1b6a-414e-b03a-d6b4cb62340d", "node_type": "1", "metadata": {"window": "Exposure to an asset class represented by an index is available through investable\ninstruments based on that index.  S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "original_text": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f52e84a4816b20bdb5ef752c8ca43a76abe01f02f2cde367e221c395d7a690bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbb2db60-3247-4257-a525-17f663e05aa5", "node_type": "1", "metadata": {"window": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "original_text": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. "}, "hash": "6af87a058d136f5453ec3e1d4831a09c4e688a196ca40567f0504b2494a0f525", "class_name": "RelatedNodeInfo"}}, "text": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "start_char_idx": 3081, "end_char_idx": 3245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbb2db60-3247-4257-a525-17f663e05aa5": {"__data__": {"id_": "dbb2db60-3247-4257-a525-17f663e05aa5", "embedding": null, "metadata": {"window": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "original_text": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db", "node_type": "1", "metadata": {"window": "S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format.  The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "original_text": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99c1e8c2984153b014b139e8c9645dd1b99af4da6f83f028dc3d05bbdbc52d35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9f3a657-0aa9-41da-b448-c22b68fde047", "node_type": "1", "metadata": {"window": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "original_text": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n"}, "hash": "94fd33a07c9cbdedeb58af86bfbda2b4c469365419d404ac5ead1555bcc36587", "class_name": "RelatedNodeInfo"}}, "text": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "start_char_idx": 3245, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9f3a657-0aa9-41da-b448-c22b68fde047": {"__data__": {"id_": "d9f3a657-0aa9-41da-b448-c22b68fde047", "embedding": null, "metadata": {"window": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "original_text": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbb2db60-3247-4257-a525-17f663e05aa5", "node_type": "1", "metadata": {"window": "The Content\nshould not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making\ninvestment and other business decisions.  S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "original_text": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47a478ae3c3da123d6821e644a070f11e7c9c34eaf6f7f3c802951be35a8c0f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14179c39-f69e-4ae8-a934-71d2d0ab8a6f", "node_type": "1", "metadata": {"window": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "original_text": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. "}, "hash": "4df25754f355abb7ad406fdf79621e59badb23f8b7ee4bc812c999fddc162fdc", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "start_char_idx": 3364, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14179c39-f69e-4ae8-a934-71d2d0ab8a6f": {"__data__": {"id_": "14179c39-f69e-4ae8-a934-71d2d0ab8a6f", "embedding": null, "metadata": {"window": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "original_text": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9f3a657-0aa9-41da-b448-c22b68fde047", "node_type": "1", "metadata": {"window": "S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such.  S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "original_text": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c88fa711a7e204fd024d17303252496ee95988c916a6a8aeae3280e1868ea4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8", "node_type": "1", "metadata": {"window": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global reserves\nthe right to disseminate its opinions and analyses. "}, "hash": "ab7e0935b93ea594e3d91d9c17e462559fa6ad56d6e31d4a6eee6fc3b9a0491d", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "start_char_idx": 3533, "end_char_idx": 3677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8": {"__data__": {"id_": "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8", "embedding": null, "metadata": {"window": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14179c39-f69e-4ae8-a934-71d2d0ab8a6f", "node_type": "1", "metadata": {"window": "S&P\nGlobal keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities.  As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "original_text": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3a5e1e1d5ce9b7e2b94e8706391f24f15e1ffc70ccfe85d0dab99c0296ff0df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6ff127a-446f-46fb-b73b-395554d21f0d", "node_type": "1", "metadata": {"window": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. "}, "hash": "4ae92a3b35599993d49e00950781b964cb774c5179c7e06bcea7a3d46ee08c86", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "start_char_idx": 3677, "end_char_idx": 3749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6ff127a-446f-46fb-b73b-395554d21f0d": {"__data__": {"id_": "c6ff127a-446f-46fb-b73b-395554d21f0d", "embedding": null, "metadata": {"window": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8", "node_type": "1", "metadata": {"window": "As a result,\ncertain divisions of S&P Global may have information that is not available to other S&P Global divisions.  S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global reserves\nthe right to disseminate its opinions and analyses. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0ee4668ea24f6664351880d7b82f37ed7ba90de609a68168ca326bd01b81bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b1dedc4-332f-4610-86af-18674b6feb4b", "node_type": "1", "metadata": {"window": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n"}, "hash": "69a1417cc281d636d3f08ef2ea626f15c31575684b8bfe8d15739f4ea2fd8904", "class_name": "RelatedNodeInfo"}}, "text": "S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "start_char_idx": 3749, "end_char_idx": 4057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b1dedc4-332f-4610-86af-18674b6feb4b": {"__data__": {"id_": "4b1dedc4-332f-4610-86af-18674b6feb4b", "embedding": null, "metadata": {"window": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6ff127a-446f-46fb-b73b-395554d21f0d", "node_type": "1", "metadata": {"window": "S&P Global has established policies and procedures to\nmaintain the confidentiality of certain nonpublic information received in connection with each analytical process.\n S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b19ad435e42395d8914fade076282421a13b24be98cbb9aa0600705775a2931", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf81ed1b-6050-41bc-86ec-2c2b7fa9fecd", "node_type": "1", "metadata": {"window": "S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "\u00a9 2022 S&P Global Market Intelligence."}, "hash": "85409136acd8cfd4c64ba4e8aece99c4bc7944b709f11670364f769bda37d6c5", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "start_char_idx": 4057, "end_char_idx": 4159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf81ed1b-6050-41bc-86ec-2c2b7fa9fecd": {"__data__": {"id_": "bf81ed1b-6050-41bc-86ec-2c2b7fa9fecd", "embedding": null, "metadata": {"window": "S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "\u00a9 2022 S&P Global Market Intelligence.", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a4c7bd5c32a3d207f4c48465c217faac299806f6db54cb2d9baec2fe4f2ddb0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b1dedc4-332f-4610-86af-18674b6feb4b", "node_type": "1", "metadata": {"window": "S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors.  S&P Global reserves\nthe right to disseminate its opinions and analyses.  S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free\nof charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global\npublications and third-party redistributors.  Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n \u00a9 2022 S&P Global Market Intelligence.", "original_text": "Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.\n", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bba14b37fb0c3117cebbae6f6bd65ee0d2b091b6e0cd3fd68f049fe4bd2b8db5", "class_name": "RelatedNodeInfo"}}, "text": "\u00a9 2022 S&P Global Market Intelligence.", "start_char_idx": 4159, "end_char_idx": 4197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"1d8cc600-46b6-4e9e-9077-7273ab74c0f9": {"doc_hash": "cbb6403513da33f2394439c904734cd113f86eaf458ca6a2b4ca4f4653e6b5a3", "ref_doc_id": "8c9e8e13-fb2a-4bfc-822b-26af95097774"}, "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474": {"doc_hash": "4569c9cd1e00ed7d69c55414e6e2d040336e2646e954603126b9b71f733fb57a", "ref_doc_id": "8c9e8e13-fb2a-4bfc-822b-26af95097774"}, "baae4b4f-0de7-4a6a-a960-26321b79a458": {"doc_hash": "9650aaff3fcc4555086f3224ca7479224191b300d4838fbb7796edc7a02e7271", "ref_doc_id": "ffc0b564-2124-4402-a81d-adf214726bb8"}, "2f2b9d66-a604-412c-aeb4-a12ffc1158d6": {"doc_hash": "c35797bc9d563410175ab747f2e1680747ef3730105e857d81d60fe7f0f1a13b", "ref_doc_id": "ffc0b564-2124-4402-a81d-adf214726bb8"}, "d1be5bca-3a7a-4620-8cb8-43b9b5d0323a": {"doc_hash": "d9a84dcc253949d45799e933ed6b1bea89bc8db757130b8c5655c9ee43cc8718", "ref_doc_id": "8c248cc7-d698-499f-af53-4d027dfd69d2"}, "b2f39111-412c-4945-8be0-9c0fd51e04ec": {"doc_hash": "83011f8ba926e32a0718ba7af2e0f45cb11f1b0833fe4e4b82f6cb7c219de689", "ref_doc_id": "8c248cc7-d698-499f-af53-4d027dfd69d2"}, "3816a440-6d24-4ef7-af85-8cd39aa32266": {"doc_hash": "3f7ed2a01b6a6901100c6bf94b5a0bb3cc87f90f9a87901a4f31510935ca228d", "ref_doc_id": "8c248cc7-d698-499f-af53-4d027dfd69d2"}, "b39f8481-da0b-4b5a-9fcf-a7ce743f321a": {"doc_hash": "cd7223a70c685befcfcac9697ac5fa58316c11acf896c4a92fe70df1c2dd5deb", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "af166dfd-e8a9-4296-9851-7d8e79ef15d1": {"doc_hash": "032b86d7f9485035cfced4922a7360e23c1178405bd18fac0e90cd57ca656143", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "4bfb3e56-5936-4050-9e09-6abece9f8bca": {"doc_hash": "3adf1a2237b8c4ed2a6e1c5f9a10db2b4381f8e81e3438a017e06453ece6c644", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "d33abce5-8de1-402a-bb56-148d3302f4af": {"doc_hash": "bdd1d8517e0e7d4230db41bf1524326fc1a5e9c9fd17abb6dfb40f106db5aa21", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af": {"doc_hash": "e8cc62e64249d24506c99138b8ef9fdade15b2fab141e7371a6e188de54c43ff", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "243475d2-de7e-4a57-a970-11d259b5ea08": {"doc_hash": "4a9f1f43aa49e7b7a3b69fca967688e57a07a3e97cc6ebca8bd139723ca99668", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "f55382f0-cb94-45cc-8d32-f00da51ef2f1": {"doc_hash": "b371021e1591a80d70b41cd54a00ef3ea9c5077a2ef2090aab02ec68d2f40dfe", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "0af511e0-2f59-4f85-bff1-0db6ba7bd316": {"doc_hash": "27a0c301ab6c905a7473de109c7ae51186efea1511677962905f895860e5a274", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "23d1cb41-f84b-4cd3-9f17-d7f8673391cc": {"doc_hash": "ad47c95e564d6f665db91ce07c54f8a0534ca6f1768d78ca914def62e3a032db", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "2282afa6-208a-4b29-8d72-7053a47f0dde": {"doc_hash": "71c2dfc870fef219fde42f0a66252d5213a2f7613f09b91588b2cbde91205d5c", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "ea3994d0-5084-4527-9729-896decc25a5b": {"doc_hash": "d548db63c08fa7bbdfb5e1a16f8a90ffdf249b85560fa06de17f604b0409cffb", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "e0126c6d-0d2d-433a-8398-ce246f4aa0a2": {"doc_hash": "b40bc227ac2f98d285341fb8653bd12515e3df3dd1a07c49f4f79fab7ae45bd4", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "06564a24-4c14-45cb-b4c6-fc96b104b2e2": {"doc_hash": "e6702a72b433b5903378840fbb175ae42bec450d2f0c9c20887733fb8f3d023a", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "f6969423-8138-421a-929f-f9c4ce9eb3b6": {"doc_hash": "6c39c9c3b9d485870cc9e2b9be552fc0589adf9f011e92f0967f8039d112d554", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "228030f0-d592-4b69-85b1-ab3a0666cc9d": {"doc_hash": "cebd5abba65a7d187b44409d5f334fa04d21f319f00a34839fa7d8c1a1483f86", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "59431d34-0849-45d4-909d-bb47d6a56d3d": {"doc_hash": "3d39d61c56d1fb18777c2e1f40960a95e95d6ad9a0278dd541db9e34b3f137ae", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "31467483-fa82-46d8-b9bb-8b2979ac0755": {"doc_hash": "af19be521f503e2994dba4d2f17a42c490c2d6d77b669d9ebeb7b9f9727e7efa", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "944fba87-926b-401f-8559-223a13a4422d": {"doc_hash": "6243c8f0d1af38be550ebb4f2e8995462027e6516118a75409ecb5d14e3ba691", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6": {"doc_hash": "1b40ee356ac55d68bfd71177dad09d0df552b315db1c7d13c0b7a591a415acab", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "7705f094-6ffb-4e7f-a771-eacd78f8fdd4": {"doc_hash": "2177d579bd2bc1e180e35bd5baa25ca46692078de6564842a10a3f48806fd1a0", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "83aea93a-3d79-40f7-9c6f-892b87494da1": {"doc_hash": "f3f08423bc6e3f48d4976cd1e4988d7408d3e008542a6a0bc0bcc49edcf44c51", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "c7b269ea-e83e-47f6-96f2-45805924f723": {"doc_hash": "36a6ab7ae21e7e235247d8c6190463280a62c05889c2abe8463d38b8ae46bad8", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "d17c5d69-be55-4482-8d1c-2bc2bf547b62": {"doc_hash": "9fc55a1f320989c9648ce90b5a2c7f8c8152440df4973fd53237b0fca972da25", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "a4670465-d3a5-48c7-b69b-0e767b092dfe": {"doc_hash": "97380045c33c84497d70156bbe66adc822b516d159d4b879656989c2c48a8e6b", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "75639319-e82b-4c09-b2de-41739f3f9c15": {"doc_hash": "5d693457c5872c67c1f9d28089f7d19a5bdb0af24632bd319ebc3320758c1d85", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5": {"doc_hash": "9c07ae5cbf5959a6c9fd26c8b7a412a79ab759c08648dc3968deaf7f5765a4d5", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "6663ccc4-d80b-4d40-b655-2fd5981a7737": {"doc_hash": "0daf7b51e16acaed5d36946ffe9c3657e4d7f2e47ae117441b0fd69984b364a0", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "fe65cf83-e80b-4169-8842-dd56af2fef54": {"doc_hash": "c7084528b64c330bc5c5c596ccc9c0d4fc51b458a44869ce24f7fcee0b0cd435", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "bde5e349-568a-46d4-912b-366c9b270a68": {"doc_hash": "f47241535de333d976a91f2842a7a8dd61217e3c0c93b9d440c95271a81e22c1", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "aafbf8ca-4c3f-4cf3-99ea-5223d916d541": {"doc_hash": "6b375a22b51b92ae8aeefd90c0faf524e29653dce072c3b8c3e4f07c73f59ff4", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "41d1437a-4a1a-4f41-8571-afd87f990888": {"doc_hash": "f5f41724733f68027494fa9a55d532145b63f227fbd4e5ee80fa94f05c3d7d2c", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "af466a80-0294-49b8-8ded-c35fc5718b4d": {"doc_hash": "c055ec63887f653e177638b83f1bf3e8780aca3c118fce74490230b8c449846a", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "0b709c23-0409-4261-9ff6-ef6e29c0a8f7": {"doc_hash": "158776c0ba9b4f8a7d85cfd74c854cb37c8682c4f44e2a7ec1988f6314a43b01", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "2029d801-9050-4d82-90f4-350291475b07": {"doc_hash": "1d90083b4413e9460c87fad0b70c02c1d6dbd9aba4f9d6f50bec0bfdbe0c1cea", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "12d9e72f-9773-4906-b958-e3903fc8b757": {"doc_hash": "d8299efe6e3957396f8ebc73b4bd436571effbd53cc4a9077f7aeea9a6cb5081", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "f7578ec0-716c-4c98-ac2a-0ff7dc62629c": {"doc_hash": "dedbf12e24d49b35f1b0c5fc62fba2e3b5243ecb32379519b56447493ace8a89", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "8aa10f87-1834-4fd7-9954-bc23724e1d1f": {"doc_hash": "ecddb8cf022e7d1e2dda1ac74c46d1c7ac87eedd2eeb3b8061a2d70822c399b0", "ref_doc_id": "a90beb30-aaa4-4486-af2f-62db4522e765"}, "220a8f8f-a531-49dc-a014-0ae9b00f04bd": {"doc_hash": "9efc1c756e9bf8daff701e6fe2434a9518492e08c25f16be837f3ab2bbd90a72", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "80aa23ff-586b-4568-b6e8-2aa67d16fff4": {"doc_hash": "fee227b444efbc3194d45e3a80cc72a1baf50162a018b7439ede0f0b61913d4a", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "e37ac073-4ef3-4751-b265-077ef5ab3c26": {"doc_hash": "1310888ba5ca1be7ca4167958a26063db820ef58a130e1c4b90779260369062a", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "53a9a98f-c21c-44de-b9ed-c4e027812c41": {"doc_hash": "74049acc771bd6057f218322755fbdf6bb658d342eea89b7372f08ff36eb8102", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "b67cd999-986a-412a-b4b9-7ef1e5442a05": {"doc_hash": "4ee594c3429db0ffab8c46ca35a794d9139b3f5054e9dce43e6e9f5c01fc971c", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "18a4b935-54b9-434b-8fcf-f1162cbf7768": {"doc_hash": "166ab255c27783c14f395a73d42c2d379f431f368df2d72b110b80fb2a736f7f", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "1abd09c6-6492-4acd-9dbb-95fc204239bc": {"doc_hash": "1370f86de519ae43fe558f827dc245dbd7db521c3b50b5862cb414f75a1b626b", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6": {"doc_hash": "62a13d3c1cd14f33474837fb61078cfddcae0bd3f514daf02ea0fcaf4de683ed", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82": {"doc_hash": "8fa32c6657aa35eac4b655943c6ee58ed09778516246d5b90d09a855e5abe99f", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "09467d52-1f6d-4cd5-8bb9-74307d68e813": {"doc_hash": "23c546b4a3a4714180e396f6bb1d058c6bd61022894a380749dd6d5b48b4f8c3", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "54b72461-7e37-4867-998d-8d0011eb3844": {"doc_hash": "ed36c71caf5f8ab6d69784cbf296a44cc61dfbf2b352f6f074d3a470f7791947", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "f1895063-caa5-44af-9f36-e8b543af38c1": {"doc_hash": "b9edef9d27558b0388c107aad09a8d7f5de1b695d536be4e9f3fe93f36813e59", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "036379f0-a38a-417b-bc38-fdc99f556c52": {"doc_hash": "995dd42bec25581535f40832e2be196eecbdff5788a75b6a9d9b83951d81d916", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "029f9e01-4807-47aa-9f2f-2b601527da43": {"doc_hash": "3338e5c2cc991a3a9b9adcaf9a48fb4d1985e06d356b3ea7d33bb979670c3678", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "a9ffa04a-c71b-482c-bfea-86f31aa49fbb": {"doc_hash": "bb14f472dcb4029cf02beeedabb6d8910b929f34c299e36975b53e5b173ea335", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "c1e34f55-209d-4999-b397-3cb0fc82866c": {"doc_hash": "33358b10733a92cccf09bfc8df370092fd0b3ed0f0c10c436c8f68a40be21fdc", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "476a9c91-e73d-448e-825e-83a65cbf1c2c": {"doc_hash": "1f79e1ae7688af6eeb5db6288ec5572abbf3764212327f1758beb4d1bb3cf821", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "fb16c6d7-d49b-4985-98c4-7d085c864e56": {"doc_hash": "4bc521796de5948e0c454527670806af9f0652c986fe206812d7334cb012c7ef", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "22fbcaa4-a606-4906-b740-a91a29d073f8": {"doc_hash": "48853375366a5a8805fc188117a9587e87997a114cf876e3e8e49d8901c2ddcb", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "840c2560-d4a0-4675-ae6b-60171f4d3e9e": {"doc_hash": "471e305cf772afbeba7afb45d1fe7390e5a6b547168c49d1cbd32b0f3dd4207c", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "a4e09316-ee27-4959-a596-77fb111a5f52": {"doc_hash": "8583777dcb01b882ca4c06d47d7afc77a78d7e927781fb278c444acc7bf0f158", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "38889468-8b67-497d-ac53-d74572bf3126": {"doc_hash": "4a14a2437202e6cd5ddcac53ef58e11ce7ece125454394693ea7d7352f35a3a1", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "65792761-58a3-43ec-a4f2-0d6ae123d603": {"doc_hash": "0147bb1a36e36f928e913ca458c975abbbf867bdf5dad4ef2c0dbb5d6134d4a5", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "13d50da7-5293-4773-8213-973698c2bebb": {"doc_hash": "29167cf132be8c6bcd3465a2085bc73b8967825db20ee7259d71675a9cf4ee15", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "0c799a55-ec88-41b9-9416-4552c31f15cf": {"doc_hash": "4055334924a7693df83e936772e1248bb3b4ae94d983c8739b2c70ebbd6ff8b9", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "60c7a3b0-94f2-4da3-af78-1e691793b804": {"doc_hash": "26723a0cbe56fbbb648a33b8b5667fb002088e19878bc971e8c7f0ecc3d8945e", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "025a11da-0296-4a71-9760-ec35ff9c2be3": {"doc_hash": "7d23cbb79748fc4be3b7463d759a632674aa4bafc82cf157e1c614ee21624cf3", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "c8af9fda-e368-4363-855e-3fbadc42333c": {"doc_hash": "ce6d2cef0c579ee51db3091bf15d27705dd0107eb5f33e16770287e252974d06", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "7e7bdfd3-60fd-417f-8826-25cf0a186152": {"doc_hash": "73d620e7dcead3ea47f3e64a631c8d87e0f61d1d42aa73f23b0d37d969d8ab7f", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca": {"doc_hash": "c08be25f6cc6f900d2b4e718521a14b7edbd7790db6c7f5df894798a01a140f0", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "09ebb750-fca1-4572-b7e1-148b1f5c20b5": {"doc_hash": "3369e2426f420032da52d7860382effe5e7436cff97d6ece71b85ee825ff64a2", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "2b949729-f200-4928-9856-e639869057fe": {"doc_hash": "db5e049f562c1df59644ea9e77eec84f37c97daf0fbc302e0b5d22a2acbfe138", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "69db5cb8-b821-46bd-a4d1-99158dc60cab": {"doc_hash": "c55eb27824148f14be38ad9a89ee9d89e26e962c684a02b8d28ccf0ee382aaae", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7": {"doc_hash": "868b69d168f6a5ec6afdc6e22940dd2993d7451ce664c975c60f876c9d67d53e", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "c21c0172-a052-4c23-bb9a-5113043cec14": {"doc_hash": "9f64e0448f277e4c33b0a3ff81a024abab90d9854edab973daeff225a50789d7", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "792829ab-6660-4661-9864-64b116948b39": {"doc_hash": "58303af46020d8a23b994b8f57a5f75b57bd4707d15cd6e6ffc54949bde9754a", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "76f47c15-efe4-4946-94d6-d3c90f435e33": {"doc_hash": "4679993ce2e6d6aba687f392b5028f0084bcad8cfb50a0838a1bcd6c57446719", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "45f177de-4c60-4694-a133-1c5953319be8": {"doc_hash": "84527469d29810fcf5d8e3af7e8dcea2ea4db4c2710a228705f65e6d2e99c900", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "8f2b676c-4972-4d77-83d5-adcafb6f6b74": {"doc_hash": "4ceeabb2cb1f1b25b5f6f5ea49803ed604b55c90f227c3c0b2dad47770b46329", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "d15d888d-990b-4078-a682-fb865e62fdf1": {"doc_hash": "1a3d47ac75f6faa031b933f5db46ffda2691ac7a2ace91c7511a42d93aa4c8f8", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "c0ebdd65-4f57-462d-adc9-6f76275777e6": {"doc_hash": "155181c1cce271aae3f4e6f5888bdbb9a725d5a71f13f2d67096bc0722eb3d0f", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381": {"doc_hash": "1781195c95357d5fb37b1ecdad5e239c603d630e1e4214eb871d24a48c8db953", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "18e88f85-76de-4b4f-af4c-df7ea4625d45": {"doc_hash": "71f16ed103f0d8f86e8280f4f532fbb685a5f0fbcf38c1cf3f2eea93a9c6aeaf", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "b0b203d4-f4b4-4869-9b18-92a98c63bd4b": {"doc_hash": "95d53767584b67e40e0c99126bf91e63ceaa8df50b9a0855e5b6404aef644629", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "a3795dcb-651c-44c9-8cd9-66c56cec1aaa": {"doc_hash": "8296a8205cf2f3c141d515dd41a98fd84fc0d49be493deda48ba6ef8c2babd58", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "7d068037-3a23-4c9b-a932-5e8c23a88773": {"doc_hash": "4a0de158db77d40c7cccced138b58c8d9d8cfd8f47d7e2b34ac218bc3c48c2b5", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "7cd86607-fc75-4a1b-a7fc-cb7d0572665f": {"doc_hash": "2c5dcb8b18455107441e3675f19315dd6acc13c3bf643c5b142e0fd45042e166", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "69ace939-7e53-4857-b4f8-0d06f37a3e4c": {"doc_hash": "206f2fba51e224f73afb7bc47204f697b15e93a73a9be54f392feefbdba18b83", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "72183ed8-14bf-499f-9b92-df70d79413a0": {"doc_hash": "c3e21d777390b284a221744f7a04d6129487e1c12806389a41b52b97920df1d7", "ref_doc_id": "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a"}, "1e488cf2-4980-4ee1-9403-92b0f5b7abc6": {"doc_hash": "b3b4e6c1241e869718f9b55627ab07d6cc0cbd3b156c5ab8079549ddb220908e", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "620bf846-42bb-4c35-a77e-17d69486dd87": {"doc_hash": "6152187193ffc24f86cd38d747e6d2dc92f7d8f5f3e8972f5b92baad6b050325", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "6177d96a-5932-4c13-98a6-a4d52c7ae5c2": {"doc_hash": "2fcb26c1e5fd9944ca58d00c726cc5de60e43b9dfe5dd5bfb1048bb77405a926", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "d7a07aaa-7443-45db-8781-e06fb7ccde96": {"doc_hash": "1000aad9dbf9320c7f51a7a9f339b68ddc6a8fd219b482bc8dd9a576857d5d69", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "61fd6d27-9fe1-4eb4-b435-7cdface11cbc": {"doc_hash": "4775895ab0d4349de01f96cda0019b9100b8d7904f1b9e0e123628acff1a220e", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "147ba826-9a62-422b-ae5a-92af14352241": {"doc_hash": "d096aa3394e260b2840ab6e0e56d9ae01b616e52860999e2f63ed8156776dbb8", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "8bdbe49e-5125-4116-b981-2e88cc6eb5e6": {"doc_hash": "101d52a3edd5f1388aa4ecdb99e64e14984f5832d21654e1deba3cec5ab03b82", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "f2153f38-13d6-4a99-a4f1-4574e68fe5f6": {"doc_hash": "d0b11487e9b13e0c44b98487023d51ad9742cedb3744309dbfff86824ca5229a", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "56195842-7ff5-4fb9-99fc-905a888c9ea7": {"doc_hash": "05d3000bbef6eb8c179f6009729e4582af814e287f6dc5232e8ad7c7da60175e", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce": {"doc_hash": "da737fb82f1605e7eb43121cafe3a983a42d9ad356f61a208116b3d540d6cc92", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "24cd5dd4-8f44-47be-b764-c4417f2e32e5": {"doc_hash": "5a15808df41a0ac67d46ea792bdf2a194c06a662f528dea62101a287ec4d503f", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "6be7aff6-b152-4376-9539-68ef228d7c85": {"doc_hash": "0a1d28588331fef9ef5f1fee682b13b529a31282a66d807598ffc5955aa81254", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "2f494ae6-ebc7-48a7-8159-b21e79212864": {"doc_hash": "bf1440ef443451ace74c284becc8305d8c33fac1f5d9b6c049264f0cbb1ae389", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b": {"doc_hash": "8a338aefd56201e4b4b8ac2c565902437a2a193c912eeaf6530284e0c8af2925", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "ab69f861-f910-479e-8014-88b12cea650c": {"doc_hash": "6ceb9cc4920cbda7f5c71fdb78bc3882f936633759353d73e9c17096c3356410", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54": {"doc_hash": "7644f8825346e52ab0329ae099ca85e6a7cfbb9f3ba7619bfe8f700f169da726", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "c72f446b-1931-4227-a955-cc307982f51d": {"doc_hash": "c8ef1465afbde3ad0662fabcfc4b83ab82c6152150b79a7ed62897babb200567", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "7922870a-c667-4194-9481-b30cb9873b2a": {"doc_hash": "d944a9916e34860a87efe6ec1368be3a174c51c6350468010d34e772de4aecc6", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "19dd6cff-0080-4d4b-a14b-f9e21e42870b": {"doc_hash": "a29b9fef071558a19f525c77a69e5f2a3cda62510c097e21ec92e226cd6edb38", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "b414088a-12cb-4c9d-827a-d81617ca928f": {"doc_hash": "6ec2d0cd60c342094a24fd42a4de53d0a24cc5a9cbea34d56f0d7e3085fd0de5", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598": {"doc_hash": "c69191c70c04875acf2bb854fb684c5b3c6731caba85815454d076bb9a6d4fe7", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "f9214301-7cb8-4248-bae0-1efd81f6c0c7": {"doc_hash": "799c22e57acb086954c788ab9c9ebb3d991667be72b3ad0cc8e44859ea32682b", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "a2afda02-ebc1-4c31-8487-e6c42088ecc9": {"doc_hash": "6dab26e8d57af8d6c9264e67584091ab9aab7576ad74bac9313e06fb0a26c8fb", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe": {"doc_hash": "f92e85ee8e42c332b045c804cc4977d233648bd0aaf68ca99bdf783ca9da56ee", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984": {"doc_hash": "88229ff4270a0cabf07c7d806bc58305f9985986cdde7e09aec2d27187a52972", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "fd4c7aa9-630d-492b-9923-117872a49d63": {"doc_hash": "0f6b8cdd1a1fdbc8281d2557c608426e5e33838883c5d220589098c1a5f54bfc", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "0b97f191-2348-41b9-b719-ff2b4cddea2e": {"doc_hash": "be298ca29b044a14781460ef5b07660e079c98d428cabbb3bfdd2f54495187f2", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "5712b8d2-42ce-4137-8455-893a245f8eae": {"doc_hash": "c4f9cdce8833b6fc1f439ada154e6255aa68c24b304746cbe019270d7504d6f1", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8": {"doc_hash": "7fcd3be6b1c39c626a8d16252436e8314e036246fa1c00664684886ab12c0826", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "1a0b175c-d5fd-4122-bdbe-3d213cde7271": {"doc_hash": "06c2219b3f41c751a77d7ed9458bdbcc5039a33efdb0a8efad0644b9a4cbef9d", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "7322196c-3c55-4abd-8ffe-2eff8b3172dc": {"doc_hash": "d169844e50a713112798167e0b89017c79e406d9f723411a1817dec98b1bef67", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "7c2ecbe2-fbf2-44b7-8971-a422b005609e": {"doc_hash": "1b5d23769038fc26932718641aacaa9718e8c193190efec495b02b9a9b9b2dd2", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "896e722f-8e70-4cc7-a5c4-80140ab5aba8": {"doc_hash": "a0cad01e3d698c93572c1a4e60e92c174911594ec864eaf895180e365e387918", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "420de852-acf5-4af5-976b-6043eba7f522": {"doc_hash": "d0485b9270b9197b4131406794287a1947d79a61a99757114560bf4be50f651a", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "a29d893c-7b5c-4daa-802a-9fa6fdc26c84": {"doc_hash": "b2a23bb873661dffb55095f63c8b9437f2f348f4e95fb1f37c9995c53c1817b3", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "6394d05b-3f54-48be-ba5b-e07af8a06b62": {"doc_hash": "6d9d24e98d6b9c243fcfdc0160d0e850bd5d439c15fc04d1a216b72a951fb22a", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "64a44ee0-9f1c-4021-8d12-7900e0560426": {"doc_hash": "41aa85599ac331f5542a98a37578eeda70e58e9321e8ebdeed7131bacd969c7b", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "8907bb9a-ef4a-43fe-b231-fa4f89c77677": {"doc_hash": "119ef74b1154b20323c7a89856ce898850c2c9f44779d5e084dac9e420ee1dd4", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "47286145-a31d-41d1-b587-f659e4ddeeb2": {"doc_hash": "7e645ea1dcff8aa510a3a64c3003c050cbb530d86a01d60e66b0fdc3a1966cb7", "ref_doc_id": "1c035e33-56c4-448e-bcae-ca731807c653"}, "302daaf6-25f9-42c9-a48f-d0d651c7dbf2": {"doc_hash": "984dae5c9a4415ad20965c50a644a293f9c5fad062839cb77543926e80c55ede", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "d33b3abc-4153-4af7-989c-ec7f61a93fd7": {"doc_hash": "d82d3e4a8d3f90567bb443f4e285919ceb5757b497a9b1889028fdd62711e3b9", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "3b7ccfa7-e857-454b-8432-02a11fe38e8a": {"doc_hash": "34f46dadba5fd57a981140a6d7aae37c8f5eeeadb81c00b4c8ae7d3c5afcc5a2", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "e138dc6e-b664-44b4-8e40-1f1d0cf4779f": {"doc_hash": "f77cb7f13846ddf19d3964b6796cef5e8ae0da90dceef67159dbe012da75d24d", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "8a253a9d-ae5a-4f3a-8a38-2a798a868e87": {"doc_hash": "a635a6e7f0333347a38e5e383a5ac76772c672a00652788069f798b9b1bdc0f0", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb": {"doc_hash": "1f90517355f8e20e1f20f456def163a8653a36ba6c207c51fc36516ce74aec5a", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "85086d6e-e59d-4004-a62c-d0808b35df17": {"doc_hash": "2d95097ea42ecc033012997691b21cbcafd2c5ba61b4ab8c239cdf1f1e57af6f", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "a20b8d28-7f49-4413-8681-bac27458d0a4": {"doc_hash": "6ff51ecd130deb315f72c04d8fb0e17472758fa3c3b92847d87d0c79a8567ab3", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd": {"doc_hash": "6ad1cb2e62b89178899caaf56051947918be8fa22e572e53acdc6f5381fddff4", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "dee5a5cf-191a-4abf-a2db-84709f94e0b1": {"doc_hash": "9b5b80f6e5bd62d160edc4bf6ff63ca6124b5dc3a3dbd8c6ef6c8ccaeb071961", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "a85559d6-8cf0-4009-a0e1-2e438499e8d0": {"doc_hash": "6b4debe81a0ba5493c4f27573abb3766febf818bbfb82c0fa88021d5060565b2", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "b3589ff8-2c1e-41f6-8290-4ea14a056332": {"doc_hash": "742bed69bf43f2edbcd8d5b33b9e25fc7ea98ee1fc2bc9a278485dabd8fa6a37", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "37f2f017-6058-46a9-86fa-193e68cd1342": {"doc_hash": "90652a8bfee2666a6a615ff95e362073f05e68908b99b9d5e15c77cdda1c364b", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "cdd060a2-d10b-4b86-a1f1-3ead72212972": {"doc_hash": "2f7aee2562e661e2cfe6e45a08cb1944434af110940f0c184e3636d1f9969de4", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "b4e737b5-b438-422f-9203-84838d67346d": {"doc_hash": "07e426f47cb3e107384c30f4c5444e067ff9833c4cd0b9d1793f194fb29b8a0e", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f": {"doc_hash": "334087525ea4abaad50124a4a91f54be0b24e446b1283158f949cacac1d1f651", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "bb607440-95f7-42c7-867e-f0a276efe673": {"doc_hash": "0bf6272799efdb86881bab12bf4c638f578a6c4dfecf73687a0e1d9e608e00a8", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "8140c79f-2f0b-4724-ac6d-23f6d877175f": {"doc_hash": "b9ac44ec6c3c04983082e66c781410e0578b00e9437268bf517f581c0d5added", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c": {"doc_hash": "9e83ca0def57e1600a91a91ab2ac4360aec2a0aea44161fa415cb07cd61984b8", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "beb108af-ed15-43cb-b1f4-8319b8d2dc03": {"doc_hash": "364f8a7bac05ed35fc53452542610f27ca9eee32d7f48548bbf98f5db6f6054f", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "d88c9a61-5943-41ed-99b4-856cfdcdf03d": {"doc_hash": "e84994137bb66017d21c3e597d568ca179367cd8bf2b2b71a4c166248718e212", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "2dc381cc-c48f-4f38-8296-4b1790be1941": {"doc_hash": "9634fc705f528baff7d5fa0fdbcd26546cda8dd16943990ad2362c6b4065ec28", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07": {"doc_hash": "c12aadd8200e1b40226d092fda012757c23e39e30867c2963183c4fb3bb40419", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "ce9020f4-c766-4f51-8902-39310c98356b": {"doc_hash": "25b8716709f6fa2a6f2c5890babddcf172850eb2e6244b498093decc0f976273", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "4ef1f69e-666f-4d07-833c-7c92518d8ff3": {"doc_hash": "a06591e64b89efdf4bbcad87a8fadb6ae43d2c77fba48fe2380c73641fcfc3c5", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "d2b984e4-3098-4a1f-ae0f-38dc69314cee": {"doc_hash": "126ab48ff3ed0a71d82bdf1e71964a02dac7f18d18f3b4901d5082d1c45ed315", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "bfb8c6f3-5a1e-4f86-a06d-13f548f05088": {"doc_hash": "54b4c8b76d1a0b986b5ce7ef18deb0153b91ca67b7ad8996ab7ae499111c0d67", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "3ec54921-df5b-482a-93db-940f653fc629": {"doc_hash": "ce6707a656fffcb1432040b8cb86eecdc3c39c6a48e65e3b5c2e601535cf3e02", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "97382acf-c93d-4a95-adc1-ea7a149af439": {"doc_hash": "24374eadeb64db611ec916b0dff04011392dcc8c16f575eb4670a14e5dc12ff5", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "e40ef72d-ec60-4b66-8a1f-db1385f36ef2": {"doc_hash": "c563d86f0dbffc42d3166f16044ddc4579034fd74e1256c7e3fd01198fdf0a83", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8": {"doc_hash": "60d0c01d4f104adb25e11f3d9361b87e8e8eb04525d26ac0d166bc73e6a225ae", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "097f4dc6-e351-4e30-a1ad-18fa7f01ba49": {"doc_hash": "c64f3871b18ec41c88c40b3587fbea1d419055bad59af8eaa05f33b42d0005ae", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f": {"doc_hash": "a0dada9c60ae5f7cf37b06470676f0fb0dc89c7ba54dd61c745323ee8e36a666", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "93d50827-d984-47bb-95ba-091758a4389a": {"doc_hash": "a17dc7cbf109028759771de89b7864d4580998a158eea9f0e5acde999c16170a", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb": {"doc_hash": "31d245aa92045c654eb640cca6250a05e166aac403cfd65b6768bc6bd411d02a", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "6ca935a0-c211-4727-8d63-c551626961f3": {"doc_hash": "bbe3674dc86c2ed9cea5794f121efe128b755898215a943a8a674eb91528ad10", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "d922699f-09de-4459-9425-0401a7206e1d": {"doc_hash": "87a22888e94412b741d57bb683c70c6ea80bdc63ee340c6b4b11113331001663", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "d227c2ab-f426-40ef-9ef5-b6ff5730414b": {"doc_hash": "3aa94c9acfde8f708ea1db43a6777d6205f6b3a4c1def76e0c53702e02428d1a", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581": {"doc_hash": "19bf0d892ae71ac08368f181ee714a8172bd36115c2c5f87ca12529a9c21fca9", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "05b6cfdc-0745-49ff-bd0c-636a0cc822d1": {"doc_hash": "6b146916a189177a18cf5fa467f46dcc3b80b23ac545924733443fd7ce62aae5", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "a35a835a-645b-48fc-90e4-81698127584c": {"doc_hash": "76c3c6f3d82fd3171b34e0ada9474a00ea078cb78e874f256fe0c72491d396da", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "2d61c32a-25ef-4900-9e37-21bce5dfa4ab": {"doc_hash": "954b9324eba6256f9c92de417ed92475dddd54dbdbf64811c8ad80e17997d99f", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "9fb6c183-53f7-403e-a77c-7cf0a7076ca8": {"doc_hash": "e0433a2e94680d0b6f42e43284bb2f25c4bb1f128076c37bb7039a5a97eeecc1", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "1ccdf695-69f6-41c2-876a-dcf234e919e8": {"doc_hash": "2b766b5ad6106db62a041e630a2486956e166acf4ef8a8492638fe6fb22ae4f7", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "e653d964-e876-46c7-83ea-561a834217cd": {"doc_hash": "9bd50739f932429e837dd1968b3bb7bc7736a63701de39b670aab2dcead11b5f", "ref_doc_id": "128a2057-a810-45cf-855e-0452a45818f1"}, "b7fac0df-da88-4aa7-9d55-fe9399f2dd2b": {"doc_hash": "0659a771b844c0555f2c670fb2047e669861720847b0d429b16aa18382d82e61", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "d259c082-668d-4fbe-bade-43b0948a2113": {"doc_hash": "43bd7f48c5893b00c5607585f66718eb9e95f33bbe571eb2e4dafb91ed075254", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "2b5cdd09-2983-48b6-b69e-6ec2a11a676f": {"doc_hash": "be0f823756e45a5d44e65af681e434d6c77ff3227b13d62b6c9b1d9f4bf0fedc", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "6a15e31c-d69d-4abf-929d-aa3ab4999ad0": {"doc_hash": "cc24315e5618f0aa6a37645c32e937d7491cf239920ac658f3f22d5db6a47f14", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "97cb06d0-723c-49d4-95db-3a0680a26b3d": {"doc_hash": "2a883f961821d3447e8e670a0cb4dc314adf9a97d08e5ee18247e5712f1b336f", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "169d161b-c378-45da-86a9-de2c0370fd3f": {"doc_hash": "43ac96964c594a7d22c6299b07bd0f64d2858ecc5291877bc18d46a5672a8d77", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "8aa913f4-d2b4-4491-8817-ca4a7afa1099": {"doc_hash": "7aa0a67fe69e2cff0676e6146e0662c58991d68d8e1b79c8b0f0fe24bfad41ab", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "be639a61-ffe1-4d71-8ac1-be854f4b18b0": {"doc_hash": "c138a684637ce903b3b50985846430d74b08c8594808262f9c5ac3b6336e1f66", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2": {"doc_hash": "8df3bd67b136e8c28540b87f68f7394f8c8df5adbde26f8e282abde52c2bc5c0", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "045c1632-0426-4af6-9c06-5ccc71b30fe5": {"doc_hash": "6fa1734b213c7dd069c17a4594de86d0b1e54f3dc602c08154b7cc98b0463589", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "bd389d65-1fe8-4f25-a317-65c7ece519ab": {"doc_hash": "831bb8bda385696c220230550ce3b0c9a72f09127f38ec9ee4f6080628b27fcc", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "521e1d4d-52ca-4816-9f18-c66161a61ab9": {"doc_hash": "8cbdc6f9a66aee3de22ffe044ee91e29d3aceeabb353a37a01311b18ca988021", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "22fc483f-700c-48a9-b61a-33036d3087c3": {"doc_hash": "bf5b8475f58111546abd485fdadf4e276e4873bc39ae1284723938ef2d1271ec", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "cee5af91-9152-46b5-b4dd-e7e67f1fa79c": {"doc_hash": "37113926e3b64c53ebbdba599acbdb96d4c3c713341b6682c58b958fe03a8abf", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "60c48808-9d68-4bd1-ad22-1646a79497fd": {"doc_hash": "77a03022a4459c4553e57bfae817b28f69589d6e44d125e18e0db56551af56b0", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "704575c9-02ea-4a4c-848a-efdc7457e91f": {"doc_hash": "c454dcf1a99c848780d99fe75fbcfe718c9a762b90451c644893e45d21d6565f", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f": {"doc_hash": "279d66a59f3ee0f36797c7e20fead2ecd26ab6352146f7c686ee22674a5a125d", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "9e754b99-3252-4e64-8dc8-bc4fe527d62c": {"doc_hash": "4655da97b2313035590f0e07a7a0be2f0cd1fd228872021ae129d84ef73a1b39", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "039e5f69-f7d1-4cbd-821c-d266762022ac": {"doc_hash": "feee67a0a8f647cba8d8fe35216835f29c34ddc25a864b92571fca37c1c3b4a5", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "b9bc1837-1151-48a4-a63e-a74dedd5f534": {"doc_hash": "bb57cc2e89559fda22c5776551547e92f29d6409795e1b03d77fbda53997cf3e", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20": {"doc_hash": "e20e6965a5590828a4efc6cd9f7b05fe8ff2c117adede62c40cc4660ee6fd06c", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "c97d77c4-b572-406b-9087-2037661a5ffb": {"doc_hash": "6a48c107b1e4d77939e215c87f9f21a75589481177f1fbbba00ab05d88e36eff", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1": {"doc_hash": "d4c22a5a7c2a4f18614bab6975357bf5c0a48b74cc7480b85cdfaed03172884a", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "5d3f2665-77f2-4c05-b799-b34018ac7e04": {"doc_hash": "b0436824d3658a898f999f743363d1bbaff0183035348aab3ef2038bd7216e19", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "60463a2e-255d-4e53-ba4e-f9f20b185843": {"doc_hash": "d09db263d68ccaf70c6bd98b979e2ed6b5889d96b8d368b0f2e2844508c83423", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "68d17ed5-5db7-436d-84d7-20aa641fe6da": {"doc_hash": "78cb5a787ad8fb52ec4842eba1a71b2c32e8acc15d07ab2aa1080e8ee6567776", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "e3f56c6f-e329-43d4-9931-5c446fd937b3": {"doc_hash": "16e4c4be97c94a7e8f6e0812abc367c84b1d42df4a7b5f4d61f6631974a74a92", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "0a0b34bb-5e79-40d8-940c-9c491fbf53f6": {"doc_hash": "868a0617c640dd1b15a69927396d9d6538ed7cd14ce84e015e149d570ec4af7f", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "3aa00263-c244-4eba-a291-7f2bdc51018d": {"doc_hash": "c00a125d016ef6803d9398c7b7b9320e9d78a470a76980f58780b6f6cb56275b", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "21b495ab-a558-4a74-81d5-1c6403b501d9": {"doc_hash": "ba5656463daed979830e5481e98eee215112767b5bca42f252710ec43aad9050", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "1b6bc75d-2884-47f7-ae01-edee16b0752c": {"doc_hash": "3e784818edc2519cbfcf8a5d3f92a2a451e208aaa44be81ce6b57172e6850278", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "84222969-ae65-456e-9d1f-9e28463d9c23": {"doc_hash": "9d94f9fddddcb8111d026795d7252bd869087529170c46cea111ee0ae2df09ef", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6": {"doc_hash": "38afd843e37b34ad11012306bba72adc7f78f0e712305a2264d0a4b288ebe8e5", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "3eae0a37-f57b-419f-8bfc-f4006826bda1": {"doc_hash": "664af77039c13d6503f7235bd4a0c201ec13a0f68701d5fbc8662e7e2dfbe77d", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "a1e0bd63-309c-4aeb-b475-4238e0239d99": {"doc_hash": "d16832961320852cd813a104782854517fcddbb17a0caeab75b7ed5d4b729055", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "f42ae78c-c230-4eaa-adc9-35c93b2fcd54": {"doc_hash": "d8b9193ec31b7a854663f7a37ec7db9c3cafb32c7f5a5a53fd5e369d1be92111", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "fa945f95-5911-452f-9bbe-d56ad3136c1e": {"doc_hash": "ba1f7803e284ebb904a46e705edad18c55ef5219ffc16ba26dc7ad73f262b527", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "33768011-ce03-432d-b611-543100d3824f": {"doc_hash": "65007fa9996db5c55eeb6331d654d745d87660219cadf10d8761eddd86d5542e", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "265b9baa-72a9-4e03-87dd-771f03240cd1": {"doc_hash": "5fc0d8cf6d4a8ed39e01ca9dfd3aa803703dd585213fea932511567482fe7ba5", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "654f8d7a-cc5b-47df-bef7-d32d88465f82": {"doc_hash": "0b7e2b30f607836e485c92358b01565c885f93e6994d0403ad7aaa1f9b3e1dcd", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "4fef9720-cd25-44d3-a59c-1ce95565f637": {"doc_hash": "d42eab3ff834354a56d79b2bb216baf64aeb3921c3054f7d90e8bf861c0f7083", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6": {"doc_hash": "5b815dd1506ad287ebf34518bd5f9870cad4a5e51ce0794d4c268c124e99743e", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "cd3ab8b2-7b15-45c9-a00e-a59b87738a23": {"doc_hash": "b15b09c0e97f5445aaba6519f6115732951a00b848e05edf4e05a3661ed66647", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "10aea57e-cb69-49a7-be21-799bb0fa89c9": {"doc_hash": "21683b68487e9c53b78821d53a099aba6f0ca0cc5909a828e940fa23ed8c2c6b", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "b141ed97-0c31-4e00-a2c7-322ed86b39d8": {"doc_hash": "d61b3bafbd3db466556e34cf2c6e6fe65b4624eecf251162cacce269919e38ab", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee": {"doc_hash": "a000e62147efbf887e44886b8c4dfe6815839290704b388b5c2ac0c7fc17e8c9", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2": {"doc_hash": "368323b429a721b04c9ebe8086226ee27a55bc9586413518c742f2b035037d50", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "7045026e-1df8-48c7-ad6b-e666c65c5a24": {"doc_hash": "b8ecaf664ff33f1d1a1f5994532f5858b583f3a8ba06485c0c87ee0003df84af", "ref_doc_id": "e2fadafe-2ce0-4c75-98b6-a6820d624291"}, "3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6": {"doc_hash": "7eaa8812fee4600475afcf13592c1a2ed819e078eb0b87baf822041b9250dc8a", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "f4b110ed-11ba-48d2-b6dd-5363e456f7c3": {"doc_hash": "dfea212e418bd7c299ae9a443dad4d5feb9d6b95230e23ef2a553a3425287e45", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "f02b6453-5e96-4b49-8498-376fd357d24f": {"doc_hash": "3c2f65a3d1f8260d303fd7ae82c1d24378c014e6851d6c9492cd78119b795788", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd": {"doc_hash": "e766ba19b036350efa6d384b8b11a0a7cfa4fb13f030cd3f96e48db4592ac0f4", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "d2999dfe-cc7c-44ce-820d-98e22e05c3e9": {"doc_hash": "4145a2fecc0ef77a648ac7bb21bfedd703f89422899be3efa41cbb2196b385ba", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "6c393e74-c882-4259-80f6-9da79819fac7": {"doc_hash": "e98e51cc5e5a3bf09ea3c929514da9ac0e1fb6513010ec56a07e63dc7667b71a", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722": {"doc_hash": "6b387049f5ceeab0b0039a2c022d7d902d71b670e185c6bce8cd2ab71d9f0304", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b": {"doc_hash": "dc0f469902d24510a79050c7ce639d4e46bea85209bb4cb166e313cee6fa97c2", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "82ab64ed-b796-462f-b240-128c52857b50": {"doc_hash": "4585be41037167f9b4ceb8a1d0e68848a89b19fb80e5802d243d544e0d0bcc24", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "c6913a13-cb84-49cb-88c7-49a663e905af": {"doc_hash": "bde1e50e1ba92933a69280a455680d98e7d27ed7c01fd2d95c75c2e4de8db40c", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "f6f42480-4183-415f-bfb0-959d47fd1b3d": {"doc_hash": "ab0a38650bfd0e2716a93fe084163f3e13979f82c9032a38823104c420d805f9", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "7817642e-5d3e-47bb-80b5-88f78b00cb2f": {"doc_hash": "24520938d4446656ed8c02aff138ebbe1a69b1834f92612ae531ea2306a81595", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "68f71b01-b16d-40cb-a0f7-59ecadcd601a": {"doc_hash": "6075ed1877204144a92cf8ef7a8758123c1544a02ad7aa13ad4ccf438797092b", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "05833ffa-5966-4176-89e8-e5b286672a04": {"doc_hash": "beaae50aded9fa131320743f215eeff34ef326baf7fd0fe0069021aefcdb8494", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "5b5dc453-93fa-4404-b8db-48b7cc3c1f79": {"doc_hash": "96de83029a522a39f0576cb88f1b22cff0eeb77a1b14f71759dd81362658149f", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "9fbd3203-5126-448d-abfa-e1344c5fb78e": {"doc_hash": "a7ea7fe08f218be38376fa2f42c25b1bf035319776e1c11f17e6377b078a3c86", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "031ce94e-1d68-4c5f-8263-e078400fb3f1": {"doc_hash": "299d515978f91d1dcc76010b09f9e701ab563df8f091e90a1dc11356c0b2272a", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "ac983dfc-7983-4f70-9026-49fc3f1e9915": {"doc_hash": "75a629f19d9d392002eb4b90cfe035b3a085c27e05c85f6671d5079eec3bf78d", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "fab75678-f8d1-4683-a78a-8b0ef8d87870": {"doc_hash": "20cf1fb6dea59e6ddffbb5c8e742258e0befb0a60b241b4900abf15f9cc15169", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "7db3f039-b699-4059-a82b-d229b1a44a92": {"doc_hash": "c9c364ed7926691d95b1058f3f0f2a780c5a3abad93e0986164b06fd8f27ce18", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "8044e8f7-89c9-4b62-843f-727feea9c77c": {"doc_hash": "c467fbc9c886cc382be95aa12503bfe81e287944e7b2b7d37d40c09697dbb21a", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "d5248f8d-601a-4f23-9024-458f7eaeed59": {"doc_hash": "79257e997b14cdf288f7636a37e75e850b842aa26b93aba2f41134e16284afd3", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "8bb32650-a9b0-44e5-a141-262401fddb9e": {"doc_hash": "31f2a7edce061ae27cd561a710eea5013063dfffed99e413583c35ed65e093d1", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a": {"doc_hash": "c9e00d83020c63ded14790c474dbfd95a05e95dac1d2de166a3fa168a4c99b00", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "21405c6e-4a17-46e3-bb55-a359d38a2fe4": {"doc_hash": "742dd260e2d9cd86f3d420f9436c4ef5989b4792f1601c48f59d05f24e2bec52", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "8fdc412b-7c6c-491e-bc37-b5fd7508d829": {"doc_hash": "f6c3390bb06fcfd11060b8728b1b1001e25b2eac2179959aded95de26d096765", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "3f8eadd0-05c1-4479-a5af-772c6e7d4a61": {"doc_hash": "f1fe069c9f235490258fe33b42687bf3889005a010a478d6c173242d0e3714a4", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "c3ddbdf9-97b9-4af0-8092-d91f4788df3b": {"doc_hash": "26bc7bd3ddaa8507e95e5f56dca1892290203778b04c836e90c9a25d9dad32bb", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "464446dc-1b84-44c1-8754-c390afcc57fb": {"doc_hash": "c495541cafbd47c714f52b3c1271a3c542ce6eae4ab8f9de98c16dcb29193165", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "cec1413c-19a5-476b-a75a-f41db188444a": {"doc_hash": "162319335e9394f370474eaf548e1670a01e1e97107adcb6572339460dd58716", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "038cd020-2de0-4d00-9992-8bd8db351bee": {"doc_hash": "01e146b8545763f556ec47ff4c4ac17e4c2c4c430cdd1026594db43215e6b513", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "d593be33-7df8-4564-a9ef-5ed5638ef1ad": {"doc_hash": "5969bbdd673453b3e6708c1c9ced9997ec511f738b2c98e05b903adc201b61d7", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "739cc948-9230-44fc-b12d-e489fddbd111": {"doc_hash": "61366f4e390394cb310cf656f62622849c7021d482ec91bb528e3e6b50935c0d", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "d66ea2d5-3efd-43d8-88bf-dc1993e0198b": {"doc_hash": "9370acced7905f0751cef0e93afbc0dbf4bf09365c7ee0d2f3d47d80932a28b0", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "cd2f1ef0-b153-484a-bde4-8c0991acbddc": {"doc_hash": "de41cbcf9a23ed4a7b5ee9a26ddcd83631699ce1e1969e18160a350c81d0f6a7", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "2c60e1ed-b114-4c10-bcc0-e36cd876ac66": {"doc_hash": "289d3828959a20e5702071343687438db2fb2d0b085808d6005dc6a197d561f1", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "72ff80ce-ae07-40c0-8896-b8c063b20f5f": {"doc_hash": "b5b06f6aebc1c89d96c1932dea798180509f99523618a25eb5e7926f6132afb0", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "5474aedc-0457-47a5-990c-bd60bb487112": {"doc_hash": "5ec9762bc9136b811c70734b45048d70cc9a880d1ee80cf1a3d273244a08c5b8", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "7f0be01d-2d2d-407b-a656-2be407aecffc": {"doc_hash": "6c6688dfaf2a421e286a799f27dd8619217b173d9a5702e20cfcb651614c2499", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "69973add-edff-4cae-ad3e-f9502b321be4": {"doc_hash": "a9c86122a6a690662de58419b801359112c897e7d490708dec290b8cb54785f3", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "44efc2e8-0685-4c5c-ac8e-04a09f43d776": {"doc_hash": "8d3fa6c78e2179e2facbee9b55d7dc0b61961b34c114ac441640953229e30eca", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79": {"doc_hash": "7c85465062e7bab4fe1271e0ec7c42f2d50922546856f1fccbffb07d039c3f88", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "cc73d6fe-890a-418b-9fcf-58b2b2df7966": {"doc_hash": "d80afb9df18dc491975f3b9b384f542c32fce01e0662e491ab83dc2d9a511880", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1": {"doc_hash": "0201cbfc46569ae3f1b9494ff42d6f8b3711bbe346a91a1c346b98248445f4ff", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "0f2e7298-ef4e-4787-a49b-960a83aad4c2": {"doc_hash": "3156f24d68b4ebe4403752ed241dce717fd9b9ec9661d8c341afa4002047db73", "ref_doc_id": "928ac21e-a4c4-41bf-83c4-53fac0b0cad9"}, "cd27e1b2-a175-4b92-9507-f50aa05a11b7": {"doc_hash": "b482e5f0c740e814daac802e6650f70546c9ad47e88da78c666b63ca158e8a58", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d": {"doc_hash": "432bdf6f0c0a6ccdf2f56e2f85765941ab13d63d8e6e2b5c6fe1ec97ff473ac9", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "191ad042-b7f6-4474-aab2-348abf26c95b": {"doc_hash": "612e43b2d63b993ffd9fd1a5f5a6ecda7f17a05af43dc8961f4ac9ef34f2ba9a", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "3eda61b2-90e0-41ac-8b78-6a900ce667f1": {"doc_hash": "28ae187ddccc7a606c665e5d370b212695dfd0600181b495cda757fc52c46921", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "a9b9a455-49cb-40ba-91b6-64e17a878652": {"doc_hash": "4a41306adf0ca06b9057a054ec86f57df259edd6ddc319bdd760c32a087db277", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8": {"doc_hash": "c6e77f487213e228cd6e930f22bc423678f9b8c164d4d68a9852044205ee4623", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "b5b1e038-1225-4eae-aa38-8dc359ee383b": {"doc_hash": "700d3896989a8f894c470d446d38132b5c577f93bb8220dfe0e251138e2ce3c6", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef": {"doc_hash": "ab89c71249394fac655d79cfeb68e7d6406386b8ff2e68b624040f4075d40c22", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "9868df5a-4c67-4f54-add9-7e331b00bd4d": {"doc_hash": "3df53f1a914a6b9319c1a51aaf68a5d6ba23acfe3481275fe108a5c215d32d85", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "7f4535f1-9074-493d-a085-815af228221c": {"doc_hash": "38742b041411087e13543ef134c645fe815be4c7f8efcaa6d34b0f8ac71ee881", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "efdc524c-f379-43d3-8fd7-901a2968bbb8": {"doc_hash": "d282e3299c8852d4bb53c3f18c2123bc7d5422d0aa86a51298b0ef1d36bb5448", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "21152ddd-2907-4258-a910-5f7f0c457ff5": {"doc_hash": "4798c159bcd3fdb1f0739a46a124b6a3ada6dcb26dd05cfe40aa66529a4eeb0f", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "b701b318-a11f-4bb6-8ec6-79ae3cacf540": {"doc_hash": "7cb0fe1bd9190704d55a2b215303e7ec40b646202e237613e052c22833ef1e27", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b": {"doc_hash": "b82e80caae3f7f4f4af477735f8b53ed514825a8c8b2cd2a8a751b8ffda8efc3", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "b03cd378-2db7-470e-b8fe-cc52724b936d": {"doc_hash": "cc8b1164e6de5f7a2b18e63604d2dcccea4548a44d96ec00dfd3c421d67df2b4", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "10725406-27a0-434b-aced-458059020722": {"doc_hash": "39e6c332e544d5f4de98f04adb0ded6486944b54ee1cb0cfe89cc2bbbe335c68", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "53120c3d-b6c1-46d4-a75a-e27a8c818fa3": {"doc_hash": "14b88d131d8e030c81fa8da365868455700f3bb126b9b6469e2b644c517f4e91", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c": {"doc_hash": "fada2a84cb7f7e2a267518f1f365428f55326bf5768ec398452093ced5ff3c17", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "979472f9-21c0-434f-b8e7-ca53f5eb2173": {"doc_hash": "1e28da446279d1d83a29f52462e52d83be6b8893e5313b254c5e0683a2ea49b8", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "787bebfc-26c5-44a8-b6c6-12033a3a9003": {"doc_hash": "77c7cdb954a092c3d35a83a1a16d7aec2b5574d9b88981d49bdbf617f513339b", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "bb64bed6-c105-4fe0-ba2f-ff7d7898978b": {"doc_hash": "5a575c557f6d3bd654ebf482e0f36a71e084b9e9ef63bac587e5419562db33e5", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "279e595c-0382-4c62-b08d-5e98db8b7e27": {"doc_hash": "4c27e34d46ad7fc4ac6c5ab53c9db6255dd2b3ac425d1905192956635b3af3f6", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "90aa93d1-5416-427f-b987-3e917d42346e": {"doc_hash": "1e0ab0ec3c2d45006a66f62b87d460c3af6511dfae7eb589aa26ec6b8e6404fc", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "0b6fb4f3-355d-42be-b9fa-955f9357b46f": {"doc_hash": "09b3ede2b6cd1a5e24b774b06dd8571011544c2aa7b46cbc70d1f760a4f1caa9", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "a6199399-174b-4667-b2a5-68fa856b16cc": {"doc_hash": "21e916b698ca1c963561fc29be69063b1c8f96a26b84ccbae701e5d543a695ae", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "98ea4131-fc07-4bc7-a197-e82a225850ef": {"doc_hash": "8c9a90aba13b601f93e529f5db105f098804433d3916d644d7f53bb99b3130c5", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d": {"doc_hash": "e4237164cdd4af597b4e28af65b05931d7358e025cf94c3c2c187eed106ecd9c", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "773e6222-2f4e-492d-adc5-542cd1c3547e": {"doc_hash": "1577f097030d16a889b7b9dcfbda02b2117ad662c3d7f2b0c3e0c8a2133aba03", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "9809b361-864e-4f7c-adf5-a967e2d7f42c": {"doc_hash": "23d0e44bf4337ab0bd205d829dc008563ca81fec5fa56930797752a8bac776a8", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "64a2f41f-b80c-4dca-8a03-874ecbdd2f73": {"doc_hash": "2ef13e392c2e958bb68663c6e2b6bbc506166440316cf1d722f307046c7c91c6", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "5fb6958f-8ebe-475f-976e-de7763b393a8": {"doc_hash": "4295e4ea89327d17320867383e16bfb6b063813e325c194c802dc8c62a10e173", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "b447c33b-6fd7-4585-86a7-3815397d358c": {"doc_hash": "bd3933e70e34c1642e2e1d1dceae0d1ef630e86979f64a88ea6208502a9a649c", "ref_doc_id": "b59b0f62-221c-4bbb-a914-c70e8c961380"}, "bc478d1b-3aee-407f-9b34-bb178aae215f": {"doc_hash": "34aed1e5464edaadb0ecbf3da417e602184155fc93c340590f19ab712218475d", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "933bf691-d8f1-436d-81a4-35f8210be68d": {"doc_hash": "8d1d132abd40495bdb1ccbeab9b59c6036b76f5204ce44497d3a6cbbba64c73f", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "8f129711-a0c7-4e9c-8cbb-245f9e740cb5": {"doc_hash": "0626bcaf0794dc07ae0ac069f69f0212a4ac575df064e9985513e31ddb704900", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "64d6f559-c48a-4083-a9a6-4a17a0dc74b4": {"doc_hash": "b9bfd25e8016f5dc7babe4d33ec80a95f71b6d1f2045b7a786639b9856edbda7", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "0b5c0825-6751-4e13-a015-875a0409071e": {"doc_hash": "a0f4f8f91b2fca6c1a1588d3836cce3a8659c1aac4ebf82483e9a2c69a3903fb", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "dc3fed86-0ed5-4f17-ad60-8196b8d54b65": {"doc_hash": "44925d5520141f938666281f4422af5edee7e8c56cb95a2f469c0c0c29a90cd7", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "f4a66be9-066b-44af-a479-06c4c12ca78c": {"doc_hash": "7c4d1538c010da1722ff787469526c7e2c1c6e06c949ec3496b7e56c4ab2c213", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "0cc81a8f-3e72-4750-9e66-afdbcc86130f": {"doc_hash": "895b3cfd9b3e307d47053a9a0cf6d219cab40f9daf55e2eeda23ff7af24861bf", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "ab5b7e2d-a8e8-489d-b77e-6f391b438607": {"doc_hash": "fbb2dd2b9e5fa75ddc68fd5e1f73dd723fc9f418140b32ed6c5d288d4bc2e82f", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a": {"doc_hash": "1cbcfc0bdbef73c46aa75b6c05a801844bbf87d7324097550d6bce2742dddcb6", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "f6983815-d7eb-4ef7-8924-4cc803761c9d": {"doc_hash": "8667a004ddcd7e0d9743a200368c6400966e6b0e93ab267ae38dc9e7e99efc0e", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "caee653d-b60b-4ed5-892e-71d6b7f4947c": {"doc_hash": "08804d7da7baab692d040e3a5561f1af2c15cce17b6db8c15149491ac7236af2", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "5f24e1d8-03ab-46c2-85d3-c4110d708495": {"doc_hash": "0dd6edc06ffc3bce5d20e88a724f82be5693b6fdbe4550d7858966462ec392c9", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "deca4694-c872-45a2-9f6d-dc69e276925f": {"doc_hash": "a83d6166bd0bac70665f801e3a20e3c88a5100ba7bd31c8e3fb38c5de1859d3f", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41": {"doc_hash": "2271af114d7648043d4bc8b8ecab3549fd3f075c94555326c12e7cec1f6dda0c", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "f18e1e37-7eb9-4a56-80c5-2dec765e8735": {"doc_hash": "1d177cbcf0c1f08ad282c08f973e9244d4a6f3284d70443b0ea7fe2ea1291be2", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "a36b792d-be97-4121-8648-e28b104a77dd": {"doc_hash": "0512514d0ae08f7dd4ddef0bc36bf279c9cf38672494a3413889839a3dcb0dae", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "378e410b-a86b-43f6-85c5-d4bd15c1bf3d": {"doc_hash": "02ea9791389c48446c1d95d2112cc91a66f1168dd82994635ed254bcd9d12d76", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "e12a7cfd-282b-4014-ad46-44a81bc1f6f1": {"doc_hash": "23899d13e9a1b20d9f0ae761ba768988cba85b97b622c4c97082c6d41b4cca98", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "432653f7-2817-4c99-8f7c-be47f3daf8d8": {"doc_hash": "605325366ecd5edae7d9f9f140c9ddf29cd30b6df38c3725b1793407b128e386", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "70861cc4-88cf-47b0-9023-81dba098f026": {"doc_hash": "25ef15f81362c19b630f2a3955bc91bed70cae728b27a879c9dfde2c57066254", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f": {"doc_hash": "2067f6298f1833f65f41d8254d239197308a7f1ecb05dd6028a4e075a52c1854", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "39da514b-4f5c-4ba7-9121-02c1513b7c81": {"doc_hash": "59150bcd0543ad1bec98ea8c5e72d35b063052a6c4251f9d8a3e1b66f02303f3", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "8cda37ce-055b-4ebc-b1af-e7f30c902951": {"doc_hash": "7a96bf2bab7379fb2f55603d60a3c596ca037784ec935f63f8c3db29b570016c", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3": {"doc_hash": "d3792b718ac05a127a9f5c14cc54b2364bf4bca242571356cc9e64f3e184b87a", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "eb3c2e08-b2fd-49c7-9062-9d6ae7345339": {"doc_hash": "de4719d8dc0739af943e7c47f2a5ccdb65739044a4478b36d660a60a5777630c", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "d8f4f225-d8df-467f-99ea-1f573ba67813": {"doc_hash": "d2e1529760c7fec46b44b51ea9b4b40b83b943a62d3cf7df01f1f581d4bfcddc", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "c987e741-6c2f-4f40-b1e7-034c0515dd14": {"doc_hash": "269b81ae6cf58227b6401db73f673b78ba7fead6c4fba10a63c06e0899128b8e", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "11242396-e904-4d80-9c67-657dfe4fa4f9": {"doc_hash": "2dd951a1e0b544e468d253dbc8b78e8a0c60c0e516c5161d9f1df5dc045a99e6", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "56f6870d-6956-4140-be0f-bfe4ad558a3e": {"doc_hash": "85132795501ecc0f17211feb2333e23b85b37db5c7b4644c4b895ed10144a441", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "e34d7623-e1c4-4525-bbdb-920d0e26567b": {"doc_hash": "a12b8d6bdff78b092894b1f25fc19051fc738a2f5385376ca4e9d87498112433", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "91f0d85a-1f3f-44c7-9663-3a53de628987": {"doc_hash": "d13971f166c0c1866135a0bfc9daa26710de668de08f089574f355bdec10a27a", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "b6bc943c-8d7d-42a6-9c36-99bf27115c27": {"doc_hash": "0ecb54dd84b82f0e9afb1bd0ec74832152ec464afb344d1afacf8b4e4def8a83", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "caff9b0d-66c5-45c3-a22f-055e7745f699": {"doc_hash": "7b20586656c48be12b2936879931075e3901a3c6f3c09fc1e434908e4a7dc8b5", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "d76dd05d-a113-4482-93dc-d29d431aaa00": {"doc_hash": "99a0d062585aadc0dace7e1669a247368e3f4bbc98b0d138f910ac90aab94bb9", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "e6139231-1e63-4d26-afdd-c9225fca96b8": {"doc_hash": "3bb9f5997f1222f1ab275c0fdeefbdd69cd00d4f3e5dbb9b296031412057bc99", "ref_doc_id": "e7751ed6-3d9e-4496-95cd-7ec66037e549"}, "0d46d928-0be0-460f-8fd8-3377508ca906": {"doc_hash": "5cc010ae2e7195bc6438926f3222e70c2d11fedec7c7aab4cfb7a9405b13dd55", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "ea4d9b24-f66e-40d6-9243-e5cb52b555a3": {"doc_hash": "936ff834950f35eb6a054d44f136d2b5a32d7e5d8b9d372626c62a4220a42b15", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0": {"doc_hash": "0911b6c322c5e09c9c6ae1f30cd4a8550f44261966baaa34da43cbf149a4b849", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "074f3e11-0102-4891-829a-e7b37cbe5ce9": {"doc_hash": "24c257fc7a7283d5534470c707bedf0ec22acda5384474cc676e34a914fa09c6", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "2c31f23d-094b-4365-8687-f95bdff9fab7": {"doc_hash": "7962eb018a2f99b835c9d21dd7f854cd05030c310154f915e2f0d25440099f77", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "690e948e-bb47-44f3-a629-456d9f63c256": {"doc_hash": "24c4abd3c0d2d7b881e03e44f143467ab8715f772f580bd2e0062aa636691cba", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "5e507426-2081-4485-ba8e-508754499e3b": {"doc_hash": "60556739363699b9ae858890be9d5a41f3e040a18e27f0edd9c9d08fb55c89fe", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "651c7e54-3c83-4251-95d7-4e1ac7aa3569": {"doc_hash": "17fe54a0229680a4812f7ee839ce34e33fa4254fd56799197ca2194dbecdabec", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "396104b3-5344-42ee-9df1-20398637dc71": {"doc_hash": "e92e6a5541726ea047f27023d3aa7c395b83e5814dbab820fe53b66728d048e9", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "5e9c3fba-df23-42de-8b24-86f1347bd783": {"doc_hash": "ac66947dc22688d5dcb6ccaf9e8c19b81c0e5e842dcb8dbe87ac2e6263d4c3f0", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "c4b3357b-ad75-4122-ba31-a14d674d92d8": {"doc_hash": "b85f5520532a7f3164cea148502071b20189887f81a177fb1e8ba980f6ad93a2", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "13531f0c-456f-45aa-b3d5-17743bfe45f4": {"doc_hash": "a2db755b48a59f0ce649e6289ac4e5f9494195b563401acabd74374d77daf0ac", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "c7bb97df-6c5f-406d-be32-be85dc3c3657": {"doc_hash": "bd8350c163be6965968d1d300634e71b8e31b7838a21202a016b4f0edad5df78", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "2df5f233-4b9e-47a3-a89a-d00ef487de3f": {"doc_hash": "4c507fd7408dfe79d50f8c5c5cae6bf9c7dbc8bd450b9ff40f5530cdfdaac69e", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "a7363960-3c10-40ae-ad8b-162dab04e454": {"doc_hash": "a6f24183d5352e3b8c4d95672d76f29e647ead12900134bdfc434b86b52d9d0c", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770": {"doc_hash": "7c4a5a0e8dea6c982ce60098321af1b8dc0a1eb7b8d816f75cf0025c51273552", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "d79a32c9-995b-4f9b-a317-bd131b8100bd": {"doc_hash": "5abbb7b7cb4a3075e7ecb7ffd6657d60e1d443c1c8f5d2a6ddcffaf1de93908f", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "b5d5b238-be11-4af2-b2d7-6b80628cc93f": {"doc_hash": "fd502742ae8ca3cfa50da3631a7e2de278e6530e55a503bf111d39e4120572c1", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "5715d32f-3c45-40bf-b72e-6ff87764507a": {"doc_hash": "492a6fd3d7f306eb52d01419b9685042f0b96b181674d0332d6717505330029f", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "0a144e3b-4659-40bb-a376-554cc75f80a6": {"doc_hash": "4624cc6c94f996acf2462e164f814920dfb215aa14198c2d85b333679d698ac0", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "352a145a-0f22-49c6-b648-45c931a34d9e": {"doc_hash": "2aada2e102da94631f1d65a0b0b0b56246917c20110b71995c91fc7c41eaa35e", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b": {"doc_hash": "3b1285805079d3509782fbd0b20f9c305c354d5e039817e4f7455e400d8dc746", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "202c0eeb-eeb1-40db-b260-beb398bdebe5": {"doc_hash": "60dfc94fe64f3779cc051a9105de0d024a5c80e76175c7c0e91a44560a325673", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "031654a7-3512-4891-aa46-e7c16a7bae0e": {"doc_hash": "a59e897811213400444268d4c4b3cd0bf460dfb0020058f3e673a2057fcf4061", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd": {"doc_hash": "8e0f46f61d40b6824bfd7bb29858a833ad00dfd8a2e05efcd77693b7a2e0a6aa", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "4524d09d-07d7-4936-a583-6e8580da09d4": {"doc_hash": "2633bcd1e8af36d835036f186bd467e9369cbb1848b49925b6763148d75d2798", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "fd909664-f408-4af9-8c3c-28ed0be5aebc": {"doc_hash": "79e2d2d3bdeb987e97ff03741ed7fa02ddbad876be24df6258733c24d8189cc1", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "aebbd7b4-8d40-407b-a321-549e0aeedbf1": {"doc_hash": "26e9064320d054f556f09e5d47d25f02208ebd49637691c92734da8639920e83", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "e4e92288-08f6-4769-8668-6fad21635345": {"doc_hash": "0b6a9119349f6339348ecb678db8703adbbb95a9293ca216cb18d32e54cb2e92", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf": {"doc_hash": "915d5edb24e322f1fdc054257fe06121790faa0f18b8c61b9e72263b6420859f", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "a8c9e2c3-5352-4a32-84fc-c1a41266a92e": {"doc_hash": "36bc6d1b05711836557a7a3cd2249198716f6eb55d129bad004d43f3ef9a5c28", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "68090e30-95b8-4342-9d0d-7ba1e0a9694c": {"doc_hash": "d2d1c72327ea74f0e50579b1f428dc2925c961c482b20d7b223503c2e0edf7a0", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "2c353a62-8fe1-47e7-9bd9-28a5b6156d58": {"doc_hash": "327bb08c6db2e5812f8e2c1beffbf208fc36b92ebbe09e7596a5fba34e91738b", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "d6e7b57a-92a0-4736-8d9a-9013326eced2": {"doc_hash": "dcac4d83bc0059f6b167858ccb1464dc2780b1bf4f609fcc0a89b0969d725c22", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "d562aec2-9f68-4615-8d9b-b2c8d306557c": {"doc_hash": "7eb0686e480996634b440bd2ab24860cbebcdcdfdb154e1442dc7649a8dea700", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "b333193a-a600-4089-9de2-3d9b60465eeb": {"doc_hash": "46b6e0d7702a68e931244475d92bf800a602ec64d6ee7997745fe71c2e170467", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "581c4d6a-f07e-4ddb-a182-39064020dfbe": {"doc_hash": "0c331a9eed84059f3ab069dd6a4fe54b190affe610673c1fe8b32ff91f404c7b", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "c177a533-546a-478d-ab95-9242b07c432f": {"doc_hash": "58797f4df88fa6fe6eff2c3080adfc9c32cee9474d633430e178b295b9f396b1", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "74ec2b62-01f0-4c93-be94-b0325099ab06": {"doc_hash": "d7f7bad07e287de67926ef94522f90b69f8edb79849b0a6d6beb058bdd82563f", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "431294c7-e3c4-45de-a202-935eb51e8d84": {"doc_hash": "6060f9de2dee803f419353435084dcb0879ec8a2e2eddadbe3f16a37244b5fe9", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "80078a43-26b1-4b14-92b8-beac9a939a00": {"doc_hash": "9189886adf191bd8e8cf46fe57e2e0e7966f12d72a63c7b7a599b80ff3d481c6", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "81180d20-2098-483d-8b1f-134518721fa0": {"doc_hash": "eac44091c42fe09a34f16f14964d995b446442f33b7b433910080af3fe18e57c", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "cd57ab92-9823-410e-be7e-8624a00e40b7": {"doc_hash": "37fce105b7eed95b9617cbf9c15fe2909af537d006f6e5aba6b2d4decc4ae63b", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "97bbe544-5f4e-4f8c-9211-22efb42b534d": {"doc_hash": "702654e8278023ccb843f4f4cfa8e1fbf3e61881b802b43b964ec78c3be236a9", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "774a24cf-0763-4768-b8f0-e7eb0d143235": {"doc_hash": "0043afee1c12ce64c45452f10051a52a7ffd553d50644abc071d05bbc9ea80e4", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "8d151cf8-c4b9-4905-afc5-9f0d33361c89": {"doc_hash": "f1b77b061e60e8dd2700ebbd1707bdcaecbf08c3332ee56e3f63101919912e5a", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "7f5d30b1-eb8f-4c06-970d-a29f359f2f07": {"doc_hash": "4ac428ba771fb09ca0cb0df00c85cf37d579875b092609ded3faae681b777f54", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e": {"doc_hash": "2b879d57cb4c28e9ad7e5bd9a706c02aa839ded7d230d8f95ea166f27020a10f", "ref_doc_id": "67e0f37a-de3e-445a-bb77-14f4f9f3e338"}, "a7ac7550-187f-40ab-8769-de5cd5d120ea": {"doc_hash": "801fdbc17c8e576e21d1e5bed3126fa7f325917fbdef67e5b5bb7a0210529174", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "e77830a5-3ebb-4f68-80d2-2ab1684c87bd": {"doc_hash": "6207532f2afaadc3987ab481e774d66eac9fe722cdf1f7b41afe7dcefc556abd", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "b0ab3463-0b50-48e2-89da-819861606980": {"doc_hash": "b4ccce7a231945d0c10351f0032d80546de729e156f3ec3ba95cad70fcc45896", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "cbd76b7d-b0de-488b-8986-206dd30850b7": {"doc_hash": "98f0ed2fdda5a3b33bbfa89ff6767edfccf2cb980fce5cf01b0ead798842b222", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "397022e6-2f4a-463f-a2ff-ee2e71f7814a": {"doc_hash": "423a72902f9fd7a51f304d3630b1e2830a8d2274fe138f47d8708ecefdbcab60", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "73e01ddb-eabc-4061-9f6b-15a91c3638fa": {"doc_hash": "7022864f64c446d746f4152893cf1db40b88554f682cca7451993504b3b0ea05", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "f5f007da-ecd6-4f3e-869d-1ec40efbc079": {"doc_hash": "246a2923c9341c9b9bac7607861da1d366fef31e215bd19aa01f4846d532ca76", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "9e5e18fe-711a-4510-9610-92404d17e35a": {"doc_hash": "c81170bdee92fa248b039bdd3747fe76f629f0bbdb26ac1fdb1a2f50af83aefd", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "42b347b1-1ba6-4dae-84f1-41dc8f2e7586": {"doc_hash": "39923fd3a051f6a5aeef1151091776d01ded1f68ba1fed90125beceecae19866", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c": {"doc_hash": "771ed9b9bd5b88d2c1b4e3e3277021b3f73cb6460ccf404926c662d0daee4174", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "0f44a8c3-e203-419d-b5ac-96e30631b588": {"doc_hash": "efa257177d07d2556cee13c9e264ca375e6e654c229640bdeab68d14baaa07b9", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f": {"doc_hash": "a19ba987ac341a24713dbd16522c01f1e2e56119239f5553ce065422c557a4c4", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "3c3d391f-f477-48c3-96aa-dafe3afc16d6": {"doc_hash": "d6e5800540d1f95ae478cee77d90b231f192d37b5862417c1c4389ff22bd8169", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "904e4ce2-6432-486d-befe-b7b6b62d480c": {"doc_hash": "885810ab580931637a6e5a1485c83a8add3a2f17708b166fb1af58f5f128eaf2", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "a10c5cf2-8e3b-41c0-bd94-ec32848405bf": {"doc_hash": "4c3715131ca49efffd77140f0aa8f35d4cc29644126545f466a2b2398ed0d5ea", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "93477de0-f52b-476e-ad56-f4a0d3128733": {"doc_hash": "af1a3f8e0ee2622bc1df8e51103b247349a7b14643d0056ef1510f62be700920", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "19939327-62ec-4803-a6a0-0c63c494852e": {"doc_hash": "bbfd67e4a95cff24a829f0f6d4bb1c9d91449694ca1397dedcd48482e4411d64", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "1708e71f-8728-4abc-a1d6-216e12a3edc8": {"doc_hash": "968b2a57440c436fa44a18357eacfbb83874e1f861758e6365c1557150bd300c", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "e28276a0-3d24-4fa9-a486-8ae96ef69763": {"doc_hash": "41880678bb3fff14a13a65161efb67df23c8e1db367ceaa70ffc986d499f81b4", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "c9279bf2-d9e6-4cad-8af4-3618249b8b82": {"doc_hash": "f4f3e093aef8146d0746bd21ed167c36eb8ebfadf1d74beea567037a8339c012", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "6e3221fb-1b7f-43ad-8a26-49378fc66b33": {"doc_hash": "96cdefc1af3a799c85c303f8640e1442def8b95582cc278e269a76d9c1979c4a", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "99056860-1a3b-4a11-8345-49aefa77cdeb": {"doc_hash": "4866c66d6cb8212288654b7e37887f96e9999c9aacbe22f56d65f429166bb83a", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "c2ec3475-8afe-4878-ab0b-67affdb1048d": {"doc_hash": "6dfb4a595ba0bf4cd5e008ab76aa7836207207ac3d85d29581d2b41ca603e5d3", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "32480dbd-b40d-48ae-b07a-127dfd10cf57": {"doc_hash": "47ffd6f6d0022120ef970c29b1cd8c2be180664449cb263803ad9de2a560b129", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "75eed641-28e3-498a-bf6d-148e83959d1f": {"doc_hash": "a690bb8c197a189bf4e40f842288bf9649b37c2219465e38ea0a07e1ad583521", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "04681c60-750f-48a7-bc4c-bd34938ce88f": {"doc_hash": "297daff4a1c5271b629152c1ff924dc8d540af7bb8ada3726d306f94c03146ba", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "ddf6aa5c-0941-4971-9aa1-2028d5c75443": {"doc_hash": "d3a5b15c7ca487de278373ca906836d6691b526db957c732d4e62f52f36e7654", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "209521b5-aedd-4cdc-a4e1-9efe9abd7b81": {"doc_hash": "9dc40147152e2ca0651450707adc8a72762a6465cc10cf6471907852868717cb", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4": {"doc_hash": "edd244c337d259869c2ea6dd9e4ab6e79d7bb70f3fb6c99b8b38dc26c0cc33a8", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "91f60cc5-bab8-4dcd-979a-dc7603cdc937": {"doc_hash": "a05ba504761bdce739c6ee27985fa18fc2bc362b7d99caa07f7e023cb71180ed", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "81a46807-6a44-4a86-80cc-82a71207ab86": {"doc_hash": "4672aa98b0b12d358175337049a25c4cec6bceef7d89f69fa8fb60f3b52cb199", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "11790c17-1ebc-40b2-9958-f3d82d391deb": {"doc_hash": "081d13ffca2bf679bab71bab857cd209814ab603f8f3159b4cf8c195bb54ae8a", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "8d6e6902-dc76-4a84-a04e-764d1d3eb09d": {"doc_hash": "287a94feb36c244ad59dbccb5f81b804a737fe00448beabec79464b3403d87d5", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4": {"doc_hash": "70af349c503c1107d563f0f60bf6eeb1ff9f197b26c4ade2596df55a4e903f19", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "9ccfbd03-8217-4349-9080-dec979c4996b": {"doc_hash": "d37d962a1a421854a7794974485cf914d5ef6607723fb94d564609806b112d69", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "bea3295d-43b1-464d-ab6d-516f3194b96d": {"doc_hash": "fd98fed0162313cc841b7bef227bd323a4497245dca186d5bcbee2c551ac1925", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3": {"doc_hash": "a018e2cb81b4535d448c3386a1020018ab1d12a8022d223954b8e317c9154725", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "99dd90b0-9671-4399-99ee-ec236f52122b": {"doc_hash": "1553aa96dcf32e667c089ff447df752ea915270eacd22e1e31fdfb3347779a39", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "73bf4cf6-1ce3-44d8-9525-b52910ab0433": {"doc_hash": "b6b637a517a51ed3461d684918bff7be67aa1108c6c534b194daaf9c4c972669", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "77089489-ac61-4d86-b086-97973cced48b": {"doc_hash": "7a6e3688b951e8f75baf9b4ba7d7f059187a5f5b447c84d919f9b3f6633eedcc", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9": {"doc_hash": "4dd67970305dc8c7e2b9ce2f93c5cf8edf2750c23a692676317f706421f9afb8", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "e3695140-2646-44e9-9629-2eeb138d680c": {"doc_hash": "e4344214cc790d4c847d37c0dc927060c96f187184f3a1dbf48065e9128711e3", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "56433d6c-f851-4205-8885-be8b300cbe8d": {"doc_hash": "287a952598d9c6ddfecbb5a7529464b63b1e94e40021d67f1f735ce3ea9324cf", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "91a0a40f-a4f5-4ad6-9353-140efc21c877": {"doc_hash": "9f813c74febf02a9471080911720a1844f2337ba6bcc6d35c99e47ec26e7877c", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "17486a67-e343-4fe6-9658-2901a6e68bb0": {"doc_hash": "06ff8f92a4bed38ebd4f3d21f9fc8b3db82027b45ea3838607dcc7f832151f28", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc": {"doc_hash": "9bc0ee84daabbabebd2a949a510760483a1847cc102c3608174d757825c478c7", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1": {"doc_hash": "6667e8bf2fc9a885d863f7d65a6627842bd6806af091a2ad1ab0cae81dca0edf", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "113badde-7340-4a99-974a-0f04fc6aedec": {"doc_hash": "ac00ecdd497e1021c750482657b6cc99fc3d0bf750dedb82a6c0a9efb5c5c115", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "5a28dc81-32c2-4084-8427-3f46528fb623": {"doc_hash": "24adc979e9d6baf91ff2c4ebf1ebb829ee61d8766c700870bec06b9a0ebdaa35", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "66874581-eb42-4e1b-ade7-bba8478d8095": {"doc_hash": "c444b03fbdd260977c32423c9d73353d7d9198d4efa621736d1d59e9442a967d", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "7d880a5c-9e1c-4381-8f10-ac551905375a": {"doc_hash": "90105b412c7a3e6d630e5316233f8b60af5a6e2dc6e8aabe38c8f33738c1293e", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "adc7438b-9ddf-431e-b16a-c229d8802fa0": {"doc_hash": "73b587bdc8d39441f451129e57deb9b4e100a6fd07259a52412be19e5ca4cee4", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "f70de659-895f-4f23-a202-0f6de42891ce": {"doc_hash": "54fef09c6cf2433a71d312f4fcb6a748f76b749d8a6096da2947beedc39a0956", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f": {"doc_hash": "f7d7c202e2f5f0446a939c36a3cf1b14943c3c903c471fa0b141384a5ccfc59d", "ref_doc_id": "2718f319-ebcd-4a04-81f5-8753264a92fc"}, "b7dbc76f-3f1c-4300-ba91-60a153e8e3e2": {"doc_hash": "f0ba4a01b562b453afe6f89a8963a5932bbb12e06feaa3fd8dc1f831f485e7be", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "2db61508-99bd-4416-b03e-ab20e30d0839": {"doc_hash": "989476071dbffc9c81bc59010ebf7e2341de137a132d2ca63ad168d751dd0f9b", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "30124779-9ce8-4531-bdf7-eda40765208f": {"doc_hash": "4d75e9969497e8ef60f7a8d10d5541f8ec2dbebd610a5f3e999efbda7f1650a8", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "354f7254-dbe1-40ac-b3de-8fa2e3a3f946": {"doc_hash": "ad0bc0f5dc607a8a9c34aea02255993307e36a3ae61ef18dd44780ec822881c1", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "c77e065c-e67c-4e1f-a595-da6b20d6e25c": {"doc_hash": "e8787a0262f016c9f3617f387f7b0097dad70fb552495a9e5b374cef225f9fc9", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a": {"doc_hash": "417b2f4dc0840f0708989ac4e0497e6987fd4a8a9280315ece711e73f74741df", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "1112aea4-d10d-4025-908a-26a648bcc59b": {"doc_hash": "496a7236c8f9c4ff22b8d2fcd8981cd13e11902e6321d2bf3c92c5f1d819ab8b", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "176676c0-0e81-48fb-bac6-b23267e00634": {"doc_hash": "2ecc93c11ccfee4673e0f001e731bfdcb7991849547a0ceca1eefa1681adbe32", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "2a0ebe08-8b68-40ea-8943-1adb1cf9712b": {"doc_hash": "b5781392213e3ea2c1ef8c444292d57425be733f5231cee5159fcdac8ccc76af", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "1da66dbd-f93f-46c8-b822-f865eeb17190": {"doc_hash": "f261861c49b1ab5a2b68d30acc876ab2939ea84948ab26fa92ffd8b148821cca", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "6b1d88da-590b-4d88-a671-f0115a317e7b": {"doc_hash": "262c5fd52ec2930688b0d5f4e8d2a8e5122cd2bd10acdca68edda034a1b36d4f", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "99da7da1-730e-4acf-9fbd-6353e297bf8d": {"doc_hash": "ff0a00c1c110aca5190bbd8b957ed6dbea420d9797654862706e6031adcecb43", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "b9956172-0b89-40d0-8e3b-4a33823d6b42": {"doc_hash": "81011e4d31b6eae25d41fd883074d8409ad652743addce5c504cb62f59261032", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "80241cda-8046-4b8c-8e03-59f690db0c85": {"doc_hash": "437963dfe31443cca0d619716d2686b3e5063013d9bfd92d41d479f9637047ed", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "ac43f16b-cba7-4981-82e0-ecf6178bccf6": {"doc_hash": "de9b579f813d931ca60d9e0b47faecb8cfd2f212ba1d5693cb42fd992e6c67f2", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "3932b089-6f80-4f9b-bf67-acbb3afc84f6": {"doc_hash": "c44fc2f7ce00e318d53cfddde68b8c7742062b358bcb088dfa5ed19e02cce285", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "60929aa6-f81a-4feb-9935-7f364f2b7c8a": {"doc_hash": "3d139b99916e43bef6e60bc2c8ae066a1ed9ec17fe06063f437e72f8b6fe14b7", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "bedbaaf1-96e0-4daa-ba4b-05f114c512de": {"doc_hash": "1f515cb7d83f9bf8eb2d08928d2bd6de6896a522dd5209f4ad123eb17c8706c7", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "f9f9690e-addb-4a05-8224-47f68758dd4e": {"doc_hash": "023dd0e811b5fb31d3422ff2d69b0fb2d91e410c4b8dfda28024e3c001109f1e", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "74f17383-18af-4f23-9561-63b9e9c8fcaf": {"doc_hash": "86e0afd65145ed6b1d84e808a872f21c4726cce5db8668af973c2acd16eec562", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "d2adfcf9-4c99-400f-a1f7-e35768cd22ff": {"doc_hash": "519591b51b71678466255673d09bcee9b5a050ecf02e083b1da6a16c57a1e218", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "97243f8b-8294-4321-af81-668412c5538b": {"doc_hash": "897b9f890f263ff76185923ea574a4f64b771f2617f4a799978a12c97bc9cfd1", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "90458ae8-c023-4906-9930-106af6ddd9b8": {"doc_hash": "72c7a06103252f19ceb9e95927bc6d2895741a65897a46e790ff294eb8fb7cd4", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "a2f227d6-221e-4ffa-89e4-c434ac9ec29b": {"doc_hash": "04ece70a876ad1b61dbe5e9dad51fc47d740b5a6ebc3f53be298e72d147711d7", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "8d50d9b9-1140-4587-bc76-a36723646e5d": {"doc_hash": "ca3b74d9b21adb7ebe9f17f74f5f523732d46ca10db49e720b30c762e1f9aeae", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d": {"doc_hash": "879bd4765a1dc1c9503a9c88661f166fef09843e478adf324c9c76c4f385573e", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d": {"doc_hash": "1f51f35b5c85d82fc9dfe9e1cf6f68e588c396418b31e99edcd985aa4693797a", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6": {"doc_hash": "62dfd41653e52f44575431394b6d4353766e33a5de4b7886f85bbb6f6fd3bda4", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "707310e8-eb6c-4771-9c3c-3fa1b566a7fd": {"doc_hash": "77b577ef42984027d6b94c6d5e35e716214f46906e54f115b693d2bf935d10a7", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "4e2409fa-b22f-49ec-93d3-a46b0d955e5f": {"doc_hash": "4e1c4bb11845b6c670832cb6fc06853321ed5a78096cfec26e2f018fd12cfa14", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "c46f537e-6939-442a-a57c-0abe0ad822d2": {"doc_hash": "55fd94d488f5eb284999ca41ea675cb5fead197362abaf957c15fd8276c93112", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "690b2419-093d-4f29-bc05-a01b6e9b5346": {"doc_hash": "30d9aec91b78f875df3c820d390f1c122a3e3b04ea955db8e1438ad724a7c933", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "682a0237-2f42-47dc-8a44-f2672cde7fd7": {"doc_hash": "87eab32b19a66d3785e5a390c4ef4af4988a7a0acec4268a1b4b62673da0eea6", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b": {"doc_hash": "c047143c955e7ab931705c31d0cff7fe5765921c6df163bb5918a24a3a5f6326", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "85e891dd-7e29-40fe-961f-d0ab61a1bebf": {"doc_hash": "843bb82806c6919b0a6f7c51d098701c42401b70b256362bd7494ed94cd7072c", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "4cd136b3-ac98-4732-b165-1676cd91bf4c": {"doc_hash": "229ad444e6d8256a5587a999cc524c02fabbff7017aa78425b44bfcc64cf36c3", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "1676ac87-02c9-4839-8a3a-bb6796ccbab1": {"doc_hash": "b6d7a9bfaeb6697b620e4b35fcf7fc18c54562316cdb7612ed53d87a64b8564a", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "cffa5d60-2ba3-475b-8617-6fdeb1221144": {"doc_hash": "51ed9e2d744adfc9a847732ca67da7a856b137a9292b010144e785fbaa65bf8e", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "fe54c565-ae8f-4646-bc4f-16b808ee1509": {"doc_hash": "fdac17ce0bd8c859ea244144f1d1b668eb6eb6e109c5769f3976bb8685ba10f9", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "65f0bca8-3ef9-414c-8301-5df968d976dd": {"doc_hash": "1050e5976db95dbec6a13700a85ad526ed79e6b38e800f728956325dac47e3ee", "ref_doc_id": "86bd87c2-d49a-49e1-92ca-b8ccf25e2952"}, "d0c8a836-e87f-4a34-82a4-eee1918bef42": {"doc_hash": "31b805e1ab102c5d4fd63e38abd8f0b546a591d4ae492b6e0e211b5b70209f44", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "de123c69-78bf-47c6-bdbe-90a09088a7ec": {"doc_hash": "edf9edb60870155aeb7b0f05bf1f957854c4a38db05a3aaa7e84d9ff6ae595e3", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "48491696-0e59-4fc3-b0f2-3bb172fb89e4": {"doc_hash": "744bbdc35fa9739b8c492962ec63598474e77e66832ac7096dab745503fc629f", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "224658ff-a24f-4083-a359-ac1b39a4a2c0": {"doc_hash": "a6f1f0e9f12a164bb8bda6d885c067236ce092afe9bd633fe3be046dd72ce442", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "cf947523-ad7a-478b-9eff-55f43264786f": {"doc_hash": "ffe7123e6009372a32a255c5764f82980e5476282bf45fcdd386172b0c763979", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "344ddd36-3a22-48e7-aef6-86ad860d91d0": {"doc_hash": "af5860207fddf49e4951555db4da0c29b1270299ddc0bb61e1560f255549285a", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "d051edaa-d12c-4b29-b5f4-8479a4e5d30a": {"doc_hash": "3b374b84245c5435d56d87b52c35cb428d9753a36259247cb5f5346a5d1eebe0", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "a06e42d8-cd8f-4595-a6bb-52b73a31d876": {"doc_hash": "07f003656b70cce17d2db7056be5d194189d90d48f7275155d6ecb76e6efa2c4", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "b2e2d9ce-4817-410d-b498-ccfa960a4eb6": {"doc_hash": "953ca352160594ecb6197a77660285d1208808748d839564ae1633eacc1dcc44", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "623eb302-b0a1-4092-aa41-0b82f4d5067b": {"doc_hash": "614f892d858382281a3873162a3ac33093d02c45e9e09890f572d4a859a95f5c", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "194e81d8-3863-4eb1-828e-f900ef9f33a7": {"doc_hash": "4826fd99a15425b3fa2a756a54efd561af7eb59d23e9d2d503e54c9a6263ae03", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "35504a88-2f74-4416-b87f-a0d1f111dc10": {"doc_hash": "71e5b9bdfdc45aa8897012cd1d8037ced29685c7d7672dc6fd8ea8d9e8f2b11c", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "db71ce6c-5402-4c62-8803-73a68dbadee8": {"doc_hash": "ed268e3aedf2397878667553c2be574e0e229daa69cb9dfdb8e3b4a072d3920d", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1": {"doc_hash": "92d81c0ea4e7c392e7a6bb91cf8cbe347ebaf140e021cbad92d1c558ffefd425", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "7c9726d0-9f51-43ae-ab46-acdb6747ca4c": {"doc_hash": "6235da94807496be3bbd10e5fb261a3a862db94e1bade7568363071ffe4fbfaf", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "1a32c3b7-613c-473e-8a10-2de942b3bc64": {"doc_hash": "a8d57552ce1bb66f2fed64fb0a91204fbc400a4bf494963a533155b0a2cf7eb6", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d": {"doc_hash": "323c316292ec03779ffede57ecf39abe59296e4e8b4869bff81b1328bbad298f", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "e6febd76-10df-4270-8ce5-61dfd05d9ba4": {"doc_hash": "3d528a6369c33f8f14b0fc382f1861b312b2d40f3f08c50f87ed2a73388796fa", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "b914c218-5275-4794-806b-52c43dbf1632": {"doc_hash": "8e21b20ec7f91f7f9fb13914c1d9797d802d13456fef2fd9ce64850c64c91340", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "a7073653-97fe-43aa-bfca-3d056ee939dd": {"doc_hash": "75289ac747744e1672e1d405fc628ede9de39e532fa655ee73f5a8be2f82e891", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "3dd4513c-5672-4f14-803c-e3fea7872e36": {"doc_hash": "55ae89280524b9dda158079ab94d9b457236d70947599bd285d22a1f88b0a0ff", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "c956c3ee-1ab8-42df-9db7-8e09e07e9941": {"doc_hash": "fb117656b5148ffcfe03cc50e4dfa04e5629f5becc6df9f1cc1c5c921fd5ad4f", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "a68eff2a-bd3c-4c58-89b2-0b0ef090218f": {"doc_hash": "127673d9a086e702e52dcc43d0e0466b3a8c0526ee93fb37900efe57438b7e18", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563": {"doc_hash": "00c887e75f42e99e5798f4d9fbfdb3ddb1fb0571942dff67fb87f9ebcc2aefcf", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "20aa7af4-aee7-44a8-aff3-c18698938d22": {"doc_hash": "cb8db3e6defd03c74c492b63a35b260cf549136ad01078752174648375ec068b", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc": {"doc_hash": "a53e0687245b3d0dc66e0ee15d1a62313469d8c609dfc19d55919310b84384ee", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "4cb0ad33-f21d-4d11-a57b-a955cd544fc9": {"doc_hash": "689e586f25f71e38740dc1946fb7870bc8f8986f3dae432e68db92837a943243", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "50b472ab-c98b-461f-9c64-7d461c7bcf7b": {"doc_hash": "569057c75cab4db8c51e9f702a0adfc63e1efbcc63cb60d7dce02739814fb4b2", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "89580ff6-7d77-4236-8b76-26b94fc44bcb": {"doc_hash": "9f43ed0f9e43504f503684da7eb8e4d50d2695fdd0219976fdbeb444d0f8db4b", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "68666d57-b033-48bf-ae1a-3bde602e636c": {"doc_hash": "4c2289563ee6826b4e343a042aaff7dc766234f6e7d69cf9fd463dae398130a2", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83": {"doc_hash": "8d29cd7cf366f6b0cb3454ce75f18dfdd354f69e5c2e9f5f831dcb49d373d7ba", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "f7c94438-88d1-4612-b9c1-aef4a1cbf416": {"doc_hash": "e16623c91fd0a9acaa78b897d432f75afe136a18d9badac3daae6098c816d7b4", "ref_doc_id": "d9f1abd9-ed46-4209-a100-85962b57e625"}, "ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48": {"doc_hash": "e05c89df09c080a04c808b328b3f2260239b79a19262d79ab64817f6e73eb461", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "3a85b429-e537-44b2-86e9-ce221001df87": {"doc_hash": "85b0abc2768b36d087465414c39124292a57b635a2fdb2494985d75fe55b40d7", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4": {"doc_hash": "d1a33a226cb819d44d143bce3589bbadcaca5e189f76c72b0435f9b07006e98e", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "b4a75dee-3d41-4fe6-b073-e767a2f1899d": {"doc_hash": "828e8610d0e8bc94737432d529de0af002590c4166fa89429b1ec513198067b2", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "c1cbaaac-c993-4fb8-81a8-a8b9508d706f": {"doc_hash": "9af9ff08b5a802f4beefa9b209fe9d1bc0ea24cf807add7a81bcfb0359ce920e", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "b15209b5-a242-442f-a89d-54510864a65f": {"doc_hash": "14acf23be24281fb7bbfd25dcfb6acdc652ba5a6633aac54a464fa9f06715cdf", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "8539d0c9-7197-482e-9aea-e0a41480ace0": {"doc_hash": "d654e7e774c8bd5df0a0bb04054a729841c3678b22abb15a6ef177bc0f84ff01", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "4772c5ec-dee2-417e-8561-32fbd75e740f": {"doc_hash": "bdefe0a51a185521e317ae58107c3e84946d919345aaf0b4343329f16b79e5e6", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "68d51fd1-b524-444e-837f-072ff64ef8a8": {"doc_hash": "cad8a90299c6e8d2743bd3765c8e247defc522d0da8927d4f0ae6760437ec8e2", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "cbcc26e6-84f7-41b6-a415-04c9b6129e2e": {"doc_hash": "0ad706518f5939b865c0b85639a42a26b7e3ab41c9886c92281191dc99ebb190", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "744c623d-05d2-4e0e-89ca-5b0042fa09d8": {"doc_hash": "c1cfb8b73fed46cfd56dd8e078180f221d6c00283e14d8fd134d2d873c049606", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "e961f0b5-13d4-4417-b343-762c83a9a8e8": {"doc_hash": "f20031eed55a8afc677668bf5988f027823b495ac1e7ada102131ef3d1dccec4", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4": {"doc_hash": "d3a63023b59c334ea6e09fe1e506233091dd0dfc69114f1e9584e6a5460845e9", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "87c8a345-f07d-4d01-b708-9ee8412aff7c": {"doc_hash": "c98ab25578340c597b9e67188b10990c54fc4aa4fbcc9ee31789fd174e4e85dd", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "6ea91b0c-388b-4780-8608-219e0fa2d417": {"doc_hash": "58f588f92a7c43e34bb299ff9c028a3084c2c024b5372a3ca7438ce040674bbb", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "619bfc41-3a87-49a2-a9b1-1f23770867dc": {"doc_hash": "fff48b1b3839f7e7299c423d1f31ee037db65e626c7c33996a3c2396ae1e5053", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "7030e0eb-d563-43d4-ae24-cdd3ee348361": {"doc_hash": "cefbb09e6379adc592b80bde2958ce2a008e9824bc36342482d403cff3c5b39c", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "84b0b7a9-dd9d-4009-9958-ace73cfa3659": {"doc_hash": "c6d2ace54716f195ee9843be5105f1424a5ab87d8a181cdd078b6134caa2d850", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "811dacea-9fc8-40b7-a89d-d7c93b62472f": {"doc_hash": "98ae7af46038e43a3425f67b61aad66e746927b9e9275a47f1dc009f09233a87", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "2e20a916-deef-4e1c-9728-81fd0561cd43": {"doc_hash": "3b7b2895823f49642c23c9c0daa11f1374e18a30d5640dc9c1468d86790d6fe5", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "ea3280f1-ee14-4e3b-9e3a-a2241293506d": {"doc_hash": "e1605d55a542af23112ea95d961e613069217f41c9cf366ad45e05e9e902cbb1", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "edf7e525-e581-4ffe-a3b7-6a66865f690a": {"doc_hash": "609e2b045b44ce2611658e5fe6b335b34886c9c3a624c977e8e542be89d0f00d", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "0feaa758-97dd-46d6-8145-5ab05833f784": {"doc_hash": "c9b4eb5e574acb1af855261c95234263dc08facc9e167cb0a399d9803c4015ce", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "f1e14c25-bacc-4072-a369-c03399893401": {"doc_hash": "db8549b66c1e3dcd8a5d52b99f873761331cbb0217b12b916d6e65881c380f95", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "39c4117b-2ecf-496b-8bb5-74ea610170ba": {"doc_hash": "59dfc5f1a0226db0c1d4d539e579cafd0b1fbda52fc98d7621a91f547dc3bba4", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "5c88a823-894a-4df3-a2cd-6346ad415a4c": {"doc_hash": "0d3f2b437ff4e4d170f12670f88d5bb3a1928846f2e703ac748995ac3ebc0dd2", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "93d7ba98-5c21-4c17-b4b2-25d836d54f5c": {"doc_hash": "c10c22f4a06088178408f61df9a72f6441ffbea7a2b8db9d55b00c419da36b53", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "afc87f15-d6d0-4587-bfd8-42cc5612ad22": {"doc_hash": "c0fc0a0f7c516b7ba3510a37f01ee08ed32b7c31024021aabbd57df2d549dc6a", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "ab3c5d10-35b5-4632-b70d-7b0911e1709c": {"doc_hash": "56890d65326464114c10fe729639c1a185d675f7304e39783cc52fc4dbd21f15", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "0aaf667a-0c44-4009-ba15-45a9687914fa": {"doc_hash": "49ec6aaf0ebe02bec4f9aa33de33d6096f45128550ab061bf926e6272b62ae0e", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "ea9615d2-c969-4402-8134-5a6cd14040b0": {"doc_hash": "04ce58d3a5f56ae381819c79a905356b212f016c9676df5d247224f4b270b192", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "d371c34e-af46-4582-a2d1-48135a41e0dc": {"doc_hash": "6a1fc293812c77037366bfca9ff0e0dd27f5567cfeea8f54e4b8da327d501fdd", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "154163cb-b262-47c4-8822-eb9195763afd": {"doc_hash": "26e319d1ee2006dbebcbb6cedeed30f016a25a8b81fa64007bcd996a628d9403", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "4960b150-5134-484a-a6a2-6c29a7e61d27": {"doc_hash": "02016d6a3c161131b8b5c84eeac716c6e9ce3755c936771c21df3a199c7c3ac1", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "e089a9a6-509d-40b4-9882-40f3c8f236e5": {"doc_hash": "7a6be00011f6754f324a440f40396e890a22faea62bda4094d78b485b8797f50", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "8535769d-a71c-4177-b70a-d817871d6baa": {"doc_hash": "3e34d2f6cf366e7515ed3bafccd0350df9a396ad5a1921408a96196e5170629e", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "aad46357-8aa4-4800-93de-660e841f6bc8": {"doc_hash": "e541e1ddd10a88dfe0280fa01119cf3568df0f12090689261f84efe6f549682c", "ref_doc_id": "495dc4b9-b74e-4643-bd36-ecc193b62fe2"}, "31b0d495-c882-462a-93ec-1f71dc350367": {"doc_hash": "1a61159568ba659666ce8ad988e9155d91f0006661437e9d2ab4ec42289bf664", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2": {"doc_hash": "95b5a6d14870cfc20d3cea274cae0bd1a71055563b6510871e6b6c2e6cdad49f", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "4c219f05-b668-4615-a527-ffb10c8dec07": {"doc_hash": "f7822262e8ed2385b7846f843038319fc7bdd6ea23ce9deba8f5b8ea3e0ffeb9", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "ee5b1af3-c1c7-40ff-93fd-991745d4ec87": {"doc_hash": "7fdc75f591995745cb9191245e78dd78a0c78b6353b7c0807d21bb9e7afb4422", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "f2a1bf48-a802-4f2f-86b0-30942cbf6349": {"doc_hash": "3971245e66b617e4d82dd6b32096cd118c214a3ac9de148f605005ce4032f04c", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "3ebdee50-c897-421f-bd06-5394a739f231": {"doc_hash": "d60602b6d497352510e7e4b47aecfd08793b59f68c634bd4c29062b888cff30d", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "1d8a6093-fe5c-4cd7-a634-49e35d4844f3": {"doc_hash": "fbc02cad8b8bcf967e3d50c09888969142fa86dbc305d47840d3ed9e00bd4b4c", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "169774b1-e835-49f4-a7bb-babb079fbe4d": {"doc_hash": "7115a06bf27f543bf0fde9cb9b6e9905ee65498974bc45ffa21d422fc94734b1", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "0a3aa474-462a-4b21-982b-6ae1313080ca": {"doc_hash": "3c8e7b8041f7bc89e527574fc7985c3b792c37bb255f6e0baa0d05d1df80025b", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "0efd9b54-c1d5-46a7-8f30-db3f08a314f8": {"doc_hash": "c615cf8b1af485733fabab65043297313d28976f3b88c50d1630db48ee257cf8", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f": {"doc_hash": "a543838f155006811b0bc5ca8bf4d48a09825945982016f870ed24cef63dbc87", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "950475a7-08d2-4cef-b008-1906ac898ce1": {"doc_hash": "d6175f1c4a6581f5ab92fe7c1f33c5f6860e3be512b74fb0b1510063db4eb336", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "b783b52d-b39a-4594-86d9-73bceba2c07b": {"doc_hash": "8bc771a46590b155279a4c28ab913f80f86bcaa1d2d4e768229dbf25c072e11b", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "88191f82-0498-4581-91f7-2612b875e66f": {"doc_hash": "26f40f1803db91a415c1568a67ce81a8cd7e5d63179354f656b26371fcc54e26", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "bb136063-9d44-42d2-8060-e653932f19a5": {"doc_hash": "227ad80148c27df3708b29b20f92c031b41b665f0a38df222f9e35b34790b323", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "a182e5b1-5dec-4102-ab79-c246973e9368": {"doc_hash": "273a0f2f87ebeefe9b5e4fbf29f209ee66d8b3a7f69f79deef40b740a19c3619", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "60b2a29d-8b44-434d-8e27-7cbac0d4f62c": {"doc_hash": "fa93cdf8d75667527bbefd09956ea0811f7c2e28cc3e84678a63b6f721cc0184", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "8e597f3d-1904-40bd-bec0-06c95a0b3237": {"doc_hash": "e1d8ab76b05efcce6b47d7dff923cd708b654f9d6818b58e2da5b860074ec2f2", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "c40aba76-1b6a-414e-b03a-d6b4cb62340d": {"doc_hash": "f52e84a4816b20bdb5ef752c8ca43a76abe01f02f2cde367e221c395d7a690bf", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db": {"doc_hash": "99c1e8c2984153b014b139e8c9645dd1b99af4da6f83f028dc3d05bbdbc52d35", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "dbb2db60-3247-4257-a525-17f663e05aa5": {"doc_hash": "47a478ae3c3da123d6821e644a070f11e7c9c34eaf6f7f3c802951be35a8c0f7", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "d9f3a657-0aa9-41da-b448-c22b68fde047": {"doc_hash": "0c88fa711a7e204fd024d17303252496ee95988c916a6a8aeae3280e1868ea4f", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "14179c39-f69e-4ae8-a934-71d2d0ab8a6f": {"doc_hash": "f3a5e1e1d5ce9b7e2b94e8706391f24f15e1ffc70ccfe85d0dab99c0296ff0df", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8": {"doc_hash": "e0ee4668ea24f6664351880d7b82f37ed7ba90de609a68168ca326bd01b81bcf", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "c6ff127a-446f-46fb-b73b-395554d21f0d": {"doc_hash": "6b19ad435e42395d8914fade076282421a13b24be98cbb9aa0600705775a2931", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "4b1dedc4-332f-4610-86af-18674b6feb4b": {"doc_hash": "bba14b37fb0c3117cebbae6f6bd65ee0d2b091b6e0cd3fd68f049fe4bd2b8db5", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}, "bf81ed1b-6050-41bc-86ec-2c2b7fa9fecd": {"doc_hash": "c3c182a9ef5ccc9799d844c46363c2f461def246fb3b78766d72365d15fdda35", "ref_doc_id": "0b473d8a-d395-4e9c-b65f-74e50e0a166f"}}, "docstore/ref_doc_info": {"8c9e8e13-fb2a-4bfc-822b-26af95097774": {"node_ids": ["1d8cc600-46b6-4e9e-9077-7273ab74c0f9", "8a8444f7-a0ed-4fc7-9a08-6a0ebde20474"], "metadata": {"window": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence1\nMcKesson Corporation  NYSE:MCK\nFQ2 2023  Earnings  Call Transcripts\nTuesday, November 1, 2022 8:30  PM GMT\nS&P Global Market Intelligence Estimates\n -FQ2 2023- -FQ3  2023- -FY 2023- -FY 2024-\n CONSENSUS ACTUAL SURPRISE CONSENSUS CONSENSUS CONSENSUS\nEPS Normalized  6.09 6.06\n (0.49  %) 6.22 24.50 NA NA 25.99\nRevenue  (mm) 70094.34 70157.00\n 0.09 71634.36 277091.12 NA NA 285764.61\nCurrency: USD\nConsensus as of  Nov-01-2022 4:35 AM GMT\n  - EPS NORMALIZED  -  \n CONSENSUS ACTUAL SURPRISE\nFQ3 2022 5.42 6.15\n 13.47  %\nFQ4 2022 6.04 5.83\n (3.48 %)\nFQ1 2023 5.30 5.83\n 10.00  %\nFQ2 2023 6.09 6.06\n (0.49 %)", "original_text": " \nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "1", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ffc0b564-2124-4402-a81d-adf214726bb8": {"node_ids": ["baae4b4f-0de7-4a6a-a960-26321b79a458", "2f2b9d66-a604-412c-aeb4-a12ffc1158d6"], "metadata": {"window": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc.  All rights reserved\nspglobal.com/marketintelligence2Table of Contents\n \nCall Participants .................................................................................. 3\nPresentation .................................................................................. 4\nQuestion and Answer .................................................................................. 11", "original_text": "Contents\nCOPYRIGHT \u00a9 2022 S&P  Global Market  Intelligence, a  division of S&P Global  Inc. ", "page_label": "2", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8c248cc7-d698-499f-af53-4d027dfd69d2": {"node_ids": ["d1be5bca-3a7a-4620-8cb8-43b9b5d0323a", "b2f39111-412c-4945-8be0-9c0fd51e04ec", "3816a440-6d24-4ef7-af85-8cd39aa32266"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 3Call Participants\nEXECUTIVES\nBrian S. Tyler\nCEO & Director\nBritt J. Vitalone\nExecutive VP & CFO\nRachel Rodriguez\nANALYSTS\nAlbert J. William Rice\nCr\u00e9dit Suisse AG, Research Division\nBrian Gil Tanquilut\nJefferies LLC, Research Division\nCharles Rhyee\nCowen and Company, LLC, Research\nDivision\nElizabeth Hammell Anderson\nEvercore ISI Institutional Equities,\nResearch Division\nEric R. Percher\nNephron Research LLC\nErin Elizabeth Wilson Wright\nMorgan Stanley, Research Division\nGeorge Robert Hill\nDeutsche Bank AG, Research Division\nKevin Caliendo\nUBS Investment Bank, Research\nDivision\nLisa Christine Gill\nJPMorgan Chase & Co, Research\nDivisionMichael Aaron Cherny\nBofA Securities, Research Division\nSteven James Valiquette\nBarclays Bank PLC, Research Division", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "3", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a90beb30-aaa4-4486-af2f-62db4522e765": {"node_ids": ["b39f8481-da0b-4b5a-9fcf-a7ce743f321a", "af166dfd-e8a9-4296-9851-7d8e79ef15d1", "4bfb3e56-5936-4050-9e09-6abece9f8bca", "d33abce5-8de1-402a-bb56-148d3302f4af", "0b4d6a33-644c-4b0e-a0d3-3e3f0242d0af", "243475d2-de7e-4a57-a970-11d259b5ea08", "f55382f0-cb94-45cc-8d32-f00da51ef2f1", "0af511e0-2f59-4f85-bff1-0db6ba7bd316", "23d1cb41-f84b-4cd3-9f17-d7f8673391cc", "2282afa6-208a-4b29-8d72-7053a47f0dde", "ea3994d0-5084-4527-9729-896decc25a5b", "e0126c6d-0d2d-433a-8398-ce246f4aa0a2", "06564a24-4c14-45cb-b4c6-fc96b104b2e2", "f6969423-8138-421a-929f-f9c4ce9eb3b6", "228030f0-d592-4b69-85b1-ab3a0666cc9d", "59431d34-0849-45d4-909d-bb47d6a56d3d", "31467483-fa82-46d8-b9bb-8b2979ac0755", "944fba87-926b-401f-8559-223a13a4422d", "f9b7e744-1c66-4a01-a87d-f3fc03b84cd6", "7705f094-6ffb-4e7f-a771-eacd78f8fdd4", "83aea93a-3d79-40f7-9c6f-892b87494da1", "c7b269ea-e83e-47f6-96f2-45805924f723", "d17c5d69-be55-4482-8d1c-2bc2bf547b62", "a4670465-d3a5-48c7-b69b-0e767b092dfe", "75639319-e82b-4c09-b2de-41739f3f9c15", "f8945d2e-2f36-4dd7-9fae-7e6b515b06f5", "6663ccc4-d80b-4d40-b655-2fd5981a7737", "fe65cf83-e80b-4169-8842-dd56af2fef54", "bde5e349-568a-46d4-912b-366c9b270a68", "aafbf8ca-4c3f-4cf3-99ea-5223d916d541", "41d1437a-4a1a-4f41-8571-afd87f990888", "af466a80-0294-49b8-8ded-c35fc5718b4d", "0b709c23-0409-4261-9ff6-ef6e29c0a8f7", "2029d801-9050-4d82-90f4-350291475b07", "12d9e72f-9773-4906-b958-e3903fc8b757", "f7578ec0-716c-4c98-ac2a-0ff7dc62629c", "8aa10f87-1834-4fd7-9954-bc23724e1d1f"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 4Presentation\nOperator\nWelcome to McKesson's Second Quarter Fiscal 2023 Earnings Conference Call.  Please be advised that today's conference is being\nrecorded.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "4", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c5b66c6a-4cc2-467b-9428-64ea5c49ea2a": {"node_ids": ["220a8f8f-a531-49dc-a014-0ae9b00f04bd", "80aa23ff-586b-4568-b6e8-2aa67d16fff4", "e37ac073-4ef3-4751-b265-077ef5ab3c26", "53a9a98f-c21c-44de-b9ed-c4e027812c41", "b67cd999-986a-412a-b4b9-7ef1e5442a05", "18a4b935-54b9-434b-8fcf-f1162cbf7768", "1abd09c6-6492-4acd-9dbb-95fc204239bc", "ee9ad59d-544d-43b1-8cf2-d1a8066b24f6", "f56a7ceb-b4d8-48c3-ab9a-f34d49810e82", "09467d52-1f6d-4cd5-8bb9-74307d68e813", "54b72461-7e37-4867-998d-8d0011eb3844", "f1895063-caa5-44af-9f36-e8b543af38c1", "036379f0-a38a-417b-bc38-fdc99f556c52", "029f9e01-4807-47aa-9f2f-2b601527da43", "a9ffa04a-c71b-482c-bfea-86f31aa49fbb", "c1e34f55-209d-4999-b397-3cb0fc82866c", "476a9c91-e73d-448e-825e-83a65cbf1c2c", "fb16c6d7-d49b-4985-98c4-7d085c864e56", "22fbcaa4-a606-4906-b740-a91a29d073f8", "840c2560-d4a0-4675-ae6b-60171f4d3e9e", "a4e09316-ee27-4959-a596-77fb111a5f52", "38889468-8b67-497d-ac53-d74572bf3126", "65792761-58a3-43ec-a4f2-0d6ae123d603", "13d50da7-5293-4773-8213-973698c2bebb", "0c799a55-ec88-41b9-9416-4552c31f15cf", "60c7a3b0-94f2-4da3-af78-1e691793b804", "025a11da-0296-4a71-9760-ec35ff9c2be3", "c8af9fda-e368-4363-855e-3fbadc42333c", "7e7bdfd3-60fd-417f-8826-25cf0a186152", "c5b10ca7-4f3b-4d7f-94af-d0e271e090ca", "09ebb750-fca1-4572-b7e1-148b1f5c20b5", "2b949729-f200-4928-9856-e639869057fe", "69db5cb8-b821-46bd-a4d1-99158dc60cab", "16fdfc6c-1739-427a-ad5e-a5a830a3f4e7", "c21c0172-a052-4c23-bb9a-5113043cec14", "792829ab-6660-4661-9864-64b116948b39", "76f47c15-efe4-4946-94d6-d3c90f435e33", "45f177de-4c60-4694-a133-1c5953319be8", "8f2b676c-4972-4d77-83d5-adcafb6f6b74", "d15d888d-990b-4078-a682-fb865e62fdf1", "c0ebdd65-4f57-462d-adc9-6f76275777e6", "7e9c5bb6-fdd4-463d-b2bb-2bf1f5e3b381", "18e88f85-76de-4b4f-af4c-df7ea4625d45", "b0b203d4-f4b4-4869-9b18-92a98c63bd4b", "a3795dcb-651c-44c9-8cd9-66c56cec1aaa", "7d068037-3a23-4c9b-a932-5e8c23a88773", "7cd86607-fc75-4a1b-a7fc-cb7d0572665f", "69ace939-7e53-4857-b4f8-0d06f37a3e4c", "72183ed8-14bf-499f-9b92-df70d79413a0"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 5a more inclusive world.  This is an important opportunity for McKesson to demonstrate our values and take actions that support our\nemployees and our communities.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "5", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1c035e33-56c4-448e-bcae-ca731807c653": {"node_ids": ["1e488cf2-4980-4ee1-9403-92b0f5b7abc6", "620bf846-42bb-4c35-a77e-17d69486dd87", "6177d96a-5932-4c13-98a6-a4d52c7ae5c2", "d7a07aaa-7443-45db-8781-e06fb7ccde96", "61fd6d27-9fe1-4eb4-b435-7cdface11cbc", "147ba826-9a62-422b-ae5a-92af14352241", "8bdbe49e-5125-4116-b981-2e88cc6eb5e6", "f2153f38-13d6-4a99-a4f1-4574e68fe5f6", "56195842-7ff5-4fb9-99fc-905a888c9ea7", "6b8cc054-1f8c-4424-a95d-7ed33d5d65ce", "24cd5dd4-8f44-47be-b764-c4417f2e32e5", "6be7aff6-b152-4376-9539-68ef228d7c85", "2f494ae6-ebc7-48a7-8159-b21e79212864", "1ffd668a-3ee4-4c5c-bcc7-e29b3e884b4b", "ab69f861-f910-479e-8014-88b12cea650c", "f9ca158b-4bbb-4d5d-92d8-ce9110f8fa54", "c72f446b-1931-4227-a955-cc307982f51d", "7922870a-c667-4194-9481-b30cb9873b2a", "19dd6cff-0080-4d4b-a14b-f9e21e42870b", "b414088a-12cb-4c9d-827a-d81617ca928f", "0e58d0a9-08bd-4e8e-a7ed-3498a64b8598", "f9214301-7cb8-4248-bae0-1efd81f6c0c7", "a2afda02-ebc1-4c31-8487-e6c42088ecc9", "f409eb8a-bdd4-47a2-a6fe-b4a7f4da75fe", "6d67e2e7-cc0a-45ae-ae90-ee35dc58a984", "fd4c7aa9-630d-492b-9923-117872a49d63", "0b97f191-2348-41b9-b719-ff2b4cddea2e", "5712b8d2-42ce-4137-8455-893a245f8eae", "7db7bd7c-dc49-4d8d-b5a4-c41d8773acd8", "1a0b175c-d5fd-4122-bdbe-3d213cde7271", "7322196c-3c55-4abd-8ffe-2eff8b3172dc", "7c2ecbe2-fbf2-44b7-8971-a422b005609e", "896e722f-8e70-4cc7-a5c4-80140ab5aba8", "420de852-acf5-4af5-976b-6043eba7f522", "a29d893c-7b5c-4daa-802a-9fa6fdc26c84", "6394d05b-3f54-48be-ba5b-e07af8a06b62", "64a44ee0-9f1c-4021-8d12-7900e0560426", "8907bb9a-ef4a-43fe-b231-fa4f89c77677", "47286145-a31d-41d1-b587-f659e4ddeeb2"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 6complex medical issues and increase adherence by more than 25%.  Leveraging our scaled network and connection to the pharmacies,\nwe continue to explore new solutions and opportunities in the adherence space.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "6", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "128a2057-a810-45cf-855e-0452a45818f1": {"node_ids": ["302daaf6-25f9-42c9-a48f-d0d651c7dbf2", "d33b3abc-4153-4af7-989c-ec7f61a93fd7", "3b7ccfa7-e857-454b-8432-02a11fe38e8a", "e138dc6e-b664-44b4-8e40-1f1d0cf4779f", "8a253a9d-ae5a-4f3a-8a38-2a798a868e87", "f29619d2-e9c4-42f8-bb7e-be17b10b5fdb", "85086d6e-e59d-4004-a62c-d0808b35df17", "a20b8d28-7f49-4413-8681-bac27458d0a4", "a27fab15-0f6a-4551-82cd-ee1e6a9c02dd", "dee5a5cf-191a-4abf-a2db-84709f94e0b1", "a85559d6-8cf0-4009-a0e1-2e438499e8d0", "b3589ff8-2c1e-41f6-8290-4ea14a056332", "37f2f017-6058-46a9-86fa-193e68cd1342", "cdd060a2-d10b-4b86-a1f1-3ead72212972", "b4e737b5-b438-422f-9203-84838d67346d", "b8f7ac0c-0f76-4c58-a10b-6c28a048a31f", "bb607440-95f7-42c7-867e-f0a276efe673", "8140c79f-2f0b-4724-ac6d-23f6d877175f", "9483bb1f-f9b2-45d5-89b3-b7c62e5bfe5c", "beb108af-ed15-43cb-b1f4-8319b8d2dc03", "d88c9a61-5943-41ed-99b4-856cfdcdf03d", "2dc381cc-c48f-4f38-8296-4b1790be1941", "6a9a8d22-f220-4e63-a3e1-a7d0254d3b07", "ce9020f4-c766-4f51-8902-39310c98356b", "4ef1f69e-666f-4d07-833c-7c92518d8ff3", "d2b984e4-3098-4a1f-ae0f-38dc69314cee", "bfb8c6f3-5a1e-4f86-a06d-13f548f05088", "3ec54921-df5b-482a-93db-940f653fc629", "97382acf-c93d-4a95-adc1-ea7a149af439", "e40ef72d-ec60-4b66-8a1f-db1385f36ef2", "83753c11-4dc2-4d83-bbdb-3b2cdf2a04a8", "097f4dc6-e351-4e30-a1ad-18fa7f01ba49", "2f8c75c4-4870-4ccf-8f0d-d7f04a81204f", "93d50827-d984-47bb-95ba-091758a4389a", "90d2ae9f-954c-4c65-b93e-e2e68fb6dadb", "6ca935a0-c211-4727-8d63-c551626961f3", "d922699f-09de-4459-9425-0401a7206e1d", "d227c2ab-f426-40ef-9ef5-b6ff5730414b", "6e34b3a8-4dd8-45b1-a3e3-97f5b004f581", "05b6cfdc-0745-49ff-bd0c-636a0cc822d1", "a35a835a-645b-48fc-90e4-81698127584c", "2d61c32a-25ef-4900-9e37-21bce5dfa4ab", "9fb6c183-53f7-403e-a77c-7cf0a7076ca8", "1ccdf695-69f6-41c2-876a-dcf234e919e8", "e653d964-e876-46c7-83ea-561a834217cd"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 7We continue to experience cost inflation and some supply chain disruption impacting different parts of our business in different\nways.  However, through dedicated and well-planned actions, we've been able to manage the impact of these macroeconomic factors.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "7", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e2fadafe-2ce0-4c75-98b6-a6820d624291": {"node_ids": ["b7fac0df-da88-4aa7-9d55-fe9399f2dd2b", "d259c082-668d-4fbe-bade-43b0948a2113", "2b5cdd09-2983-48b6-b69e-6ec2a11a676f", "6a15e31c-d69d-4abf-929d-aa3ab4999ad0", "97cb06d0-723c-49d4-95db-3a0680a26b3d", "169d161b-c378-45da-86a9-de2c0370fd3f", "8aa913f4-d2b4-4491-8817-ca4a7afa1099", "be639a61-ffe1-4d71-8ac1-be854f4b18b0", "c6209ef2-8d1e-4158-bdf6-2b3f8ed6e0f2", "045c1632-0426-4af6-9c06-5ccc71b30fe5", "bd389d65-1fe8-4f25-a317-65c7ece519ab", "521e1d4d-52ca-4816-9f18-c66161a61ab9", "22fc483f-700c-48a9-b61a-33036d3087c3", "cee5af91-9152-46b5-b4dd-e7e67f1fa79c", "60c48808-9d68-4bd1-ad22-1646a79497fd", "704575c9-02ea-4a4c-848a-efdc7457e91f", "3e6e6e43-4241-4e2f-83c5-58b8ac4a923f", "9e754b99-3252-4e64-8dc8-bc4fe527d62c", "039e5f69-f7d1-4cbd-821c-d266762022ac", "b9bc1837-1151-48a4-a63e-a74dedd5f534", "ed125c8e-0bd0-4d3d-af4c-48effbf4ee20", "c97d77c4-b572-406b-9087-2037661a5ffb", "af7cc55b-06f3-4b9d-9b16-a00cbb99dbc1", "5d3f2665-77f2-4c05-b799-b34018ac7e04", "60463a2e-255d-4e53-ba4e-f9f20b185843", "68d17ed5-5db7-436d-84d7-20aa641fe6da", "e3f56c6f-e329-43d4-9931-5c446fd937b3", "0a0b34bb-5e79-40d8-940c-9c491fbf53f6", "3aa00263-c244-4eba-a291-7f2bdc51018d", "21b495ab-a558-4a74-81d5-1c6403b501d9", "1b6bc75d-2884-47f7-ae01-edee16b0752c", "84222969-ae65-456e-9d1f-9e28463d9c23", "ef8b4fb5-2903-4e37-b012-79b51e9d2ca6", "3eae0a37-f57b-419f-8bfc-f4006826bda1", "a1e0bd63-309c-4aeb-b475-4238e0239d99", "f42ae78c-c230-4eaa-adc9-35c93b2fcd54", "fa945f95-5911-452f-9bbe-d56ad3136c1e", "33768011-ce03-432d-b611-543100d3824f", "265b9baa-72a9-4e03-87dd-771f03240cd1", "654f8d7a-cc5b-47df-bef7-d32d88465f82", "4fef9720-cd25-44d3-a59c-1ce95565f637", "65ab35ac-f1d1-4a79-aeab-b0c1925aa1a6", "cd3ab8b2-7b15-45c9-a00e-a59b87738a23", "10aea57e-cb69-49a7-be21-799bb0fa89c9", "b141ed97-0c31-4e00-a2c7-322ed86b39d8", "60fc8863-b288-4dec-b09c-d5d8cdb3b2ee", "63c97fb3-673c-4e3f-b8d1-4b133cc3c6d2", "7045026e-1df8-48c7-ad6b-e666c65c5a24"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 8Moving to a review of our second quarter fiscal 2023 results.  My comments today will refer to our adjusted results on a year-over-\nyear basis, unless I state otherwise. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "8", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "928ac21e-a4c4-41bf-83c4-53fac0b0cad9": {"node_ids": ["3f1d2b2d-9be3-4c43-aba6-7b7043f7acb6", "f4b110ed-11ba-48d2-b6dd-5363e456f7c3", "f02b6453-5e96-4b49-8498-376fd357d24f", "0ae5bb7d-4522-4c8a-a9d4-0e6fe5b2f2cd", "d2999dfe-cc7c-44ce-820d-98e22e05c3e9", "6c393e74-c882-4259-80f6-9da79819fac7", "9fb25e12-d3a5-4a52-a5c3-4a5eb3a4e722", "34b2aec8-fec2-4f35-95d8-6b1c90e48d6b", "82ab64ed-b796-462f-b240-128c52857b50", "c6913a13-cb84-49cb-88c7-49a663e905af", "f6f42480-4183-415f-bfb0-959d47fd1b3d", "7817642e-5d3e-47bb-80b5-88f78b00cb2f", "68f71b01-b16d-40cb-a0f7-59ecadcd601a", "05833ffa-5966-4176-89e8-e5b286672a04", "5b5dc453-93fa-4404-b8db-48b7cc3c1f79", "9fbd3203-5126-448d-abfa-e1344c5fb78e", "031ce94e-1d68-4c5f-8263-e078400fb3f1", "ac983dfc-7983-4f70-9026-49fc3f1e9915", "fab75678-f8d1-4683-a78a-8b0ef8d87870", "7db3f039-b699-4059-a82b-d229b1a44a92", "8044e8f7-89c9-4b62-843f-727feea9c77c", "d5248f8d-601a-4f23-9024-458f7eaeed59", "8bb32650-a9b0-44e5-a141-262401fddb9e", "e5818914-20a0-43e6-81b5-9ad4ef8a1d9a", "21405c6e-4a17-46e3-bb55-a359d38a2fe4", "8fdc412b-7c6c-491e-bc37-b5fd7508d829", "3f8eadd0-05c1-4479-a5af-772c6e7d4a61", "c3ddbdf9-97b9-4af0-8092-d91f4788df3b", "464446dc-1b84-44c1-8754-c390afcc57fb", "cec1413c-19a5-476b-a75a-f41db188444a", "038cd020-2de0-4d00-9992-8bd8db351bee", "d593be33-7df8-4564-a9ef-5ed5638ef1ad", "739cc948-9230-44fc-b12d-e489fddbd111", "d66ea2d5-3efd-43d8-88bf-dc1993e0198b", "cd2f1ef0-b153-484a-bde4-8c0991acbddc", "2c60e1ed-b114-4c10-bcc0-e36cd876ac66", "72ff80ce-ae07-40c0-8896-b8c063b20f5f", "5474aedc-0457-47a5-990c-bd60bb487112", "7f0be01d-2d2d-407b-a656-2be407aecffc", "69973add-edff-4cae-ad3e-f9502b321be4", "44efc2e8-0685-4c5c-ac8e-04a09f43d776", "c5e2e8af-40b7-4564-8fcb-1ccc36a63f79", "cc73d6fe-890a-418b-9fcf-58b2b2df7966", "5ba1b7e4-6135-4ab8-bf93-035ce304ecd1", "0f2e7298-ef4e-4787-a49b-960a83aad4c2"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 9The year-over-year impact from our McKesson Ventures portfolio was partially offset by lower opioid-related litigation expenses\nin the quarter.  We incurred opioid-related litigation expenses of $9 million in the second quarter, and we anticipate that fiscal 2023\nopioid-related litigation expenses will be approximately $50 million.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "9", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b59b0f62-221c-4bbb-a914-c70e8c961380": {"node_ids": ["cd27e1b2-a175-4b92-9507-f50aa05a11b7", "2fb6012f-c8f3-44d3-bbc4-4e37d080e19d", "191ad042-b7f6-4474-aab2-348abf26c95b", "3eda61b2-90e0-41ac-8b78-6a900ce667f1", "a9b9a455-49cb-40ba-91b6-64e17a878652", "9a9a7ee8-3063-4ab0-8dc5-0da2e0dab9e8", "b5b1e038-1225-4eae-aa38-8dc359ee383b", "dcf2b5ce-4aeb-4a86-8f99-6dc323c0a7ef", "9868df5a-4c67-4f54-add9-7e331b00bd4d", "7f4535f1-9074-493d-a085-815af228221c", "efdc524c-f379-43d3-8fd7-901a2968bbb8", "21152ddd-2907-4258-a910-5f7f0c457ff5", "b701b318-a11f-4bb6-8ec6-79ae3cacf540", "9d890a9e-d11f-4b26-84d6-de04b6ef1f3b", "b03cd378-2db7-470e-b8fe-cc52724b936d", "10725406-27a0-434b-aced-458059020722", "53120c3d-b6c1-46d4-a75a-e27a8c818fa3", "f45fce86-1dd9-43d0-bbb5-01fe09ea7b9c", "979472f9-21c0-434f-b8e7-ca53f5eb2173", "787bebfc-26c5-44a8-b6c6-12033a3a9003", "bb64bed6-c105-4fe0-ba2f-ff7d7898978b", "279e595c-0382-4c62-b08d-5e98db8b7e27", "90aa93d1-5416-427f-b987-3e917d42346e", "0b6fb4f3-355d-42be-b9fa-955f9357b46f", "a6199399-174b-4667-b2a5-68fa856b16cc", "98ea4131-fc07-4bc7-a197-e82a225850ef", "4b4a41e8-d5ea-4c73-91a7-3b7cea9de97d", "773e6222-2f4e-492d-adc5-542cd1c3547e", "9809b361-864e-4f7c-adf5-a967e2d7f42c", "64a2f41f-b80c-4dca-8a03-874ecbdd2f73", "5fb6958f-8ebe-475f-976e-de7763b393a8", "b447c33b-6fd7-4585-86a7-3815397d358c"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 10In the Prescription Technology Solutions segment, we anticipate revenue growth of 10% to 16% and operating profit growth of 16%\nto 22%.  We will continue to invest and build capabilities that focus on increasing access, affordability and adherence solutions for\npatients. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "10", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e7751ed6-3d9e-4496-95cd-7ec66037e549": {"node_ids": ["bc478d1b-3aee-407f-9b34-bb178aae215f", "933bf691-d8f1-436d-81a4-35f8210be68d", "8f129711-a0c7-4e9c-8cbb-245f9e740cb5", "64d6f559-c48a-4083-a9a6-4a17a0dc74b4", "0b5c0825-6751-4e13-a015-875a0409071e", "dc3fed86-0ed5-4f17-ad60-8196b8d54b65", "f4a66be9-066b-44af-a479-06c4c12ca78c", "0cc81a8f-3e72-4750-9e66-afdbcc86130f", "ab5b7e2d-a8e8-489d-b77e-6f391b438607", "6c50e8aa-3f37-4d5c-99a1-37db8c379b8a", "f6983815-d7eb-4ef7-8924-4cc803761c9d", "caee653d-b60b-4ed5-892e-71d6b7f4947c", "5f24e1d8-03ab-46c2-85d3-c4110d708495", "deca4694-c872-45a2-9f6d-dc69e276925f", "2489b4c5-c8ec-4ae4-a55c-a744e70c6c41", "f18e1e37-7eb9-4a56-80c5-2dec765e8735", "a36b792d-be97-4121-8648-e28b104a77dd", "378e410b-a86b-43f6-85c5-d4bd15c1bf3d", "e12a7cfd-282b-4014-ad46-44a81bc1f6f1", "432653f7-2817-4c99-8f7c-be47f3daf8d8", "70861cc4-88cf-47b0-9023-81dba098f026", "ebebaf71-0b0b-4931-81f9-4d5f6f60cf8f", "39da514b-4f5c-4ba7-9121-02c1513b7c81", "8cda37ce-055b-4ebc-b1af-e7f30c902951", "1d66784e-1e7c-4878-8a14-7cf5bfc94cc3", "eb3c2e08-b2fd-49c7-9062-9d6ae7345339", "d8f4f225-d8df-467f-99ea-1f573ba67813", "c987e741-6c2f-4f40-b1e7-034c0515dd14", "11242396-e904-4d80-9c67-657dfe4fa4f9", "56f6870d-6956-4140-be0f-bfe4ad558a3e", "e34d7623-e1c4-4525-bbdb-920d0e26567b", "91f0d85a-1f3f-44c7-9663-3a53de628987", "b6bc943c-8d7d-42a6-9c36-99bf27115c27", "caff9b0d-66c5-45c3-a22f-055e7745f699", "d76dd05d-a113-4482-93dc-d29d431aaa00", "e6139231-1e63-4d26-afdd-c9225fca96b8"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 11Question and Answer\nOperator\n[Operator Instructions] Our first question comes from Eric Percher with Nephron Research.\n Eric R. Percher\nNephron Research LLC\nA question with respect to the strength in pharma on the op profit line, and I think you differentiated that strength coming from\nprovider and health system versus the national account. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "11", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "67e0f37a-de3e-445a-bb77-14f4f9f3e338": {"node_ids": ["0d46d928-0be0-460f-8fd8-3377508ca906", "ea4d9b24-f66e-40d6-9243-e5cb52b555a3", "27fa5aaa-afe6-4757-aef6-1bb1d128bdc0", "074f3e11-0102-4891-829a-e7b37cbe5ce9", "2c31f23d-094b-4365-8687-f95bdff9fab7", "690e948e-bb47-44f3-a629-456d9f63c256", "5e507426-2081-4485-ba8e-508754499e3b", "651c7e54-3c83-4251-95d7-4e1ac7aa3569", "396104b3-5344-42ee-9df1-20398637dc71", "5e9c3fba-df23-42de-8b24-86f1347bd783", "c4b3357b-ad75-4122-ba31-a14d674d92d8", "13531f0c-456f-45aa-b3d5-17743bfe45f4", "c7bb97df-6c5f-406d-be32-be85dc3c3657", "2df5f233-4b9e-47a3-a89a-d00ef487de3f", "a7363960-3c10-40ae-ad8b-162dab04e454", "9de13ad0-cafd-4cbe-a1f8-5e9ebda5a770", "d79a32c9-995b-4f9b-a317-bd131b8100bd", "b5d5b238-be11-4af2-b2d7-6b80628cc93f", "5715d32f-3c45-40bf-b72e-6ff87764507a", "0a144e3b-4659-40bb-a376-554cc75f80a6", "352a145a-0f22-49c6-b648-45c931a34d9e", "5a4f564c-cf33-4fb1-8d03-b62ff39e1d2b", "202c0eeb-eeb1-40db-b260-beb398bdebe5", "031654a7-3512-4891-aa46-e7c16a7bae0e", "4ec974cd-aa53-4216-8ed5-69d1fdcf7bfd", "4524d09d-07d7-4936-a583-6e8580da09d4", "fd909664-f408-4af9-8c3c-28ed0be5aebc", "aebbd7b4-8d40-407b-a321-549e0aeedbf1", "e4e92288-08f6-4769-8668-6fad21635345", "3974a9f7-fc78-4c6c-a267-1a6ebfb5bbdf", "a8c9e2c3-5352-4a32-84fc-c1a41266a92e", "68090e30-95b8-4342-9d0d-7ba1e0a9694c", "2c353a62-8fe1-47e7-9bd9-28a5b6156d58", "d6e7b57a-92a0-4736-8d9a-9013326eced2", "d562aec2-9f68-4615-8d9b-b2c8d306557c", "b333193a-a600-4089-9de2-3d9b60465eeb", "581c4d6a-f07e-4ddb-a182-39064020dfbe", "c177a533-546a-478d-ab95-9242b07c432f", "74ec2b62-01f0-4c93-be94-b0325099ab06", "431294c7-e3c4-45de-a202-935eb51e8d84", "80078a43-26b1-4b14-92b8-beac9a939a00", "81180d20-2098-483d-8b1f-134518721fa0", "cd57ab92-9823-410e-be7e-8624a00e40b7", "97bbe544-5f4e-4f8c-9211-22efb42b534d", "774a24cf-0763-4768-b8f0-e7eb0d143235", "8d151cf8-c4b9-4905-afc5-9f0d33361c89", "7f5d30b1-eb8f-4c06-970d-a29f359f2f07", "9d88d583-4a8b-4cfb-99e7-2757f8e12e0e"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 12CEO & Director\nYes.  Sure, Michael. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "12", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2718f319-ebcd-4a04-81f5-8753264a92fc": {"node_ids": ["a7ac7550-187f-40ab-8769-de5cd5d120ea", "e77830a5-3ebb-4f68-80d2-2ab1684c87bd", "b0ab3463-0b50-48e2-89da-819861606980", "cbd76b7d-b0de-488b-8986-206dd30850b7", "397022e6-2f4a-463f-a2ff-ee2e71f7814a", "73e01ddb-eabc-4061-9f6b-15a91c3638fa", "f5f007da-ecd6-4f3e-869d-1ec40efbc079", "9e5e18fe-711a-4510-9610-92404d17e35a", "42b347b1-1ba6-4dae-84f1-41dc8f2e7586", "ec8cbd26-e59d-4abf-a03e-c73d37ab2a8c", "0f44a8c3-e203-419d-b5ac-96e30631b588", "c2fb4b0f-f1e8-4462-9d3c-0318ae4c161f", "3c3d391f-f477-48c3-96aa-dafe3afc16d6", "904e4ce2-6432-486d-befe-b7b6b62d480c", "a10c5cf2-8e3b-41c0-bd94-ec32848405bf", "93477de0-f52b-476e-ad56-f4a0d3128733", "19939327-62ec-4803-a6a0-0c63c494852e", "1708e71f-8728-4abc-a1d6-216e12a3edc8", "e28276a0-3d24-4fa9-a486-8ae96ef69763", "c9279bf2-d9e6-4cad-8af4-3618249b8b82", "6e3221fb-1b7f-43ad-8a26-49378fc66b33", "99056860-1a3b-4a11-8345-49aefa77cdeb", "c2ec3475-8afe-4878-ab0b-67affdb1048d", "32480dbd-b40d-48ae-b07a-127dfd10cf57", "75eed641-28e3-498a-bf6d-148e83959d1f", "04681c60-750f-48a7-bc4c-bd34938ce88f", "ddf6aa5c-0941-4971-9aa1-2028d5c75443", "209521b5-aedd-4cdc-a4e1-9efe9abd7b81", "3ed37b10-6c8e-40fa-bc9a-1ea6d5ff6ff4", "91f60cc5-bab8-4dcd-979a-dc7603cdc937", "81a46807-6a44-4a86-80cc-82a71207ab86", "11790c17-1ebc-40b2-9958-f3d82d391deb", "8d6e6902-dc76-4a84-a04e-764d1d3eb09d", "b4636a6e-30c1-48c2-a7f2-e1942ca7ecd4", "9ccfbd03-8217-4349-9080-dec979c4996b", "bea3295d-43b1-464d-ab6d-516f3194b96d", "5d0d0cc5-7afc-4e1d-8c5b-8bbfd0f88fa3", "99dd90b0-9671-4399-99ee-ec236f52122b", "73bf4cf6-1ce3-44d8-9525-b52910ab0433", "77089489-ac61-4d86-b086-97973cced48b", "19ec5a8f-2e97-4bd6-827b-3b1f0fb058a9", "e3695140-2646-44e9-9629-2eeb138d680c", "56433d6c-f851-4205-8885-be8b300cbe8d", "91a0a40f-a4f5-4ad6-9353-140efc21c877", "17486a67-e343-4fe6-9658-2901a6e68bb0", "d333e97f-5ccb-4cd9-ba7e-b2c3696bbcfc", "f51523b2-4a9d-41d0-bb3c-75a33cf0a7c1", "113badde-7340-4a99-974a-0f04fc6aedec", "5a28dc81-32c2-4084-8427-3f46528fb623", "66874581-eb42-4e1b-ade7-bba8478d8095", "7d880a5c-9e1c-4381-8f10-ac551905375a", "adc7438b-9ddf-431e-b16a-c229d8802fa0", "f70de659-895f-4f23-a202-0f6de42891ce", "3f9bdb9e-2e2f-4cba-ba28-afcd8928dc0f"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 13So you guys normally don't call out very many monthly trends, which I think everybody kind of understands.  But back at that investor\nconference in September, you guys did call out that roughly 7% prescription volume growth across your business in fiscal 1Q ending\nin June, and you mentioned that July was kind of softer versus that trend. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "13", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "86bd87c2-d49a-49e1-92ca-b8ccf25e2952": {"node_ids": ["b7dbc76f-3f1c-4300-ba91-60a153e8e3e2", "2db61508-99bd-4416-b03e-ab20e30d0839", "30124779-9ce8-4531-bdf7-eda40765208f", "354f7254-dbe1-40ac-b3de-8fa2e3a3f946", "c77e065c-e67c-4e1f-a595-da6b20d6e25c", "c51cfc1e-cc4d-4fc9-b87d-91f805aa8c2a", "1112aea4-d10d-4025-908a-26a648bcc59b", "176676c0-0e81-48fb-bac6-b23267e00634", "2a0ebe08-8b68-40ea-8943-1adb1cf9712b", "1da66dbd-f93f-46c8-b822-f865eeb17190", "6b1d88da-590b-4d88-a671-f0115a317e7b", "99da7da1-730e-4acf-9fbd-6353e297bf8d", "b9956172-0b89-40d0-8e3b-4a33823d6b42", "80241cda-8046-4b8c-8e03-59f690db0c85", "ac43f16b-cba7-4981-82e0-ecf6178bccf6", "3932b089-6f80-4f9b-bf67-acbb3afc84f6", "60929aa6-f81a-4feb-9935-7f364f2b7c8a", "bedbaaf1-96e0-4daa-ba4b-05f114c512de", "f9f9690e-addb-4a05-8224-47f68758dd4e", "74f17383-18af-4f23-9561-63b9e9c8fcaf", "d2adfcf9-4c99-400f-a1f7-e35768cd22ff", "97243f8b-8294-4321-af81-668412c5538b", "90458ae8-c023-4906-9930-106af6ddd9b8", "a2f227d6-221e-4ffa-89e4-c434ac9ec29b", "8d50d9b9-1140-4587-bc76-a36723646e5d", "6dc0c844-dc2d-4fc5-a9cd-460f1079a98d", "98cd93b5-8ded-4ff3-a3b0-eac138d1fa2d", "2bf8e8b3-e705-4eb3-a64a-dc73c1a225b6", "707310e8-eb6c-4771-9c3c-3fa1b566a7fd", "4e2409fa-b22f-49ec-93d3-a46b0d955e5f", "c46f537e-6939-442a-a57c-0abe0ad822d2", "690b2419-093d-4f29-bc05-a01b6e9b5346", "682a0237-2f42-47dc-8a44-f2672cde7fd7", "9ddacffc-4ad5-47a4-a5ef-e817a5b6451b", "85e891dd-7e29-40fe-961f-d0ab61a1bebf", "4cd136b3-ac98-4732-b165-1676cd91bf4c", "1676ac87-02c9-4839-8a3a-bb6796ccbab1", "cffa5d60-2ba3-475b-8617-6fdeb1221144", "fe54c565-ae8f-4646-bc4f-16b808ee1509", "65f0bca8-3ef9-414c-8301-5df968d976dd"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 14base.  So it's kind of a follow-the-patient kind of strategy. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "14", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d9f1abd9-ed46-4209-a100-85962b57e625": {"node_ids": ["d0c8a836-e87f-4a34-82a4-eee1918bef42", "de123c69-78bf-47c6-bdbe-90a09088a7ec", "48491696-0e59-4fc3-b0f2-3bb172fb89e4", "224658ff-a24f-4083-a359-ac1b39a4a2c0", "cf947523-ad7a-478b-9eff-55f43264786f", "344ddd36-3a22-48e7-aef6-86ad860d91d0", "d051edaa-d12c-4b29-b5f4-8479a4e5d30a", "a06e42d8-cd8f-4595-a6bb-52b73a31d876", "b2e2d9ce-4817-410d-b498-ccfa960a4eb6", "623eb302-b0a1-4092-aa41-0b82f4d5067b", "194e81d8-3863-4eb1-828e-f900ef9f33a7", "35504a88-2f74-4416-b87f-a0d1f111dc10", "db71ce6c-5402-4c62-8803-73a68dbadee8", "f9a8b2cd-44b0-43a8-a057-ceb74b86c5c1", "7c9726d0-9f51-43ae-ab46-acdb6747ca4c", "1a32c3b7-613c-473e-8a10-2de942b3bc64", "2336e208-2d5e-4b81-b3a3-695c3f7d7a3d", "e6febd76-10df-4270-8ce5-61dfd05d9ba4", "b914c218-5275-4794-806b-52c43dbf1632", "a7073653-97fe-43aa-bfca-3d056ee939dd", "3dd4513c-5672-4f14-803c-e3fea7872e36", "c956c3ee-1ab8-42df-9db7-8e09e07e9941", "a68eff2a-bd3c-4c58-89b2-0b0ef090218f", "fd43cf16-a13e-48b6-ab2b-af6d4cb3c563", "20aa7af4-aee7-44a8-aff3-c18698938d22", "c11d525c-1bba-4b50-9c5d-054dd1d2e4bc", "4cb0ad33-f21d-4d11-a57b-a955cd544fc9", "50b472ab-c98b-461f-9c64-7d461c7bcf7b", "89580ff6-7d77-4236-8b76-26b94fc44bcb", "68666d57-b033-48bf-ae1a-3bde602e636c", "f7f8a454-cfbf-4c01-9ef5-e135ce7e0a83", "f7c94438-88d1-4612-b9c1-aef4a1cbf416"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 15CEO & Director\nSo I'll start with kind of the business model.  I mean in our portfolio today, we have a mix of really transaction-based -- think of it as a\nclick every time a transaction goes through. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "15", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "495dc4b9-b74e-4643-bd36-ecc193b62fe2": {"node_ids": ["ce6a1a36-7a1e-439b-ba9d-5e99c5b63a48", "3a85b429-e537-44b2-86e9-ce221001df87", "dfa4c9ac-819b-4555-8d6e-ff3ae3611eb4", "b4a75dee-3d41-4fe6-b073-e767a2f1899d", "c1cbaaac-c993-4fb8-81a8-a8b9508d706f", "b15209b5-a242-442f-a89d-54510864a65f", "8539d0c9-7197-482e-9aea-e0a41480ace0", "4772c5ec-dee2-417e-8561-32fbd75e740f", "68d51fd1-b524-444e-837f-072ff64ef8a8", "cbcc26e6-84f7-41b6-a415-04c9b6129e2e", "744c623d-05d2-4e0e-89ca-5b0042fa09d8", "e961f0b5-13d4-4417-b343-762c83a9a8e8", "f7e93c0d-a7b1-49b8-8a4e-83c3b698c5b4", "87c8a345-f07d-4d01-b708-9ee8412aff7c", "6ea91b0c-388b-4780-8608-219e0fa2d417", "619bfc41-3a87-49a2-a9b1-1f23770867dc", "7030e0eb-d563-43d4-ae24-cdd3ee348361", "84b0b7a9-dd9d-4009-9958-ace73cfa3659", "811dacea-9fc8-40b7-a89d-d7c93b62472f", "2e20a916-deef-4e1c-9728-81fd0561cd43", "ea3280f1-ee14-4e3b-9e3a-a2241293506d", "edf7e525-e581-4ffe-a3b7-6a66865f690a", "0feaa758-97dd-46d6-8145-5ab05833f784", "f1e14c25-bacc-4072-a369-c03399893401", "39c4117b-2ecf-496b-8bb5-74ea610170ba", "5c88a823-894a-4df3-a2cd-6346ad415a4c", "93d7ba98-5c21-4c17-b4b2-25d836d54f5c", "afc87f15-d6d0-4587-bfd8-42cc5612ad22", "ab3c5d10-35b5-4632-b70d-7b0911e1709c", "0aaf667a-0c44-4009-ba15-45a9687914fa", "ea9615d2-c969-4402-8134-5a6cd14040b0", "d371c34e-af46-4582-a2d1-48135a41e0dc", "154163cb-b262-47c4-8822-eb9195763afd", "4960b150-5134-484a-a6a2-6c29a7e61d27", "e089a9a6-509d-40b4-9882-40f3c8f236e5", "8535769d-a71c-4177-b70a-d817871d6baa", "aad46357-8aa4-4800-93de-660e841f6bc8"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 16Brian S. Tyler\nCEO & Director\nThank you for the question.  We're really encouraged by the great feedback we've got from the oncology community broadly, including\nthe biopharma manufacturers who are deep in oncology. ", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "16", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0b473d8a-d395-4e9c-b65f-74e50e0a166f": {"node_ids": ["31b0d495-c882-462a-93ec-1f71dc350367", "dc7d1fe4-ba97-4aeb-a845-d66f4439bfe2", "4c219f05-b668-4615-a527-ffb10c8dec07", "ee5b1af3-c1c7-40ff-93fd-991745d4ec87", "f2a1bf48-a802-4f2f-86b0-30942cbf6349", "3ebdee50-c897-421f-bd06-5394a739f231", "1d8a6093-fe5c-4cd7-a634-49e35d4844f3", "169774b1-e835-49f4-a7bb-babb079fbe4d", "0a3aa474-462a-4b21-982b-6ae1313080ca", "0efd9b54-c1d5-46a7-8f30-db3f08a314f8", "dc76bfcd-75ef-4956-a6fc-f5bb19e6700f", "950475a7-08d2-4cef-b008-1906ac898ce1", "b783b52d-b39a-4594-86d9-73bceba2c07b", "88191f82-0498-4581-91f7-2612b875e66f", "bb136063-9d44-42d2-8060-e653932f19a5", "a182e5b1-5dec-4102-ab79-c246973e9368", "60b2a29d-8b44-434d-8e27-7cbac0d4f62c", "8e597f3d-1904-40bd-bec0-06c95a0b3237", "c40aba76-1b6a-414e-b03a-d6b4cb62340d", "e3cc1fc9-501f-4685-b2c1-0de70ceaa1db", "dbb2db60-3247-4257-a525-17f663e05aa5", "d9f3a657-0aa9-41da-b448-c22b68fde047", "14179c39-f69e-4ae8-a934-71d2d0ab8a6f", "e6e4cedf-7c64-46c1-8b00-3f046e8a6ea8", "c6ff127a-446f-46fb-b73b-395554d21f0d", "4b1dedc4-332f-4610-86af-18674b6feb4b", "bf81ed1b-6050-41bc-86ec-2c2b7fa9fecd"], "metadata": {"window": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc.  All Rights reserved.\n spglobal.com/marketintelligence 17Copyright \u00a9 2022 by S&P Global Market Intelligence, a division of S&P Global Inc.  All rights reserved.\n", "original_text": "MCKESSON CORPORATION FQ2 2023 EARNINGS CALL  NOV 01, 2022\nCopyright \u00a9 2022 S&P Global Market Intelligence, a division of S&P Global Inc. ", "page_label": "17", "file_name": "MCK-Q2-FY23-ECT.pdf", "file_path": "pdfs\\MCK-Q2-FY23-ECT.pdf", "file_type": "application/pdf", "file_size": 381527, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}